Potential_gene_ID	Potential_drug_ID	Drug_name	Drug_CID	Status	Reference
PT00118	M6APDG03816	JNJ-26483327	.	Phase 1	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00022	M6APDG03817	Cyclolignan picropodophyllin	.	Phase 1	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00051	M6APDG04127	Ertumaxomab	.	Phase 2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00051	M6APDG04268	NeuVax	.	Phase 3	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00051	M6APDG04316	227Th-labelled HER2-TTC	.	Preclinical	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00050	M6APDG03320	Afatinib	CID: 10184653	Approved	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00050	M6APDG00563	AZD4769	CID: 124437	Discontinued in Phase 1	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00051	M6APDG00150	BMS-599626	CID: 10437018	Phase 2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00045	M6APDG00318	PHA-739358	CID: 11442891	Phase 2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00078	M6APDG03326	Roscovitine	CID: 160355	Phase 2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00050	M6APDG00150	BMS-599626	CID: 10437018	Phase 2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00057	M6APDG02173	CMX-2043	CID: 49802864	Phase 2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00079	M6APDG03326	Roscovitine	CID: 160355	Phase 2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00080	M6APDG01092	P276-00	CID: 23643975	Phase 2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00045	M6APDG00625	AT9283	CID: 135398495	Phase 3	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
PT00221	M6APDG03419	AVT-02 UE	.	Discontinued in Phase 2	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
PT00038	M6APDG02278	Acitretin	CID: 5284513	Approved	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
PT00022	M6APDG03382	Somatomedin-1	.	Approved	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00186	M6APDG03895	OMP-52M51	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00044	M6APDG03898	DT-200	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00051	M6APDG03905	HER2-CAR T Cells	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00042	M6APDG03925	Navicixizumab	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00112	M6APDG03932	HH2853	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00046	M6APDG03939	AI-850	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00165	M6APDG03949	ABBV-399	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00068	M6APDG03952	TEN010	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00044	M6APDG03957	EZN-4176	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG03969	MM-151	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00239	M6APDG03985	DS-1205	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00239	M6APDG03963	ONO-7475	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00239	M6APDG03951	BPI-9016 M	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00077	M6APDG04004	SL-172154	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00032	M6APDG04010	Anti-PD-L1 CSR T cells	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00032	M6APDG04011	LY3300054	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00051	M6APDG04063	AU105	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00042	M6APDG04067	SNN-0029	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00038	M6APDG04072	OPB-31121	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00038	M6APDG04073	IMX-110	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00165	M6APDG04075	Anti-C-met CAR-T cells	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG04077	EGFR antisense DNA	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00081	M6APDG04039	GLR2007	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00077	M6APDG04096	AO-176	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00222	M6APDG04097	IMSA101	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00031	M6APDG04203	SGT-53	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00031	M6APDG04204	INGN-225	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG04226	Depatuxizumab	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00057	M6APDG04231	PTX-200	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00029	M6APDG04224	MM-141	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00124	M6APDG04234	RO7121661	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00124	M6APDG04235	GSK4069889	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00239	M6APDG04176	BI-505	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00249	M6APDG04237	MRG-201	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00032	M6APDG04240	Pidilizumab	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00165	M6APDG04297	Beperminogene perplasmid	.	Phase 3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00239	M6APDG04341	Cu-anti-hAXL	.	Preclinical	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00038	M6APDG03721	ISIS 113210	.	Investigative	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00155	M6APDG02209	PF-4708671	CID: 51371303	Clinical trial	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00064	M6APDG00821	KU-60019	CID: 15953870	Clinical trial	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00026	M6APDG01084	T-5224	CID: 23626877	Discontinued in Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00028	M6APDG00404	JNJ-26854165	CID: 11609586	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00074	M6APDG00269	Briciclib	CID: 11248490	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00031	M6APDG02326	CGM097	CID: 53240420	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00168	M6APDG02928	GDC-0994	CID: 71727581	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00112	M6APDG02828	GSK2816126	CID: 68210102	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00068	M6APDG00601	ABBV-744	CID: 132010322	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00034	M6APDG02521	CYC140	CID: 57336523	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00052	M6APDG00481	H3B-6527	CID: 118029202	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00052	M6APDG03061	BLU-554	CID: 91885617	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00178	M6APDG00528	Palomid-529	CID: 11998575	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00167	M6APDG02928	GDC-0994	CID: 71727581	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00057	M6APDG03030	M2698	CID: 89808643	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00079	M6APDG03334	SNS-032	CID: 3025986	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00043	M6APDG02511	XL418	CID: 56963011	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00110	M6APDG00728	KO-947	CID: 136653617	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00110	M6APDG02546	MK-8353	CID: 58282870	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00060	M6APDG00572	JNJ-64619178	CID: 126637809	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00212	M6APDG00528	Palomid-529	CID: 11998575	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00231	M6APDG00469	CEP-11981	CID: 11751922	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00206	M6APDG03207	IRX-5183	CID: 9867758	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00064	M6APDG00027	M3541	CID: 100714	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00064	M6APDG00573	AZD1390	CID: 126689157	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00038	M6APDG00258	WP-1066	CID: 11210478	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00068	M6APDG03284	OTX-015	CID: 9936746	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00052	M6APDG00482	FGF401	CID: 118036971	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG00479	CK-101	CID: 117909640	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00178	M6APDG02822	ME-344	CID: 68026984	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00212	M6APDG02822	ME-344	CID: 68026984	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00092	M6APDG00856	CTCE-9908	CID: 16186350	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00028	M6APDG02551	AMG 232	CID: 58573469	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00051	M6APDG00808	CI-1033	CID: 156414	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00038	M6APDG02880	Golotimod	CID: 6992140	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG00808	CI-1033	CID: 156414	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00057	M6APDG00808	CI-1033	CID: 156414	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00029	M6APDG00524	BEZ235	CID: 11977753	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00029	M6APDG02795	SF1126	CID: 66577114	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00080	M6APDG01093	P-276	CID: 23643976	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00227	M6APDG03165	Disitertide	CID: 9833838	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00057	M6APDG01153	GDC-0068	CID: 24788740	Phase 3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00057	M6APDG01266	AZD5363	CID: 25227436	Phase 3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00051	M6APDG03267	HKI-272	CID: 9915743	Phase 3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00052	M6APDG02362	PD-0183812	CID: 5330258	Terminated	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00057	M6APDG02652	Squalestatin 1	CID: 6438355	Terminated	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00164	M6APDG02964	UNC2025	CID: 73425588	Investigative	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00052	M6APDG01102	ACTB-1003	CID: 23653175	Investigative	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00110	M6APDG01868	SNEWIQPRLPQH	CID: 44560069	Investigative	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00018	M6APDG02514	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	CID: 5712	Investigative	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00040	M6APDG03921	AST-005	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00040	M6APDG03922	AVX-470	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00024	M6APDG03943	OP-R003	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00089	M6APDG04090	CEQ-508	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00093	M6APDG04211	Anti-IP10	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00024	M6APDG04212	ALD-518	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00024	M6APDG04213	Clazakizumab	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00035	M6APDG04225	ONO-5129	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00024	M6APDG04296	Olokizumab	.	Phase 3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00097	M6APDG03591	ISIS 138678	.	Investigative	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00025	M6APDG01228	Ruxolitinib	CID: 25126798	Approved	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00072	M6APDG02910	PRI-724	CID: 71509318	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00184	M6APDG03896	BMS-986299	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00044	M6APDG03897	Drug 2881078	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00130	M6APDG03917	BIIB 028	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00029	M6APDG03192	Novolimus	CID: 9854320	Approved	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00123	M6APDG01358	Lithium	CID: 3028194	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG03966	EGFR806-specific CAR T cell	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00057	M6APDG04086	Triciribine prodrug	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00099	M6APDG04087	HPN328	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00004	M6APDG04091	OT-58	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00042	M6APDG04374	ALN-VEG01	.	Terminated	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00029	M6APDG02116	PWT-33597	CID: 46917355	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00239	M6APDG01195	MGCD265	CID: 24901704	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00101	M6APDG00560	S-tubercidinylhomocysteine	CID: 124349	Investigative	Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.
PT00046	M6APDG03627	BP-100-1.02	.	Investigative	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
PT00039	M6APDG03575	Lerdelimumab	.	Investigative	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
PT00044	M6APDG03329	Apalutamide	CID: 24872560	Approved	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
PT00040	M6APDG00266	PNU-282987	CID: 11243536	Terminated	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
PT00032	M6APDG03370	Durvalumab	.	Approved	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
PT00032	M6APDG03872	FAZ053	.	Phase 1	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
PT00032	M6APDG03873	MSB2311	.	Phase 1	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
PT00032	M6APDG03874	BMS-986189	.	Phase 1	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
PT00032	M6APDG04055	NM21-1480	.	Phase 1/2	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
PT00032	M6APDG03538	CA-327	.	Investigative	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
PT00134	M6APDG03372	PLEGRIDY	.	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00241	M6APDG03375	Pro-urokinase	.	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00032	M6APDG03388	Avelumab	.	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00015	M6APDG04378	ON-09300	.	Terminated	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00193	M6APDG00282	KU-0058948	CID: 11291932	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00051	M6APDG00351	Dacomitinib	CID: 11511120	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00197	M6APDG02354	Romiplostim	CID: 5329098	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00015	M6APDG01401	FENBUFEN	CID: 3335	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00080	M6APDG02023	LY2835219	CID: 46220502	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00081	M6APDG02023	LY2835219	CID: 46220502	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00202	M6APDG02982	PCO371	CID: 76283707	Phase 1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00227	M6APDG01145	TG-C	CID: 24768536	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00015	M6APDG01997	NS398	CID: 4553	Terminated	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
PT00042	M6APDG03378	Ranibizumab	.	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
PT00044	M6APDG03346	Dehydroepiandrosterone	CID: 5881	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
PT00165	M6APDG01241	Tepotinib	CID: 25171648	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
PT00146	M6APDG02542	ASP-015K	CID: 57928403	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
PT00185	M6APDG00925	5,7-Dichlorokynurenic Acid	CID: 1779	Investigative	Effects of D-cycloserine and cycloleucine, ligands for the NMDA-associated strychnine-insensitive glycine site, on brain-stimulation reward and spontaneous locomotion. Pharmacol Biochem Behav. 1990 Aug;36(4):735-8.
PT00046	M6APDG04267	RG7601	.	Phase 3	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
PT00040	M6APDG04315	ABX-0401	.	Preclinical	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
PT00140	M6APDG03484	DVD-Ig	.	Investigative	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
PT00011	M6APDG03257	BB-1101	CID: 9908389	Terminated	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
PT00138	M6APDG04113	IMD-1041	.	Phase 2	How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13.
PT00036	M6APDG03813	BI 1701963	.	Phase 1	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00205	M6APDG04036	CYT-0851	.	Phase 1/2	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG04346	TK-DLI	.	Preregistration	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00130	M6APDG03481	PU24S	.	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG00729	DEOXYCYTIDINE	CID: 13711	Approved	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00184	M6APDG00578	Dapansutrile	CID: 12714644	Phase 2	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00185	M6APDG02593	ELIPRODIL	CID: 60703	Phase 2	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00212	M6APDG03332	AZD-2014	CID: 25262792	Phase 2	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG01922	RP101	CID: 446727	Phase 2/3	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00033	M6APDG00876	Buparlisib	CID: 16654980	Phase 3	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG01305	L-NIL	CID: 2733506	Terminated	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00144	M6APDG00872	SKF-107260	CID: 164393	Terminated	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00170	M6APDG00532	SC-102	CID: 12106168	Terminated	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG01296	Heme	CID: 26945	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00015	M6APDG01296	Heme	CID: 26945	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG00753	1400W	CID: 1433	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00193	M6APDG00704	ME0328	CID: 135566764	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00022	M6APDG01397	AMP-PNP	CID: 33113	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00167	M6APDG01985	KT-5720	CID: 454202	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00147	M6APDG02597	[3H]cAMP	CID: 6076	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00241	M6APDG01929	CRA_8696	CID: 447476	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00169	M6APDG02522	JNK-IN-8	CID: 57340686	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00241	M6APDG01930	CRA_10655	CID: 447480	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00174	M6APDG00126	UK-356618	CID: 10370504	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00012	M6APDG00126	UK-356618	CID: 10370504	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00011	M6APDG00126	UK-356618	CID: 10370504	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00199	M6APDG00141	CP-775146	CID: 10410059	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00175	M6APDG03133	FUTOENONE	CID: 9819306	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00174	M6APDG01564	WAY-151693	CID: 4368	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00123	M6APDG02387	CHIR-98014	CID: 53396311	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00173	M6APDG00913	Acetate Ion	CID: 175	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00044	M6APDG01333	Calusterone	CID: 28204	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00241	M6APDG01072	Benzamidine	CID: 2332	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG01582	Nitroarginine	CID: 440005	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG00886	Cacodylate Ion	CID: 167250	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG03041	L-Homoarginine	CID: 9085	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG02541	Deoxythymidine	CID: 5789	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00133	M6APDG00654	7-Methyl-Gpppa	CID: 135415790	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00229	M6APDG00886	Cacodylate Ion	CID: 167250	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG01008	5-Nitroindazole	CID: 21501	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG01120	6-Nitroindazole	CID: 24239	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00022	M6APDG00951	Alpha-D-Mannose	CID: 185698	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00071	M6APDG01302	2-Pyridinethiol	CID: 2723698	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG02210	Ethylisothiourea	CID: 5139	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00174	M6APDG03005	3-Methylpyridine	CID: 7970	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00054	M6APDG02182	Pyrophosphate 2-	CID: 4995	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00175	M6APDG03005	3-Methylpyridine	CID: 7970	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG00810	2-Aminothiazoline	CID: 15689	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00167	M6APDG02517	ERK inhibitor III	CID: 5721470	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00170	M6APDG01320	Small molecule 34	CID: 27934	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00193	M6APDG03184	3-Methoxybenzamide	CID: 98487	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00174	M6APDG01834	Hydroxyaminovaline	CID: 444599	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00176	M6APDG02834	Methyl Mercury Ion	CID: 6860	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00057	M6APDG00626	Akt inhibitor VIII	CID: 135398501	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00175	M6APDG01834	Hydroxyaminovaline	CID: 444599	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG00962	7-nitro-1H-indazole	CID: 1893	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG00551	N,N-dimethylarginine	CID: 123831	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00176	M6APDG02955	Cysteinesulfonic Acid	CID: 72886	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00078	M6APDG01459	Indirubin-3'-monoxime	CID: 3707	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG03106	Thymidine-5'-Phosphate	CID: 9700	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00176	M6APDG00875	Cysteine Sulfenic Acid	CID: 165339	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG01855	S-Isopropyl-Isothiourea	CID: 445319	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00071	M6APDG01925	2-Aminoethanimidic Acid	CID: 4471892	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00079	M6APDG00489	2-Amino-6-Chloropyrazine	CID: 118458	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG00553	N-Omega-Hydroxy-L-Arginine	CID: 123895	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00044	M6APDG01107	Delta1-dihydrotestosterone	CID: 236666	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG01921	5-Bromothienyldeoxyuridine	CID: 446725	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG02123	S-(Dimethylarsenic)Cysteine	CID: 46936846	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG01418	1,2,4-Triazole-Carboxamidine	CID: 3387240	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00170	M6APDG03034	3-(Benzyloxy)Pyridin-2-Amine	CID: 90334	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00079	M6APDG01999	6-O-Cyclohexylmethyl Guanine	CID: 4564	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG00689	5,6-Cyclic-Tetrahydropteridine	CID: 135509077	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG00690	6s-5,6,7,8-Tetrahydrobiopterin	CID: 135509079	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00166	M6APDG02002	6-Benzyloxy-9H-purin-2-ylamine	CID: 4578	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG00948	6-(Dihydroxy-Isobutyl)-Thymine	CID: 1855	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG01931	(South)-Methanocarba-Thymidine	CID: 447628	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00071	M6APDG00013	Z-Arg-Leu-Val-Agly-Ile-Val-OMe	CID: 10033311	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00071	M6APDG02295	3-Amino-4-Oxybenzyl-2-Butanone	CID: 5289348	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00241	M6APDG00867	2-Amino-5-Hydroxy-Benzimidazole	CID: 162636	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG01853	9-Hydroxypropyladenine, S-Isomer	CID: 445210	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG01854	9-Hydroxypropyladenine, R-Isomer	CID: 445211	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00133	M6APDG00656	7-Methyl-Guanosine-5'-Triphosphate	CID: 135419182	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG00653	9-(4-Hydroxybutyl)-N2-Phenylguanine	CID: 135415618	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00170	M6APDG02330	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE	CID: 5326871	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG01577	L-2-Amino-4-(Guanidinooxy)Butyric Acid	CID: 439202	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00193	M6APDG00870	Carba-Nicotinamide-Adenine-Dinucleotide	CID: 163884	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG01959	5-Iodo-2'-Deoxyuridine-5'-Monophosphate	CID: 449489	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00079	M6APDG00202	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	CID: 10730551	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00079	M6APDG01902	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	CID: 445967	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00241	M6APDG00104	5-Methylsulfanyl-thiophene-2-carboxamidine	CID: 10313318	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00079	M6APDG03079	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	CID: 92180	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00079	M6APDG02504	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	CID: 5687	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG00463	N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane	CID: 11740154	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00147	M6APDG02122	Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate	CID: 46936216	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00150	M6APDG01926	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	CID: 447202	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00014	M6APDG01849	2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine	CID: 445109	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00079	M6APDG01936	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine	CID: 447956	Investigative	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
PT00033	M6APDG01196	PP121	CID: 24905142	Investigative	Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36.
PT00022	M6APDG04252	Rinfabate	.	Phase 2/3	Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
PT00049	M6APDG03507	ISIS 113048	.	Investigative	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
PT00214	M6APDG00054	SIS-3	CID: 10138988	Preclinical	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
PT00130	M6APDG02790	GNF-PF-67	CID: 66541	Investigative	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
PT00035	M6APDG00400	GNF-PF-3037	CID: 1160447	Investigative	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
PT00130	M6APDG00214	ZEARALANONE	CID: 108003	Investigative	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
PT00214	M6APDG02261	ELLAGIC ACID	CID: 5281855	Investigative	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
PT00025	M6APDG01905	Atropisomer 1	CID: 44605611	Investigative	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
PT00035	M6APDG01616	(E)-6-Nitrooctadec-5-enoic Acid	CID: 44220889	Investigative	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
PT00130	M6APDG03062	17-desmethoxy-17-aminogeldanamycin	CID: 91929099	Investigative	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
PT00050	M6APDG02808	NERATINIB MALEATE	CID: 67307512	Approved	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
PT00197	M6APDG03358	Becaplermin	.	Approved	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
PT00015	M6APDG01420	Flurbiprofen	CID: 3394	Approved	Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82.
PT00213	M6APDG04179	MB-12066	.	Phase 2	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
PT00044	M6APDG03528	SX-ARPC	.	Investigative	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
PT00044	M6APDG03527	ASC-JMZ1	.	Investigative	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
PT00044	M6APDG03526	Testetrol	.	Investigative	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
PT00044	M6APDG03529	Andromustine	.	Investigative	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
PT00044	M6APDG01534	EPI-001	CID: 4166922	Investigative	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
PT00035	M6APDG02770	GW-2331	CID: 657048	Investigative	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
PT00199	M6APDG02770	GW-2331	CID: 657048	Investigative	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
PT00044	M6APDG00418	CH-4933468	CID: 11632731	Investigative	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
PT00040	M6APDG03230	PKF-242-484	CID: 9886977	Investigative	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
PT00029	M6APDG01204	PF-04691502	CID: 25033539	Phase 2	The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43.
PT00046	M6APDG03340	Venetoclax	CID: 49846579	Approved	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
PT00051	M6APDG03267	HKI-272	CID: 9915743	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
PT00134	M6APDG03356	Interferon beta-1a	.	Approved	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
PT00011	M6APDG00719	Folate gamma-hydroxamic acid	CID: 136177317	Investigative	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
PT00173	M6APDG00393	3-(4-Phenylethynylbenzoyl)nonanoic acid	CID: 11581319	Investigative	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
PT00012	M6APDG00393	3-(4-Phenylethynylbenzoyl)nonanoic acid	CID: 11581319	Investigative	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
PT00011	M6APDG00393	3-(4-Phenylethynylbenzoyl)nonanoic acid	CID: 11581319	Investigative	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
PT00173	M6APDG00403	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CID: 11609208	Investigative	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
PT00011	M6APDG01757	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CID: 44411812	Investigative	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
PT00173	M6APDG00177	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	CID: 10565532	Investigative	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
PT00012	M6APDG00862	Methotrexate gamma-L-phenylalaninehydroxamic acid	CID: 16216218	Investigative	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
PT00134	M6APDG03367	PEGylated IFN beta 1-a	.	Approved	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
PT00024	M6APDG04284	Sirukumab	.	Phase 3	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
PT00051	M6APDG03353	Margetuximab	.	Approved	Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
PT00051	M6APDG03373	Trastuzumab	.	Approved	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00050	M6APDG03384	Cetuximab	.	Approved	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00050	M6APDG04227	ABT-414	.	Phase 2	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00035	M6APDG02147	Pioglitazone	CID: 4829	Approved	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00170	M6APDG00684	FR167653	CID: 135484078	Discontinued in Phase 1	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00170	M6APDG00865	PAMAPIMOD	CID: 16220188	Discontinued in Phase 2	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00051	M6APDG00337	AZD8931	CID: 11488320	Phase 2	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00035	M6APDG00531	MBX-102	CID: 12082259	Phase 2/3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00170	M6APDG00112	VX-702	CID: 10341154	Phase 2a	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00213	M6APDG00747	2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione	CID: 1403654	Investigative	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
PT00051	M6APDG03374	Pertuzumab	.	Approved	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
PT00241	M6APDG03349	Urokinase	.	Approved	Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
PT00040	M6APDG03351	Golimumab	.	Approved	Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
PT00040	M6APDG03354	Adalimumab	.	Approved	Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
PT00040	M6APDG03359	Infliximab	.	Approved	Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
PT00040	M6APDG03363	Certolizumab	.	Approved	Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
PT00040	M6APDG03365	Enbrel	.	Approved	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
PT00040	M6APDG03376	Etanercept	.	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
PT00042	M6APDG03369	Bevacizumab	.	Approved	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
PT00042	M6APDG03429	Bevasiranib	.	Discontinued in Phase 3	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
PT00042	M6APDG03377	Brolucizumab	.	Approved	Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
PT00042	M6APDG03379	Aflibercept	.	Approved	FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
PT00140	M6APDG03360	Canakinumab	.	Approved	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
PT00140	M6APDG03361	Rilonacept	.	Approved	Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86.
PT00022	M6APDG03352	Teprotumumab	.	Approved	IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
PT00022	M6APDG03381	Mecasermin	.	Approved	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
PT00196	M6APDG03350	Olaratumab	.	Approved	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG03249	RPR-101511	CID: 9903563	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG03249	RPR-101511	CID: 9903563	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00958	RPR-108514A	CID: 18770833	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00958	RPR-108514A	CID: 18770833	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00030	3-Pyridin-4-yl-quinoline	CID: 10081720	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00082	3-((E)-Styryl)-quinoline	CID: 10243001	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00030	3-Pyridin-4-yl-quinoline	CID: 10081720	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00081	3-Thiophen-3-yl-quinoline	CID: 10242258	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00083	3-(1H-Indol-3-yl)-quinoline	CID: 10243546	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00083	3-(1H-Indol-3-yl)-quinoline	CID: 10243546	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00147	6,7-Dimethoxy-3-phenyl-quinoline	CID: 10422972	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00147	6,7-Dimethoxy-3-phenyl-quinoline	CID: 10422972	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00137	6,7-Dimethoxy-3-p-tolyl-quinoline	CID: 10401378	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00670	3-Pyridin-3-yl-quinoline-6,7-diol	CID: 135453851	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00137	6,7-Dimethoxy-3-p-tolyl-quinoline	CID: 10401378	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00670	3-Pyridin-3-yl-quinoline-6,7-diol	CID: 135453851	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00135	7-Fluoro-3-thiophen-3-yl-quinoline	CID: 10398928	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00144	5-Fluoro-3-thiophen-3-yl-quinoline	CID: 10421346	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00473	7-Methoxy-3-pyridin-4-yl-quinoline	CID: 11776270	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00135	7-Fluoro-3-thiophen-3-yl-quinoline	CID: 10398928	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00473	7-Methoxy-3-pyridin-4-yl-quinoline	CID: 11776270	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00031	6-Methoxy-3-thiophen-3-yl-quinoline	CID: 10083051	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00038	3-Benzyloxy-6,7-dimethoxy-quinoline	CID: 10085863	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00109	7-Methoxy-3-thiophen-3-yl-quinoline	CID: 10331922	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00031	6-Methoxy-3-thiophen-3-yl-quinoline	CID: 10083051	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00038	3-Benzyloxy-6,7-dimethoxy-quinoline	CID: 10085863	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00109	7-Methoxy-3-thiophen-3-yl-quinoline	CID: 10331922	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00146	3-Cyclopentyl-6,7-dimethoxy-quinoline	CID: 10422592	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00146	3-Cyclopentyl-6,7-dimethoxy-quinoline	CID: 10422592	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00004	6,7-Dimethoxy-3-((E)-styryl)-quinoline	CID: 10017166	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00021	5,7-Dimethyl-3-thiophen-3-yl-quinoline	CID: 10060170	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00047	6,7-Difluoro-3-thiophen-3-yl-quinoline	CID: 10106010	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00090	6,7-Dichloro-3-thiophen-3-yl-quinoline	CID: 10265642	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00152	6,7-Dimethoxy-3-pyridin-3-yl-quinoline	CID: 10445611	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00474	4-(6,7-Dimethoxy-quinolin-3-yl)-phenol	CID: 11778467	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00004	6,7-Dimethoxy-3-((E)-styryl)-quinoline	CID: 10017166	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00021	5,7-Dimethyl-3-thiophen-3-yl-quinoline	CID: 10060170	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00047	6,7-Difluoro-3-thiophen-3-yl-quinoline	CID: 10106010	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00090	6,7-Dichloro-3-thiophen-3-yl-quinoline	CID: 10265642	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00152	6,7-Dimethoxy-3-pyridin-3-yl-quinoline	CID: 10445611	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00474	4-(6,7-Dimethoxy-quinolin-3-yl)-phenol	CID: 11778467	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG01383	5,7-Dimethoxy-3-pyridin-4-yl-quinoline	CID: 3139	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00120	5,7-Dimethoxy-3-thiophen-3-yl-quinoline	CID: 10355832	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00153	6,7-Dimethoxy-3-phenylethynyl-quinoline	CID: 10446889	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00160	6,7-Dimethoxy-3-thiophen-2-yl-quinoline	CID: 10468421	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00120	5,7-Dimethoxy-3-thiophen-3-yl-quinoline	CID: 10355832	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00153	6,7-Dimethoxy-3-phenylethynyl-quinoline	CID: 10446889	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00160	6,7-Dimethoxy-3-thiophen-2-yl-quinoline	CID: 10468421	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG03310	3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline	CID: 9972296	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG03317	5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline	CID: 9994707	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG03310	3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline	CID: 9972296	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00033	3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline	CID: 10083699	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00149	Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine	CID: 10424517	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00149	Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine	CID: 10424517	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00017	3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline	CID: 10039460	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00139	3-Cyclohexylethynyl-6,7-dimethoxy-quinoline	CID: 10402251	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00017	3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline	CID: 10039460	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00139	3-Cyclohexylethynyl-6,7-dimethoxy-quinoline	CID: 10402251	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG03309	3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline	CID: 9971060	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00032	7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline	CID: 10083695	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00037	6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline	CID: 10085862	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00084	4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid	CID: 10244811	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00154	6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline	CID: 10447210	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG03222	6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline	CID: 9882618	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00032	7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline	CID: 10083695	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00084	4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid	CID: 10244811	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00154	6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline	CID: 10447210	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG03222	6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline	CID: 9882618	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00025	3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline	CID: 10065445	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00140	3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline	CID: 10402592	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00025	3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline	CID: 10065445	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00140	3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline	CID: 10402592	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00111	3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline	CID: 10336427	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00196	M6APDG00475	5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one	CID: 11778521	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00111	3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline	CID: 10336427	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00197	M6APDG00475	5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one	CID: 11778521	Investigative	A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
PT00020	M6APDG03383	ISIS 1570	.	Approved	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025396)
PT00050	M6APDG03362	HEGF	.	Approved	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
PT00051	M6APDG00785	Merimepodib	CID: 153241	Approved	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
PT00050	M6APDG03364	Panitumumab	.	Approved	Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
PT00050	M6APDG03385	Necitumumab	.	Approved	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
PT00051	M6APDG02904	Masoprocol	CID: 71398	Approved	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
PT00117	M6APDG03355	Follitropin beta	.	Approved	Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004;3(3):161-71.
PT00117	M6APDG03357	Menotropins	.	Approved	Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any diffe... Fertil Steril. 2009 Apr;91(4 Suppl):1522-5.
PT00021	M6APDG03366	Emapalumab	.	Approved	A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
PT00089	M6APDG03371	Recombinant human endostatin	.	Approved	Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148.
PT00032	M6APDG03368	RG-7446	.	Approved	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
PT00032	M6APDG03386	Bavencio	.	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
PT00032	M6APDG03387	Atezolizumab	.	Approved	PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
PT00173	M6APDG03398	V85546	.	Discontinued in Phase 1	Clinical pipeline report, company report or official report of AstraZeneca (2009).
PT00051	M6APDG04199	Her2-targeted autologous T-cell therapy	.	Phase 2	Clinical pipeline report, company report or official report of AstraZeneca (2009).
PT00040	M6APDG02415	Thalidomide	CID: 5426	Approved	Clinical pipeline report, company report or official report of AstraZeneca (2009).
PT00029	M6APDG02424	TAFA-93	CID: 54601137	Discontinued in Phase 1	Clinical pipeline report, company report or official report of AstraZeneca (2009).
PT00130	M6APDG03173	CCT-018159	CID: 984170	Preclinical	Clinical pipeline report, company report or official report of AstraZeneca (2009).
PT00044	M6APDG03390	GSK2849466	.	Discontinued in Phase 1	Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 1998 May 1;55(9):1427-33.
PT00044	M6APDG03399	Opterone	.	Discontinued in Phase 1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036899)
PT00040	M6APDG03400	ALS-00T2-0501	.	Discontinued in Phase 1	IND Filed for AME-527, Monoclonal Antibody That Is a Potential Treatment for Rheumatoid Arthritis. P&T Community. 2015.
PT00022	M6APDG03394	Figitumumab	.	Discontinued in Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00113	M6APDG03806	BI-853520	.	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00119	M6APDG03807	OTSA-101-DTPA-90Y	.	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00154	M6APDG03808	TP-1454	.	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00043	M6APDG03809	LY2780301	.	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00198	M6APDG03810	BLY719	.	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00134	M6APDG04117	AZ-01, PEGylated interferon-beta	.	Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00024	M6APDG04118	YSIL6	.	Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00024	M6APDG04119	CDP-6038	.	Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00050	M6APDG04250	Indium-111	.	Phase 2/3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00031	M6APDG04260	Contusugene ladenovec	.	Phase 3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00081	M6APDG04307	INOC-005	.	Preclinical	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00080	M6APDG00384	Apremilast	CID: 11561674	Approved	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00081	M6APDG00384	Apremilast	CID: 11561674	Approved	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00035	M6APDG03333	ADD-3878	CID: 2750	Discontinued	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00035	M6APDG02490	GSK-677954	CID: 56603715	Discontinued in Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00162	M6APDG02836	PT-14	CID: 6875	Discontinued in Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00199	M6APDG03279	BM-17.0744	CID: 9929731	Discontinued in Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00033	M6APDG02507	GSK2636771	CID: 56949517	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00051	M6APDG01544	ARRY-380	CID: 42598643	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00113	M6APDG00454	PF-562271	CID: 11713159	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00031	M6APDG02389	SAR-405838	CID: 53476877	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00050	M6APDG01134	AST-1306	CID: 24739943	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00043	M6APDG03030	M2698	CID: 89808643	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00080	M6APDG02812	P1446A-05	CID: 67409219	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00016	M6APDG00211	GSK618334	CID: 107969	Phase 1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00051	M6APDG02201	Tarloxotinib	CID: 51038316	Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00165	M6APDG01904	LY2801653	CID: 44603533	Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00035	M6APDG03232	Naveglitazar	CID: 9888484	Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00050	M6APDG00783	VATALANIB	CID: 151194	Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00199	M6APDG03232	Naveglitazar	CID: 9888484	Phase 2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00040	M6APDG00540	Celastrol	CID: 122724	Preclinical	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00199	M6APDG02903	Romazarit	CID: 71321	Preclinical	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
PT00196	M6APDG03389	CEP-2563	.	Discontinued in Phase 1	Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3. Lipids. 1987 Nov;22(11):884-90.
PT00035	M6APDG03396	DS-6930	.	Discontinued in Phase 1	Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.J Pharmacol Sci.2008 Sep;108(1):40-8.
PT00199	M6APDG03397	MP-136	.	Discontinued in Phase 1	Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.J Pharmacol Sci.2008 Sep;108(1):40-8.
PT00197	M6APDG03389	CEP-2563	.	Discontinued in Phase 1	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
PT00013	M6APDG03510	EX5	.	Investigative	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
PT00197	M6APDG02591	1-Phenyl-1H-benzoimidazole	CID: 606669	Investigative	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
PT00023	M6APDG00433	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	CID: 11658882	Investigative	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
PT00015	M6APDG03395	GR-253035	.	Discontinued in Phase 1	Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008 Jan;8(1):73-90.
PT00015	M6APDG03490	C-myb	.	Investigative	Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008 Jan;8(1):73-90.
PT00199	M6APDG03393	DRF 10945	.	Discontinued in Phase 1	A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent... Mol Endocrinol. 2005 Jun;19(6):1593-605.
PT00199	M6APDG03401	LG-101280	.	Discontinued in Phase 1	CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection.
PT00035	M6APDG04338	MC-3002	.	Preclinical	CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection.
PT00199	M6APDG03402	AR-H049020	.	Discontinued in Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
PT00199	M6APDG00782	KRP-297	CID: 151183	Discontinued in Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
PT00199	M6APDG00554	pristanic acid	CID: 123929	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
PT00208	M6APDG03403	CDP-1050	.	Discontinued in Phase 1	The Ryanodine Receptor Stabilizer S44121 / Arm036 Improves Peripheral and Respiratory Muscle Function in a Mouse Model of Heart Failure. Circulation. 2014; 130: A13726.
PT00208	M6APDG01630	(O10eq)-guanidino acetylryanodine	CID: 44275894	Investigative	The Ryanodine Receptor Stabilizer S44121 / Arm036 Improves Peripheral and Respiratory Muscle Function in a Mouse Model of Heart Failure. Circulation. 2014; 130: A13726.
PT00092	M6APDG03391	Garnocestim	.	Discontinued in Phase 1	Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha. Clin Cancer Res. 2002 Dec;8(12):3955-60.
PT00092	M6APDG03392	SURADISTA	.	Discontinued in Phase 1	Comparative evaluation of CC chemokine-induced migration of murine CD8alpha+ and CD8alpha- dendritic cells and their in vivo trafficking. J Leukoc Biol. 2004 Feb;75(2):275-85.
PT00040	M6APDG03404	AME-527	.	Discontinued in Phase 1/2	Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. PLoS One. 2014; 9(12): e113465.
PT00040	M6APDG03582	DOM-0215	.	Investigative	Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. PLoS One. 2014; 9(12): e113465.
PT00040	M6APDG03405	CYT-007-TNFQb	.	Discontinued in Phase 1/2	CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
PT00021	M6APDG04340	VPM-4-001	.	Preclinical	CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
PT00140	M6APDG03406	CDP-484	.	Discontinued in Phase 1/2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
PT00048	M6APDG03953	ION 224	.	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
PT00044	M6APDG03407	GW-275919	.	Discontinued in Phase 2	Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
PT00044	M6APDG03791	PS-178990	.	Phase 1	Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
PT00044	M6APDG04031	ARV-471	.	Phase 1/2	Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
PT00044	M6APDG00893	LGD2941	CID: 16750192	Discontinued in Phase 1	Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
PT00044	M6APDG03418	Testosterone glucoside	.	Discontinued in Phase 2	AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27.
PT00044	M6APDG03420	NP-619	.	Discontinued in Phase 2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010426)
PT00051	M6APDG03421	Her-2-Bi-armed ATC	.	Discontinued in Phase 2	Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins (Basel) 2011 July; 3(7): 848-883.
PT00031	M6APDG03410	INGN-234	.	Discontinued in Phase 2	Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41.
PT00040	M6APDG03422	ISIS 104838	.	Discontinued in Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
PT00114	M6APDG03577	MT-061	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
PT00114	M6APDG03579	FAS-031	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
PT00114	M6APDG03578	Anti-Fas mabs	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
PT00040	M6APDG03413	CRx-191	.	Discontinued in Phase 2	AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel ... J Pharmacol Exp Ther. 2005 May;313(2):492-501.
PT00022	M6APDG03423	AVE-1642	.	Discontinued in Phase 2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031207)
PT00172	M6APDG03412	XL784	.	Discontinued in Phase 2	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
PT00012	M6APDG04310	DX-2802	.	Preclinical	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
PT00011	M6APDG04311	RO-26-2853	.	Preclinical	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
PT00175	M6APDG03185	PG-530742	CID: 9848869	Discontinued in Phase 2	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
PT00174	M6APDG01918	MMI270	CID: 446504	Investigative	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
PT00035	M6APDG03416	AVE-0847	.	Discontinued in Phase 2	Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
PT00199	M6APDG03416	AVE-0847	.	Discontinued in Phase 2	Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
PT00035	M6APDG03424	Reglixane	.	Discontinued in Phase 2	DOI: 10.1038/scibx.2012.669
PT00199	M6APDG03424	Reglixane	.	Discontinued in Phase 2	DOI: 10.1038/scibx.2012.669
PT00197	M6APDG03415	CDP-860	.	Discontinued in Phase 2	Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51. 
PT00050	M6APDG03417	RG7160	.	Discontinued in Phase 2	Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats.J Pharmacol Exp Ther.2013 Jun;345(3):393-403.
PT00015	M6APDG03408	RQ-00317076	.	Discontinued in Phase 2	Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death. Br J Pharmacol. 2001 Oct;134(3):673-81.
PT00015	M6APDG03409	CRx-401	.	Discontinued in Phase 2	4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a ... J Med Chem. 2002 Mar 28;45(7):1511-7.
PT00021	M6APDG03411	TG-1042	.	Discontinued in Phase 2	T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11.
PT00021	M6APDG03413	CRx-191	.	Discontinued in Phase 2	Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
PT00021	M6APDG03414	Fontolizumab	.	Discontinued in Phase 2	Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8.
PT00130	M6APDG03430	HBP-347	.	Discontinued in Phase 3	Clinical pipeline report, company report or official report of Debiopharm (2011).
PT00040	M6APDG03427	Segard	.	Discontinued in Phase 3	CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo... Aliment Pharmacol Ther. 2006 Mar 1;23(5):617-28.
PT00040	M6APDG03431	CDP571	.	Discontinued in Phase 3	US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
PT00150	M6APDG03425	Sitimagene ceradenovec	.	Discontinued in Phase 3	Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41.
PT00039	M6APDG03432	Ranagengliotucel-T	.	Discontinued in Phase 3	National Cancer Institute Drug Dictionary (drug id 590662).
PT00008	M6APDG03428	Neutralase	.	Discontinued in Phase 3	PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011 Feb 15;104(4):635-42.
PT00015	M6APDG03426	PMI-001	.	Discontinued in Phase 3	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
PT00015	M6APDG00914	SB 203580	CID: 176155	Terminated	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
PT00015	M6APDG01960	Nimesulide	CID: 4495	Terminated	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
PT00015	M6APDG01824	1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea	CID: 44447102	Investigative	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
PT00028	M6APDG03848	DS-3032	.	Phase 1	Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741.
PT00028	M6APDG03852	RG7775	.	Phase 1	Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36. 
PT00028	M6APDG03892	BI 907828	.	Phase 1	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
PT00143	M6APDG03853	OS2966	.	Phase 1	Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.
PT00143	M6APDG03887	JSM 6427	.	Phase 1	Convection-Enhanced Delivery of a First-in-Class Anti-beta1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics. 2020 Dec 30;13(1):40.
PT00134	M6APDG03802	ARX-424	.	Phase 1	Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65.
PT00134	M6APDG03893	Gene therapy, IFN-b	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00040	M6APDG03920	PF-05230905	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00146	M6APDG03928	SNA-125	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00146	M6APDG04209	ATI-501	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00092	M6APDG02698	Plerixafor	CID: 65015	Approved	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00227	M6APDG01520	Pirfenidone	CID: 40632	Approved	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00195	M6APDG00380	AdPEDR	CID: 11557063	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00181	M6APDG00053	OT-551	CID: 10131000	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00146	M6APDG02349	AG490	CID: 5328779	Terminated	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00173	M6APDG03867	FP-025	.	Phase 1	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
PT00174	M6APDG03347	Curcumin	CID: 969516	Phase 3	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
PT00172	M6APDG00585	SC-44463	CID: 128564	Terminated	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
PT00012	M6APDG00585	SC-44463	CID: 128564	Terminated	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
PT00011	M6APDG00585	SC-44463	CID: 128564	Terminated	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
PT00175	M6APDG00585	SC-44463	CID: 128564	Terminated	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
PT00173	M6APDG03800	Neovastat	.	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
PT00173	M6APDG03540	PUP-1	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
PT00173	M6APDG03541	WAY-644	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
PT00173	M6APDG00078	RXP-470	CID: 102258832	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
PT00072	M6APDG03833	FT-7051	.	Phase 1	Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14309-14.
PT00014	M6APDG03855	Autologous cell based gene therapy	.	Phase 1	Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.
PT00193	M6APDG03885	NMS-03305293	.	Phase 1	AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
PT00121	M6APDG03894	Unacylated ghrelin	.	Phase 1	National Cancer Institute Drug Dictionary (drug id 741867).
PT00025	M6APDG03854	Peginterferon beta	.	Phase 1	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
PT00025	M6APDG01228	Ruxolitinib	CID: 25126798	Approved	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
PT00146	M6APDG00484	PF-06651600	CID: 118115473	Phase 2/3	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
PT00025	M6APDG02349	AG490	CID: 5328779	Terminated	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
PT00044	M6APDG03851	EPI-7386	.	Phase 1	Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J Cancer. 2014 Jan 21;5(2):133-42.
PT00044	M6APDG03899	CC-94676	.	Phase 1	Clinical pipeline report, company report or official report of ESSA Pharma.
PT00044	M6APDG04028	TAS3681	.	Phase 1	ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
PT00041	M6APDG03900	APO-010	.	Phase 1	ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. BMC Musculoskeletal Disorders 2010,11:221.
PT00051	M6APDG03795	TrasGEX	.	Phase 1	Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82.
PT00051	M6APDG03796	CAR-T Cells targeting HER2	.	Phase 1	Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res.2000 Aug;6(8):3334-41.
PT00051	M6APDG03847	Zemab	.	Phase 1	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013 Jul;24(7):1740-8.
PT00051	M6APDG03859	Cipatinib	.	Phase 1	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
PT00051	M6APDG03863	HER2p63-71 peptide vaccine	.	Phase 1	Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res. 2015 Apr 14;5:24.
PT00051	M6APDG03880	GBR1302	.	Phase 1	A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355.
PT00051	M6APDG03901	MVA HER-2 AutoVac	.	Phase 1	Clinical pipeline report, company report or official report of Takeda (2009).
PT00045	M6APDG01135	MK-5108	CID: 24748204	Phase 1	Clinical pipeline report, company report or official report of Takeda (2009).
PT00051	M6APDG03902	Recombinant human Erbb3 fragment therapeutic tumor vaccine	.	Phase 1	WO patent application no. 2014,1441,21, Classification and actionability indices for lung cancer.
PT00051	M6APDG03903	VM-206	.	Phase 1	J Clin Oncol 32:5s, 2014 (suppl; abstr 2515).
PT00051	M6APDG03904	MM-302	.	Phase 1	ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice
PT00051	M6APDG03906	MEDI4276	.	Phase 1	Clinical pipeline report, company report or official report of Mustang Bio.
PT00051	M6APDG03907	NJH395	.	Phase 1	Clinical pipeline report, company report or official report of Adagene.
PT00051	M6APDG03908	AIP-303	.	Phase 1	Clinical pipeline report, company report or official report of Beijing Mabworks Biotech.
PT00051	M6APDG03909	MBS301	.	Phase 1	Clinical pipeline report, company report or official report of GeneQuantum Healthcare.
PT00051	M6APDG03910	GQ1001	.	Phase 1	Clinical pipeline report, company report or official report of Molecular Templates.
PT00051	M6APDG03911	MT-5111	.	Phase 1	Clinical pipeline report, company report or official report of Zymeworks.
PT00051	M6APDG03912	ZW49	.	Phase 1	National Cancer Institute Drug Dictionary (drug name BAY2701439).
PT00051	M6APDG03913	DZD1516	.	Phase 1	Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals.
PT00051	M6APDG03914	M802	.	Phase 1	Clinical pipeline report, company report or official report of Silverback Therapeutics.
PT00051	M6APDG03915	SBT6050	.	Phase 1	Clinical pipeline report, company report or official report of Shionogi (2011).
PT00050	M6APDG03972	MCLA-158	.	Phase 1	Clinical pipeline report, company report or official report of Shionogi (2011).
PT00051	M6APDG04018	HER2-specific CAR T cell	.	Phase 1	ClinicalTrials.gov (NCT02442297) T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
PT00051	M6APDG04022	HER2-specific T cells	.	Phase 1	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
PT00051	M6APDG03816	JNJ-26483327	.	Phase 1	ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
PT00051	M6APDG04025	CAR-T cells targeting HER2	.	Phase 1	ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases
PT00051	M6APDG04026	MB-103	.	Phase 1	ClinicalTrials.gov (NCT03696771) Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer. U.S. National Institutes of Health.
PT00051	M6APDG04030	BAY 2701439	.	Phase 1	ClinicalTrials.gov (NCT04509596) DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer. U.S. National Institutes of Health.
PT00213	M6APDG03865	SRT2379	.	Phase 1	The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.
PT00113	M6APDG03849	IN10018	.	Phase 1	Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.
PT00031	M6APDG03857	ONYX-015	.	Phase 1	SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65.
PT00031	M6APDG03916	Dendritic cell vaccine	.	Phase 1	National Cancer Institute Drug Dictionary (drug id 761551).
PT00130	M6APDG03799	PU-AD	.	Phase 1	Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
PT00130	M6APDG01070	KW-2478	CID: 23116322	Phase 2	Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
PT00130	M6APDG03821	RTA-901	.	Phase 1	SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
PT00040	M6APDG03824	INB03	.	Phase 1	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
PT00146	M6APDG01905	Atropisomer 1	CID: 44605611	Investigative	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
PT00040	M6APDG03918	PMI-005	.	Phase 1	Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 December 15; 16(24): 6139-6149.
PT00040	M6APDG03919	CYT-609	.	Phase 1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033173)
PT00040	M6APDG03923	ABBV-257	.	Phase 1	Clinical pipeline report, company report or official report of INmune Bio.
PT00042	M6APDG03924	SFLT-01	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG03967	PF-05230907	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG03968	SYN004	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00135	M6APDG03973	BI-836845	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00032	M6APDG03990	RG6084	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00092	M6APDG03992	BMS-936564	.	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00051	M6APDG04062	HER-2-targeting CAR T Cells	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00034	M6APDG04081	TKM-PLK1	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG04082	EGFR CART	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00050	M6APDG04076	Sym015	.	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00136	M6APDG04131	Xentuzumab	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00032	M6APDG04241	M7824	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00105	M6APDG03595	ISIS 114232	.	Investigative	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00165	M6APDG02423	Altiratinib	CID: 54576299	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00032	M6APDG00861	CA-170	CID: 16212596	Phase 1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00012	M6APDG00535	BLZ-100	CID: 121488172	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00165	M6APDG02173	CMX-2043	CID: 49802864	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00092	M6APDG03060	BL-8040	CID: 91865076	Phase 3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00042	M6APDG03926	ABI-011	.	Phase 1	Clinical pipeline report, company report or official report of Neuronova.
PT00160	M6APDG03927	MMI-0100	.	Phase 1	National Cancer Institute Drug Dictionary (drug id 577812).
PT00168	M6APDG03929	VAN-10-4-eluting stent	.	Phase 1	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
PT00167	M6APDG03929	VAN-10-4-eluting stent	.	Phase 1	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
PT00168	M6APDG03930	ASN007	.	Phase 1	National Cancer Institute Drug Dictionary (drug name JSI1187).
PT00167	M6APDG00534	LY3214996	CID: 121408882	Phase 1	National Cancer Institute Drug Dictionary (drug name JSI1187).
PT00168	M6APDG03931	JSI-1187	.	Phase 1	Clinical pipeline report, company report or official report of HaiHe Biopharma.
PT00167	M6APDG03931	JSI-1187	.	Phase 1	Clinical pipeline report, company report or official report of HaiHe Biopharma.
PT00009	M6APDG03843	EDP-322	.	Phase 1	Mechanisms of tetrandrine and 5-bromotetrandrine in reversing multidrug resistance may relate to down-regulation of multidrug resistance associated protein 7 expression. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):558-63.
PT00020	M6APDG03933	AIC100	.	Phase 1	National Cancer Institute Drug Dictionary (drug id 561410).
PT00038	M6APDG03823	DSP-0337	.	Phase 1	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
PT00046	M6APDG01199	ABT-263	CID: 24978538	Phase 3	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
PT00092	M6APDG03059	Balixafortide	CID: 91864511	Phase 3	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
PT00022	M6APDG00904	Fucose	CID: 17106	Investigative	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
PT00022	M6APDG03150	NVP-ADW742	CID: 9825149	Investigative	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
PT00038	M6APDG03861	TAK-114	.	Phase 1	Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005.
PT00038	M6APDG03878	OPB-111077	.	Phase 1	Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289.
PT00038	M6APDG03934	OPB-51602	.	Phase 1	Clinical pipeline report, company report or official report of Moleculin Biotech.
PT00095	M6APDG03935	MK-4621	.	Phase 1	Clinical pipeline report, company report or official report of CureVac.
PT00095	M6APDG03936	CV8102	.	Phase 1	Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200)
PT00247	M6APDG03937	GSK-2130579A	.	Phase 1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)
PT00247	M6APDG03938	INNO-305	.	Phase 1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033385)
PT00150	M6APDG03798	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	.	Phase 1	Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7.
PT00093	M6APDG03793	NG-641	.	Phase 1	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.
PT00093	M6APDG04163	MDX-1100	.	Phase 2	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.
PT00157	M6APDG03820	IO-202	.	Phase 1	WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res. 2008 Jun 1;68(11):4377-83.
PT00046	M6APDG03805	Pc4	.	Phase 1	Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55.
PT00046	M6APDG03882	BGB-11417	.	Phase 1	A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res. 2020 Sep 1;28(4):331-344.
PT00046	M6APDG03883	LP-108	.	Phase 1	Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020 May 21;9(5):1287.
PT00046	M6APDG03940	BCL201	.	Phase 1	National Cancer Institute Drug Dictionary (drug name LP-108).
PT00046	M6APDG03941	VOB560	.	Phase 1	Clinical pipeline report, company report or official report of BeiGene.
PT00024	M6APDG03838	C326	.	Phase 1	Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807.
PT00024	M6APDG03942	MEDI5117	.	Phase 1	A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma
PT00024	M6APDG03944	Gerilimzumab	.	Phase 1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380)
PT00226	M6APDG03815	ABBV-CX-2029	.	Phase 1	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
PT00201	M6APDG03801	Anti-CD133-CAR vector-transduced T cells	.	Phase 1	Inhibition of lipopolysaccharide-induced interferon regulatory factor 3 activation and protection from septic shock by hydroxystilbenes. Shock. 2004 May;21(5):470-5.
PT00201	M6APDG04019	ICT-121	.	Phase 1	ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
PT00120	M6APDG03829	OMP-18R5	.	Phase 1	Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci. 2010 Jul;99(7):3100-21.
PT00165	M6APDG03840	ABT-700	.	Phase 1	Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47.
PT00165	M6APDG03881	TR1801-ADC	.	Phase 1	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
PT00239	M6APDG03830	INCB81776	.	Phase 1	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
PT00165	M6APDG03945	Autologous T Cells Expressing MET scFv CAR	.	Phase 1	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
PT00165	M6APDG03946	REGN5093	.	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG04216	LY-2875358	.	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG04277	Amivantamab	.	Phase 3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03613	TP-801	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03618	LA-480	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03615	RP-1040	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03616	DP-3590	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03619	PRS-110	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03623	ALD-805	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03621	APS-3010	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03614	mab 224G11	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03624	HuMax-cMet	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03617	BAY-85-3474	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03620	Anti-cMET mab	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03622	CMET Avimer polypeptides	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG00341	Tivantinib	CID: 11494412	Phase 3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG00428	AM7	CID: 11650194	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG00157	PHA-665752	CID: 10461815	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
PT00165	M6APDG03947	Hepapoietin	.	Phase 1	J Clin Oncol 32:5s, 2014 (suppl; abstr 2507).
PT00165	M6APDG03948	LY3164530	.	Phase 1	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
PT00231	M6APDG01143	ARRY-614	CID: 24765037	Discontinued in Phase 1	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
PT00165	M6APDG03950	CBT-101	.	Phase 1	Clinical pipeline report, company report or official report of Turning Point Therapeutics.
PT00165	M6APDG03951	BPI-9016 M	.	Phase 1	Clinical pipeline report, company report or official report of Exelixis.
PT00140	M6APDG03954	CYT-013-IL1bQb	.	Phase 1	A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176.
PT00204	M6APDG03792	Iomab-ACT	.	Phase 1	Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31.
PT00204	M6APDG03812	LM-CD45	.	Phase 1	CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul;91(7):886-94.
PT00204	M6APDG03955	Anti-CD45 mabs	.	Phase 1	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
PT00044	M6APDG03956	ISIS-AR	.	Phase 1	2011 Pipeline of Santaris Pharma.
PT00045	M6APDG03827	HPP-607	.	Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00080	M6APDG04039	GLR2007	.	Phase 1/2	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00080	M6APDG04307	INOC-005	.	Preclinical	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00078	M6APDG02566	ZK 304709	CID: 59733314	Discontinued in Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00078	M6APDG02877	R547	CID: 6918852	Discontinued in Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00079	M6APDG02566	ZK 304709	CID: 59733314	Discontinued in Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00079	M6APDG02877	R547	CID: 6918852	Discontinued in Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00080	M6APDG02566	ZK 304709	CID: 59733314	Discontinued in Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00080	M6APDG02877	R547	CID: 6918852	Discontinued in Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00078	M6APDG00278	RGB-286638	CID: 11285001	Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00078	M6APDG02013	PHA-793887	CID: 46191454	Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00079	M6APDG00278	RGB-286638	CID: 11285001	Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00080	M6APDG00278	RGB-286638	CID: 11285001	Phase 1	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00079	M6APDG00890	TG02	CID: 16739650	Phase 1/2	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00078	M6APDG01092	P276-00	CID: 23643975	Phase 2	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00078	M6APDG01953	L-751250	CID: 448991	Preclinical	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00079	M6APDG01953	L-751250	CID: 448991	Preclinical	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00045	M6APDG00210	Deguelin	CID: 107935	Investigative	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
PT00045	M6APDG03842	GSK1070916A	.	Phase 1	Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Invest New Drugs.2013 Apr;31(2):370-80.
PT00045	M6APDG03858	BI-811283	.	Phase 1	A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):409-22.
PT00045	M6APDG03958	BI-831266	.	Phase 1	doi: 10.1158/1535-7163.TARG-13-B281
PT00046	M6APDG03860	BP1002	.	Phase 1	Combination of novel imidazopyridazine mps-1 kinase inhibitors and bcl-2 family protein inhibitors. ACS Med Chem Lett. 2014 Jul 30;6(1):7-8.
PT00022	M6APDG03797	BIIB 022	.	Phase 1	A primary adrenal steroid, 11beta-hydroxyandrostenedione, has an osteotropic effect and little androgenic activity. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):203-11.
PT00022	M6APDG03814	RG-7010	.	Phase 1	The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg. 2007 Jul;46(1):108-15.
PT00022	M6APDG03959	HF-0299	.	Phase 1	Clinical pipeline report, company report or official report of Fusion Pharmaceuticals.
PT00022	M6APDG03960	FPI-1434	.	Phase 1	Clinical pipeline report, company report or official report of Amgen (2009).
PT00036	M6APDG03961	AZD4785	.	Phase 1	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
PT00228	M6APDG03962	TGF-BR2 mab	.	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2616).
PT00012	M6APDG03800	Neovastat	.	Phase 1	National Cancer Institute Drug Dictionary (drug id 747683).
PT00195	M6APDG03804	PEDF gene therapy	.	Phase 1	Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35.
PT00018	M6APDG03803	EZN-2968	.	Phase 1	2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squam... Clin Cancer Res. 2004 Dec 15;10(24):8665-73.
PT00164	M6APDG03830	INCB81776	.	Phase 1	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
PT00165	M6APDG04041	ChronSeal	.	Phase 1/2	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
PT00197	M6APDG01144	TAK-593	CID: 24767976	Phase 1	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
PT00164	M6APDG03888	PF-07265807	.	Phase 1	A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
PT00239	M6APDG03888	PF-07265807	.	Phase 1	A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
PT00164	M6APDG03963	ONO-7475	.	Phase 1	National Cancer Institute Drug Dictionary (drug name RXDX106).
PT00239	M6APDG03986	AVB-S6-500	.	Phase 1	National Cancer Institute Drug Dictionary (drug name RXDX106).
PT00165	M6APDG00734	TPX-0022	CID: 137455315	Phase 1	National Cancer Institute Drug Dictionary (drug name RXDX106).
PT00091	M6APDG03793	NG-641	.	Phase 1	The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41.
PT00098	M6APDG03825	PF-04840082	.	Phase 1	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 9;114(2):371-9.
PT00049	M6APDG03828	ARQ-171	.	Phase 1	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
PT00109	M6APDG04137	Ifabotuzumab	.	Phase 2	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
PT00164	M6APDG03039	ONO-7475	CID: 90645873	Phase 1/2	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
PT00211	M6APDG02902	(R)-PFI-2	CID: 71300326	Preclinical	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
PT00108	M6APDG03964	DS-8895	.	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822).
PT00108	M6APDG04020	MEDI-547	.	Phase 1	ClinicalTrials.gov (NCT02575261) CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
PT00035	M6APDG03831	DSP-8658	.	Phase 1	Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16.
PT00199	M6APDG03832	CDT-fenofibrate	.	Phase 1	Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16.
PT00050	M6APDG03839	AMG 595	.	Phase 1	AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487.
PT00050	M6APDG03864	MR1-1	.	Phase 1	AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24.
PT00050	M6APDG03871	AP32788	.	Phase 1	TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.
PT00050	M6APDG03877	BCA101	.	Phase 1	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
PT00050	M6APDG03965	IMGN289	.	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG04107	S-222611	.	Phase 1b	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03654	EDP-13	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03657	MT-062	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03662	MDP-01	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03663	AFM-21	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03649	AL-6802	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03652	ARX-AHD	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03653	RX-1792	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03655	GI-3000	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03660	SYM-011	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03648	Bmab-200	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03656	AGT-2000	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03659	FHT-2107	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03647	IPS-01003	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03650	HM-61713B	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03651	TGF alpha	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03661	mabionHER2	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03664	Anti-EGFR mab	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03658	Anti-EGFR humanized mabs	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03646	LA22-radioimmunoconjugates	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG00296	SKI-758	CID: 11341869	Approved	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG02520	CO-1686	CID: 57335384	Phase 3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG02951	EGF816	CID: 72703790	Phase 3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG00990	AG 9	CID: 2063	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG01906	WZ-3146	CID: 44607360	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03281	RM-6427	CID: 9931101	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG00845	NRC-2694	CID: 16129168	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG02557	Epitinib	CID: 59142777	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
PT00050	M6APDG03859	Cipatinib	.	Phase 1	Company report (Biooncology)
PT00050	M6APDG03948	LY3164530	.	Phase 1	National Cancer Institute Drug Dictionary (drug id 596693).
PT00051	M6APDG01137	CUDC-101	CID: 24756910	Phase 1	National Cancer Institute Drug Dictionary (drug id 596693).
PT00118	M6APDG01076	CEP-5104	CID: 23378546	Investigative	National Cancer Institute Drug Dictionary (drug id 596693).
PT00050	M6APDG03970	CLN-081	.	Phase 1	Clinical pipeline report, company report or official report of SystImmune.
PT00050	M6APDG03971	D2C7	.	Phase 1	Clinical pipeline report, company report or official report of Merus.
PT00051	M6APDG04066	ISB 1302	.	Phase 1/2	Clinical pipeline report, company report or official report of Merus.
PT00050	M6APDG03816	JNJ-26483327	.	Phase 1	ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
PT00050	M6APDG04024	Anti-EGFR CAR T	.	Phase 1	ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
PT00050	M6APDG04029	SI-B001	.	Phase 1	ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
PT00135	M6APDG03850	MEDI-573	.	Phase 1	Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.Mol Cancer Ther.2014 Feb;13(2):399-409.
PT00015	M6APDG03818	CA102N	.	Phase 1	Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and ... Clin Pharmacol Ther. 2008 Jun;83(6):857-66.
PT00057	M6APDG03974	ARQ 751	.	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
PT00057	M6APDG04230	RX-0201	.	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
PT00057	M6APDG03673	VLI-27	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
PT00057	M6APDG03674	NU-1001-41	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
PT00057	M6APDG01147	LD-101	CID: 24773090	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
PT00057	M6APDG02863	CI-1040	CID: 6918454	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
PT00011	M6APDG03800	Neovastat	.	Phase 1	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
PT00172	M6APDG00164	L-696418	CID: 10478364	Terminated	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
PT00011	M6APDG00164	L-696418	CID: 10478364	Terminated	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
PT00175	M6APDG03045	CM-352	CID: 91623362	Investigative	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
PT00132	M6APDG03876	LY3410738	.	Phase 1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
PT00044	M6APDG00735	Ethylestrenol	CID: 13765	Approved	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
PT00021	M6APDG01847	Fumaric acid	CID: 444972	Phase 3	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
PT00079	M6APDG03868	PF-07104091	.	Phase 1	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
PT00080	M6APDG03869	PF-07220060	.	Phase 1	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
PT00081	M6APDG03835	G1T28-1	.	Phase 1	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
PT00043	M6APDG03837	LYS-6KAKT1	.	Phase 1	Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53.
PT00029	M6APDG03856	DS-3078	.	Phase 1	Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7.
PT00029	M6APDG03975	BI 860585	.	Phase 1	A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results, Mol Cancer Ther November,2013, 12, C173.
PT00029	M6APDG03976	DS-7423	.	Phase 1	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials
PT00029	M6APDG03977	LAM-001	.	Phase 1	National Cancer Institute Drug Dictionary (drug id 728650).
PT00099	M6APDG03978	AMG 119	.	Phase 1	Clinical pipeline report, company report or official report of Amgen.
PT00099	M6APDG03979	AMG 757	.	Phase 1	Clinical pipeline report, company report or official report of Harpoon Therapeutics.
PT00124	M6APDG03889	INCAGN2390	.	Phase 1	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
PT00032	M6APDG03890	TAK-252	.	Phase 1	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
PT00124	M6APDG03980	LY3321367	.	Phase 1	Clinical pipeline report, company report or official report of Symphogen.
PT00124	M6APDG03981	Sym023	.	Phase 1	Clinical pipeline report, company report or official report of Agenus.
PT00124	M6APDG03982	LY3415244	.	Phase 1	Clinical pipeline report, company report or official report of BeiGene.
PT00032	M6APDG04017	INBRX-105	.	Phase 1	Clinical pipeline report, company report or official report of BeiGene.
PT00066	M6APDG03819	IT-139	.	Phase 1	A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2008 Apr;88(4):375-86.
PT00066	M6APDG03983	SAM-6	.	Phase 1	NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82.
PT00245	M6APDG03044	OICR-9429	CID: 91623360	Investigative	NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82.
PT00021	M6APDG03846	AMG 811	.	Phase 1	Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
PT00021	M6APDG03984	CIGB-128	.	Phase 1	EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents.
PT00076	M6APDG03862	BIWA 4	.	Phase 1	Modulation of CD44 Activity by A6-Peptide.Front Immunol.2015 Mar 30;6:135.
PT00060	M6APDG03875	PF-06939999	.	Phase 1	A patent review of arginine methyltransferase inhibitors (2010-2018). Expert Opin Ther Pat. 2019 Feb;29(2):97-114.
PT00060	M6APDG03987	PRT543	.	Phase 1	Clinical pipeline report, company report or official report of Prelude Therapeutics.
PT00060	M6APDG03988	PRT811	.	Phase 1	National Cancer Institute Drug Dictionary (drug name PF-06939999).
PT00080	M6APDG03835	G1T28-1	.	Phase 1	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
PT00030	M6APDG04147	Resten-NG	.	Phase 2	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
PT00080	M6APDG00652	AG-024322	CID: 135413565	Phase 1	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
PT00080	M6APDG02332	Ro 31-7453	CID: 5327686	Phase 2	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
PT00080	M6APDG02362	PD-0183812	CID: 5330258	Terminated	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
PT00080	M6APDG00189	10-hydroxy-18-methoxybetaenone	CID: 10644450	Investigative	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
PT00209	M6APDG03870	Ferroportin mab	.	Phase 1	Hepcidin agonists as therapeutic tools. Blood. 2018 Apr 19;131(16):1790-1794.
PT00199	M6APDG03794	AVE0897	.	Phase 1	Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93.
PT00199	M6APDG03822	TPST-1120	.	Phase 1	Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):140-6.
PT00181	M6APDG03989	HPP971	.	Phase 1	National Cancer Institute Drug Dictionary (drug id 756624).
PT00207	M6APDG03834	ISIS-CRP	.	Phase 1	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG03082	Naringenin	CID: 932	Phase 1	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02249	Chrysin	CID: 5281607	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02229	ACACETIN	CID: 5280442	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02230	APIGENIN	CID: 5280443	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02250	DIOSMETIN	CID: 5281612	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02235	KAEMPFEROL	CID: 5280863	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG01584	ERIODICTYOL	CID: 440735	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02234	CHRYSOERIOL	CID: 5280666	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02254	KAEMPFERIDE	CID: 5281666	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02256	TAMARIXETIN	CID: 5281699	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02253	ISORHAMNETIN	CID: 5281654	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG00829	ISOSAKUTANETIN	CID: 160481	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG02968	HOMOERIODICTYOL	CID: 73635	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00006	M6APDG01071	N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide	CID: 2321450	Investigative	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
PT00206	M6APDG03844	SY-1425	.	Phase 1	Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12.
PT00048	M6APDG03991	PF-06427878	.	Phase 1	2011 Pipeline of Arisaph Pharmaceuticals.
PT00092	M6APDG03826	GMI-1359	.	Phase 1	A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
PT00092	M6APDG03836	ALX-0651	.	Phase 1	Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7.
PT00092	M6APDG03845	CTCE-0214	.	Phase 1	BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66.
PT00092	M6APDG03866	PF-06747143	.	Phase 1	Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS One. 2016 Mar 8;11(3):e0150585.
PT00092	M6APDG03993	LY2624587	.	Phase 1	Clinical pipeline report, company report or official report of GlycoMimetics.
PT00010	M6APDG03811	AG-270	.	Phase 1	Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74.
PT00227	M6APDG03994	SRK-181	.	Phase 1	Clinical pipeline report, company report or official report of AbbVie.
PT00227	M6APDG03995	ABBV-151	.	Phase 1	Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 January; 5(1): 78-94.
PT00077	M6APDG03996	TTI-621	.	Phase 1	Clinical pipeline report, company report or official report of I-MAB Biopharma.
PT00077	M6APDG03997	TJC4	.	Phase 1	Clinical pipeline report, company report or official report of ImmuneOncia Therapeutics.
PT00077	M6APDG03998	IMC-002	.	Phase 1	Clinical pipeline report, company report or official report of Trillium Therapeutics.
PT00077	M6APDG03999	TTI-622	.	Phase 1	Clinical pipeline report, company report or official report of ZAI Lab.
PT00077	M6APDG04000	ZL-1201	.	Phase 1	Clinical pipeline report, company report or official report of Innovent Biologics.
PT00077	M6APDG04001	IBI188	.	Phase 1	National Cancer Institute Drug Dictionary (drug name CC 90002).
PT00077	M6APDG04002	CC-90002	.	Phase 1	Clinical pipeline report, company report or official report of TG Theraputics.
PT00077	M6APDG04003	TG-1801	.	Phase 1	Clinical pipeline report, company report or official report of Shattuck Labs.
PT00032	M6APDG04015	ALPN-202	.	Phase 1	Clinical pipeline report, company report or official report of Shattuck Labs.
PT00222	M6APDG03884	TAK-676	.	Phase 1	Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020 Jun 1;11(1):2739.
PT00222	M6APDG03886	SYNB1891	.	Phase 1	Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323.
PT00222	M6APDG03891	BMS-986301	.	Phase 1	E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743.
PT00222	M6APDG04005	SB 11285	.	Phase 1	Clinical pipeline report, company report or official report of Silicon Therapeutics.
PT00222	M6APDG04006	SNX281	.	Phase 1	National Cancer Institute Drug Dictionary (drug name GSK3745417).
PT00222	M6APDG04007	GSK3745417	.	Phase 1	National Cancer Institute Drug Dictionary (drug name ML2118).
PT00222	M6APDG04008	MK-2118	.	Phase 1	National Cancer Institute Drug Dictionary (drug name TAK676).
PT00222	M6APDG04009	E7766	.	Phase 1	Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
PT00032	M6APDG03841	MCLA-145	.	Phase 1	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65.
PT00032	M6APDG03879	Cosibelimab	.	Phase 1	CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019 Aug 1;24(15):2804.
PT00032	M6APDG04012	PD-L1 t-haNK	.	Phase 1	Clinical pipeline report, company report or official report of Kadmon.
PT00032	M6APDG04013	CA-170	.	Phase 1	Clinical pipeline report, company report or official report of Genmab.
PT00032	M6APDG04014	GEN1046	.	Phase 1	Clinical pipeline report, company report or official report of Alpine Immune Sciences.
PT00032	M6APDG03982	LY3415244	.	Phase 1	Clinical pipeline report, company report or official report of Innovent.
PT00032	M6APDG04016	IBI318	.	Phase 1	Clinical pipeline report, company report or official report of Inhibrx.
PT00032	M6APDG04021	Anti-PD-L1	.	Phase 1	ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
PT00032	M6APDG04023	KD033	.	Phase 1	Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
PT00032	M6APDG04027	FS118	.	Phase 1	ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health.
PT00028	M6APDG04049	ASTX295	.	Phase 1/2	Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41.
PT00143	M6APDG04034	131I-radretumab	.	Phase 1/2	Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides. J Physiol. 2003 Feb 15;547(Pt 1):159-68.
PT00193	M6APDG04054	AMXI 5001	.	Phase 1/2	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
PT00193	M6APDG00630	NU1025	CID: 135398517	Terminated	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
PT00141	M6APDG02799	Piceatannol	CID: 667639	Investigative	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
PT00180	M6APDG04046	UshStat	.	Phase 1/2	Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25.
PT00044	M6APDG04061	ARV-110	.	Phase 1/2	Targeting estrogen receptor alpha for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020 Nov 15;206:112689.
PT00051	M6APDG04042	AVX901	.	Phase 1/2	Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8.
PT00051	M6APDG04050	Zenocutuzomab	.	Phase 1/2	A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res. 2014;2014:326545.
PT00051	M6APDG04057	A166	.	Phase 1/2	TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2019 Apr;18(4):733-742.
PT00051	M6APDG04064	Sym013	.	Phase 1/2	Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
PT00050	M6APDG04064	Sym013	.	Phase 1/2	Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
PT00051	M6APDG04065	TAS-0728	.	Phase 1/2	Clinical pipeline report, company report or official report of Ichnos Sciences.
PT00051	M6APDG04099	AGN-208397	.	Phase 1/2	ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health.
PT00051	M6APDG04102	Anti-HER2 CAR-T	.	Phase 1/2	ClinicalTrials.gov (NCT01935843) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
PT00051	M6APDG04103	CART-HER-2	.	Phase 1/2	ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
PT00051	M6APDG04104	ABY-025	.	Phase 1/2	ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
PT00031	M6APDG04035	ISA-P53-01	.	Phase 1/2	Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38.
PT00241	M6APDG04032	HTU-PA	.	Phase 1/2	Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
PT00040	M6APDG04051	ART621	.	Phase 1/2	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
PT00051	M6APDG04177	DN24-02	.	Phase 2	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
PT00042	M6APDG04178	RG7221	.	Phase 2	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
PT00165	M6APDG00841	E-7050	CID: 16118392	Phase 1	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
PT00050	M6APDG01137	CUDC-101	CID: 24756910	Phase 1	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
PT00042	M6APDG04052	MP0250	.	Phase 1/2	Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
PT00168	M6APDG04068	HH2710	.	Phase 1/2	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
PT00167	M6APDG04068	HH2710	.	Phase 1/2	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
PT00168	M6APDG04069	ASTX029	.	Phase 1/2	DOI: 10.1158/1538-7445.AM2015-4693
PT00167	M6APDG04069	ASTX029	.	Phase 1/2	DOI: 10.1158/1538-7445.AM2015-4693
PT00112	M6APDG04056	SHR2554	.	Phase 1/2	Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
PT00112	M6APDG04070	CPI-0209	.	Phase 1/2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
PT00109	M6APDG04071	KB-004	.	Phase 1/2	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
PT00049	M6APDG03596	ISIS 113019	.	Investigative	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
PT00049	M6APDG03597	ISIS 113020	.	Investigative	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
PT00049	M6APDG03598	ISIS 113021	.	Investigative	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
PT00049	M6APDG03599	ISIS 113022	.	Investigative	US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
PT00038	M6APDG04074	GLG-801	.	Phase 1/2	Clinical pipeline report, company report or official report of Purple Biotech.
PT00062	M6APDG04202	Mydicar	.	Phase 2	Clinical pipeline report, company report or official report of Purple Biotech.
PT00247	M6APDG04100	WT-4869	.	Phase 1/2	ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health.
PT00046	M6APDG04040	APG-1252	.	Phase 1/2	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7.
PT00046	M6APDG04059	AZD0466	.	Phase 1/2	Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
PT00165	M6APDG04076	Sym015	.	Phase 1/2	Clinical pipeline report, company report or official report of Eli Lilly.
PT00068	M6APDG04047	PLX2853	.	Phase 1/2	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
PT00068	M6APDG04048	INCB57643	.	Phase 1/2	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
PT00068	M6APDG00504	AZD5153	CID: 118693659	Phase 1	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
PT00068	M6APDG02131	GSK525762	CID: 46943432	Phase 1	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
PT00190	M6APDG04045	IPP-204106	.	Phase 1/2	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
PT00197	M6APDG03127	AGL 2043	CID: 9817165	Investigative	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
PT00046	M6APDG04078	Beclanorsen	.	Phase 1/2	Clinical pipeline report, company report or official report of ProNAi.
PT00108	M6APDG04060	CAR-T cells targeting EphA2	.	Phase 1/2	MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394.
PT00108	M6APDG04079	BT5528	.	Phase 1/2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1619).
PT00035	M6APDG04038	T3D-959	.	Phase 1/2	MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88.
PT00035	M6APDG04136	CHS-131	.	Phase 2	MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88.
PT00197	M6APDG04080	SNN-0031	.	Phase 1/2	National Cancer Institute Drug Dictionary (drug id 452042).
PT00196	M6APDG00277	MP470	CID: 11282283	Phase 2	National Cancer Institute Drug Dictionary (drug id 452042).
PT00050	M6APDG04033	SN-32793	.	Phase 1/2	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
PT00050	M6APDG03457	PD182905	.	Investigative	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
PT00050	M6APDG02803	CGP-53353	CID: 6711154	Terminated	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
PT00050	M6APDG04083	EMB-01	.	Phase 1/2	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
PT00246	M6APDG01175	MK-1775	CID: 24856436	Phase 2	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
PT00050	M6APDG04084	ZN-e4	.	Phase 1/2	Clinical pipeline report, company report or official report of Affimed Therapeutics.
PT00050	M6APDG04085	AFM24	.	Phase 1/2	Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
PT00050	M6APDG04101	EMD 55900	.	Phase 1/2	ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
PT00050	M6APDG04105	CART-EGFR	.	Phase 1/2	ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer
PT00123	M6APDG04044	Neu-120	.	Phase 1/2	Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
PT00162	M6APDG04053	AP-1030	.	Phase 1/2	Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
PT00124	M6APDG04088	BGB-A425	.	Phase 1/2	Clinical pipeline report, company report or official report of GlaxoSmithKline.
PT00021	M6APDG04037	VIR-201	.	Phase 1/2	Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
PT00082	M6APDG04043	MTL-CEPBA	.	Phase 1/2	The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
PT00041	M6APDG03508	ISIS 17020	.	Investigative	The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
PT00239	M6APDG04089	Enapotamab vedotin	.	Phase 1/2	Clinical pipeline report, company report or official report of Ono Pharmaceutical.
PT00164	M6APDG01595	MK-2461	CID: 44137946	Phase 1/2	Clinical pipeline report, company report or official report of Ono Pharmaceutical.
PT00080	M6APDG04092	FCN-437	.	Phase 1/2	Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
PT00081	M6APDG04092	FCN-437	.	Phase 1/2	Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
PT00038	M6APDG04093	ISIS-STAT3	.	Phase 1/2	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
PT00038	M6APDG03716	ISIS 17152	.	Investigative	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
PT00038	M6APDG03717	ISIS 17148	.	Investigative	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
PT00038	M6APDG03718	ISIS 113176	.	Investigative	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
PT00038	M6APDG03719	ISIS 113187	.	Investigative	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
PT00038	M6APDG03720	ISIS 113209	.	Investigative	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
PT00052	M6APDG04094	INCB62079	.	Phase 1/2	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03723	ISIS 29135	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03724	ISIS 29136	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03725	ISIS 29137	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03726	ISIS 29138	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03727	ISIS 29139	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03728	ISIS 29154	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03729	ISIS 29155	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03730	ISIS 29156	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03731	ISIS 29159	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03732	ISIS 29160	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03733	ISIS 29161	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03734	ISIS 29112	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03735	ISIS 29176	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03736	ISIS 29177	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03737	ISIS 29178	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03738	ISIS 29200	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00043	M6APDG03739	ISIS 29201	.	Investigative	US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
PT00077	M6APDG04058	DSP-107	.	Phase 1/2	Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
PT00077	M6APDG04095	ALX148	.	Phase 1/2	Clinical pipeline report, company report or official report of KAHR Medical.
PT00032	M6APDG04098	BGB-A333	.	Phase 1/2	Clinical pipeline report, company report or official report of Gilead Sciences.
PT00040	M6APDG04106	COVA322	.	Phase 1/2a	Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6195-8.
PT00051	M6APDG04107	S-222611	.	Phase 1b	New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
PT00181	M6APDG04170	ABT-RTA-408	.	Phase 2	New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
PT00028	M6APDG04145	ALRN-6924	.	Phase 2	MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26.
PT00134	M6APDG04193	PF-06823859	.	Phase 2	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
PT00134	M6APDG04194	Interferon beta 1a	.	Phase 2	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
PT00134	M6APDG04332	TV-1390	.	Preclinical	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
PT00014	M6APDG04195	VAS-203	.	Phase 2	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
PT00165	M6APDG01969	MK-8033	CID: 45142457	Phase 1	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
PT00057	M6APDG02329	ARQ 092	CID: 53262401	Phase 2	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
PT00026	M6APDG03094	TWS-119	CID: 9549289	Investigative	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
PT00193	M6APDG04124	Stenoparib	.	Phase 2	Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
PT00193	M6APDG04196	AG140699	.	Phase 2	Clinical pipeline report, company report or official report of Allarity Therapeutics.
PT00232	M6APDG00702	PMID27841036-Compound-37	CID: 135565981	Phase 2	Clinical pipeline report, company report or official report of Allarity Therapeutics.
PT00025	M6APDG04197	CTP-543	.	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
PT00025	M6APDG03552	AMG-JAK2-01	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
PT00025	M6APDG02063	NS-018	CID: 46866319	Phase 1/2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
PT00025	M6APDG00589	ON-044580	CID: 129860730	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
PT00044	M6APDG04143	ASCJ-9	.	Phase 2	Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010 May 28;285(22):17054-64.
PT00044	M6APDG04159	AZD5312	.	Phase 2	New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013 Feb;182(2):460-73.
PT00044	M6APDG04171	Testogen TDS	.	Phase 2	Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4:e764.
PT00017	M6APDG04198	SXC-2023	.	Phase 2	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00027	M6APDG03566	ISIS 122970	.	Investigative	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00027	M6APDG03567	ISIS 122971	.	Investigative	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00027	M6APDG03568	ISIS 122974	.	Investigative	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00027	M6APDG03569	ISIS 122975	.	Investigative	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00027	M6APDG03570	ISIS 122976	.	Investigative	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00027	M6APDG03571	ISIS 122984	.	Investigative	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00027	M6APDG03572	ISIS 122985	.	Investigative	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00027	M6APDG03573	ISIS 122986	.	Investigative	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00027	M6APDG03574	ISIS 122990	.	Investigative	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
PT00005	M6APDG04139	BGS-649	.	Phase 2	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
PT00005	M6APDG01284	NSC-93358	CID: 261365	Investigative	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
PT00041	M6APDG04155	DE-098	.	Phase 2	Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100.
PT00041	M6APDG04166	APG-101	.	Phase 2	Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
PT00051	M6APDG04128	MGAH22	.	Phase 2	Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20;25(24):3680-7.
PT00051	M6APDG04151	MM-111	.	Phase 2	Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.
PT00051	M6APDG04192	KN026	.	Phase 2	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475.
PT00050	M6APDG01229	HM-78136B	CID: 25127713	Phase 2	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475.
PT00051	M6APDG04200	HER-2 Protein AutoVac	.	Phase 2	Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011; 13(6): R123.
PT00051	M6APDG04201	MRG002	.	Phase 2	Clinical pipeline report, company report or official report of Alphamab Oncology.
PT00051	M6APDG04247	MCLA-128	.	Phase 2	ClinicalTrials.gov (NCT04839510) A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer. U.S. National Institutes of Health.
PT00031	M6APDG04144	ALT-801	.	Phase 2	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91.
PT00031	M6APDG04165	Ad-p53	.	Phase 2	Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8.
PT00114	M6APDG04190	TVB-2640	.	Phase 2	Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
PT00241	M6APDG04162	Saruplase	.	Phase 2	Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
PT00130	M6APDG04134	Efungumab	.	Phase 2	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
PT00130	M6APDG04317	KOS-2484	.	Preclinical	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
PT00130	M6APDG03493	KOSN1559	.	Investigative	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
PT00130	M6APDG00516	AT13387	CID: 11955716	Phase 1	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
PT00130	M6APDG01608	SNX-5422	CID: 44195571	Phase 1/2	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
PT00130	M6APDG02999	2-Methyl-2,4-Pentanediol	CID: 7870	Investigative	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
PT00130	M6APDG01469	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine	CID: 3777900	Investigative	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
PT00040	M6APDG04114	ESBA-105	.	Phase 2	Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. Mol Pharmacol. 2003 Mar;63(3):690-8.
PT00040	M6APDG04125	ABT-122	.	Phase 2	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
PT00015	M6APDG02526	S-2474	CID: 57370228	Discontinued in Phase 2	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
PT00015	M6APDG02586	TEBUFELONE	CID: 60542	Discontinued in Phase 2	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
PT00005	M6APDG00273	FORMESTANE	CID: 11273	Withdrawn from market	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
PT00040	M6APDG04130	Pegsunercept	.	Phase 2	Inhibition of experimental periodontitis by a topical boron-based antimicrobial. J Dent Res. 2008 Feb;87(2):148-52.
PT00040	M6APDG04133	AP-301-IH	.	Phase 2	Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008 May;172(5):1411-8.
PT00040	M6APDG04135	TNF alpha kinoid	.	Phase 2	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
PT00040	M6APDG04205	DLX-105	.	Phase 2	Modulation of Anti-Tumor Necrosis Factor Alpha (TNF-alpha) Antibody Secretion in Mice Immunized with TNF-alpha Kinoid. Clin Vaccine Immunol. 2012 May; 19(5): 699-703.
PT00042	M6APDG04206	RO5520985	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00140	M6APDG04219	ABT-981	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00022	M6APDG04224	MM-141	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00231	M6APDG01213	DCC-2036	CID: 25066467	Phase 1/2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00042	M6APDG04207	Abicipar pegol	.	Phase 2	Clinical pipeline report, company report or official report of Genentech (2009).
PT00061	M6APDG04208	AEM-28	.	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00037	M6APDG04269	GED-0301	.	Phase 3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00165	M6APDG01551	XL880	CID: 42642645	Phase 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
PT00020	M6APDG04167	APC-8015F	.	Phase 2	A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15.
PT00020	M6APDG04176	BI-505	.	Phase 2	Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6.
PT00247	M6APDG04109	WT1 peptide vaccine	.	Phase 2	Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22.
PT00150	M6APDG02124	BVDU-MP	CID: 46936977	Investigative	Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22.
PT00247	M6APDG04129	WT1-targeted autologous dendritic cell vaccine	.	Phase 2	Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42.
PT00247	M6APDG04153	FPI-01	.	Phase 2	Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer ImmunolImmunother. 2012 Mar;61(3):313-22.
PT00093	M6APDG04152	JT02	.	Phase 2	Antitumor efficacy of a thrombospondin 1 mimetic CovX-body. Transl Oncol. 2011 Aug;4(4):249-57.
PT00093	M6APDG04154	NI-0801	.	Phase 2	A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9.
PT00093	M6APDG04210	BMS-936557	.	Phase 2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267)
PT00234	M6APDG04126	CVX-045	.	Phase 2	A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun;30(3):303-9.
PT00024	M6APDG04214	PF-04236921	.	Phase 2	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
PT00163	M6APDG04145	ALRN-6924	.	Phase 2	Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014 Jan;124(1):6-12.
PT00047	M6APDG04244	PF-4523655	.	Phase 2	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
PT00232	M6APDG04124	Stenoparib	.	Phase 2	Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22.
PT00019	M6APDG04110	AZX-100	.	Phase 2	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00021	M6APDG04254	Emapalumab	.	Phase 2/3 Trial	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00169	M6APDG03448	STAUROSPORINONE	.	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00170	M6APDG03448	STAUROSPORINONE	.	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00155	M6APDG03448	STAUROSPORINONE	.	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00116	M6APDG03058	NP-G2-044	CID: 91844684	Phase 1	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00057	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00169	M6APDG02211	NM-PP1	CID: 5154691	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00170	M6APDG02645	ML-3403	CID: 6419739	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00220	M6APDG02457	URMC-099	CID: 54764565	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00057	M6APDG00064	A-443654	CID: 10172943	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00169	M6APDG01116	RO-316233	CID: 2399	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00167	M6APDG01116	RO-316233	CID: 2399	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00170	M6APDG00072	GW-788388	CID: 10202642	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00057	M6APDG01116	RO-316233	CID: 2399	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00123	M6APDG01541	SB-415286	CID: 4210951	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00155	M6APDG01116	RO-316233	CID: 2399	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00155	M6APDG01541	SB-415286	CID: 4210951	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00155	M6APDG02191	Ro31-8220	CID: 5083	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00167	M6APDG00309	Ro-4396686	CID: 11396738	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00167	M6APDG00669	DEBROMOHYMENIALDISINE	CID: 135451156	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00170	M6APDG03084	6-Benzylsulfanyl-9H-purine	CID: 93558	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00057	M6APDG00315	4,5,6-trihydroxy-3-methylphthalide	CID: 11424128	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00170	M6APDG00079	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine	CID: 10236389	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00123	M6APDG00003	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	CID: 10017019	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00057	M6APDG02556	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	CID: 5908088	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00169	M6APDG01100	2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide	CID: 23647253	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00167	M6APDG00255	(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine	CID: 11195892	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00169	M6APDG00350	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide	CID: 11507052	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00170	M6APDG02089	N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide	CID: 46886448	Investigative	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
PT00182	M6APDG04215	P54	.	Phase 2	Clinical pipeline report, company report or official report of Catabasis Pharmaceuticals Inc.
PT00182	M6APDG04245	CAT 1004	.	Phase 2	ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
PT00179	M6APDG04246	LR3001	.	Phase 2	ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
PT00165	M6APDG04180	HM-5016504	.	Phase 2	The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94.
PT00165	M6APDG04217	Emibetuzumab	.	Phase 2	Clinical pipeline report, company report or official report of AbbVie.
PT00165	M6APDG04218	Telisotuzumab vedotin	.	Phase 2	Clinical pipeline report, company report or official report of Apollomics.
PT00052	M6APDG04121	ISIS-FGFR4	.	Phase 2	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
PT00167	M6APDG02191	Ro31-8220	CID: 5083	Investigative	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
PT00118	M6APDG03115	JNJ-10198409	CID: 9797370	Investigative	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
PT00196	M6APDG00077	Di(1H-indol-2-yl)methanone	CID: 10220822	Investigative	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
PT00197	M6APDG00676	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	CID: 135464491	Investigative	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
PT00050	M6APDG00793	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 15422868	Investigative	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
PT00140	M6APDG04146	AC-201	.	Phase 2	Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69.
PT00140	M6APDG04181	LY-2189102	.	Phase 2	Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
PT00204	M6APDG04220	[131I]-BC8	.	Phase 2	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
PT00090	M6APDG04221	HCB1019	.	Phase 2	Company report (FirstString Research)
PT00188	M6APDG04142	Tarextumab	.	Phase 2	Clinical pipeline report, company report or official report of Oncotelic.
PT00046	M6APDG04222	PNT-2258	.	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1728).
PT00022	M6APDG04116	VPI-2690B	.	Phase 2	Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
PT00022	M6APDG04173	Cixutumumab	.	Phase 2	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
PT00022	M6APDG04148	TT-100	.	Phase 2	Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 Jul;26(7):1459-64.
PT00022	M6APDG04223	AMG 479	.	Phase 2	Clinical pipeline report, company report or official report of Roche (2009).
PT00051	M6APDG00994	Lapatinib	CID: 208908	Approved	Clinical pipeline report, company report or official report of Roche (2009).
PT00199	M6APDG00308	Indeglitazar	CID: 11395145	Discontinued in Phase 2	Clinical pipeline report, company report or official report of Roche (2009).
PT00051	M6APDG01552	Varlitinib	CID: 42642648	Phase 2/3	Clinical pipeline report, company report or official report of Roche (2009).
PT00046	M6APDG00097	Thymoquinone	CID: 10281	Phase 2/3	Clinical pipeline report, company report or official report of Roche (2009).
PT00050	M6APDG01552	Varlitinib	CID: 42642648	Phase 2/3	Clinical pipeline report, company report or official report of Roche (2009).
PT00196	M6APDG04158	XL-820	.	Phase 2	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
PT00197	M6APDG04158	XL-820	.	Phase 2	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
PT00196	M6APDG04175	MEDI-575	.	Phase 2	Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
PT00098	M6APDG04138	DKN-01	.	Phase 2	The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010 Apr;333(1):2-13.
PT00098	M6APDG04161	BHQ880	.	Phase 2	Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013 Mar 29;288(13):9408-17.
PT00035	M6APDG04120	OMS405	.	Phase 2	FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Metabolism. 2005 Sep;54(9):1250-8.
PT00035	M6APDG04168	MBX-2044	.	Phase 2	PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets. 2013 Nov;14(12):1501-7.
PT00050	M6APDG04140	Matuzumab	.	Phase 2	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
PT00051	M6APDG02016	4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide	CID: 46207013	Investigative	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
PT00050	M6APDG04148	TT-100	.	Phase 2	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92.
PT00050	M6APDG04160	MEHD-7945A	.	Phase 2	EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma.Radiat Res.2013 Mar;179(3):304-12.
PT00050	M6APDG04172	RM-1929	.	Phase 2	Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206.
PT00050	M6APDG04186	ABX-EGF	.	Phase 2	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
PT00050	M6APDG04228	HER1-VSSP vaccine	.	Phase 2	BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
PT00022	M6APDG02943	AXL-1717	CID: 72435	Phase 2	BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
PT00050	M6APDG04229	CetuGEX	.	Phase 2	Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083.
PT00135	M6APDG04131	Xentuzumab	.	Phase 2	Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
PT00246	M6APDG04232	ZN-c3	.	Phase 2	National Cancer Institute Drug Dictionary (drug id 770319).
PT00162	M6APDG04122	PF-446687	.	Phase 2	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
PT00162	M6APDG01739	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	CID: 44408443	Investigative	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
PT00110	M6APDG04233	SEphB4-HSA	.	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03698	X-387	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03693	P-6915	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03701	CU-906	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03703	P-2281	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03694	SB-2280	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03695	SX-MTR1	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03696	EC-0565	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03700	EC-0845	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03699	AR-mTOR-26	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03702	HM-5016699	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03697	PF-03772304	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03218	Zotarolimus	CID: 9876378	Approved	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG02559	GDC-0349	CID: 59239165	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG00525	BGT226	CID: 11978790	Phase 1/2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG03332	AZD-2014	CID: 25262792	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG02444	Salirasib	CID: 5469318	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG01979	OXA-01	CID: 45276387	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
PT00029	M6APDG04164	ABI-009	.	Phase 2	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
PT00165	M6APDG02114	JNJ-38877605	CID: 46911863	Phase 1	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
PT00045	M6APDG01201	SNS-314	CID: 24995524	Phase 1	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
PT00246	M6APDG00487	9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	CID: 11844342	Investigative	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
PT00086	M6APDG04189	RetinoStat	.	Phase 2	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
PT00233	M6APDG04141	Mapatumumab	.	Phase 2	BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.
PT00076	M6APDG04108	SPL-108	.	Phase 2	UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65.
PT00076	M6APDG04236	A-6	.	Phase 2	Clinical pipeline report, company report or official report of Splash Pharmaceuticals.
PT00138	M6APDG04156	SAR-113945	.	Phase 2	Inhibition of I B phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45.
PT00031	M6APDG04150	OPI-1002	.	Phase 2	Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27.
PT00152	M6APDG00520	APTO-253	CID: 11960271	Phase 1	Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27.
PT00239	M6APDG04174	BGB-324	.	Phase 2	The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.
PT00149	M6APDG04184	CXA10	.	Phase 2	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
PT00181	M6APDG04184	CXA10	.	Phase 2	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.
PT00047	M6APDG04115	PF-04523655	.	Phase 2	Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004 Apr 1;18(7):830-50.
PT00030	M6APDG04111	AVI-5126	.	Phase 2	Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56.
PT00209	M6APDG04157	LY2928057	.	Phase 2	The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013 Mar;52(3):225-36.
PT00199	M6APDG04123	GFT14	.	Phase 2	The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61.
PT00035	M6APDG00985	Netoglitazone	CID: 204109	Phase 2	The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61.
PT00199	M6APDG04169	ZYH7	.	Phase 2	Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
PT00199	M6APDG04225	ONO-5129	.	Phase 2	Clinical pipeline report, company report or official report of Zydus Cadila.
PT00249	M6APDG04183	Cobomarsen	.	Phase 2	The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice. Eur J Pharmacol. 2017 May 5;802:76-84.
PT00181	M6APDG04182	SFX-01	.	Phase 2	Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325.
PT00181	M6APDG04185	OT551	.	Phase 2	The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
PT00149	M6APDG04323	VCB102	.	Preclinical	The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
PT00187	M6APDG04142	Tarextumab	.	Phase 2	The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation. Free Radic Res. 2010 May;44(5):529-40.
PT00136	M6APDG04238	Dusigitumab	.	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811).
PT00052	M6APDG03722	ABC-4	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811).
PT00048	M6APDG04112	ARI-3037MO	.	Phase 2	Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
PT00092	M6APDG04132	POL-6326	.	Phase 2	Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65.
PT00131	M6APDG04239	VDA-1102	.	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2019).
PT00222	M6APDG04187	ADU- S100	.	Phase 2	Siltuximab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. 2018 Dec 3.
PT00222	M6APDG04188	MK-1454	.	Phase 2	Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5.
PT00032	M6APDG04149	KN035	.	Phase 2	PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18.
PT00032	M6APDG04191	INCB86550	.	Phase 2	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
PT00032	M6APDG04242	CX-072	.	Phase 2	National Cancer Institute Drug Dictionary (drug name INCB086550).
PT00032	M6APDG04243	Bintrafusp alfa	.	Phase 2	National Cancer Institute Drug Dictionary (drug id 740856).
PT00024	M6APDG04248	Sirukumab	.	Phase 2 Trial	Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82.
PT00024	M6APDG04249	Clazakizumab	.	Phase 2 Trial	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
PT00039	M6APDG04253	OT-101	.	Phase 2/3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017210)
PT00123	M6APDG04251	AMO-02	.	Phase 2/3	Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6.
PT00123	M6APDG01457	PAULLONE	CID: 369401	Investigative	Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6.
PT00024	M6APDG04255	Olokizumab	.	Phase 2/3 Trial	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452.
PT00134	M6APDG04275	Biferonex	.	Phase 3	The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107.
PT00134	M6APDG04276	FP-1201	.	Phase 3	Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65.
PT00039	M6APDG04294	AP12009	.	Phase 3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875).
PT00041	M6APDG03576	F61F12	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875).
PT00041	M6APDG04303	VB-111	.	Phase 3	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
PT00051	M6APDG04264	PF-05280014	.	Phase 3	Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
PT00046	M6APDG00506	Oblimersen	CID: 118984457	Phase 3	Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
PT00051	M6APDG04278	Trastuzumab-DM1	.	Phase 3	Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin( )). BioDrugs. 2014 Oct;28(5):451-9.
PT00031	M6APDG04290	QPI-1002	.	Phase 3	Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94.
PT00040	M6APDG04262	PF-06410293	.	Phase 3	TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.
PT00040	M6APDG04273	Golnerminogene pradenovac	.	Phase 3	Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
PT00040	M6APDG04279	ABP 501	.	Phase 3	Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics. 2014 Jul 31;8:211-20.
PT00040	M6APDG04295	PF-06438179	.	Phase 3	Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions. BMC Proc. 2013; 7(Suppl 6): P30.
PT00042	M6APDG04265	Faricimab	.	Phase 3	Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
PT00166	M6APDG04302	O6-Benzylguanine alkylade	.	Phase 3	ClinicalTrials.gov (NCT00003847) VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health.
PT00009	M6APDG04293	CBT-1	.	Phase 3	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
PT00107	M6APDG01238	BIX-01294	CID: 25150857	Preclinical	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
PT00112	M6APDG02899	GSK343	CID: 71268957	Investigative	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
PT00150	M6APDG04256	Radiosensitizer gene therapy	.	Phase 3	Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54.
PT00165	M6APDG04280	RG3638	.	Phase 3	Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
PT00140	M6APDG04261	XOMA 052	.	Phase 3	Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41.
PT00204	M6APDG04263	Iomab-B	.	Phase 3	131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91.
PT00204	M6APDG04298	131I-labelled aCD45	.	Phase 3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 728).
PT00090	M6APDG04289	Act1	.	Phase 3	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
PT00012	M6APDG00330	Galarubicin	CID: 114759	Discontinued in Phase 2	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
PT00090	M6APDG04299	Granexin gel	.	Phase 3	Company report (OncoMed Pharmaceuticals)
PT00039	M6APDG04283	Belagenpumatucel-L	.	Phase 3	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
PT00048	M6APDG03086	Vitamin B3	CID: 938	Approved	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
PT00012	M6APDG04271	Andecaliximab	.	Phase 3	Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
PT00200	M6APDG04272	VP-102	.	Phase 3	The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009 Apr;8(4):947-58.
PT00018	M6APDG04270	IT-101	.	Phase 3	A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608.
PT00139	M6APDG04300	VM-501	.	Phase 3	Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
PT00093	M6APDG02879	N-Methylleucine	CID: 6951123	Investigative	Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
PT00178	M6APDG04282	RBT-101	.	Phase 3	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
PT00035	M6APDG03328	BMS-298585	CID: 206044	Phase 3	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
PT00199	M6APDG03328	BMS-298585	CID: 206044	Phase 3	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
PT00035	M6APDG04258	ZYH-1	.	Phase 3	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
PT00199	M6APDG04258	ZYH-1	.	Phase 3	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
PT00199	M6APDG02275	8S-HETE	CID: 5283154	Investigative	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
PT00035	M6APDG00791	reglitazar	CID: 154000	Investigative	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
PT00050	M6APDG04266	Rindopepimut	.	Phase 3	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
PT00050	M6APDG00301	BMS-690514	CID: 11349170	Phase 2	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
PT00050	M6APDG04274	Zalutumumab	.	Phase 3	Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
PT00050	M6APDG00351	Dacomitinib	CID: 11511120	Approved	Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
PT00050	M6APDG04277	Amivantamab	.	Phase 3	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.
PT00050	M6APDG04285	DE-766	.	Phase 3	Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9.
PT00050	M6APDG04291	ASP1929	.	Phase 3	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
PT00165	M6APDG01263	MGCD516	CID: 25212148	Phase 2/3	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
PT00050	M6APDG04305	SYM-004	.	Phase 3	ClinicalTrials.gov (NCT04305795) An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors. U.S. National Institutes of Health.
PT00015	M6APDG04259	ThermoProfen	.	Phase 3	Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.
PT00067	M6APDG04281	DWP-431	.	Phase 3	Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer. J Med Chem. 2014 Oct 9;57(19):8099-110.
PT00124	M6APDG04257	MBG453	.	Phase 3	Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14.
PT00054	M6APDG01957	4-phospho-D-erythronate	CID: 449304	Investigative	Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14.
PT00037	M6APDG04269	GED-0301	.	Phase 3	Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8.
PT00092	M6APDG04287	Ulocuplumab	.	Phase 3	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
PT00030	M6APDG03094	TWS-119	CID: 9549289	Investigative	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
PT00077	M6APDG04286	Hu5F9-G4	.	Phase 3	A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells. Cell. 2015 Jun 18;161(7):1668-80.
PT00192	M6APDG03057	KML110	CID: 91827387	Investigative	A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells. Cell. 2015 Jun 18;161(7):1668-80.
PT00032	M6APDG04288	KN046	.	Phase 3	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
PT00032	M6APDG04292	MPDL-3280A	.	Phase 3	GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.
PT00032	M6APDG04301	MEDI4736	.	Phase 3	Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
PT00032	M6APDG04304	CS1001	.	Phase 3	ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
PT00024	M6APDG04306	Siltuximab	.	Phase 3 Trial	Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90.
PT00193	M6APDG04333	CPH-102	.	Preclinical	NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Cancer Res 2018;78(13 Suppl):Abstract nr 4843.
PT00236	M6APDG04321	BAP-15	.	Preclinical	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
PT00237	M6APDG04322	ADC-03	.	Preclinical	Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
PT00114	M6APDG04318	FAS1	.	Preclinical	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
PT00114	M6APDG02267	Cerulenin	CID: 5282054	Approved	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
PT00114	M6APDG00778	2-Hexadecynoic acid	CID: 151047	Investigative	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
PT00114	M6APDG04334	FSA2	.	Preclinical	Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
PT00242	M6APDG04314	Cruentaren	.	Preclinical	A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4150-3.
PT00218	M6APDG04335	IMX-942	.	Preclinical	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
PT00241	M6APDG03581	ATN-658	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
PT00241	M6APDG03580	UPA-targeted oncolytic Sendai virus	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
PT00241	M6APDG00795	Amediplase	CID: 154656	Phase 3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
PT00168	M6APDG04308	COR-D	.	Preclinical	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
PT00031	M6APDG03051	COTI-2	CID: 91810660	Phase 1	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
PT00201	M6APDG04336	CAR-T cells targeting CD133	.	Preclinical	Immunotargeting of cancer stem cells. Contemp Oncol (Pozn) 2015; 19(1A): A52-A59.
PT00169	M6APDG04308	COR-D	.	Preclinical	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
PT00169	M6APDG02863	CI-1040	CID: 6918454	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
PT00165	M6APDG04320	Mteron-F1	.	Preclinical	NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants. Invest New Drugs. 2014 Jun;32(3):389-99.
PT00237	M6APDG04331	ADC-01	.	Preclinical	Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers (Basel). 2020 Jun 15;12(6):1579.
PT00078	M6APDG04309	ON-01135	.	Preclinical	Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76.
PT00078	M6APDG01322	CGP74514A	CID: 2794188	Investigative	Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76.
PT00078	M6APDG01998	Purvalanol A	CID: 456214	Investigative	Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76.
PT00108	M6APDG04337	MEDI-543	.	Preclinical	Clinical pipeline report, company report or official report of Daiichi Sankyo.
PT00167	M6APDG04308	COR-D	.	Preclinical	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
PT00078	M6APDG02117	SCH 727965	CID: 46926350	Discontinued in Phase 3	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
PT00123	M6APDG01575	Quinoxaline1	CID: 438981	Investigative	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
PT00050	M6APDG04339	111In-hEGF	.	Preclinical	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
PT00022	M6APDG00662	BMS-695735	CID: 135441202	Preclinical	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
PT00071	M6APDG04326	SD1002	.	Preclinical	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
PT00071	M6APDG04327	SD1003	.	Preclinical	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
PT00071	M6APDG02785	CA-074Me	CID: 6610318	Preclinical	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
PT00022	M6APDG04319	ATL-1101	.	Preclinical	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01125	NSC-54162	CID: 243918	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01128	NSC-56071	CID: 244824	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01130	NSC-57893	CID: 245689	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG00910	NSC-623548	CID: 17413	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01118	NSC-158324	CID: 24193827	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01292	NSC-106084	CID: 266989	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01334	NSC-137546	CID: 283188	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01335	NSC-138419	CID: 283555	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01342	NSC-154957	CID: 290753	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01407	NSC-345763	CID: 335596	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01408	NSC-348926	CID: 336008	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01428	NSC-401077	CID: 344265	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01444	NSC-622444	CID: 360384	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01570	NSC-319745	CID: 43709	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00101	M6APDG01576	(L-)-S-adenosyl-L-homocysteine	CID: 439155	Investigative	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
PT00079	M6APDG04307	INOC-005	.	Preclinical	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00080	M6APDG04353	CYC-103	.	Terminated	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00081	M6APDG04353	CYC-103	.	Terminated	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00079	M6APDG03461	Oxindole 95	.	Investigative	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00079	M6APDG00883	PHA848125	CID: 16718576	Phase 2	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00079	M6APDG02184	9-Nitropaullone	CID: 5005498	Investigative	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00079	M6APDG00651	10Z-Hymenialdisine	CID: 135413546	Investigative	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00080	M6APDG02146	Cdk4 inhibitor III	CID: 481747	Investigative	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00079	M6APDG01459	Indirubin-3'-monoxime	CID: 3707	Investigative	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00079	M6APDG01460	Indirubin-5-sulfonate	CID: 3708	Investigative	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00081	M6APDG00080	Deschloroflavopiridol	CID: 102397231	Investigative	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00081	M6APDG02251	3,7,3',4'-TETRAHYDROXYFLAVONE	CID: 5281614	Investigative	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00079	M6APDG02000	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	CID: 4565	Investigative	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
PT00162	M6APDG04312	IDDBCP-150101	.	Preclinical	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
PT00162	M6APDG04313	Melanotetan II	.	Preclinical	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
PT00162	M6APDG00526	Setmelanotide	CID: 11993702	Approved	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
PT00162	M6APDG02864	PMX-53	CID: 6918468	Phase 2	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
PT00162	M6APDG03293	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	CID: 9948320	Investigative	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
PT00239	M6APDG04324	YW327.6S2	.	Preclinical	MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer. Contrast Media Mol Imaging. 2017 May 14;2017:1686525.
PT00239	M6APDG04328	DP-3975	.	Preclinical	AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
PT00239	M6APDG04329	GL21.T	.	Preclinical	AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
PT00239	M6APDG02502	LDC1267	CID: 56847486	Investigative	AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
PT00149	M6APDG04330	VCB101	.	Preclinical	NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. 2020 Jun 14;10(6):904.
PT00251	M6APDG00796	RGLS4326	CID: 154824286	Phase 1	NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. 2020 Jun 14;10(6):904.
PT00199	M6APDG04342	MC-3001	.	Preclinical	Fibrates as therapy for osteoarthritis and rheumatoid arthritis A systematic review. Ther Adv Musculoskelet Dis. 2013 February; 5(1): 33-44.
PT00199	M6APDG04338	MC-3002	.	Preclinical	Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010 September; 6(5): 657-691.
PT00181	M6APDG04325	TFM735	.	Preclinical	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
PT00181	M6APDG02931	Omaveloxolone	CID: 71811910	Phase 2	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
PT00181	M6APDG04343	CAT4001	.	Preclinical	Clinical pipeline report, company report or official report of Aclipse Therapeutics.
PT00181	M6APDG04344	M102	.	Preclinical	Clinical pipeline report, company report or official report of vTv Therapeutics.
PT00092	M6APDG04345	MAb173	.	Preclinical	CN patent application no. 101094684, With the combination of chemokine activation progenitor cells/stem cells.
PT00134	M6APDG04364	Maxy-10	.	Terminated	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032947)
PT00044	M6APDG04362	LG-2293	.	Terminated	GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res. 2013 Jun;72:9-24.
PT00044	M6APDG04365	ZD-3980	.	Terminated	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006840)
PT00031	M6APDG04366	TAR-1	.	Terminated	Prevent Oral Cancer With Mouthwash. Introgen Therapeutics.
PT00130	M6APDG04367	EC-154	.	Terminated	US patent application no. 2014,0079,636, Targeted therapeutics.
PT00040	M6APDG04348	TNFQb therapeutic vaccines	.	Terminated	Effect of the carbocyclic nucleoside analogue MDL 201,112 on inhibition of interferon-gamma-induced priming of Lewis (LEW/N) rat macrophages for enhanced respiratory burst and MHC class II Ia+ antigen expression. J Leukoc Biol. 1994 Aug;56(2):133-44.
PT00040	M6APDG04368	FR-133605	.	Terminated	US patent application no. 8007,790, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
PT00061	M6APDG04369	Apolipoprotein E	.	Terminated	Clinical pipeline report, company report or official report of LipimetiX.
PT00020	M6APDG04359	A-252444.0	.	Terminated	Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
PT00020	M6APDG04370	MOR-102	.	Terminated	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012566)
PT00020	M6APDG04371	GI-270384X	.	Terminated	Clinical pipeline report, company report or official report of AffyImmune Therapeutics.
PT00204	M6APDG04372	OX-30	.	Terminated	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002932)
PT00176	M6APDG04358	MX-7065	.	Terminated	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
PT00176	M6APDG02821	ANTHRAQUINONE	CID: 6780	Investigative	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
PT00176	M6APDG00257	ADOCIAQUINONE B	CID: 11201041	Investigative	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
PT00176	M6APDG01427	4-ethoxynaphthalene-1,2-dione	CID: 343759	Investigative	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
PT00012	M6APDG04349	CDP-845	.	Terminated	Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis. 1997 Mar;15(2):184-95.
PT00020	M6APDG04373	INXC-ICAM1	.	Terminated	US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.
PT00020	M6APDG03639	ISIS 1931	.	Investigative	US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.
PT00020	M6APDG00859	Alicaforsen	CID: 16197725	Phase 3	US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.
PT00035	M6APDG04355	AKP-320	.	Terminated	A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30.
PT00199	M6APDG03465	DB-900	.	Investigative	A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30.
PT00035	M6APDG04354	CS-204	.	Terminated	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
PT00015	M6APDG04357	NMI-150	.	Terminated	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
PT00035	M6APDG04375	BVT-142	.	Terminated	The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab. 2010 February; 30(2): 352-360.
PT00050	M6APDG04347	AZD-9935	.	Terminated	The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608.
PT00050	M6APDG04351	Heparin-EGF-like factor	.	Terminated	A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000 May;41(5):903-11.
PT00015	M6APDG04376	S-33516	.	Terminated	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007983)
PT00015	M6APDG04377	L-768277	.	Terminated	Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res. 2011 Autumn; 10(4): 655-683.
PT00011	M6APDG04349	CDP-845	.	Terminated	Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
PT00172	M6APDG03141	BB-3644	CID: 9822724	Terminated	Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
PT00175	M6APDG01918	MMI270	CID: 446504	Investigative	Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
PT00123	M6APDG04361	SAN-61	.	Terminated	AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.J Neurochem.2013 May;125(3):446-56.
PT00029	M6APDG04379	SCR-44001	.	Terminated	EP patent application no. 2275103, Mtor inhibitors in the treatment of endocrine tumors.
PT00076	M6APDG04356	Bivatuzumab mertansine	.	Terminated	A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72.
PT00045	M6APDG00318	PHA-739358	CID: 11442891	Phase 2	A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72.
PT00016	M6APDG04352	B-5354a	.	Terminated	F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J Antibiot (Tokyo). 2000 May;53(5):459-66.
PT00199	M6APDG04354	CS-204	.	Terminated	O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3185-90.
PT00199	M6APDG04360	CS-207	.	Terminated	Discovery of cyclic amine-substituted benzoic acids as PPARalpha agonists. Bioorg Med Chem Lett. 2012 Jan 1;22(1):334-8.
PT00199	M6APDG04363	KRP-105	.	Terminated	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
PT00035	M6APDG00903	FARGLITAZAR	CID: 170364	Phase 3	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
PT00199	M6APDG00993	TESAGLITAZAR	CID: 208901	Phase 3	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
PT00035	M6APDG00584	AD-5075	CID: 128440	Terminated	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
PT00199	M6APDG04375	BVT-142	.	Terminated	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026848)
PT00092	M6APDG04350	KRH-2731	.	Terminated	Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology. 2000 Mar 15;268(2):329-44.
PT00031	M6APDG03707	AHL	.	Investigative	2011 Pipeline of Quark Pharm.
PT00044	M6APDG03565	DL-3	.	Investigative	Clinical pipeline report, company report or official report of Progenics Pharmaceuticals Serometrix.
PT00162	M6APDG03477	AMSH	.	Investigative	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
PT00013	M6APDG03741	677T	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
PT00231	M6APDG02423	Altiratinib	CID: 54576299	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
PT00193	M6APDG03548	S-111	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00193	M6APDG03550	S-070	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00193	M6APDG03545	KR-33889	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00193	M6APDG03546	INO-1002	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00193	M6APDG03547	ANG-2684	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00193	M6APDG03551	HYDAMTIQ	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00193	M6APDG03549	BPI-704001	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00193	M6APDG02149	PJ34	CID: 4858	Preclinical	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00193	M6APDG03272	A-620223	CID: 9925908	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00193	M6APDG00762	PD-128763	CID: 148140	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
PT00025	M6APDG03458	K-454	.	Investigative	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23.
PT00146	M6APDG03459	VX-467	.	Investigative	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23.
PT00044	M6APDG03482	ARN34	.	Investigative	Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. J Med Chem. 2006 Dec 14;49(25):7366-72.
PT00044	M6APDG00252	YM-175735	CID: 11178122	Investigative	Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. J Med Chem. 2006 Dec 14;49(25):7366-72.
PT00044	M6APDG03524	SARMs	.	Investigative	EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
PT00114	M6APDG03522	MG-28	.	Investigative	A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774-9.
PT00034	M6APDG03625	NMS-1	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
PT00034	M6APDG00303	BI 2536	CID: 11364421	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
PT00034	M6APDG02043	MLN-0905	CID: 46235922	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
PT00035	M6APDG03645	ZY H2	.	Investigative	CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof.
PT00199	M6APDG03645	ZY H2	.	Investigative	CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof.
PT00023	M6APDG03668	IKI-1	.	Investigative	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
PT00043	M6APDG03500	ISC-4	.	Investigative	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
PT00057	M6APDG00288	A-674563	CID: 11314340	Investigative	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
PT00155	M6APDG01102	ACTB-1003	CID: 23653175	Investigative	2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
PT00162	M6APDG03486	HS014	.	Investigative	Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
PT00231	M6APDG03742	ABTAA	.	Investigative	Cmpany report (Arraybiopharma)
PT00092	M6APDG03781	CX-02	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00092	M6APDG03780	ND-401	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00092	M6APDG03784	AT-009	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00092	M6APDG03785	LP-0067	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00092	M6APDG03783	KUR-CXCR4	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00092	M6APDG03782	CXCR4 gene disrupted T cells	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00085	M6APDG02956	Custirsen	CID: 72941942	Phase 3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00092	M6APDG00822	NB-325	CID: 15954275	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00092	M6APDG00536	ATI-2341	CID: 121513892	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00092	M6APDG00458	GSK-812397	CID: 11718722	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
PT00146	M6APDG03583	AD-412	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
PT00061	M6APDG02841	CN-105	CID: 69085	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
PT00146	M6APDG02561	VX-509	CID: 59422203	Phase 2/3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
PT00146	M6APDG02380	PF-956980	CID: 53344620	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
PT00046	M6APDG03600	WL-276	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7920).
PT00174	M6APDG03454	PD-156	.	Investigative	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
PT00012	M6APDG02495	GS-5745	CID: 56776542	Phase 3	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
PT00035	M6APDG03465	DB-900	.	Investigative	Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato) oxovanadium(IV) in ZDF rats. Canadian Journal of Physiology and Pharmacology. 12/2003; 81(11):1049-55.
PT00197	M6APDG03480	XB-387	.	Investigative	A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.
PT00050	M6APDG03437	ON-128	.	Investigative	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
PT00050	M6APDG02133	PD-158780	CID: 4707	Investigative	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
PT00050	M6APDG02967	(3-Bromo-phenyl)-quinazolin-4-yl-amine	CID: 735125	Investigative	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
PT00050	M6APDG01649	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline	CID: 44331083	Investigative	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
PT00050	M6APDG00166	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CID: 10494722	Investigative	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
PT00050	M6APDG03441	ICR 62	.	Investigative	Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26.
PT00050	M6APDG00138	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CID: 10401956	Investigative	Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26.
PT00050	M6APDG03455	OSI-75	.	Investigative	Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22.
PT00170	M6APDG03665	DP-802	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
PT00170	M6APDG03667	PHA-666859	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
PT00170	M6APDG03666	UCB-1277763	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
PT00170	M6APDG02270	Ozagrel	CID: 5282440	Phase 4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
PT00123	M6APDG03692	DM-204	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030).
PT00123	M6APDG01895	9-ING-41	CID: 44582816	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030).
PT00231	M6APDG03509	AP-101	.	Investigative	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
PT00196	M6APDG01196	PP121	CID: 24905142	Investigative	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
PT00173	M6APDG03515	MMP-408	.	Investigative	Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. J Med Chem. 2013 Feb 14;56(3):1149-59.
PT00044	M6APDG03476	GTx-027	.	Investigative	17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol Lett. 2006 Aug 20;165(2):149-55.
PT00044	M6APDG03491	HYG-440	.	Investigative	Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47-58.
PT00041	M6APDG03539	APG-103	.	Investigative	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
PT00031	M6APDG01572	Kevetrin	CID: 437740	Phase 2	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
PT00046	M6APDG00311	Obatoclax	CID: 11404337	Phase 2	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
PT00216	M6APDG02865	Imisopasem manganese	CID: 6918487	Phase 2	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
PT00213	M6APDG03501	YK-3237	.	Investigative	Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specif... J Med Chem. 2010 Feb 11;53(3):1407-11.
PT00213	M6APDG02191	Ro31-8220	CID: 5083	Investigative	Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specif... J Med Chem. 2010 Feb 11;53(3):1407-11.
PT00036	M6APDG03438	PNT-300	.	Investigative	Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem. 1996 Nov 8;271(45):28259-65.
PT00165	M6APDG03518	ALD-806	.	Investigative	Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6.
PT00224	M6APDG03626	TAT-120	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2844).
PT00070	M6APDG03519	SJ-8002	.	Investigative	Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86.
PT00170	M6APDG03512	GSK-280	.	Investigative	Novel triazolopyridylbenzamides as potent and selective p38alpha inhibitors. Bioorg Med Chem Lett. 2012 May 15;22(10):3431-6.
PT00015	M6APDG03445	CR-4174	.	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00193	M6APDG02994	Niraparib Tosylate	CID: 78357761	Approved	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00044	M6APDG00820	Enzalutamide	CID: 15951529	Approved	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00130	M6APDG01014	Amlexanox	CID: 2161	Approved	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00130	M6APDG01339	Cromoglicate	CID: 2882	Approved	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00172	M6APDG00605	GM6001	CID: 132519	Discontinued in Phase 2	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00008	M6APDG02529	PG-545	CID: 57412324	Phase 1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00031	M6APDG02304	APR-246	CID: 52918385	Phase 2	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00185	M6APDG02445	L-695902	CID: 54695867	Terminated	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00123	M6APDG01937	I-5	CID: 448008	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00025	M6APDG01222	AZ960	CID: 25099184	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00241	M6APDG00904	Fucose	CID: 17106	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG01119	BOHEMINE	CID: 2422	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00170	M6APDG03212	Talmapimod	CID: 9871074	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00081	M6APDG00681	RGB-286147	CID: 135473382	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00173	M6APDG01949	PF-00356231	CID: 448942	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00170	M6APDG02944	2-Chlorophenol	CID: 7245	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00170	M6APDG02298	Triazolopyridine	CID: 5289514	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00015	M6APDG02237	Prostaglandin G2	CID: 5280883	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG02696	TRIAZOLOPYRIMIDINE	CID: 64962	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00004	M6APDG01337	aminooxyacetic acid	CID: 286	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00014	M6APDG01962	Se-Ethyl-Isoselenourea	CID: 449633	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00014	M6APDG01468	2-Propanol, Isopropanol	CID: 3776	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG00921	Lysine Nz-Carboxylic Acid	CID: 17754054	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00014	M6APDG00874	3-bromo-7-nitro-1H-indazole	CID: 1649	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00014	M6APDG01230	Hydroxydimethylarsine Oxide	CID: 2513	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00185	M6APDG00570	(RS)-(tetrazol-5-yl)glycine	CID: 126383	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00035	M6APDG02320	9-hydroxyoctadecadienoic acid	CID: 5312830	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00014	M6APDG00961	[1,3]Thiazinan-(2E)-ylideneamine	CID: 189081	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00054	M6APDG02492	5-deoxy-5-phosphono-D-arabinonate	CID: 56603745	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG02825	N-phenyl-1H-pyrazole-3-carboxamide	CID: 680935	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG03022	5-hydroxynaphthalene-1-sulfonamide	CID: 87031	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00173	M6APDG01273	N-(biphenyl-4-ylsulfonyl)-D-leucine	CID: 25271580	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG00790	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	CID: 1540	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00241	M6APDG02418	Thieno[2,3-B]Pyridine-2-Carboxamidine	CID: 5438	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG02375	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE	CID: 5330608	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00173	M6APDG02126	N-oxo-2-(phenylsulfonylamino)ethanamide	CID: 46937108	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00014	M6APDG00710	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin	CID: 135905887	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00035	M6APDG00936	3-(5-methoxy-1H-indol-3-yl)propanoic acid	CID: 181137	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00035	M6APDG02313	15-deoxy-Delta(12, 14)-prostaglandin J(2)	CID: 5311211	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00170	M6APDG01079	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE	CID: 2352168	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00241	M6APDG00896	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine	CID: 16758228	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00241	M6APDG01553	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea	CID: 4286	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00130	M6APDG01952	8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-	CID: 448968	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00193	M6APDG02769	2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide	CID: 657038	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00130	M6APDG02293	9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine	CID: 5289227	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00130	M6APDG02294	9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine	CID: 5289228	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00130	M6APDG00246	2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol	CID: 11160307	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00173	M6APDG01155	N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine	CID: 24794392	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00035	M6APDG00242	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid	CID: 11149906	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00241	M6APDG01934	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	CID: 447732	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00035	M6APDG00325	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid	CID: 11460087	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG03275	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	CID: 9926933	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00193	M6APDG00779	2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide	CID: 1511	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00035	M6APDG00336	(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid	CID: 11483970	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00173	M6APDG02125	N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide	CID: 46937106	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00005	M6APDG01658	1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole	CID: 44341253	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00130	M6APDG00613	6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE	CID: 13373715	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00035	M6APDG02669	(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid	CID: 6443013	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG01932	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	CID: 447649	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00079	M6APDG03316	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	CID: 9994066	Investigative	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
PT00015	M6APDG03670	CX-9051	.	Investigative	US patent application no. 6,274,627, Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor.
PT00015	M6APDG03672	XGP-110	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
PT00015	M6APDG03671	PAC-10649	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
PT00015	M6APDG03669	Silicon-modified indomethacin	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
PT00057	M6APDG03511	ALM-301	.	Investigative	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
PT00022	M6APDG01892	GSK1511931	CID: 44581765	Investigative	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
PT00117	M6APDG03682	PRX-111	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253).
PT00117	M6APDG03683	Long-acting FSH conjugate	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253).
PT00117	M6APDG02398	Suramin	CID: 5361	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253).
PT00162	M6APDG03449	BL-6020	.	Investigative	Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry. 2000 Dec 5;39(48):14900-11.
PT00086	M6APDG03513	Endo-CD	.	Investigative	Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91.
PT00199	M6APDG03452	LL-6531	.	Investigative	Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett. 2001 May 7;11(9):1225-7.
PT00051	M6APDG03453	PNT-500	.	Investigative	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
PT00051	M6APDG02950	Redoxal	CID: 72571	Investigative	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
PT00050	M6APDG03096	EGFR inhibitor	CID: 9549299	Investigative	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
PT00051	M6APDG03319	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CID: 9995195	Investigative	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
PT00051	M6APDG01635	(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine	CID: 44279279	Investigative	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
PT00227	M6APDG03525	ART-144	.	Investigative	The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-beta1 pathway in human lung fibroblasts. Immunol Lett. 2015 Jun;165(2):90-101.
PT00193	M6APDG03450	ANG-2864	.	Investigative	Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001 Jan;7(1):108-13.
PT00193	M6APDG00697	2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one	CID: 135547083	Investigative	Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001 Jan;7(1):108-13.
PT00025	M6APDG03506	SGI-1252	.	Investigative	A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer. 2010 Apr;1(4):331-45.
PT00044	M6APDG03521	ASC-JMX2	.	Investigative	Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One. 2014 Jul 29;9(7):e103202.
PT00005	M6APDG03489	MR-20814	.	Investigative	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
PT00005	M6APDG00334	LIQUIRTIGENIN	CID: 114829	Investigative	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
PT00005	M6APDG00088	2-(4-hydroxyphenyl)-7-methoxychroman-4-one	CID: 10265122	Investigative	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
PT00005	M6APDG02618	7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one	CID: 620596	Investigative	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
PT00005	M6APDG02610	2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one	CID: 6116651	Investigative	New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
PT00241	M6APDG03442	ATF-HI-8	.	Investigative	Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep. 1999 May-Jun;6(3):523-6.
PT00106	M6APDG03601	Hebervis	.	Investigative	Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52.
PT00034	M6APDG03496	CHR-4125	.	Investigative	Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21.
PT00034	M6APDG00832	GSK579289A	CID: 16051023	Investigative	Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21.
PT00125	M6APDG03517	KAR-1880	.	Investigative	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33.
PT00167	M6APDG03516	AEZS-131	.	Investigative	Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013 Jul;3(7):742-50.
PT00117	M6APDG03436	FSHR NAM	.	Investigative	The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65.
PT00123	M6APDG03505	CP-70949	.	Investigative	Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells. Bioorg Med Chem. 2010 Sep 15;18(18):6785-95.
PT00020	M6APDG03472	ISIS-1939	.	Investigative	Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol. 2005 Oct;153(4):758-66.
PT00036	M6APDG03474	ISIS 7453	.	Investigative	Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84.
PT00123	M6APDG03448	STAUROSPORINONE	.	Investigative	Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84.
PT00026	M6APDG02485	TAM-67	CID: 5626	Investigative	Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84.
PT00036	M6APDG03602	ISIS 6957	.	Investigative	US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.
PT00036	M6APDG03603	ISIS 6958	.	Investigative	US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.
PT00153	M6APDG03433	ISIS 6603	.	Investigative	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
PT00153	M6APDG03604	ISIS 6432	.	Investigative	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
PT00153	M6APDG03605	ISIS 6443	.	Investigative	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
PT00153	M6APDG03606	ISIS 6431	.	Investigative	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
PT00153	M6APDG03607	ISIS 6442	.	Investigative	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
PT00153	M6APDG03608	ISIS 6435	.	Investigative	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
PT00153	M6APDG03609	ISIS 6434	.	Investigative	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
PT00153	M6APDG03610	ISIS 6445	.	Investigative	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
PT00153	M6APDG03611	ISIS 6553	.	Investigative	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
PT00153	M6APDG03612	ISIS 6581	.	Investigative	US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
PT00020	M6APDG03640	ISIS 2974	.	Investigative	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
PT00020	M6APDG03641	ISIS 3067	.	Investigative	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
PT00020	M6APDG03642	ISIS 3224	.	Investigative	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
PT00020	M6APDG03643	ISIS 11665	.	Investigative	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
PT00020	M6APDG03644	ISIS 11159	.	Investigative	US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
PT00243	M6APDG03502	ISIS 3804	.	Investigative	Symbiopolyol, a VCAM-1 inhibitor from a symbiotic dinoflagellate of the jellyfish Mastigias papua. J Nat Prod. 2010 Jul 23;73(7):1318-22.
PT00243	M6APDG03675	ISIS 5884	.	Investigative	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
PT00243	M6APDG03676	ISIS 3792	.	Investigative	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
PT00243	M6APDG03677	ISIS 5874	.	Investigative	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
PT00243	M6APDG03678	ISIS 5876	.	Investigative	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
PT00243	M6APDG03679	ISIS 5875	.	Investigative	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
PT00243	M6APDG03680	ISIS 3805	.	Investigative	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
PT00243	M6APDG03681	ISIS 3801	.	Investigative	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
PT00202	M6APDG02986	Abaloparatide	CID: 76943386	Approved	US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
PT00079	M6APDG03684	VER-54505	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973).
PT00079	M6APDG03246	PHA-690509	CID: 9902100	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973).
PT00092	M6APDG03494	CTCE-0324	.	Investigative	Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem. 2008 Dec 25;51(24):7915-20.
PT00092	M6APDG00251	isothiourea-1a	CID: 11176403	Investigative	Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem. 2008 Dec 25;51(24):7915-20.
PT00051	M6APDG03786	ISIS 9002	.	Investigative	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
PT00051	M6APDG03787	ISIS 9003	.	Investigative	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
PT00051	M6APDG03788	ISIS 9005	.	Investigative	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
PT00051	M6APDG03789	ISIS 12882	.	Investigative	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
PT00051	M6APDG03790	ISIS 12883	.	Investigative	US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
PT00028	M6APDG03479	ISIS 16518	.	Investigative	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21.
PT00031	M6APDG02135	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	CID: 4722579	Investigative	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21.
PT00028	M6APDG03564	ISIS 16507	.	Investigative	US patent application no. 6,238,921, Antisense oligonucleotide modulation of human mdm2 expression.
PT00083	M6APDG03563	ISIS 116508	.	Investigative	US patent application no. 6,238,921, Antisense oligonucleotide modulation of human mdm2 expression.
PT00051	M6APDG03435	PF 5208766	.	Investigative	WO patent application no. 2005,0443,02, Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer.
PT00144	M6APDG03584	ISIS 25237	.	Investigative	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
PT00168	M6APDG00459	BVD-523	CID: 11719003	Phase 2	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
PT00035	M6APDG02969	[125I]SB-236636	CID: 73755028	Investigative	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
PT00191	M6APDG03498	WAY-254011	.	Investigative	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
PT00191	M6APDG00187	2-(2-hexylphenyl)isoindoline-1,3-dione	CID: 10638446	Investigative	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
PT00191	M6APDG01857	N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide	CID: 44537911	Investigative	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
PT00191	M6APDG01987	N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide	CID: 45481821	Investigative	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
PT00191	M6APDG01988	N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide	CID: 45481844	Investigative	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.
PT00020	M6APDG03504	ISIS 11158	.	Investigative	Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73.
PT00050	M6APDG03435	PF 5208766	.	Investigative	Effects of hEGF (MG111) on gastric mucosal potential difference in rats. Scand J Gastroenterol Suppl. 1989;162:198-201.
PT00026	M6APDG03483	ISIS 10582	.	Investigative	Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4338-42.
PT00026	M6APDG01289	Pergularinine	CID: 264751	Investigative	Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4338-42.
PT00248	M6APDG03690	ISIS 14548	.	Investigative	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
PT00248	M6APDG03685	ISIS 114527	.	Investigative	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
PT00248	M6APDG03686	ISIS 114530	.	Investigative	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
PT00248	M6APDG03687	ISIS 114531	.	Investigative	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
PT00248	M6APDG03688	ISIS 114532	.	Investigative	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
PT00248	M6APDG03689	ISIS 114537	.	Investigative	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
PT00248	M6APDG03691	ISIS 114559	.	Investigative	US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
PT00053	M6APDG03523	AS-1708727	.	Investigative	(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12853-8.
PT00043	M6APDG03492	ISIS 29202	.	Investigative	Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-o... J Med Chem. 2008 Sep 25;51(18):5663-79.
PT00057	M6APDG00588	Lactoquinomycin	CID: 12967404	Investigative	Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-o... J Med Chem. 2008 Sep 25;51(18):5663-79.
PT00023	M6APDG03462	ISIS 23544	.	Investigative	Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
PT00138	M6APDG01327	SC-514	CID: 2807869	Investigative	Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
PT00023	M6APDG03740	ISIS 23559	.	Investigative	US patent application no. 6,395,545, Antisense modulation of inhibitor-kappa B kinase-alpha expression.
PT00043	M6APDG00307	SB-747651A	CID: 11393719	Investigative	US patent application no. 6,395,545, Antisense modulation of inhibitor-kappa B kinase-alpha expression.
PT00037	M6APDG03514	ISIS 28477	.	Investigative	A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7.
PT00037	M6APDG03759	ISIS 28465	.	Investigative	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
PT00037	M6APDG03760	ISIS 28466	.	Investigative	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
PT00037	M6APDG03761	ISIS 28472	.	Investigative	US patent application no. 6,159,697, Antisense modulation of Smad7 expression.
PT00206	M6APDG03434	Ro-40-0655	.	Investigative	Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. Mol Pharmacol. 1991 Oct;40(4):556-62.
PT00033	M6APDG03451	ISIS 32039	.	Investigative	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
PT00033	M6APDG00598	LY-292223	CID: 131255	Investigative	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
PT00033	M6APDG03762	ISIS 31982	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03763	ISIS 31996	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03764	ISIS 31963	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03765	ISIS 32000	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03766	ISIS 32002	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03767	ISIS 32003	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03768	ISIS 32004	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03769	ISIS 32005	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03770	ISIS 32006	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03771	ISIS 32008	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03772	ISIS 32010	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03773	ISIS 32014	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03774	ISIS 32015	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03775	ISIS 32020	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03776	ISIS 32021	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03777	ISIS 32024	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03778	ISIS 32028	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00033	M6APDG03779	ISIS 32035	.	Investigative	US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
PT00051	M6APDG03471	ISIS 12884	.	Investigative	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
PT00053	M6APDG03470	ISIS 188782	.	Investigative	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
PT00196	M6APDG00062	CP-673451	CID: 10158940	Investigative	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
PT00167	M6APDG00340	FR-180204	CID: 11493598	Investigative	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
PT00057	M6APDG00307	SB-747651A	CID: 11393719	Investigative	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
PT00079	M6APDG02711	PYRAZOLOPYRIDAZINE 2	CID: 6539367	Investigative	Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
PT00035	M6APDG03466	ISIS 105989	.	Investigative	Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. J Med Chem. 2004 Aug 12;47(17):4118-27.
PT00035	M6APDG03542	ISIS 105990	.	Investigative	US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression.
PT00035	M6APDG03543	ISIS 106008	.	Investigative	US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression.
PT00035	M6APDG03544	ISIS 105987	.	Investigative	US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression.
PT00053	M6APDG03553	ISIS 188755	.	Investigative	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
PT00053	M6APDG03554	ISIS 188757	.	Investigative	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
PT00053	M6APDG03555	ISIS 188759	.	Investigative	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
PT00053	M6APDG03556	ISIS 188761	.	Investigative	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
PT00053	M6APDG03557	ISIS 188763	.	Investigative	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
PT00053	M6APDG03558	ISIS 188778	.	Investigative	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
PT00053	M6APDG03559	ISIS 188780	.	Investigative	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
PT00053	M6APDG03560	ISIS 188781	.	Investigative	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
PT00147	M6APDG01440	5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline	CID: 3542	Investigative	US patent application no. 7,229,976, Modulation of forkhead box O1A expression.
PT00083	M6APDG03561	ISIS 116505	.	Investigative	US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression.
PT00083	M6APDG03562	ISIS 116507	.	Investigative	US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression.
PT00075	M6APDG02362	PD-0183812	CID: 5330258	Terminated	US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression.
PT00027	M6APDG03456	ISIS 122991	.	Investigative	Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer. 2001 Nov;34(2):185-94.
PT00144	M6APDG03473	ISIS 196103	.	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00355	C[-Arg-Gly-Asp-Acpca36-]	CID: 11518823	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00371	C[-Arg-Gly-Asp-Acpca35-]	CID: 11540460	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00372	C[-Arg-Gly-Asp-Acpca22-]	CID: 11540715	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00387	C[-Arg-Gly-Asp-Acpca19-]	CID: 11569720	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00395	C[-Arg-Gly-Asp-Acpca34-]	CID: 11584047	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00406	C[-Arg-Gly-Asp-Acpca21-]	CID: 11613122	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00432	C[-Arg-Gly-Asp-Acpca20-]	CID: 11656381	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00365	C-[-Arg-Gly-Asp-Acpca31-]	CID: 11533023	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00394	C-[-Arg-Gly-Asp-Acpca32-]	CID: 11583738	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00144	M6APDG00453	C-[-Arg-Gly-Asp-Acpca30-]	CID: 11712622	Investigative	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
PT00097	M6APDG03585	ISIS 138612	.	Investigative	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
PT00097	M6APDG03586	ISIS 138613	.	Investigative	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
PT00097	M6APDG03587	ISIS 138616	.	Investigative	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
PT00097	M6APDG03588	ISIS 138647	.	Investigative	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
PT00097	M6APDG03589	ISIS 138648	.	Investigative	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
PT00097	M6APDG03590	ISIS 138649	.	Investigative	US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
PT00105	M6APDG03592	ISIS 114170	.	Investigative	US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
PT00105	M6APDG03593	ISIS 114184	.	Investigative	US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
PT00105	M6APDG03594	ISIS 114197	.	Investigative	US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
PT00020	M6APDG00523	lifitegrast	CID: 11965427	Approved	US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
PT00165	M6APDG03463	PF-00614435	.	Investigative	Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003 Nov;2(11):1085-92.
PT00018	M6APDG03488	ISIS 298746	.	Investigative	Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10.
PT00018	M6APDG03628	ISIS 175510	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03629	ISIS 298697	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03630	ISIS 298711	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03631	ISIS 298712	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03632	ISIS 298699	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03633	ISIS 298700	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03634	ISIS 298701	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03635	ISIS 298702	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03636	ISIS 298743	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03637	ISIS 298744	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00018	M6APDG03638	ISIS 298745	.	Investigative	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00137	M6APDG01461	I3C	CID: 3712	Phase 3	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
PT00145	M6APDG03503	ISIS 148715	.	Investigative	Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53(15):5844-57.
PT00248	M6APDG03464	ISIS 114563	.	Investigative	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
PT00078	M6APDG02709	AZAKENPAULLONE	CID: 6538897	Investigative	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
PT00123	M6APDG02709	AZAKENPAULLONE	CID: 6538897	Investigative	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
PT00078	M6APDG01115	Bisindolylmaleimide-I	CID: 2396	Investigative	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
PT00123	M6APDG01115	Bisindolylmaleimide-I	CID: 2396	Investigative	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
PT00029	M6APDG03520	PF-05094037	.	Investigative	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7.
PT00045	M6APDG03485	ISIS 173813	.	Investigative	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
PT00045	M6APDG00716	Indirubin-3-methoxime	CID: 136043836	Investigative	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
PT00045	M6APDG00717	Indirubin-3-acetoxime	CID: 136043837	Investigative	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
PT00045	M6APDG01459	Indirubin-3'-monoxime	CID: 3707	Investigative	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
PT00045	M6APDG01950	6-bromoindirubin-3-oxime	CID: 448949	Investigative	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
PT00045	M6APDG00718	7-fluoroindirubin-3-acetoxime	CID: 136104466	Investigative	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
PT00045	M6APDG03704	ISIS 173840	.	Investigative	US patent application no. 7,375,212, Modulation of Aurora B expression.
PT00045	M6APDG03705	ISIS 173848	.	Investigative	US patent application no. 7,375,212, Modulation of Aurora B expression.
PT00045	M6APDG03706	ISIS 173831	.	Investigative	US patent application no. 7,375,212, Modulation of Aurora B expression.
PT00102	M6APDG03499	ISIS 133245	.	Investigative	Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6.
PT00102	M6APDG03708	ISIS 133206	.	Investigative	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
PT00102	M6APDG03709	ISIS 133207	.	Investigative	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
PT00102	M6APDG03710	ISIS 133208	.	Investigative	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
PT00102	M6APDG03711	ISIS 133211	.	Investigative	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
PT00102	M6APDG03712	ISIS 133242	.	Investigative	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
PT00102	M6APDG03713	ISIS 133243	.	Investigative	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
PT00102	M6APDG03714	ISIS 133244	.	Investigative	US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.
PT00207	M6APDG03487	ISIS 104258	.	Investigative	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00208	M6APDG00247	ARM036	CID: 11161474	Discontinued in Phase 2	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00138	M6APDG01623	Staurosporine	CID: 44259	Phase 2	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00207	M6APDG02211	NM-PP1	CID: 5154691	Investigative	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00169	M6APDG02191	Ro31-8220	CID: 5083	Investigative	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00045	M6APDG00424	CGP-57380	CID: 11644425	Investigative	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00045	M6APDG00658	HESPERADIN	CID: 135421442	Investigative	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00123	M6APDG02223	8-OH-MANZAMINE A	CID: 5270765	Investigative	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00169	M6APDG01115	Bisindolylmaleimide-I	CID: 2396	Investigative	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00073	M6APDG01122	4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine	CID: 242623	Investigative	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
PT00207	M6APDG03743	ISIS 104211	.	Investigative	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
PT00207	M6APDG03744	ISIS 104253	.	Investigative	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
PT00207	M6APDG03745	ISIS 104254	.	Investigative	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
PT00207	M6APDG03746	ISIS 104255	.	Investigative	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
PT00207	M6APDG03747	ISIS 104256	.	Investigative	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
PT00207	M6APDG03748	ISIS 104257	.	Investigative	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
PT00207	M6APDG00758	Src kinase inhibitor I	CID: 1474853	Investigative	US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
PT00215	M6APDG03530	ISIS 101998	.	Investigative	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
PT00215	M6APDG03749	ISIS 101960	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00215	M6APDG03750	ISIS 101952	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00215	M6APDG03751	ISIS 101983	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00215	M6APDG03752	ISIS 101984	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00215	M6APDG03753	ISIS 101985	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00215	M6APDG03754	ISIS 101986	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00215	M6APDG03755	ISIS 101987	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00215	M6APDG03756	ISIS 101995	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00215	M6APDG03757	ISIS 101996	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00215	M6APDG03758	ISIS 101997	.	Investigative	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00006	M6APDG02824	PINOCEMBRIN	CID: 68071	Phase 2	US patent application no. 6,277,636, Antisense inhibition of MADH6 expression.
PT00015	M6APDG03447	Bimetopyrole	.	Investigative	Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun. 2000 Jul 5;273(2):772-5.
PT00057	M6APDG03448	STAUROSPORINONE	.	Investigative	Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol. 2008 Sep;4(9):538-47.
PT00057	M6APDG02653	MYRIOCIN	CID: 6438394	Investigative	Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol. 2008 Sep;4(9):538-47.
PT00162	M6APDG03497	D-Phe-Arg-2-Nal-NHCH3	.	Investigative	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
PT00162	M6APDG01148	C[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2	CID: 24774356	Investigative	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
PT00162	M6APDG00885	Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2	CID: 16724004	Investigative	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
PT00193	M6APDG03468	Thieno-phenanthridin-6-one	.	Investigative	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
PT00193	M6APDG00702	PMID27841036-Compound-37	CID: 135565981	Phase 2	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
PT00193	M6APDG00693	DR2313	CID: 135522417	Investigative	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
PT00193	M6APDG00908	4-amino-1,8-naphthalimide	CID: 1720	Investigative	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
PT00130	M6APDG03443	Geldanamycin-estradiol hybrid	.	Investigative	Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
PT00130	M6APDG01146	SNX-2112	CID: 24772860	Investigative	Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
PT00051	M6APDG03443	Geldanamycin-estradiol hybrid	.	Investigative	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
PT00050	M6APDG02134	PD-168393	CID: 4708	Investigative	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
PT00051	M6APDG02134	PD-168393	CID: 4708	Investigative	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
PT00050	M6APDG02335	N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine	CID: 5328045	Investigative	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
PT00241	M6APDG03446	Recombinant human pro-urokinase	.	Investigative	Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol. 2000 Apr;7(4):299-312.
PT00071	M6APDG03460	Gold trichloride sodium chloride	.	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00217	M6APDG02142	Terameprocol	CID: 476861	Phase 2	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01675	Z-leu-Val-Agly-Val-OBzl	CID: 44355152	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01673	Z-Arg-Leu-Val-Agly-Ala-Gly-NH2	CID: 44355110	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01676	Z-Ala-Leu-Phe-Agly-Ile-Val-OMe	CID: 44355205	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01677	Z-Ala-Leu-lle-Agly-Ile-Val-OMe	CID: 44355206	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01681	Z-Ala-Leu-Nal-Agly-Ile-Val-OMe	CID: 44355523	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01682	Z-Ala-Leu-His-Agly-Ile-Val-OMe	CID: 44355524	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01672	Z-Arg-Leu-Val-Agly-Ileu-Val-OMe	CID: 44355092	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01680	Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl	CID: 44355522	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01671	Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2	CID: 44355091	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01678	Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe	CID: 44355267	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00071	M6APDG01679	Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2	CID: 44355268	Investigative	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
PT00115	M6APDG03715	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1443).
PT00046	M6APDG03478	modified HA14-1 compounds (cancer)	.	Investigative	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
PT00046	M6APDG02988	QEDIIRNIARHLAQVGDSMDR	CID: 77280325	Investigative	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
PT00046	M6APDG00836	N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide	CID: 16090304	Investigative	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
PT00046	M6APDG00677	5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine	CID: 135468219	Investigative	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.
PT00185	M6APDG03475	4-Chloro-3-hydroxy-1H-quinolin-2-one	.	Investigative	Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41.
PT00250	M6APDG03444	Anti-miR-191 modified oligonucleotide	.	Investigative	Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.
PT00117	M6APDG03439	Recombinant follicle stimulating hormone	.	Investigative	A naturally occurring basically charged human follicle-stimulating hormone (FSH) variant inhibits FSH-induced androgen aromatization and tissue-type plasminogen activator enzyme activity in vitro. Neuroendocrinology. 1998 Mar;67(3):153-63.
PT00029	M6APDG03467	Rapamycin complexed with immunophilin FKBP12	.	Investigative	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
PT00029	M6APDG00016	2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one	CID: 10039361	Investigative	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
PT00029	M6APDG03198	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	CID: 9860529	Investigative	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
PT00185	M6APDG03440	4-Benzyl-1-phenethyl-piperidine hydrochloride	.	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00185	M6APDG00200	Phenethyl-(4-phenyl-butyl)-amine	CID: 10708590	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00185	M6APDG00199	4-[2-(4-Phenyl-butoxy)-ethyl]-phenol	CID: 10707190	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00185	M6APDG00854	(R)-2-Amino-7-phosphono-heptanoic acid	CID: 1617430	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00185	M6APDG00198	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol	CID: 10707108	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00185	M6APDG00208	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol	CID: 10782907	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00185	M6APDG00110	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol	CID: 10336113	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00185	M6APDG01510	6-Nitro-1,4-dihydro-quinoxaline-2,3-dione	CID: 4038142	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00185	M6APDG02443	4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one	CID: 54688796	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00185	M6APDG00195	4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol	CID: 10685438	Investigative	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506.
PT00125	M6APDG03469	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	.	Investigative	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
PT00125	M6APDG00280	4-Butyrylamino-N-hydroxy-benzamide	CID: 11287488	Investigative	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
PT00125	M6APDG00321	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CID: 11449823	Investigative	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
PT00125	M6APDG01683	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CID: 44361923	Investigative	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
PT00125	M6APDG00276	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CID: 11277483	Investigative	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
PT00125	M6APDG00327	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	CID: 11472431	Investigative	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
PT00125	M6APDG00286	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	CID: 11312563	Investigative	Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
PT00005	M6APDG03495	6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione	.	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01523	NSC-12999	CID: 408350	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG02644	NSC-75308	CID: 6415854	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00687	NSC-131736	CID: 135494055	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01388	NSC-289311	CID: 324288	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01414	NSC-356483	CID: 337660	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01415	NSC-356781	CID: 337743	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01422	NSC-368272	CID: 339906	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01423	NSC-368280	CID: 339914	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01446	NSC-625409	CID: 361928	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01482	NSC-683634	CID: 388623	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01891	NSC-666292	CID: 44580826	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00205	5-(2-(1H-imidazol-1-yl)ethyl)quinoline	CID: 10751574	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00204	7-((1H-imidazol-1-yl)methyl)isoquinoline	CID: 10750911	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00549	4-((1H-imidazol-1-yl)methyl)benzonitrile	CID: 1236449	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG03273	1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole	CID: 9926623	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00119	2-(3-hydroxyphenyl)-7-methoxychroman-4-one	CID: 10355761	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00174	1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one	CID: 10546089	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00274	4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one	CID: 11276192	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG02395	1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone	CID: 53602	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00173	1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole	CID: 10537337	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00261	7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one	CID: 11230598	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00285	4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one	CID: 11311402	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG00206	5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline	CID: 10774864	Investigative	Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50.
PT00005	M6APDG01043	Methadone	CID: 22267	Approved	Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005 Jan 1;69(1):187-97.
PT00005	M6APDG01487	Letrozole	CID: 3902	Approved	Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208-13.
PT00005	M6APDG01494	Levomethadyl acetate hydrochloride	CID: 39371	Approved	N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
PT00005	M6APDG01598	Testosterone cypionate	CID: 441404	Approved	Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev. 2008 Mar;57(2):431-43.
PT00005	M6APDG03346	Dehydroepiandrosterone	CID: 5881	Approved	Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet. 1975 Nov 15;2(7942):943-6.
PT00005	M6APDG03250	Nandrolone	CID: 9904	Approved	Aromatization of testosterone and 19-nortestosterone by a single enzyme from equine testicular microsomes. Differences from human placental aromatase. J Steroid Biochem. 1988 Jan;29(1):119-25.
PT00087	M6APDG00050	Pazopanib	CID: 10113978	Approved	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
PT00087	M6APDG00066	Apixaban	CID: 10182969	Approved	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
PT00087	M6APDG00235	Amitriptyline hydrochloride	CID: 11065	Approved	The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol. 2000 Dec;50(6):573-80.
PT00087	M6APDG00284	Riociguat	CID: 11304743	Approved	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
PT00087	M6APDG00354	Trifarotene	CID: 11518241	Approved	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
PT00087	M6APDG00468	Losartan potassium	CID: 11751549	Approved	Drug-drug interaction between losartan and paclitaxel in human liver microsomes with different CYP2C8 genotypes. Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):493-8.
PT00087	M6APDG00514	Quinine sulfate	CID: 11949689	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG00517	Nilotinib	CID: 11957582	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG00544	Imatinib mesylate	CID: 123596	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG00820	Enzalutamide	CID: 15951529	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG01105	Cerivastatin sodium	CID: 23663992	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG01497	Loratadine	CID: 3957	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG01514	Mefenamic acid	CID: 4044	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG01586	Quinidine	CID: 441074	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG01598	Testosterone cypionate	CID: 441404	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG01851	Dabrafenib mesylate	CID: 44516822	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG02193	Rofecoxib	CID: 5090	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG03345	Estradiol	CID: 5757	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG02598	Atorvastatin calcium	CID: 60822	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG02705	Testosterone undecanoate	CID: 65157	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG03089	Testosterone enanthate	CID: 9416	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG03129	Estradiol acetate	CID: 9818306	Approved	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
PT00087	M6APDG00546	Almotriptan malate	CID: 123607	Approved	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
PT00087	M6APDG00558	Desloratadine	CID: 124087	Approved	Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015 Sep;43(9):1294-302.
PT00087	M6APDG00636	Clozapine	CID: 135398737	Approved	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
PT00087	M6APDG00666	Eltrombopag olamine	CID: 135449331	Approved	Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther Drug Monit. 2018 Aug;40(4):386-388.
PT00087	M6APDG00740	Estradiol valerate	CID: 13791	Approved	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
PT00087	M6APDG03088	Estradiol cypionate	CID: 9403	Approved	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
PT00087	M6APDG00798	Capsaicin	CID: 1548943	Approved	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
PT00087	M6APDG00807	Naproxen	CID: 156391	Approved	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
PT00087	M6APDG00860	Warfarin sodium	CID: 16204922	Approved	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
PT00087	M6APDG00920	Phenytoin	CID: 1775	Approved	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
PT00087	M6APDG01439	Zidovudine	CID: 35370	Approved	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
PT00087	M6APDG01455	Lidocaine	CID: 3676	Approved	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
PT00087	M6APDG01528	Nicardipine hydrochloride	CID: 41114	Approved	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
PT00087	M6APDG01539	Mirtazapine	CID: 4205	Approved	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
PT00087	M6APDG02388	Sulfinpyrazone	CID: 5342	Approved	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
PT00087	M6APDG01025	Anastrozole	CID: 2187	Approved	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
PT00087	M6APDG01043	Methadone	CID: 22267	Approved	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
PT00087	M6APDG01063	Azelastine	CID: 2267	Approved	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
PT00087	M6APDG01104	Fluvastatin sodium	CID: 23663976	Approved	Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):104-8.
PT00087	M6APDG01106	Montelukast sodium	CID: 23663996	Approved	Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37.
PT00087	M6APDG01126	Benzyl alcohol	CID: 244	Approved	Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65.
PT00087	M6APDG03329	Apalutamide	CID: 24872560	Approved	Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705.
PT00087	M6APDG03331	Glasdegib	CID: 25166913	Approved	Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017 Dec;47(12):1064-1076.
PT00087	M6APDG01244	Ixazomib	CID: 25183872	Approved	Ninlaro- European Medicines Agency - European Union
PT00087	M6APDG01248	Caffeine	CID: 2519	Approved	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
PT00087	M6APDG01276	Carbamazepine	CID: 2554	Approved	Potential interaction between ritonavir and carbamazepine. Pharmacotherapy. 2000 Jul;20(7):851-4.
PT00087	M6APDG01290	Celecoxib	CID: 2662	Approved	Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
PT00087	M6APDG01294	Selegiline hydrochloride	CID: 26758	Approved	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
PT00087	M6APDG01314	Cisapride	CID: 2769	Approved	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
PT00087	M6APDG01341	Cyclophosphamide	CID: 2907	Approved	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
PT00087	M6APDG01456	Ifosfamide	CID: 3690	Approved	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
PT00087	M6APDG01343	Dapsone	CID: 2955	Approved	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
PT00087	M6APDG01356	Diazepam	CID: 3016	Approved	Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol. 2000 Apr 14;394(2-3):199-209.
PT00087	M6APDG01361	Buprenorphine hydrochloride	CID: 3033050	Approved	Buprenorphine in cancer pain. Support Care Cancer. 2005 Nov;13(11):878-87.
PT00087	M6APDG02282	Naloxone	CID: 5284596	Approved	Buprenorphine in cancer pain. Support Care Cancer. 2005 Nov;13(11):878-87.
PT00087	M6APDG03336	Domperidone	CID: 3151	Approved	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
PT00087	M6APDG01454	Ibuprofen	CID: 3672	Approved	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
PT00087	M6APDG01503	Dexibuprofen	CID: 39912	Phase 4	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
PT00087	M6APDG01465	Halofantrine	CID: 37393	Approved	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
PT00087	M6APDG01466	Irbesartan	CID: 3749	Approved	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
PT00087	M6APDG02569	Ethinyl estradiol	CID: 5991	Approved	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
PT00087	M6APDG01475	Ketorolac	CID: 3826	Approved	Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
PT00087	M6APDG01481	Lansoprazole	CID: 3883	Approved	Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16.
PT00087	M6APDG01519	Mephenytoin	CID: 4060	Approved	Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994 Feb 22;33(7):1743-52.
PT00087	M6APDG01536	Torasemide	CID: 41781	Approved	Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
PT00087	M6APDG01568	Sitagliptin	CID: 4369359	Approved	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
PT00087	M6APDG01593	Amiodarone hydrochloride	CID: 441325	Approved	Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005 May;33(5):630-6.
PT00087	M6APDG01944	Diethylstilbestrol	CID: 448537	Approved	Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21.
PT00087	M6APDG02005	Omeprazole	CID: 4594	Approved	Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct;24(10):1081-7.
PT00087	M6APDG02139	Perphenazine	CID: 4748	Approved	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
PT00087	M6APDG02141	Phenobarbital	CID: 4763	Approved	Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
PT00087	M6APDG02156	Propofol	CID: 4943	Approved	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
PT00087	M6APDG02185	Diclofenac sodium	CID: 5018304	Approved	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
PT00087	M6APDG02219	Sulfadiazine	CID: 5215	Approved	Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
PT00087	M6APDG02244	Mycophenolate mofetil	CID: 5281078	Approved	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
PT00087	M6APDG02272	Pitavastatin calcium	CID: 5282451	Approved	Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8.
PT00087	M6APDG02274	Terbinafine hydrochloride	CID: 5282481	Approved	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
PT00087	M6APDG03105	Eszopiclone	CID: 969472	Approved	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
PT00015	M6APDG01343	Dapsone	CID: 2955	Approved	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
PT00087	M6APDG00609	ML-3000	CID: 133021	Discontinued	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
PT00087	M6APDG01033	Antipyrine	CID: 2206	Investigative	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
PT00087	M6APDG02291	Morphine	CID: 5288826	Approved	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
PT00087	M6APDG02311	Istradefylline	CID: 5311037	Approved	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
PT00087	M6APDG02324	Lovastatin	CID: 53232	Approved	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
PT00087	M6APDG02353	Sulfamethoxazole	CID: 5329	Approved	Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol. 2007 May 1;178(9):5533-42.
PT00087	M6APDG02410	Tazarotene	CID: 5381	Approved	Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos. 2003 Apr;31(4):476-81.
PT00087	M6APDG02413	Temazepam	CID: 5391	Approved	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
PT00087	M6APDG02415	Thalidomide	CID: 5426	Approved	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
PT00087	M6APDG02419	Simvastatin	CID: 54454	Approved	Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
PT00087	M6APDG02431	Piroxicam	CID: 54676228	Approved	Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9 J Pain Res. 2017 Jul 6;10:1581-1589.
PT00087	M6APDG02432	Meloxicam	CID: 54677470	Approved	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
PT00087	M6APDG02438	Phenprocoumon	CID: 54680692	Approved	Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May;60(3):173-82.
PT00087	M6APDG02472	Tolbutamide	CID: 5505	Approved	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
PT00087	M6APDG02478	Trimethadione	CID: 5576	Approved	Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
PT00087	M6APDG02479	Trimethoprim	CID: 5578	Approved	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
PT00087	M6APDG02516	Zafirlukast	CID: 5717	Approved	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
PT00087	M6APDG02482	Troglitazone	CID: 5591	Approved	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
PT00087	M6APDG02501	Vortioxetine hydrobromide	CID: 56843850	Approved	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
PT00087	M6APDG02587	Pioglitazone hydrochloride	CID: 60560	Approved	The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin Pharmacol Toxicol. 2009 Dec;105(6):374-9.
PT00087	M6APDG02595	Bromfenac	CID: 60726	Approved	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
PT00087	M6APDG02627	Diltiazem hydrochloride	CID: 62920	Approved	Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther. 1997 Jul;282(1):294-300.
PT00087	M6APDG02629	Verapamil hydrochloride	CID: 62969	Approved	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
PT00087	M6APDG02776	Repaglinide	CID: 65981	Approved	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
PT00087	M6APDG02820	Velpatasvir	CID: 67683363	Approved	FDA Label of Vosevi. The 2020 official website of the U.S. Food and Drug Administration.
PT00087	M6APDG03031	Voxilaprevir	CID: 89921642	Approved	FDA Label of Vosevi. The 2020 official website of the U.S. Food and Drug Administration.
PT00087	M6APDG02827	Brigatinib	CID: 68165256	Approved	Brigatinib: first global approval. Drugs. 2017 Jul;77(10):1131-1135.
PT00087	M6APDG02845	Levomilnacipran	CID: 6917779	Approved	The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol. 2016;14(2):191-9.
PT00087	M6APDG02850	Treprostinil	CID: 6918140	Approved	FDA label of Treprostinil. The 2020 official website of the U.S. Food and Drug Administration.
PT00087	M6APDG02906	Loperamide hydrochloride	CID: 71420	Approved	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
PT00087	M6APDG02929	Lorlatinib	CID: 71731823	Approved	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
PT00087	M6APDG02992	Rosiglitazone	CID: 77999	Approved	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
PT00087	M6APDG03023	Pentamidine isethionate	CID: 8813	Approved	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
PT00087	M6APDG03027	Nicotine	CID: 89594	Approved	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
PT00087	M6APDG03029	Enasidenib	CID: 89683805	Approved	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
PT00087	M6APDG03191	Cabazitaxel	CID: 9854073	Approved	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
PT00087	M6APDG03265	Selexipag	CID: 9913767	Approved	FDA Label of Uptravi. The 2020 official website of the U.S. Food and Drug Administration.
PT00087	M6APDG03286	Lapatinib ditosylate	CID: 9941095	Approved	Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
PT00006	M6APDG00567	Erythromycin stearate	CID: 12559	Approved	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
PT00006	M6APDG01009	Theophylline	CID: 2153	Approved	Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
PT00006	M6APDG01248	Caffeine	CID: 2519	Approved	Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
PT00006	M6APDG01421	Flutamide	CID: 3397	Approved	Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
PT00006	M6APDG01598	Testosterone cypionate	CID: 441404	Approved	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
PT00006	M6APDG02570	Progesterone	CID: 5994	Approved	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
PT00006	M6APDG01911	Rosuvastatin	CID: 446157	Approved	Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
PT00006	M6APDG02152	Procarbazine	CID: 4915	Approved	Tumour cytochrome P450 and drug activation. Curr Pharm Des. 2002;8(15):1335-47.
PT00006	M6APDG03345	Estradiol	CID: 5757	Approved	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
PT00006	M6APDG02553	Estrone	CID: 5870	Approved	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
PT00006	M6APDG02996	Hydrogen peroxide	CID: 784	Approved	NADPH- and hydroperoxide-supported 17beta-estradiol hydroxylation catalyzed by a variant form (432L, 453S) of human cytochrome P450 1B1. J Steroid Biochem Mol Biol. 2000 Sep;74(1-2):11-8.
PT00006	M6APDG03231	Oxaliplatin	CID: 9887054	Approved	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
PT00013	M6APDG00576	Methotrexate	CID: 126941	Approved	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
PT00013	M6APDG00634	Folic acid	CID: 135398658	Approved	Genetic variation: impact on folate (and choline) bioefficacy. Int J Vitam Nutr Res. 2010 Oct;80(4-5):319-29.
PT00013	M6APDG01516	Menadione	CID: 4055	Approved	Purification and properties of 5,10-methylenetetrahydrofolate reductase, an iron-sulfur flavoprotein from Clostridium formicoaceticum. J Biol Chem. 1984 Sep 10;259(17):10845-9.
PT00013	M6APDG02400	Benazepril	CID: 5362124	Approved	Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7.
PT00008	M6APDG02987	Heparin	CID: 772	Approved	Heparanase affects secretory granule homeostasis of murine mast cells through degrading heparin. J Allergy Clin Immunol. 2011 Dec;128(6):1310-1317.e8.
PT00015	M6APDG01448	Etoposide	CID: 36462	Approved	Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
PT00056	M6APDG01585	Nabumetone	CID: 4409	Approved	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
PT00056	M6APDG02570	Progesterone	CID: 5994	Approved	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
PT00056	M6APDG03322	Dihydrotestosterone	CID: 10635	Phase 4	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
PT00056	M6APDG02694	Fenofibric acid	CID: 64929	Approved	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
PT00004	M6APDG02393	Arsenic	CID: 5359596	Approved	Association of genetic variation in cystathionine-beta-synthase and arsenic metabolism. Environ Res. 2010 Aug;110(6):580-7.
PT00238	M6APDG02582	Uridine	CID: 6029	Approved	Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
PT00238	M6APDG02616	Cytidine	CID: 6175	Investigative	Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
PT00087	M6APDG01129	ABT-001	CID: 2449	Discontinued	Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
PT00087	M6APDG03333	ADD-3878	CID: 2750	Discontinued	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
PT00087	M6APDG00819	CKD-501	CID: 15951505	Phase 3	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
PT00087	M6APDG03348	DRF-2593	CID: 9889200	Phase 3	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
PT00087	M6APDG03321	Aleglitazar	CID: 10274777	Discontinued in Phase 3	Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: an analysis of the AleCardio trial. Diabetes Obes Metab. 2020 Jan;22(1):30-38.
PT00087	M6APDG02624	Cyamemazine	CID: 62865	Investigative	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
PT00087	M6APDG03087	Paraoxon	CID: 9395	Investigative	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
PT00006	M6APDG01357	Dibutylphthalate	CID: 3026	Investigative	Inhibition of human cytochrome p450 1b1 further clarifies its role in the activation of dibenzo[a,l]pyrene in cells in culture. J Biochem Mol Toxicol. 2007;21(3):101-9.
PT00015	M6APDG01846	Arachidonic acid	CID: 444899	Investigative	PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenet Genomics. 2011 Sep;21(9):607-13.
PT00015	M6APDG01913	Icosapentum	CID: 446284	Investigative	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
PT00015	M6APDG02232	Icosatrienoic acid	CID: 5280581	Investigative	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
PT00015	M6APDG02239	Alpha-linolenic acid	CID: 5280934	Investigative	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
PT00015	M6APDG02470	BML3-C01	CID: 5497181	Investigative	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
PT00015	M6APDG02656	Eicosadienoic acid	CID: 6439848	Investigative	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
PT00015	M6APDG01865	SC-411	CID: 445580	Phase 3	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
PT00015	M6APDG02238	Gamma-linolenic acid	CID: 5280933	Phase 4	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
PT00010	M6APDG02612	Methionine	CID: 6137	Investigative	Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology. 2007 Jul;133(1):207-18.
PT00056	M6APDG02136	BRN-3548355	CID: 47289	Investigative	Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
PT00058	M6APDG02634	All-trans-retinal	CID: 638015	Investigative	Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition. Chem Biol Interact. 2013 Feb 25;202(1-3):78-84.
PT00058	M6APDG03008	Decanal	CID: 8175	Investigative	Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition. Chem Biol Interact. 2013 Feb 25;202(1-3):78-84.
PT00096	M6APDG00814	Hombreol	CID: 15818	Investigative	Transcriptional regulation of type 11 17beta-hydroxysteroid dehydrogenase expression in prostate cancer cells. Mol Cell Endocrinol. 2011 Jun 6;339(1-2):45-53.
PT00087	M6APDG00060	MK-0822	CID: 10152654	Phase 1	Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27.
PT00087	M6APDG00369	M-813	CID: 115368	Phase 1	Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
PT00087	M6APDG00559	H3B-6545	CID: 124091040	Phase 1	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
PT00087	M6APDG00927	AG-1549	CID: 1783	Phase 1	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
PT00087	M6APDG03018	AZD-9496	CID: 86287635	Phase 1	Complete substrate inhibition of cytochrome P450 2C8 by AZD9496, an oral selective estrogen receptor degrader. Drug Metab Dispos. 2018 Sep;46(9):1268-1276.
PT00013	M6APDG00642	ISO-901	CID: 135400185	Phase 1	Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol. 2006 Jun;57(6):835-40.
PT00016	M6APDG03341	YP-005	CID: 5283560	Phase 1	Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem. 2003 Nov 28;278(48):47408-15.
PT00087	M6APDG00279	TAK-652	CID: 11285792	Phase 2	Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139-48.
PT00087	M6APDG03332	AZD-2014	CID: 25262792	Phase 2	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
PT00087	M6APDG03043	GSK-1278863	CID: 91617630	Phase 2	Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015 Dec;30(6):410-8.
PT00087	M6APDG02635	QLT-091001	CID: 638034	Phase 2/3	Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica. 1999 Mar;29(3):231-41.
PT00087	M6APDG01856	NSC-122758	CID: 445354	Phase 3	Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica. 1999 Mar;29(3):231-41.
PT00087	M6APDG02860	EMD-128130	CID: 6918388	Phase 2/3	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
PT00087	M6APDG03324	BNP-1350	CID: 148202	Phase 3	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
PT00087	M6APDG03328	BMS-298585	CID: 206044	Phase 3	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
PT00087	M6APDG03330	CYT-387	CID: 25062766	Phase 3	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
PT00087	M6APDG03335	Rivoglitazone	CID: 3055168	Phase 3	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
PT00087	M6APDG02176	LY-2484595	CID: 49836058	Phase 3	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
PT00087	M6APDG02288	LAU-7b	CID: 5288209	Phase 3	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol. 2011 Feb;162(4):989-99.
PT00087	M6APDG03344	Dasabuvir	CID: 56640146	Phase 3	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
PT00087	M6APDG02838	LAS-17177	CID: 68867	Phase 3	The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 Jul;35(7):1149-56.
PT00006	M6APDG01081	HSDB-3466	CID: 2355	Phase 3	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
PT00006	M6APDG01856	NSC-122758	CID: 445354	Phase 3	Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
PT00015	M6APDG02499	Omega-6-FA	CID: 56842208	Phase 3	Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
PT00056	M6APDG00623	AK-602	CID: 135353969	Phase 3	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
PT00005	M6APDG03322	Dihydrotestosterone	CID: 10635	Phase 4	Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
PT00087	M6APDG01020	Amodiaquine	CID: 2165	Phase 4	Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007 Aug;82(2):197-203.
PT00087	M6APDG02411	Tegafur	CID: 5386	Phase 4	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
PT00087	M6APDG02458	Ombitasvir	CID: 54767916	Phase 4	Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1148-57.
PT00087	M6APDG02525	Zopiclone	CID: 5735	Phase 4	Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos. 1999 Sep;27(9):1068-73.
PT00087	M6APDG02540	Cefaloridine	CID: 5773	Phase 4	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004 Oct;311(1):228-36.
PT00087	M6APDG02573	Aminophenazone	CID: 6009	Phase 4	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
PT00087	M6APDG02626	Mestranol	CID: 6291	Phase 4	Loss of orally administered drugs in GI tract. Saudi Pharm J. 2012 Oct;20(4):331-44.
PT00087	M6APDG02847	Beraprost	CID: 6917951	Phase 4	Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro. Yakugaku Zasshi. 2008 Oct;128(10):1459-65.
PT00087	M6APDG03006	Ketobemidone	CID: 80069	Phase 4	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
PT00006	M6APDG01020	Amodiaquine	CID: 2165	Phase 4	Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
PT00006	M6APDG03028	Melatonin	CID: 896	Phase 4	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
PT00015	M6APDG02500	Omega-3 Fatty acids	CID: 56842239	Phase 4	Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63.
PT00011	M6APDG00848	Amylin	CID: 16132430	Phase 4	Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem. 2013 Feb 1;288(5):3553-9.
PT00012	M6APDG00848	Amylin	CID: 16132430	Phase 4	Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem. 2013 Feb 1;288(5):3553-9.
PT00009	M6APDG00920	Phenytoin	CID: 1775	Approved	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
PT00009	M6APDG01426	Oxcarbazepine	CID: 34312	Approved	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
PT00009	M6APDG02141	Phenobarbital	CID: 4763	Approved	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
PT00009	M6APDG00969	Tacrine	CID: 1935	Approved	Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes. J Pharm Pharm Sci. 2014;17(3):427-38.
PT00009	M6APDG00978	Acebutolol	CID: 1978	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG00065	Cinchonidine	CID: 101744	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG00868	Pimozide	CID: 16362	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01059	Azasetron	CID: 2264	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01409	Amoxicillin	CID: 33613	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01478	Labetalol	CID: 3869	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01524	Vindesine	CID: 40839	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01914	Nevirapine	CID: 4463	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01963	Nimodipine	CID: 4497	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01983	Norfloxacin	CID: 4539	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02220	Spiperone	CID: 5265	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02243	Olopatadine	CID: 5281071	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02310	Cefotetan	CID: 53025	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02434	Tenoxicam	CID: 54677971	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02477	Triflupromazine	CID: 5568	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02538	Pemirolast	CID: 57697	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02585	Levodopa	CID: 6047	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02633	Pirarubicin	CID: 636397	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02642	Efavirenz	CID: 64139	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02687	Lovastatin acid	CID: 64727	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02846	Saphris	CID: 6917875	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG03156	Midostaurin	CID: 9829523	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00003	M6APDG02419	Simvastatin	CID: 54454	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00003	M6APDG03346	Dehydroepiandrosterone	CID: 5881	Approved	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02893	Pafenolol	CID: 71144	Discontinued in Phase 1	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG00209	S9788	CID: 107903	Discontinued in Phase 2	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01363	Droloxifene	CID: 3033767	Discontinued in Phase 2	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG03334	SNS-032	CID: 3025986	Phase 1	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG00543	Gallopamil	CID: 1234	Phase 2	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01623	Staurosporine	CID: 44259	Phase 2	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02474	Gepirone	CID: 55191	Phase 2	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02010	Sitafloxacin	CID: 461399	Phase 2/3	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02397	Morphine-6-glucuronide	CID: 5360621	Phase 3	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02682	Belotecan	CID: 6456014	Phase 3	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01386	Ebastine	CID: 3191	Phase 4	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02461	Tenofovir disoproxil	CID: 5481350	Phase 4	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01945	Epothilone A	CID: 448799	Preclinical	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG00545	Niguldipine	CID: 1236	Terminated	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG01275	Calphostin C	CID: 2533	Terminated	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG00869	Mithramycin	CID: 163659	Withdrawn	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG00941	Melagatran	CID: 183797	Withdrawn	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02435	Isoxicam	CID: 54677972	Withdrawn	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG02590	Mibefradil	CID: 60663	Withdrawn	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG03100	Ximelagatran	CID: 9574101	Withdrawn	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
PT00009	M6APDG00980	Dactinomycin	CID: 2019	Approved	Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
PT00009	M6APDG00074	Emetine	CID: 10219	Approved	Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
PT00009	M6APDG02947	Nonactin	CID: 72519	Preclinical	Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
PT00009	M6APDG00066	Apixaban	CID: 10182969	Approved	Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27.
PT00009	M6APDG03320	Afatinib	CID: 10184653	Approved	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50.
PT00003	M6APDG03320	Afatinib	CID: 10184653	Approved	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50.
PT00009	M6APDG00073	Cepharanthine	CID: 10206	Approved	Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J Pharmacol Exp Ther. 1995 Oct;275(1):73-8.
PT00009	M6APDG00094	Betrixaban	CID: 10275777	Approved	Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015 Jun 26;11:343-51.
PT00009	M6APDG00096	Edoxaban	CID: 10280735	Approved	Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600.
PT00009	M6APDG00099	Binimetinib	CID: 10288191	Approved	The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
PT00003	M6APDG00099	Binimetinib	CID: 10288191	Approved	The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
PT00009	M6APDG00107	Boceprevir	CID: 10324367	Approved	Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
PT00009	M6APDG01355	Telaprevir	CID: 3010818	Approved	Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
PT00009	M6APDG00115	beta-Acetyldigoxin	CID: 10350481	Approved	P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43.
PT00009	M6APDG00213	Ramosetron	CID: 108000	Approved	Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier. J Pharm Pharmacol. 2002 Aug;54(8):1055-63.
PT00009	M6APDG00233	Tadalafil	CID: 110635	Approved	In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil. Biol Pharm Bull. 2017;40(8):1314-1319.
PT00009	M6APDG00249	Regorafenib	CID: 11167602	Approved	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm Res. 2015 Jul;32(7):2205-16.
PT00009	M6APDG00284	Riociguat	CID: 11304743	Approved	Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, initro. Pulm Pharmacol Ther. 2014 Aug;28(2):130-7.
PT00009	M6APDG00359	Paliperidone	CID: 115237	Approved	Invega (paliperidone) extended release tablets FDA Label
PT00009	M6APDG00361	Pazopanib hydrochloride	CID: 11525740	Approved	Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53.
PT00003	M6APDG00361	Pazopanib hydrochloride	CID: 11525740	Approved	Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53.
PT00009	M6APDG00379	Carfilzomib	CID: 11556711	Approved	Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013 Apr;88(4):265-72.
PT00009	M6APDG00513	Empagliflozin	CID: 11949646	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG00596	Olmesartan medoxomil	CID: 130881	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG01186	Simeprevir	CID: 24873435	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG01293	Deflazacort	CID: 26709	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG02047	Tenofovir	CID: 464205	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG02060	Posaconazole	CID: 468595	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG02174	Gilteritinib	CID: 49803313	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG02303	Eliglustat tartrate	CID: 52918379	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG02659	Cannabidiol	CID: 644019	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG02667	Nilotinib	CID: 644241	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG02870	Indacaterol	CID: 6918554	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG03213	Brilinta	CID: 9871419	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG00114	Relugolix	CID: 10348973	Phase 3	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG00833	Asunaprevir	CID: 16076883	Phase 3	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG01838	Vibegron	CID: 44472635	Phase 3	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG01695	Metildigoxin	CID: 443946	Preclinical	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
PT00009	M6APDG00557	Baloxavir marboxil	CID: 124081896	Approved	Baloxavir Marboxil FDA label
PT00009	M6APDG00558	Desloratadine	CID: 124087	Approved	P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8.
PT00009	M6APDG01497	Loratadine	CID: 3957	Approved	P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8.
PT00009	M6APDG00565	Glutathione	CID: 124886	Approved	Upregulation of cellular glutathione levels in human ABCB5- and murine Abcb5-transfected cells. BMC Pharmacol Toxicol. 2015 Dec 15;16:37.
PT00009	M6APDG00568	Erythromycin	CID: 12560	Approved	Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82.
PT00009	M6APDG00576	Methotrexate	CID: 126941	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG00635	Rifampicin	CID: 135398735	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG00772	Levofloxacin	CID: 149096	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01010	Amiodarone	CID: 2157	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01078	Bepridil	CID: 2351	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01288	Cefoperazone	CID: 2630	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01297	Chlorambucil	CID: 2708	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01304	Chlorpromazine	CID: 2726	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01309	Cimetidine	CID: 2756	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01349	Ranitidine	CID: 3001055	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01365	Quinine	CID: 3034034	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01404	Fentanyl	CID: 3345	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01452	Hydroxyurea	CID: 3657	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01455	Lidocaine	CID: 3676	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01473	Ketoconazole	CID: 3823	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01490	Diltiazem	CID: 39186	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01537	Epirubicin	CID: 41867	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01542	Mitoxantrone	CID: 4212	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01587	Cisplatin	CID: 441203	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01590	Pentazocine	CID: 441278	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01869	Tacrolimus	CID: 445643	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01943	Nifedipine	CID: 4485	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01964	Nisoldipine	CID: 4499	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01965	Nitrendipine	CID: 4507	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02154	Propafenone	CID: 4932	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02324	Lovastatin	CID: 53232	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02419	Simvastatin	CID: 54454	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02429	Doxycycline	CID: 54671203	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02430	Tetracycline	CID: 54675776	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02460	Ceftriaxone	CID: 5479530	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02476	Trifluoperazine	CID: 5566	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02584	Sparfloxacin	CID: 60464	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02620	Cytarabine	CID: 6253	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02699	Amprenavir	CID: 65016	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02804	Actinomycin D	CID: 6713178	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02844	Itraconazole	CID: 6917738	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02945	Grepafloxacin	CID: 72474	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02963	Gramicidin D	CID: 73357	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG03015	Clarithromycin	CID: 84029	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG01439	Zidovudine	CID: 35370	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG01537	Epirubicin	CID: 41867	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG01910	Cerivastatin	CID: 446156	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG01927	Nicardipine	CID: 4474	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG02003	Ofloxacin	CID: 4583	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG02227	Quercetin	CID: 5280343	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG02277	Cyclosporine	CID: 5284373	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG02442	Pravastatin	CID: 54687	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG02484	Delavirdine	CID: 5625	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG02539	Reserpine	CID: 5770	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG02643	Nelfinavir	CID: 64143	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG03081	Lopinavir	CID: 92727	Approved	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02264	Valspodar	CID: 5281884	Discontinued in Phase 3	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG00757	Hoechst 33342	CID: 1464	Investigative	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG00817	Paraquat	CID: 15938	Investigative	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01540	Tiapamil	CID: 42107	Investigative	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG01579	Leupeptin	CID: 439527	Investigative	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02323	Bcecf-Am	CID: 53229972	Investigative	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02767	Azidopine	CID: 656406	Investigative	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG02249	Chrysin	CID: 5281607	Investigative	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02390	Bisantrene	CID: 5351322	Phase 2	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00003	M6APDG02862	Ortataxel	CID: 6918412	Phase 2	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG00929	Asimadoline	CID: 179340	Phase 3	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG03347	Curcumin	CID: 969516	Phase 3	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02459	Pepstatin A	CID: 5478883	Preclinical	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02262	Trans-flupentixol	CID: 5281878	Withdrawn	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG02414	Terfenadine	CID: 5405	Withdrawn	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
PT00009	M6APDG00612	Vinblastine	CID: 13342	Approved	Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
PT00009	M6APDG00621	Pomalidomide	CID: 134780	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08910)
PT00009	M6APDG00634	Folic acid	CID: 135398658	Approved	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
PT00009	M6APDG00636	Clozapine	CID: 135398737	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG00639	Olanzapine	CID: 135398745	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG01012	Amisulpride	CID: 2159	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG03336	Domperidone	CID: 3151	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG01413	Fluphenazine	CID: 3372	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG01441	Haloperidol	CID: 3559	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG02138	Perazine	CID: 4744	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG02139	Perphenazine	CID: 4748	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG02183	Quetiapine	CID: 5002	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG02263	Flupentixol	CID: 5281881	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG02327	Fluvoxamine	CID: 5324346	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG02940	Levomepromazine	CID: 72287	Approved	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
PT00009	M6APDG00650	Aprepitant	CID: 135413536	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG01325	Clomipramine	CID: 2801	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG01378	Dipyridamole	CID: 3108	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG01379	Bromocriptine	CID: 31101	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG01867	Neostigmine	CID: 4456	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG02379	Paroxetine	CID: 53316721	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG02420	Thioridazine	CID: 5452	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG02462	Atomoxetine	CID: 54841	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG02479	Trimethoprim	CID: 5578	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG02539	Reserpine	CID: 5770	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG02603	Ziprasidone	CID: 60854	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG02604	Zolmitriptan	CID: 60857	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG02835	Sertraline	CID: 68617	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG02991	Eletriptan	CID: 77993	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG03011	Ergotamine	CID: 8223	Approved	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG01055	Astemizole	CID: 2247	Withdrawn	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
PT00009	M6APDG00659	Nintedanib	CID: 135423438	Approved	Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):533-541.
PT00009	M6APDG00699	Talazoparib	CID: 135565082	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
PT00003	M6APDG00699	Talazoparib	CID: 135565082	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
PT00009	M6APDG00761	Docetaxel	CID: 148124	Approved	Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
PT00009	M6APDG00767	Arsenic trioxide	CID: 14888	Approved	Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26.
PT00009	M6APDG00774	Ezetimibe	CID: 150311	Approved	Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.
PT00009	M6APDG00799	Clomifene	CID: 1548953	Approved	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
PT00009	M6APDG01353	Toremifene	CID: 3005573	Approved	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
PT00009	M6APDG01944	Diethylstilbestrol	CID: 448537	Approved	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
PT00009	M6APDG03345	Estradiol	CID: 5757	Approved	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
PT00009	M6APDG02608	Clomiphene citrate	CID: 60974	Approved	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
PT00009	M6APDG01958	4-Hydroxytamoxifen	CID: 449459	Phase 3	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
PT00009	M6APDG02534	Corticosterone	CID: 5753	Phase 3	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
PT00009	M6APDG01606	Nafoxidine	CID: 4416	Preclinical	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
PT00009	M6APDG00864	Ivacaftor	CID: 16220172	Approved	Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1). Sci Rep. 2017 Dec 13;7(1):17481.
PT00009	M6APDG00930	Eslicarbazepine acetate	CID: 179344	Approved	In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011 Oct;52(10):1894-904.
PT00009	M6APDG03220	S-licarbazepine	CID: 9881504	Approved	In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011 Oct;52(10):1894-904.
PT00009	M6APDG00942	Dicloxacillin	CID: 18381	Approved	Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res. 2002 Apr;19(4):457-62.
PT00009	M6APDG00987	Beclomethasone	CID: 20469	Approved	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
PT00009	M6APDG01720	Fluticasone propionate	CID: 444036	Approved	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
PT00009	M6APDG02535	Hydrocortisone	CID: 5754	Approved	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
PT00009	M6APDG02851	Ciclesonide	CID: 6918155	Approved	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
PT00009	M6APDG01021	Beclomethasone dipropionate	CID: 21700	Phase 4	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
PT00009	M6APDG00992	Albendazole	CID: 2082	Approved	The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9.
PT00009	M6APDG01004	Darunavir	CID: 213039	Approved	Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010 Nov;65(11):2319-28.
PT00009	M6APDG01013	Amitriptyline	CID: 2160	Approved	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
PT00009	M6APDG01054	Aspirin	CID: 2244	Approved	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
PT00009	M6APDG01061	Azathioprine	CID: 2265	Approved	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
PT00009	M6APDG01326	Clonidine	CID: 2803	Approved	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
PT00009	M6APDG01458	Imipramine	CID: 3696	Approved	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
PT00009	M6APDG01015	Dabigatran	CID: 216210	Approved	Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849.
PT00009	M6APDG01239	Daclatasvir	CID: 25154714	Approved	Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849.
PT00009	M6APDG01016	Tolvaptan	CID: 216237	Approved	In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol. 2011 May;51(5):761-9.
PT00009	M6APDG01018	Lenalidomide	CID: 216326	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00480)
PT00009	M6APDG01043	Methadone	CID: 22267	Approved	In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology. 2007;80(4):304-11.
PT00009	M6APDG01044	Cortisone	CID: 222786	Approved	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
PT00009	M6APDG02552	Prednisone	CID: 5865	Approved	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
PT00009	M6APDG03107	Betamethasone	CID: 9782	Approved	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
PT00009	M6APDG01057	Atenolol	CID: 2249	Approved	Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500.
PT00009	M6APDG01113	Bicalutamide	CID: 2375	Approved	Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
PT00003	M6APDG01113	Bicalutamide	CID: 2375	Approved	Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
PT00009	M6APDG01114	Colchicine	CID: 23890	Approved	Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61.
PT00009	M6APDG01162	Canagliflozin	CID: 24812758	Approved	In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
PT00003	M6APDG01162	Canagliflozin	CID: 24812758	Approved	In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
PT00009	M6APDG01164	Ibrutinib	CID: 24821094	Approved	P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Mol Pharm. 2018 Nov 5;15(11):5124-5134.
PT00009	M6APDG01172	Ponatinib	CID: 24826799	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
PT00003	M6APDG01172	Ponatinib	CID: 24826799	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
PT00009	M6APDG01252	Verapamil	CID: 2520	Approved	Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells. Protein Expr Purif. 2009 Jul;66(1):7-14.
PT00009	M6APDG01291	Celiprolol	CID: 2663	Approved	Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
PT00009	M6APDG01410	Timolol	CID: 33624	Approved	Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
PT00009	M6APDG01295	Cetirizine	CID: 2678	Approved	Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction. Chirality. 2010 Jul;22(7):684-92.
PT00009	M6APDG01300	Thiamphenicol	CID: 27200	Approved	Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. J Pharm Sci. 2018 Apr;107(4):1178-1184.
PT00009	M6APDG02562	Chloramphenicol	CID: 5959	Approved	Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. J Pharm Sci. 2018 Apr;107(4):1178-1184.
PT00009	M6APDG01303	Digoxin	CID: 2724385	Approved	MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochem Biophys Res Commun. 2010 Jul 16;398(1):7-12.
PT00009	M6APDG01315	Citalopram	CID: 2771	Approved	ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. Int J Legal Med. 2013 May;127(3):579-86.
PT00009	M6APDG01321	Clofazimine	CID: 2794	Approved	Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26.
PT00009	M6APDG01344	Debrisoquine	CID: 2966	Approved	Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.
PT00009	M6APDG01346	Desipramine	CID: 2995	Approved	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG01481	Lansoprazole	CID: 3883	Approved	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG01538	Midazolam	CID: 4192	Approved	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG01909	Fluvastatin	CID: 446155	Approved	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG02005	Omeprazole	CID: 4594	Approved	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG02051	Pantoprazole	CID: 4679	Approved	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG02512	Guanabenz	CID: 5702063	Approved	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG02575	Testosterone	CID: 6013	Approved	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG02777	Tolafentrine	CID: 65990	Discontinued in Phase 2	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG01000	Alprenolol	CID: 2119	Withdrawn	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
PT00009	M6APDG01348	Estrone sulfate	CID: 3001028	Approved	Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
PT00009	M6APDG01910	Cerivastatin	CID: 446156	Approved	Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
PT00009	M6APDG01350	Telithromycin	CID: 3002190	Approved	Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95.
PT00009	M6APDG02843	Roxithromycin	CID: 6915744	Withdrawn	Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95.
PT00009	M6APDG01356	Diazepam	CID: 3016	Approved	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
PT00009	M6APDG02570	Progesterone	CID: 5994	Approved	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
PT00009	M6APDG01362	Nizatidine	CID: 3033637	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00585)
PT00009	M6APDG01369	Prucalopride	CID: 3052762	Approved	Resolor, INN-prucalopride
PT00009	M6APDG01372	Dihydroergocristine	CID: 3065	Approved	Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.
PT00009	M6APDG01387	Epinastine	CID: 3241	Approved	Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004 May;32(5):519-24.
PT00009	M6APDG01399	Famciclovir	CID: 3324	Approved	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
PT00009	M6APDG01521	Mequitazine	CID: 4066	Approved	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
PT00009	M6APDG02148	Pirenzepine	CID: 4848	Approved	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
PT00009	M6APDG02158	Protriptyline	CID: 4976	Approved	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
PT00009	M6APDG02279	Acrivastine	CID: 5284514	Approved	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
PT00009	M6APDG02314	Nalbuphine	CID: 5311304	Approved	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
PT00009	M6APDG03104	Methysergide	CID: 9681	Approved	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
PT00009	M6APDG01400	Felodipine	CID: 3333	Approved	The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. J Clin Pharm Ther. 2017 Jun;42(3):345-349.
PT00009	M6APDG01405	Fexofenadine	CID: 3348	Approved	Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 Aug;78(2):191-201.
PT00009	M6APDG01417	Fluoxetine	CID: 3386	Approved	Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006 Jun 18;237(2):180-7.
PT00009	M6APDG01439	Zidovudine	CID: 35370	Approved	The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
PT00009	M6APDG01592	Abacavir	CID: 441300	Approved	The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
PT00009	M6APDG02484	Delavirdine	CID: 5625	Approved	The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
PT00009	M6APDG01448	Etoposide	CID: 36462	Approved	Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
PT00009	M6APDG01462	Indomethacin	CID: 3715	Approved	Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007 Oct 22;97(8):1077-83.
PT00009	M6APDG01480	Lamotrigine	CID: 3878	Approved	Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75.
PT00009	M6APDG01492	Ritonavir	CID: 392622	Approved	MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS. 2005 Oct 14;19(15):1617-25.
PT00009	M6APDG01496	Loperamide	CID: 3955	Approved	In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008 Feb;36(2):268-75.
PT00009	M6APDG01498	Losartan	CID: 3961	Approved	Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43.
PT00009	M6APDG01500	Vecuronium	CID: 39765	Approved	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
PT00009	M6APDG01522	Mefloquine	CID: 40692	Approved	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
PT00009	M6APDG02007	Ondansetron	CID: 4595	Approved	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
PT00009	M6APDG01518	Meperidine	CID: 4058	Approved	Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3638-40.
PT00009	M6APDG01554	Idarubicin	CID: 42890	Approved	Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
PT00003	M6APDG01554	Idarubicin	CID: 42890	Approved	Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
PT00009	M6APDG01588	Digitoxin	CID: 441207	Approved	The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients. Eur J Clin Pharmacol. 2008 Apr;64(4):367-72.
PT00009	M6APDG01589	Saquinavir	CID: 441243	Approved	Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.
PT00009	M6APDG01610	Baricitinib	CID: 44205240	Approved	Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clin Transl Sci. 2017 Nov;10(6):509-519.
PT00009	M6APDG01703	Bupropion	CID: 444	Approved	Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.
PT00009	M6APDG01903	Hydroxybupropion	CID: 446	Discontinued in Phase 2	Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.
PT00009	M6APDG00328	Desmethylsertraline	CID: 114743	Preclinical	Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.
PT00009	M6APDG01835	Dabrafenib	CID: 44462760	Approved	Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
PT00003	M6APDG01835	Dabrafenib	CID: 44462760	Approved	Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
PT00009	M6APDG01911	Rosuvastatin	CID: 446157	Approved	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
PT00003	M6APDG01911	Rosuvastatin	CID: 446157	Approved	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
PT00009	M6APDG01923	Azithromycin	CID: 447043	Approved	Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats. World J Gastroenterol. 2017 Nov 21;23(43):7678-7692.
PT00009	M6APDG01927	Nicardipine	CID: 4474	Approved	Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
PT00009	M6APDG01984	Rhodamine 123	CID: 4541001	Discontinued in Phase 1	Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
PT00009	M6APDG01347	Valinomycin	CID: 3000706	Investigative	Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
PT00009	M6APDG01980	Sofosbuvir	CID: 45375808	Approved	Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018 Dec;104(6):1191-1198.
PT00009	M6APDG02008	Melphalan	CID: 460612	Approved	Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer. 1998;77(2):201-9.
PT00009	M6APDG02151	Prazosin	CID: 4893	Approved	Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9.
PT00009	M6APDG03340	Venetoclax	CID: 49846579	Approved	Venclexta FDA label
PT00009	M6APDG02187	Raloxifene	CID: 5035	Approved	Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Transl Res. 2012 Oct;160(4):298-308.
PT00009	M6APDG02189	Risperidone	CID: 5073	Approved	Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005 Jul;78(1):43-51.
PT00009	M6APDG02227	Quercetin	CID: 5280343	Approved	Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604.
PT00009	M6APDG03082	Naringenin	CID: 932	Phase 1	Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604.
PT00009	M6APDG02231	beta-Carotene	CID: 5280489	Approved	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
PT00009	M6APDG02241	Amphotericin B	CID: 5280965	Approved	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
PT00009	M6APDG02246	Fucoxanthin	CID: 5281239	Phase 2	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
PT00009	M6APDG02617	Cycloheximide	CID: 6197	Preclinical	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
PT00009	M6APDG02244	Mycophenolate mofetil	CID: 5281078	Approved	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
PT00003	M6APDG02244	Mycophenolate mofetil	CID: 5281078	Approved	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
PT00003	M6APDG02668	Mycophenolic acid glucuronide	CID: 6442661	Phase 1	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
PT00009	M6APDG02271	Triprolidine	CID: 5282443	Approved	Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos. 2007 Aug;35(8):1341-9.
PT00009	M6APDG02277	Cyclosporine	CID: 5284373	Approved	Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model. J Pharmacol Exp Ther. 2008 Nov;327(2):592-9.
PT00009	M6APDG02281	Levetiracetam	CID: 5284583	Approved	Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46.
PT00009	M6APDG02283	Topiramate	CID: 5284627	Approved	The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res. 2009 Nov;26(11):2464-70.
PT00009	M6APDG02284	Trospium chloride	CID: 5284631	Approved	Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
PT00009	M6APDG02291	Morphine	CID: 5288826	Approved	Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005 Aug;49(7):902-8.
PT00009	M6APDG02300	Imatinib	CID: 5291	Approved	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
PT00009	M6APDG02315	Vinorelbine	CID: 5311497	Approved	Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.
PT00009	M6APDG02317	Silodosin	CID: 5312125	Approved	The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug Metab Pharmacokinet. 2013;28(3):239-43.
PT00009	M6APDG02352	Bosutinib	CID: 5328940	Approved	In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol. 2015 Jul 7;8:81.
PT00009	M6APDG02363	Palbociclib	CID: 5330286	Approved	Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
PT00003	M6APDG02363	Palbociclib	CID: 5330286	Approved	Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
PT00009	M6APDG02391	Romidepsin	CID: 5352062	Approved	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
PT00009	M6APDG02392	Sumatriptan	CID: 5358	Approved	HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J Pharm Sci. 2001 Oct;90(10):1608-19. Comparative Study
PT00009	M6APDG02403	Indinavir	CID: 5362440	Approved	HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998 Mar 17;37(11):3594-601.
PT00009	M6APDG02409	Gatifloxacin	CID: 5379	Approved	Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm. 2010 Aug 16;395(1-2):114-21.
PT00009	M6APDG02438	Phenprocoumon	CID: 54680692	Approved	Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):259-65.
PT00009	M6APDG02447	Omadacycline	CID: 54697325	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12455)
PT00009	M6APDG02455	Cabergoline	CID: 54746	Approved	Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012 Sep;167(3):327-35.
PT00009	M6APDG02466	Aliskiren fumarate	CID: 5493444	Approved	Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys. Biopharm Drug Dispos. 2015 Jan;36(1):15-33.
PT00009	M6APDG02475	Tramadol	CID: 5523	Approved	Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015 Mar;70:234-8.
PT00009	M6APDG02508	Ranolazine	CID: 56959	Approved	Ranolazine-tacrolimus interaction. Ann Pharmacother. 2010 Nov;44(11):1844-9.
PT00009	M6APDG02527	Ceritinib	CID: 57379345	Approved	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2015 Dec 12;3:54-66.
PT00009	M6APDG02531	Mitomycin	CID: 5746	Approved	In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
PT00009	M6APDG02536	Prednisolone	CID: 5755	Approved	The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60.
PT00009	M6APDG02537	Estriol	CID: 5756	Approved	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
PT00009	M6APDG02553	Estrone	CID: 5870	Approved	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
PT00009	M6APDG02569	Ethinyl estradiol	CID: 5991	Approved	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
PT00009	M6APDG02548	Aldosterone	CID: 5839	Approved	MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007 Feb;17(2):137-44.
PT00009	M6APDG02567	Vincristine	CID: 5978	Approved	L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
PT00009	M6APDG02588	Clopidogrel	CID: 60606	Approved	Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
PT00009	M6APDG02592	Topotecan	CID: 60700	Approved	Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
PT00003	M6APDG02682	Belotecan	CID: 6456014	Phase 3	Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
PT00009	M6APDG02602	Irinotecan	CID: 60838	Approved	Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
PT00009	M6APDG02609	Ajmaline	CID: 6100671	Approved	ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett. 1994 Apr 25;343(2):168-72.
PT00009	M6APDG02630	L-tryptophan	CID: 6305	Approved	Pharmacogenetics of antidepressants. Front Pharmacol. 2011 Feb 16;2:6.
PT00009	M6APDG02631	Ivermectin	CID: 6321424	Approved	MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol. 2003 Jan 24;460(2-3):85-91.
PT00009	M6APDG02643	Nelfinavir	CID: 64143	Approved	Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42.
PT00009	M6APDG02651	Rifaximin	CID: 6436173	Approved	Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability. AAPS J. 2017 May;19(3):806-813.
PT00009	M6APDG02675	Ixabepilone	CID: 6445540	Approved	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
PT00003	M6APDG00612	Vinblastine	CID: 13342	Approved	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
PT00003	M6APDG00761	Docetaxel	CID: 148124	Approved	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
PT00009	M6APDG02680	Axitinib	CID: 6450551	Approved	Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
PT00009	M6APDG02683	Sunitinib malate	CID: 6456015	Approved	JNK-AKT-NF-kB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells. Biochem Pharmacol. 2018 Oct;156:120-134.
PT00009	M6APDG02701	Oseltamivir	CID: 65028	Approved	Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61.
PT00009	M6APDG02813	Methylprednisolone	CID: 6741	Approved	Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6.
PT00009	M6APDG02845	Levomilnacipran	CID: 6917779	Approved	P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier inivo. Neuropharmacology. 2016 Apr;103:104-11.
PT00009	M6APDG02857	Temsirolimus	CID: 6918289	Approved	Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017 Sep;80(3):653-659.
PT00009	M6APDG02866	Ambrisentan	CID: 6918493	Approved	Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20.
PT00009	M6APDG02868	vildagliptin	CID: 6918537	Approved	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
PT00009	M6APDG02871	Fesoterodine fumarate	CID: 6918558	Approved	Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73.
PT00009	M6APDG02873	Ingenol-3-angelate	CID: 6918670	Approved	The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 2010 Jun 1;70(11):4509-19.
PT00009	M6APDG02876	Panobinostat	CID: 6918837	Approved	Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76.
PT00009	M6APDG02921	Ivosidenib	CID: 71657455	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB14568)
PT00009	M6APDG03081	Lopinavir	CID: 92727	Approved	Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
PT00009	M6APDG03146	Lenvatinib	CID: 9823820	Approved	Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.
PT00009	M6APDG03164	Moxidectin	CID: 9832912	Approved	Moxidectin and the avermectins: Consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012 Apr 14;2:134-53.
PT00003	M6APDG03164	Moxidectin	CID: 9832912	Approved	Moxidectin and the avermectins: Consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012 Apr 14;2:134-53.
PT00009	M6APDG03216	Rivaroxaban	CID: 9875401	Approved	Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019 Feb 6.
PT00003	M6APDG00066	Apixaban	CID: 10182969	Approved	Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013 Apr;41(4):827-35.
PT00003	M6APDG00249	Regorafenib	CID: 11167602	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
PT00003	M6APDG00284	Riociguat	CID: 11304743	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
PT00003	M6APDG00513	Empagliflozin	CID: 11949646	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
PT00003	M6APDG00596	Olmesartan medoxomil	CID: 130881	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
PT00003	M6APDG01980	Sofosbuvir	CID: 45375808	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
PT00003	M6APDG02047	Tenofovir	CID: 464205	Approved	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
PT00003	M6APDG00413	Idelalisib	CID: 11625818	Approved	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB09054)
PT00003	M6APDG00509	Clofarabine	CID: 119182	Approved	Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
PT00003	M6APDG00982	Cladribine	CID: 20279	Approved	Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
PT00003	M6APDG00565	Glutathione	CID: 124886	Approved	Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J Biol Chem. 2010 May 28;285(22):16582-7.
PT00003	M6APDG00568	Erythromycin	CID: 12560	Approved	ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
PT00003	M6APDG01378	Dipyridamole	CID: 3108	Approved	ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
PT00003	M6APDG02273	Pitavastatin	CID: 5282452	Approved	ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
PT00003	M6APDG00569	Dehydroepiandrosterone sulfate	CID: 12594	Approved	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
PT00003	M6APDG02606	Lurtotecan	CID: 60956	Discontinued in Phase 2	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
PT00003	M6APDG01075	Benzo(a)pyrene	CID: 2336	Phase 1	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
PT00003	M6APDG00891	Phenethyl isothiocyanate	CID: 16741	Phase 3	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
PT00003	M6APDG01580	Puromycin	CID: 439530	Preclinical	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
PT00003	M6APDG00576	Methotrexate	CID: 126941	Approved	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
PT00003	M6APDG00627	Entecavir	CID: 135398508	Approved	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
PT00003	M6APDG00628	Acyclovir	CID: 135398513	Approved	Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. Can J Physiol Pharmacol. 2011 Sep;89(9):675-80.
PT00003	M6APDG00634	Folic acid	CID: 135398658	Approved	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
PT00003	M6APDG00635	Rifampicin	CID: 135398735	Approved	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
PT00003	M6APDG01042	Deoxycholic acid	CID: 222528	Approved	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
PT00003	M6APDG01108	Cephalothin	CID: 23675321	Approved	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
PT00003	M6APDG02430	Tetracycline	CID: 54675776	Approved	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
PT00003	M6APDG02688	Dirithromycin	CID: 6473883	Approved	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
PT00003	M6APDG01109	Quinacrine	CID: 237	Phase 2	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
PT00003	M6APDG00637	Ganciclovir	CID: 135398740	Approved	Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim. 2010 Jun;46(6):497-501.
PT00003	M6APDG00641	Raltitrexed	CID: 135400182	Approved	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG03268	NB-506	CID: 9915861	Discontinued in Phase 2	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG03102	Gimatecan	CID: 9577124	Phase 1/2	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG01027	BN-80915	CID: 219023	Phase 2	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG02390	Bisantrene	CID: 5351322	Phase 2	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG02938	UCN-01	CID: 72271	Phase 2	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG02942	9-Aminocamptothecin	CID: 72402	Phase 2	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG03324	BNP-1350	CID: 148202	Phase 3	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG02854	Exatecan mesylate	CID: 6918249	Phase 3	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG03121	J-107088	CID: 9808998	Phase 3	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG02157	Protoporphyrin	CID: 4971	Preclinical	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
PT00003	M6APDG00647	Pemetrexed	CID: 135410875	Approved	pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos. 2011 Sep;39(9):1478-85.
PT00003	M6APDG00667	Eltrombopag	CID: 135449332	Approved	Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51.
PT00003	M6APDG00774	Ezetimibe	CID: 150311	Approved	Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
PT00003	M6APDG00980	Dactinomycin	CID: 2019	Approved	Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.
PT00003	M6APDG00994	Lapatinib	CID: 208908	Approved	The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
PT00003	M6APDG00996	Alfuzosin	CID: 2092	Approved	In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71.
PT00003	M6APDG01040	Cholic acid	CID: 221493	Approved	Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
PT00003	M6APDG00055	Glycocholic acid	CID: 10140	Phase 3	Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
PT00003	M6APDG02797	Taurocholic acid	CID: 6675	Terminated	Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
PT00003	M6APDG01299	Chlorothiazide	CID: 2720	Approved	ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. Drug Metab Pharmacokinet. 2012;27(3):349-53.
PT00003	M6APDG01301	Thioguanine	CID: 2723601	Approved	ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
PT00003	M6APDG02578	Adefovir	CID: 60172	Approved	ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
PT00003	M6APDG02796	Mercaptopurine	CID: 667490	Approved	ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
PT00003	M6APDG01309	Cimetidine	CID: 2756	Approved	Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5.
PT00003	M6APDG01313	Ciprofloxacin	CID: 2764	Approved	Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
PT00003	M6APDG01348	Estrone sulfate	CID: 3001028	Approved	ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9.
PT00003	M6APDG01348	Estrone sulfate	CID: 3001028	Approved	Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012 May;101(5):1888-97.
PT00003	M6APDG02240	Genistein	CID: 5280961	Phase 2	Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012 May;101(5):1888-97.
PT00003	M6APDG01360	Diclofenac	CID: 3033	Approved	Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
PT00003	M6APDG01374	Vandetanib	CID: 3081361	Approved	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46.
PT00003	M6APDG01433	Glibenclamide	CID: 3488	Approved	Glyburide transport across the human placenta. Obstet Gynecol. 2015 Mar;125(3):583-8.
PT00003	M6APDG01448	Etoposide	CID: 36462	Approved	Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
PT00003	M6APDG01451	Hydroxychloroquine	CID: 3652	Approved	MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
PT00003	M6APDG02441	Teriflunomide	CID: 54684141	Approved	MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
PT00003	M6APDG01485	Leflunomide	CID: 3899	Approved	Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7.
PT00003	M6APDG01516	Menadione	CID: 4055	Approved	The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3279-86.
PT00003	M6APDG01542	Mitoxantrone	CID: 4212	Approved	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
PT00003	M6APDG01573	Oxaliplatin	CID: 43805	Approved	Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
PT00003	M6APDG01587	Cisplatin	CID: 441203	Approved	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
PT00009	M6APDG03327	AG1478	CID: 2051	Preclinical	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
PT00003	M6APDG03327	AG1478	CID: 2051	Preclinical	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
PT00003	M6APDG01589	Saquinavir	CID: 441243	Approved	Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem. 2010 Dec;115(6):1495-507.
PT00003	M6APDG01592	Abacavir	CID: 441300	Approved	QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev. 2009 Jan 31;61(1):34-46.
PT00003	M6APDG01610	Baricitinib	CID: 44205240	Approved	Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17.
PT00003	M6APDG01703	Bupropion	CID: 444	Approved	Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010 Oct 1;80(7):1080-6.
PT00003	M6APDG01909	Fluvastatin	CID: 446155	Approved	Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. Pharm Res. 2015 May;32(5):1634-47.
PT00003	M6APDG01968	Apatinib	CID: 45139106	Approved	Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010 Oct 15;70(20):7981-91.
PT00003	M6APDG01983	Norfloxacin	CID: 4539	Approved	Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5.
PT00003	M6APDG02051	Pantoprazole	CID: 4679	Approved	Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.
PT00003	M6APDG02151	Prazosin	CID: 4893	Approved	P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res. 2011 Jan 25;1370:238-45.
PT00003	M6APDG02155	Riboflavin	CID: 493570	Approved	Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol. 2007 Feb;27(4):1247-53.
PT00003	M6APDG02181	Pyrimethamine	CID: 4993	Approved	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
PT00003	M6APDG02480	Trimetrexate	CID: 5583	Approved	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
PT00003	M6APDG02567	Vincristine	CID: 5978	Approved	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
PT00003	M6APDG02416	Piritrexim	CID: 54369	Phase 2	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
PT00003	M6APDG00646	AG 337	CID: 135409535	Phase 3	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
PT00003	M6APDG02186	Rabeprazole	CID: 5029	Approved	Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9.
PT00003	M6APDG02188	Riluzole	CID: 5070	Approved	Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett. 2009 Mar 6;452(1):12-6.
PT00003	M6APDG02245	Entacapone	CID: 5281081	Approved	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. Drug Metab Dispos. 2017 Dec;45(12):1282-1291.
PT00003	M6APDG02272	Pitavastatin calcium	CID: 5282451	Approved	Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
PT00003	M6APDG02300	Imatinib	CID: 5291	Approved	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
PT00003	M6APDG02386	Sulfasalazine	CID: 5339	Approved	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
PT00003	M6APDG02401	Verteporfin	CID: 5362420	Approved	The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
PT00003	M6APDG03345	Estradiol	CID: 5757	Approved	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
PT00003	M6APDG02570	Progesterone	CID: 5994	Approved	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
PT00003	M6APDG02572	Cholesterol	CID: 5997	Phase 2	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
PT00003	M6APDG02575	Testosterone	CID: 6013	Approved	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int. 2008 Dec;102(11):1694-9.
PT00003	M6APDG02592	Topotecan	CID: 60700	Approved	Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8.
PT00003	M6APDG02601	Lamivudine	CID: 60825	Approved	The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol. 2007 Nov;64(5):645-54.
PT00003	M6APDG02602	Irinotecan	CID: 60838	Approved	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
PT00003	M6APDG02633	Pirarubicin	CID: 636397	Approved	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
PT00003	M6APDG02667	Nilotinib	CID: 644241	Approved	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
PT00003	M6APDG02781	Nitrofurantoin	CID: 6604200	Approved	The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005 May;67(5):1758-64.
PT00003	M6APDG02827	Brigatinib	CID: 68165256	Approved	NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
PT00003	M6APDG02939	Hesperetin	CID: 72281	Approved	Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun. 2004 Apr 23;317(1):269-75.
PT00003	M6APDG02945	Grepafloxacin	CID: 72474	Approved	Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos. 2007 Oct;35(10):1873-9.
PT00003	M6APDG02992	Rosiglitazone	CID: 77999	Approved	ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43.
PT00003	M6APDG03216	Rivaroxaban	CID: 9875401	Approved	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70.
PT00177	M6APDG00761	Docetaxel	CID: 148124	Approved	Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
PT00177	M6APDG02047	Tenofovir	CID: 464205	Approved	Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011 Jul 1;204(1):145-53.
PT00002	M6APDG02472	Tolbutamide	CID: 5505	Approved	ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007 Feb;453(5):703-18.
PT00001	M6APDG02974	Glycine	CID: 750	Approved	Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1046-53.
PT00001	M6APDG00226	L-carnitine	CID: 10917	Approved	A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70.
PT00001	M6APDG00628	Acyclovir	CID: 135398513	Approved	Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
PT00001	M6APDG00637	Ganciclovir	CID: 135398740	Approved	Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
PT00001	M6APDG00638	Valacyclovir	CID: 135398742	Approved	Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47.
PT00001	M6APDG00649	Valganciclovir	CID: 135413535	Approved	Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
PT00001	M6APDG02564	L-glutamine	CID: 5961	Approved	High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
PT00007	M6APDG02227	Quercetin	CID: 5280343	Approved	Oral Bioavailability and Disposition of Phytochemicals
PT00007	M6APDG02543	D-glucose	CID: 5793	Approved	The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38.
PT00017	M6APDG01395	L-glutamic acid	CID: 33032	Approved	The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017 Aug 25;292(34):14240-14249.
PT00003	M6APDG01984	Rhodamine 123	CID: 4541001	Discontinued in Phase 1	Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. Exp Mol Med. 2017 Mar 17;49(3):e303.
PT00009	M6APDG02774	Apafant	CID: 65889	Discontinued in Phase 2	Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. Eur J Pharm Sci. 2002 Aug;16(3):119-28.
PT00009	M6APDG02849	Dexniguldipine	CID: 6918097	Discontinued in Phase 2	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
PT00009	M6APDG02022	NSC325663	CID: 462199	Phase 2	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
PT00009	M6APDG01556	Bouvardin	CID: 429598	Preclinical	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
PT00009	M6APDG01611	Cephaeline	CID: 442195	Preclinical	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
PT00009	M6APDG01919	Okadaic acid	CID: 446512	Preclinical	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
PT00009	M6APDG02292	Nogalamycin	CID: 5289019	Preclinical	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
PT00009	M6APDG02427	Metkephamid	CID: 5464184	Preclinical	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
PT00003	M6APDG01647	E3040	CID: 443292	Discontinued in Phase 2	Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005 May 11;7(1):E118-33.
PT00003	M6APDG00505	Azidothymidine monophosphate	CID: 118879755	Preclinical	Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005 May 11;7(1):E118-33.
PT00009	M6APDG02524	Flesinoxan	CID: 57347	Discontinued in Phase 3	Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. Eur J Pharm Sci. 2001 Aug;14(1):81-6.
PT00003	M6APDG00059	Becatecarin	CID: 101524	Discontinued in Phase 3	Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemother Pharmacol. 2009 Aug;64(3):575-83.
PT00003	M6APDG02600	Befloxatone	CID: 60824	Discontinued in Phase 3	Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J Nucl Med. 2011 Mar;52(3):415-23.
PT00003	M6APDG00240	Hematoporphyrin	CID: 11103	Investigative	Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res. 2009 Feb;26(2):449-58.
PT00003	M6APDG02265	Estradiol-17beta-glucuronide	CID: 5281887	Investigative	Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites. Drug Metab Dispos. 2014 Apr;42(4):575-85.
PT00007	M6APDG01131	Arsenite	CID: 24577	Investigative	Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid. Biochem Biophys Res Commun. 2006 Dec 15;351(2):424-30.
PT00007	M6APDG01583	Dehydroascorbic acid	CID: 440667	Investigative	Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem. 1997 Jul 25;272(30):18982-9.
PT00009	M6APDG00101	Genz 644282	CID: 10294813	Phase 1	Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther. 2011 Aug;10(8):1490-9.
PT00009	M6APDG00342	Norbuprenorphine	CID: 114976	Phase 1	Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15.
PT00009	M6APDG01450	Substance P	CID: 36511	Phase 1	Transport of somatostatin and substance P by human P-glycoprotein. FEBS Lett. 2004 Sep 10;574(1-3):55-61.
PT00009	M6APDG02236	Prostaglandin A2	CID: 5280880	Phase 1	Unveiling the role of multidrug resistance proteins in hypertension. Hypertension. 2009 Aug;54(2):210-6.
PT00009	M6APDG03341	YP-005	CID: 5283560	Phase 1	Lipid dependence of ABC transporter localization and function. Chem Phys Lipids. 2009 Oct;161(2):57-64.
PT00009	M6APDG02837	Talinolol	CID: 68770	Phase 1	Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci. 2007 Oct;96(10):2808-17.
PT00003	M6APDG03325	AZD-1152-HQPA	CID: 16007391	Phase 1	P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer. 2011 Jun 16;11:254.
PT00003	M6APDG00979	Benzoylphenylurea	CID: 19851629	Phase 1	American Association for Cancer Research.
PT00003	M6APDG03341	YP-005	CID: 5283560	Phase 1	Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem. 2010 Apr 2;285(14):10477-86.
PT00007	M6APDG00217	2-Deoxyglucose	CID: 108223	Phase 1/2	Glutamine 161 of Glut1 glucose transporter is critical for transport activity and exofacial ligand binding. J Biol Chem. 1994 Aug 12;269(32):20533-8.
PT00009	M6APDG00043	(Z)-endoxifen	CID: 10090750	Phase 2	P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther. 2011 Jun;337(3):710-7.
PT00009	M6APDG00168	Norverapamil	CID: 104972	Phase 2	Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82.
PT00009	M6APDG03326	Roscovitine	CID: 160355	Phase 2	ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos. 2010 Nov;38(11):2000-6.
PT00009	M6APDG02572	Cholesterol	CID: 5997	Phase 2	Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem Biophys Res Commun. 2000 Oct 5;276(3):909-16.
PT00009	M6APDG03122	Dolastatin 10	CID: 9810929	Phase 2	Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.
PT00009	M6APDG03139	CP-122721	CID: 9821217	Phase 2	P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1252-9.
PT00003	M6APDG00165	SN-38	CID: 104842	Phase 2	Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001 Nov 9;288(4):827-32.
PT00003	M6APDG00602	C-1311	CID: 132127	Phase 2	C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol. 2007 Jun 30;74(1):41-53.
PT00003	M6APDG00763	HPPH	CID: 148160	Phase 2	Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. Mol Pharm. 2010 Oct 4;7(5):1789-804.
PT00003	M6APDG01493	SJG-136	CID: 393111	Phase 2	Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters. AAPS J. 2010 Dec;12(4):617-27.
PT00003	M6APDG01525	Oxfendazole	CID: 40854	Phase 2	Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos. 2005 May;33(5):614-8.
PT00003	M6APDG02287	Flavopiridol	CID: 5287969	Phase 2	The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 2012 Sep;11(9):2033-44.
PT00003	M6APDG02654	Phosphatidylserine	CID: 6438639	Phase 2	ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010 Apr 24;86(17-18):631-7.
PT00003	M6APDG03215	CP-724714	CID: 9874913	Phase 2	Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem. 2009 Feb;4(2):188-95.
PT00003	M6APDG00163	Butyrate	CID: 104775	Phase 2/3	The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein. Am J Physiol Cell Physiol. 2011 Nov;301(5):C984-94.
PT00003	M6APDG00466	Uric acid	CID: 1175	Phase 2/3	Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One. 2012;7(2):e30456.
PT00001	M6APDG00756	Nitric oxide	CID: 145068	Phase 2/3	Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.
PT00009	M6APDG01199	ABT-263	CID: 24978538	Phase 3	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun. 2011 May 6;408(2):344-9.
PT00009	M6APDG00260	ABT-737	CID: 11228183	Terminated	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun. 2011 May 6;408(2):344-9.
PT00009	M6APDG02686	Simvastatin acid	CID: 64718	Phase 3	Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004 Sep;21(9):1686-91.
PT00009	M6APDG02775	Pazufloxacin	CID: 65957	Phase 3	Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Eur J Pharmacol. 2004 Oct 6;501(1-3):151-9.
PT00009	M6APDG03101	Tenofovir alafenamide	CID: 9574768	Phase 3	Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
PT00003	M6APDG03101	Tenofovir alafenamide	CID: 9574768	Phase 3	Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
PT00003	M6APDG01124	Camptothecin	CID: 24360	Phase 3	The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9.
PT00009	M6APDG03322	Dihydrotestosterone	CID: 10635	Phase 4	P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90.
PT00009	M6APDG00906	Biotin	CID: 171548	Phase 4	Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery. Mol Pharm. 2006 May-Jun;3(3):329-39.
PT00009	M6APDG01437	Guanfacine	CID: 3519	Phase 4	An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatr Dis Treat. 2011;7:501-5.
PT00003	M6APDG01453	Hypericin	CID: 3663	Phase 4	Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009 Dec;8(12):1716-23.
PT00003	M6APDG02259	Daidzein	CID: 5281708	Phase 4	Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol. 2007 Oct;72(4):967-75.
PT00003	M6APDG02258	Coumestrol	CID: 5281707	Preclinical	Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol. 2007 Oct;72(4):967-75.
PT00003	M6APDG02831	Nifurtimox	CID: 6842999	Phase 4	The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein. Brain Res. 2012 Feb 3;1436:111-21.
PT00001	M6APDG02892	D-serine	CID: 71077	Phase 4	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
PT00001	M6APDG02625	L-threonine	CID: 6288	Preclinical	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
PT00210	M6APDG02568	Sucrose	CID: 5988	Phase 4	The SLC45 gene family of putative sugar transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):655-60.
PT00009	M6APDG00100	N-desethyl sunitinib	CID: 10292573	Preclinical	P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012 Apr;341(1):164-73.
PT00003	M6APDG00100	N-desethyl sunitinib	CID: 10292573	Preclinical	P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012 Apr;341(1):164-73.
PT00009	M6APDG00477	Silvestrol	CID: 11787114	Preclinical	Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J. 2011 Sep;13(3):357-64.
PT00009	M6APDG00552	Geneticin	CID: 123865	Preclinical	ATP-binding cassette transporters as pitfalls in selection of transgenic cells. Anal Biochem. 2010 Apr 15;399(2):246-50.
PT00009	M6APDG01580	Puromycin	CID: 439530	Preclinical	ATP-binding cassette transporters as pitfalls in selection of transgenic cells. Anal Biochem. 2010 Apr 15;399(2):246-50.
PT00009	M6APDG00663	Coelenterazine	CID: 135445694	Preclinical	Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1702-7.
PT00009	M6APDG01132	Bunitrolol	CID: 2473	Preclinical	Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm Drug Dispos. 1999 Mar;20(2):85-90.
PT00009	M6APDG02044	MG-132	CID: 462382	Preclinical	Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells. Biosci Biotechnol Biochem. 2010;74(9):1913-9.
PT00009	M6APDG02650	Abamectin B1A	CID: 6434889	Preclinical	Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur J Pharm Sci. 2007 Jan;30(1):84-94.
PT00009	M6APDG03103	Selamectin	CID: 9578507	Preclinical	Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur J Pharm Sci. 2007 Jan;30(1):84-94.
PT00009	M6APDG02657	E-guggulsterone	CID: 6439929	Preclinical	Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun. 2008 May 2;369(2):363-8.
PT00003	M6APDG00192	Homocamptothecin	CID: 10666346	Preclinical	ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007 Mar;26(1):39-57.
PT00003	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer Ther. 2011 Jan;10(1):117-25.
PT00003	M6APDG00949	Scutellarin	CID: 185617	Preclinical	Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
PT00003	M6APDG01605	Pancratistatin	CID: 441597	Preclinical	Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol. 2009 Nov;76(5):946-56.
PT00003	M6APDG03343	JNJ 7706621	CID: 5330790	Preclinical	Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther. 2006 Oct;5(10):2459-67.
PT00003	M6APDG02894	Enrofloxacin	CID: 71188	Preclinical	Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther. 2006 Aug;29(4):279-87.
PT00003	M6APDG01366	Parabis	CID: 3037	Withdrawn	Human and rat ABC transporter efflux of bisphenol a and bisphenol a glucuronide: interspecies comparison and implications for pharmacokinetic assessment. Toxicol Sci. 2012 Aug;128(2):317-25.
PT00002	M6APDG01432	Glimepiride	CID: 3476	Approved	Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
PT00002	M6APDG02140	Nicorandil	CID: 47528	Approved	US patent application no. 8,669,257, Phenazine derivatives and uses thereof as potassium channel modulators.
PT00002	M6APDG02472	Tolbutamide	CID: 5505	Approved	A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) chann... J Mol Cell Cardiol. 2005 Jul;39(1):1-6.
PT00002	M6APDG02776	Repaglinide	CID: 65981	Approved	Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. 
PT00193	M6APDG03085	Nicotinamide	CID: 936	Approved	Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11.
PT00025	M6APDG00884	Fedratinib	CID: 16722836	Approved	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
PT00025	M6APDG01610	Baricitinib	CID: 44205240	Approved	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
PT00146	M6APDG03274	Tofacitinib	CID: 9926791	Approved	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
PT00113	M6APDG01226	VS-6063	CID: 25117126	Phase 2	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
PT00044	M6APDG00467	Clascoterone	CID: 11750009	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
PT00044	M6APDG01113	Bicalutamide	CID: 2375	Approved	Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr J. 2004 Aug;51(4):425-34.
PT00044	M6APDG01382	Fludrocortisone	CID: 31378	Approved	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
PT00015	M6APDG02432	Meloxicam	CID: 54677470	Approved	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
PT00044	M6APDG01412	Flufenamic Acid	CID: 3371	Approved	Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, ... Endocrinology. 1984 Jun;114(6):2100-6.
PT00044	M6APDG01421	Flutamide	CID: 3397	Approved	CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
PT00044	M6APDG01956	Nilutamide	CID: 4493	Approved	Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
PT00044	M6APDG02280	Cyproterone	CID: 5284537	Approved	Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44.
PT00044	M6APDG02554	Oxandrolone	CID: 5878	Approved	Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74.
PT00044	M6APDG02574	Dromostanolone	CID: 6011	Approved	Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
PT00044	M6APDG02575	Testosterone	CID: 6013	Approved	Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
PT00044	M6APDG02677	Fluoxymesterone	CID: 6446	Approved	The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4.
PT00044	M6APDG02807	Darolutamide	CID: 67171867	Approved	Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
PT00044	M6APDG03047	Hydroxyflutamide	CID: 91649	Approved	Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
PT00044	M6APDG03250	Nandrolone	CID: 9904	Approved	An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
PT00005	M6APDG00738	Testolactone	CID: 13769	Approved	Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
PT00005	M6APDG02581	Exemestane	CID: 60198	Approved	Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
PT00005	M6APDG01006	Aminoglutethimide	CID: 2145	Approved	Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
PT00005	M6APDG01025	Anastrozole	CID: 2187	Approved	Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
PT00005	M6APDG01487	Letrozole	CID: 3902	Approved	Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
PT00005	M6APDG02565	FADROZOLE	CID: 59693	Approved	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG03196	Coumate	CID: 9859866	Phase 2	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG00007	MR-20494	CID: 10019821	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG00754	LUDARTIN	CID: 14355826	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG02098	MR-16089	CID: 46887422	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG02230	APIGENIN	CID: 5280443	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG02426	Gamma-mangostin	CID: 5464078	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG02965	DEHYDROLEUCODIN	CID: 73440	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG02268	7,4'-Dihydroxyflavone	CID: 5282073	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG02097	9-Hydroxy-7,8-benzoflavone	CID: 46887421	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG01476	1-(9H-fluoren-9-yl)-1H-imidazole	CID: 3828439	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG01398	N-[2-(4'-Nitrophenyl)ethyl]-imidazole	CID: 3317166	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG00029	1-(3-(4-fluorophenyl)propyl)-1H-imidazole	CID: 10081625	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG00191	8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one	CID: 10659706	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG00471	3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one	CID: 11760063	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG01697	2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol	CID: 44394887	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG00118	11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B	CID: 10354739	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG02103	1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole	CID: 46887506	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG02742	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539795	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG00493	3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone	CID: 11847169	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG00364	3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine	CID: 11529133	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG00542	3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione	CID: 12331302	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00005	M6APDG02760	5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole	CID: 6540043	Investigative	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
PT00051	M6APDG03320	Afatinib	CID: 10184653	Approved	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
PT00050	M6APDG01374	Vandetanib	CID: 3081361	Approved	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
PT00198	M6APDG02494	Alpelisib	CID: 56649450	Approved	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
PT00051	M6APDG02808	NERATINIB MALEATE	CID: 67307512	Approved	Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem. 2009 May 14;52(9):2673-82.
PT00040	M6APDG01018	Lenalidomide	CID: 216326	Approved	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
PT00140	M6APDG01578	Glucosamine	CID: 439213	Approved	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
PT00040	M6APDG01591	Nafamostat	CID: 4413	Approved	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
PT00040	M6APDG02137	Pentoxifylline	CID: 4740	Approved	Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
PT00112	M6APDG02792	Tazemetostat	CID: 66558664	Approved	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
PT00150	M6APDG00640	Penciclovir	CID: 135398748	Approved	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9.
PT00150	M6APDG01971	3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine	CID: 452142	Investigative	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9.
PT00046	M6APDG01505	MCI-186	CID: 4021	Approved	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.
PT00106	M6APDG02497	Epidermal growth factor	CID: 56841751	Approved	Clinical pipeline report, company report or official report of AbbVie.
PT00214	M6APDG00900	FLUORESCEIN	CID: 16850	Approved	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2824).
PT00165	M6APDG01223	Cabozantinib	CID: 25102847	Approved	Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607... J Med Chem. 2009 Mar 12;52(5):1251-4.
PT00165	M6APDG01235	Capmatinib	CID: 25145656	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
PT00140	M6APDG02613	Gallium nitrate	CID: 61635	Approved	Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98.
PT00055	M6APDG00161	Bempedoic acid	CID: 10472693	Approved	A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013 Mar 15;8(3):559-67.
PT00172	M6APDG02049	Prinomastat	CID: 466151	Approved	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
PT00011	M6APDG02049	Prinomastat	CID: 466151	Approved	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
PT00175	M6APDG01403	RS-130830	CID: 3342298	Discontinued in Phase 2	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
PT00196	M6APDG00480	Avapritinib	CID: 118023034	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
PT00196	M6APDG02354	Romiplostim	CID: 5329098	Approved	A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
PT00196	M6APDG02917	Ripretinib	CID: 71584930	Approved	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
PT00197	M6APDG01203	E-3810	CID: 25031915	Phase 3	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
PT00196	M6APDG03115	JNJ-10198409	CID: 9797370	Investigative	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
PT00197	M6APDG03115	JNJ-10198409	CID: 9797370	Investigative	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
PT00003	M6APDG02386	Sulfasalazine	CID: 5339	Approved	The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul;29(7):639-644.
PT00035	M6APDG02242	Rosiglitazone XR	CID: 5281055	Approved	Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
PT00035	M6APDG00782	KRP-297	CID: 151183	Discontinued in Phase 2	Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
PT00035	M6APDG02417	Thiazolidinedione	CID: 5437	Approved	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
PT00199	M6APDG00362	Pemafibrate	CID: 11526038	Approved	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
PT00199	M6APDG01488	Bezafibrate	CID: 39042	Approved	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
PT00199	M6APDG03239	L-796449	CID: 9891946	Investigative	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
PT00035	M6APDG02482	Troglitazone	CID: 5591	Approved	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
PT00035	M6APDG03153	Lobeglitazone	CID: 9826451	Approved	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
PT00050	M6APDG00785	Merimepodib	CID: 153241	Approved	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
PT00050	M6APDG01966	Nitroglycerin	CID: 4510	Approved	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
PT00050	M6APDG00994	Lapatinib	CID: 208908	Approved	Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26.
PT00050	M6APDG02497	Epidermal growth factor	CID: 56841751	Approved	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
PT00185	M6APDG02619	Cycloserine	CID: 6234	Approved	Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
PT00154	M6APDG02855	CAP-232	CID: 6918265	Phase 2a	Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
PT00015	M6APDG00521	Valdecoxib	CID: 119607	Approved	Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
PT00015	M6APDG00547	Etoricoxib	CID: 123619	Approved	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
PT00015	M6APDG00780	Lumiracoxib	CID: 151166	Approved	Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42.
PT00015	M6APDG00807	Naproxen	CID: 156391	Approved	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
PT00015	M6APDG01280	Carprofen	CID: 2581	Approved	Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62.
PT00015	M6APDG01290	Celecoxib	CID: 2662	Approved	The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res. 2009 May 26;4:17.
PT00015	M6APDG01370	Diflunisal	CID: 3059	Approved	Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
PT00015	M6APDG01396	Etodolac	CID: 3308	Approved	Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62.
PT00015	M6APDG01412	Flufenamic Acid	CID: 3371	Approved	Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
PT00015	M6APDG01454	Ibuprofen	CID: 3672	Approved	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
PT00015	M6APDG01462	Indomethacin	CID: 3715	Approved	Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors, Bioorg. Med. Chem. Lett. 6(22):2677-2682 (1996).
PT00015	M6APDG01474	Ketoprofen	CID: 3825	Approved	The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42.
PT00015	M6APDG01514	Mefenamic acid	CID: 4044	Approved	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
PT00015	M6APDG02193	Rofecoxib	CID: 5090	Approved	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
PT00015	M6APDG01585	Nabumetone	CID: 4409	Approved	Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7.
PT00015	M6APDG01946	Niflumic Acid	CID: 4488	Approved	Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14.
PT00015	M6APDG02048	Aminosalicylic Acid	CID: 4649	Approved	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
PT00015	M6APDG02144	Phenylbutazone	CID: 4781	Approved	Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91.
PT00015	M6APDG02434	Tenoxicam	CID: 54677971	Approved	Pfizer. Product Development Pipeline. March 31 2009.
PT00015	M6APDG02437	Tiaprofenic acid	CID: 5468	Approved	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6.
PT00015	M6APDG02473	Tolmetin	CID: 5509	Approved	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
PT00117	M6APDG02622	Urofollitropin	CID: 62819	Approved	Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014 Mar 1;14(3):552-9.
PT00132	M6APDG02921	Ivosidenib	CID: 71657455	Approved	Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. Eur J Med Chem. 2009 Apr;44(4):1383-95.
PT00162	M6APDG02399	Methylnaltrexone bromide	CID: 5361917	Approved	Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
PT00162	M6APDG03288	Bremelanotide	CID: 9941379	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
PT00029	M6APDG03331	Glasdegib	CID: 25166913	Approved	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
PT00029	M6APDG02857	Temsirolimus	CID: 6918289	Approved	Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
PT00054	M6APDG02853	GHRP-2	CID: 6918245	Approved	Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62.
PT00138	M6APDG00767	Arsenic trioxide	CID: 14888	Approved	The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66.
PT00198	M6APDG00700	BAY 80-6946	CID: 135565596	Approved	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
PT00018	M6APDG02338	HIF-1alpha	CID: 5328127	Phase 4	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.
PT00239	M6APDG02174	Gilteritinib	CID: 49803313	Approved	Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. J Med Chem. 2015 Jul 23;58(14):5649-73.
PT00080	M6APDG02363	Palbociclib	CID: 5330286	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
PT00081	M6APDG02363	Palbociclib	CID: 5330286	Approved	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
PT00080	M6APDG02519	Ribociclib Succinate	CID: 57334219	Approved	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
PT00169	M6APDG01232	NKP-1339	CID: 25134754	Phase 1	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
PT00170	M6APDG00914	SB 203580	CID: 176155	Terminated	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
PT00080	M6APDG02823	Trilaciclib	CID: 68029831	Approved	Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
PT00081	M6APDG02823	Trilaciclib	CID: 68029831	Approved	Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
PT00199	M6APDG01312	Ciprofibrate	CID: 2763	Approved	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
PT00035	M6APDG00069	Glitazone	CID: 10198397	Phase 4	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
PT00199	M6APDG01402	Fenofibrate	CID: 3339	Approved	Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
PT00199	M6APDG03153	Lobeglitazone	CID: 9826451	Approved	Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
PT00025	M6APDG00884	Fedratinib	CID: 16722836	Approved	The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
PT00081	M6APDG02519	Ribociclib Succinate	CID: 57334219	Approved	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
PT00078	M6APDG02004	Olomoucine	CID: 4592	Terminated	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
PT00079	M6APDG02004	Olomoucine	CID: 4592	Terminated	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
PT00123	M6APDG00579	RO-320432	CID: 127757	Terminated	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
PT00241	M6APDG01954	PMID18163548C4	CID: 449051	Clinical trial	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
PT00241	M6APDG03227	UK-356202	CID: 9885167	Clinical trial	Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
PT00174	M6APDG02771	PMID17935984C1	CID: 657061	Clinical trial	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
PT00172	M6APDG00765	BMS 275291	CID: 148203	Discontinued in Phase 3	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
PT00002	M6APDG01533	CCX915	CID: 41214	Discontinued in Phase 1	The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats.J Cereb Blood Flow Metab.2007 Feb;27(2):348-55.
PT00002	M6APDG03142	BMS-191095	CID: 9822753	Discontinued in Phase 1	BTS-67582 (Knoll Pharmaceuticals Co). IDrugs. 1999 Apr;2(4):355-9.
PT00044	M6APDG02833	MX-4509	CID: 68570	Discontinued in Phase 1	Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activity. J Neurobiol. 2003 Nov;57(2):163-71.
PT00044	M6APDG02981	PF-06260414	CID: 76071881	Discontinued in Phase 1	Influence of testosterone and a novel SARM on gene expression in whole blood of Macaca fascicularis. J Steroid Biochem Mol Biol. 2009 Apr;114(3-5):167-73.
PT00019	M6APDG03202	SB-242235	CID: 9863367	Discontinued in Phase 1	Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2007 May;23(4):269-75.
PT00051	M6APDG02672	TAK165	CID: 6444692	Discontinued in Phase 1	Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther. 2010 June; 12(3): 340-349.
PT00130	M6APDG03240	IPI-493	CID: 9893658	Discontinued in Phase 1	Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells. Cell Immunol. 2009;259(1):49-55.
PT00144	M6APDG03124	DMP-802	CID: 9812185	Discontinued in Phase 1	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00144	M6APDG00012	DMP-757	CID: 10031011	Terminated	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00144	M6APDG01665	Ro-43-5054	CID: 44343754	Terminated	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00144	M6APDG03144	SB-223245	CID: 9823503	Terminated	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00144	M6APDG00106	L-746233	CID: 10324223	Investigative	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00144	M6APDG00464	L-750034	CID: 11743533	Investigative	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00144	M6APDG03266	L-734115	CID: 9913833	Investigative	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00144	M6APDG03304	L-739758	CID: 9958398	Investigative	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00144	M6APDG01645	RWJ-53419	CID: 44322318	Investigative	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00144	M6APDG00593	Gly-Arg-Gly-Asp-Ser-Pro-Lys	CID: 130667	Investigative	Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
PT00009	M6APDG00510	ELACRIDAR	CID: 119373	Discontinued in Phase 1	Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Biochem Pharmacol.2008 Mar 15;75(6):1302-12.
PT00009	M6APDG02681	ONT-093	CID: 6450807	Discontinued in Phase 1	2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties. J Med Chem. 2008 Dec 11;51(23):7602-13.
PT00034	M6APDG03233	HMN-214	CID: 9888590	Discontinued in Phase 1	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
PT00034	M6APDG02161	PCM-075	CID: 49792852	Phase 2	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
PT00034	M6APDG01139	CYC-800	CID: 24759764	Preclinical	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
PT00034	M6APDG02966	ZK-thiazolidinone	CID: 73442801	Preclinical	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
PT00034	M6APDG03092	DAP-81	CID: 9548005	Preclinical	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
PT00034	M6APDG01202	Ro5203280	CID: 25015677	Investigative	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
PT00044	M6APDG00608	RU-58841	CID: 132981	Discontinued in Phase 1	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
PT00045	M6APDG02207	PF-03814735	CID: 51346455	Discontinued in Phase 1	SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
PT00035	M6APDG00512	E-3030	CID: 11949481	Discontinued in Phase 1	The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats. J Pharmacol Sci. 2006 Aug;101(4):311-7.
PT00035	M6APDG03236	LY-929	CID: 9890585	Discontinued in Phase 1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036558)
PT00050	M6APDG02132	PD-153035	CID: 4705	Discontinued in Phase 1	GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126-38.
PT00050	M6APDG02672	TAK165	CID: 6444692	Discontinued in Phase 1	EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.Diabetes.2009 Dec;58(12):2910-9.
PT00170	M6APDG00312	R-1487	CID: 11406590	Discontinued in Phase 1	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
PT00170	M6APDG00102	Dilmapimod	CID: 10297982	Phase 2	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
PT00170	M6APDG03114	SB 235699	CID: 9797240	Discontinued in Phase 1	Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433-7.
PT00170	M6APDG03202	SB-242235	CID: 9863367	Discontinued in Phase 1	Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem. 2010 Mar 25;53(6):2345-53.
PT00015	M6APDG01385	DUP 697	CID: 3177	Discontinued in Phase 1	New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37.
PT00015	M6APDG03135	Apricoxib	CID: 9820073	Discontinued in Phase 2	New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37.
PT00015	M6APDG01655	SC-57666	CID: 443373	Discontinued in Phase 1	Clinical pipeline report, company report or official report of raqualia.
PT00015	M6APDG03299	E-6087	CID: 9953093	Discontinued in Phase 1	Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut. 2005 May; 54(5): 608-616.
PT00123	M6APDG00698	AZD-1080	CID: 135564570	Discontinued in Phase 1	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
PT00138	M6APDG03020	MLN0415	CID: 86630595	Discontinued in Phase 1	I B kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy. 2011 Jan;41(1):104-15.
PT00199	M6APDG00512	E-3030	CID: 11949481	Discontinued in Phase 1	Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58.
PT00035	M6APDG03237	YM-440	CID: 9890786	Discontinued in Phase 2	Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58.
PT00199	M6APDG03236	LY-929	CID: 9890585	Discontinued in Phase 1	CN patent application no. 100577175, Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators.
PT00206	M6APDG01491	LG100268	CID: 3922	Discontinued in Phase 1	Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl). 2004 Feb;82(2):116-25.
PT00241	M6APDG03241	WX-UK1	CID: 9895194	Discontinued in Phase 1/2	Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6.
PT00022	M6APDG02503	KW-2450	CID: 56847547	Discontinued in Phase 1/2	Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growthfactor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5445-56.
PT00029	M6APDG01271	AZD8055	CID: 25262965	Discontinued in Phase 1/2	Clinical pipeline report, company report or official report of tatcongress.
PT00002	M6APDG00555	KRN-2391	CID: 123957	Discontinued in Phase 2	Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
PT00002	M6APDG03229	BTS-67582	CID: 9885406	Discontinued in Phase 2	Effects of KRN2391 on ionic currents in rabbit femoral arterial myocytes
PT00173	M6APDG00605	GM6001	CID: 132519	Discontinued in Phase 2	Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
PT00012	M6APDG00605	GM6001	CID: 132519	Discontinued in Phase 2	Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
PT00011	M6APDG00605	GM6001	CID: 132519	Discontinued in Phase 2	Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
PT00173	M6APDG01136	AZD1236	CID: 24751752	Discontinued in Phase 2	Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7.
PT00044	M6APDG02919	HE-2000	CID: 71613	Discontinued in Phase 2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028305)
PT00005	M6APDG00924	YM-511	CID: 177865	Discontinued in Phase 2	The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98.
PT00005	M6APDG02848	NKS-01	CID: 6918079	Discontinued in Phase 2	Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men. Br J Clin Pharmacol. 2001 Dec;52(6):702-4.
PT00005	M6APDG02852	VOROZOLE	CID: 6918191	Discontinued in Phase 2	A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007 Oct;114(10):1822-30.
PT00005	M6APDG02856	FINROZOLE	CID: 6918277	Discontinued in Phase 2	First dual aromatase-steroid sulfatase inhibitors. J Med Chem. 2003 Jul 17;46(15):3193-6.
PT00213	M6APDG02670	GSK184072	CID: 6443207	Discontinued in Phase 2	SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8.
PT00241	M6APDG01664	PAI-2	CID: 443433	Discontinued in Phase 2	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
PT00130	M6APDG02289	Geldanamycin	CID: 5288382	Discontinued in Phase 2	US patent application no. 2013,0023,420, Susceptibility to hsp90-inhibitors.
PT00040	M6APDG03217	Camobucol	CID: 9875498	Discontinued in Phase 2	Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med. 2001 Apr;29(4):765-9.
PT00009	M6APDG00764	Tariquidar	CID: 148201	Discontinued in Phase 2	A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxoru... Clin Cancer Res. 2004 May 15;10(10):3265-72.
PT00009	M6APDG01367	Biricodar	CID: 3037617	Discontinued in Phase 2	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
PT00009	M6APDG02412	TRISMETHOXYRESVERATROL	CID: 5388063	Investigative	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
PT00009	M6APDG00392	[1,1':2',1'']-terphenyl-4,3'',5''-triol	CID: 11579996	Investigative	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
PT00009	M6APDG00370	4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl	CID: 11537051	Investigative	Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.
PT00174	M6APDG00605	GM6001	CID: 132519	Discontinued in Phase 2	Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
PT00175	M6APDG02402	Batimastat	CID: 5362422	Preclinical	Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
PT00174	M6APDG01403	RS-130830	CID: 3342298	Discontinued in Phase 2	Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
PT00078	M6APDG01982	BAY 10-00394	CID: 45380979	Discontinued in Phase 2	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
PT00172	M6APDG01403	RS-130830	CID: 3342298	Discontinued in Phase 2	Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
PT00011	M6APDG02858	Tanomastat	CID: 6918336	Discontinued in Phase 3	Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
PT00196	M6APDG00594	SRI-62-834	CID: 130724	Discontinued in Phase 2	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
PT00057	M6APDG01152	BMS-754807	CID: 24785538	Phase 1	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
PT00197	M6APDG00988	AG1295	CID: 2048	Terminated	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
PT00012	M6APDG01403	RS-130830	CID: 3342298	Discontinued in Phase 2	Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix m... Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31.
PT00011	M6APDG01403	RS-130830	CID: 3342298	Discontinued in Phase 2	Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix m... Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31.
PT00035	M6APDG00308	Indeglitazar	CID: 11395145	Discontinued in Phase 2	A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8.
PT00035	M6APDG03119	Sodelglitazar	CID: 9805950	Discontinued in Phase 2	Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7.
PT00199	M6APDG03119	Sodelglitazar	CID: 9805950	Discontinued in Phase 2	Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7.
PT00197	M6APDG00594	SRI-62-834	CID: 130724	Discontinued in Phase 2	Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated w... J Clin Oncol. 2005 Feb 10;23(5):973-81.
PT00050	M6APDG02861	PKI166	CID: 6918403	Discontinued in Phase 2	Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.
PT00185	M6APDG02463	YM-90K	CID: 5486547	Discontinued in Phase 2	Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
PT00015	M6APDG00816	Tilmacoxib	CID: 159271	Discontinued in Phase 2	Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer. IDrugs. 2009 Nov;12(11):711-22.
PT00015	M6APDG00933	R-ketoprofen	CID: 180540	Discontinued in Phase 2	Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation appro... Bioorg Med Chem Lett. 2009 Aug 1;19(15):4509-14.
PT00015	M6APDG02226	GSK-644784	CID: 5280119	Discontinued in Phase 2	ClinicalTrials.gov (NCT00506298) Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes. U.S. National Institutes of Health.
PT00011	M6APDG00330	Galarubicin	CID: 114759	Discontinued in Phase 2	Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:44-6.
PT00079	M6APDG01982	BAY 10-00394	CID: 45380979	Discontinued in Phase 2	Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009 Feb;8(2):324-32.
PT00021	M6APDG00787	TAK-603	CID: 153980	Discontinued in Phase 2	Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53.
PT00080	M6APDG01982	BAY 10-00394	CID: 45380979	Discontinued in Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1976).
PT00199	M6APDG00412	AVE-8134	CID: 11625114	Discontinued in Phase 2	Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene. Biochem Pharmacol. 2009 Sep 1;78(5):523-30.
PT00199	M6APDG02490	GSK-677954	CID: 56603715	Discontinued in Phase 2	Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6471-5.
PT00199	M6APDG03149	KRP-101	CID: 9825046	Discontinued in Phase 2	Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H949-57.
PT00199	M6APDG03291	NS-220	CID: 9947731	Discontinued in Phase 2	The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin. 2009 Jul;30(7):935-46.
PT00175	M6APDG00605	GM6001	CID: 132519	Discontinued in Phase 2	Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. J Med Chem. 2015 Apr 9;58(7):2941-57.
PT00227	M6APDG02958	Mannose phosphate	CID: 73014169	Discontinued in Phase 2	Clinical pipeline report, company report or official report of Scholar Rock.
PT00144	M6APDG02607	XEMILOFIBAN	CID: 60957	Discontinued in Phase 3	Synthesis and antiplatelet activity of DMP 757 analogs, Bioorg. Med. Chem. Lett. 5(18):2097-2100 (1995).
PT00009	M6APDG00789	LY335979	CID: 153997	Discontinued in Phase 3	In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. J Antimicrob Chemother. 2015 Jan;70(1):173-7.
PT00015	M6APDG01364	PRINOMIDE TROMETHAMINE	CID: 3033812	Discontinued in Phase 3	Development of a botanical anti-arthritis drug, PMI-001. SBIR.STTR America's Seed Fund.
PT00015	M6APDG03163	GW-406381	CID: 9832687	Discontinued in Phase 3	Dexketoprofene, selective cox-1 inhibitor nsaids, without gastrointestinal injury in rats. Acta Gastroenterol Latinoam. 2002 May;32(1):17-20.
PT00011	M6APDG00765	BMS 275291	CID: 148203	Discontinued in Phase 3	Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
PT00175	M6APDG02452	AM-2S	CID: 54726664	Investigative	Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
PT00079	M6APDG02117	SCH 727965	CID: 46926350	Discontinued in Phase 3	AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.Int J Radiat Oncol Biol Phys.2012 Nov 15;84(4):e507-14.
PT00199	M6APDG03321	Aleglitazar	CID: 10274777	Discontinued in Phase 3	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
PT00028	M6APDG02924	HDM201	CID: 71678098	Phase 1	MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 Nov;34(11):2858-2874.
PT00033	M6APDG00720	BAY 1082439	CID: 136336430	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2154).
PT00033	M6APDG02302	AZD8186	CID: 52913813	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7967).
PT00025	M6APDG00894	SB-1578	CID: 16750271	Phase 1	Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008 Jul;22(7):1320-34.
PT00025	M6APDG02105	AC430	CID: 46892373	Phase 1	Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J. 2014 Jan 10;4:e174.
PT00044	M6APDG00333	TESTOSTERONE BUCICLATE	CID: 114819	Phase 1	Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett. 2010 Dec 2;2(2):124-9.
PT00044	M6APDG01609	RAD-140	CID: 44200882	Phase 1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039743)
PT00044	M6APDG02106	AZD-3514	CID: 46893585	Phase 1	Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008; 6: e010.
PT00005	M6APDG03082	Naringenin	CID: 932	Phase 1	Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activ... J Med Chem. 2008 Jul 24;51(14):4226-38.
PT00051	M6APDG00409	TAK-285	CID: 11620908	Phase 1	Clinical pipeline report, company report or official report of Zensun.
PT00213	M6APDG02046	SRT3025	CID: 46245047	Phase 1	Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69.
PT00113	M6APDG01215	VS-4718	CID: 25073775	Phase 1	Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45.
PT00113	M6APDG02019	GSK-2256098	CID: 46214930	Phase 1	FAK Inhibition disrupts a beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61.
PT00113	M6APDG02927	CEP-37440	CID: 71721648	Phase 1	Clinical pipeline report, company report or official report of InxMed.
PT00031	M6APDG02924	HDM201	CID: 71678098	Phase 1	Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23.
PT00059	M6APDG03036	GSK3368715	CID: 90462880	Phase 1	Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing soli... Ann Oncol. 2009 Apr;20(4):741-5.
PT00130	M6APDG01599	Debio 0932	CID: 44156921	Phase 1	Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41.
PT00130	M6APDG01951	PU3	CID: 448965	Phase 1	Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31.
PT00130	M6APDG03190	Alvespimycin hydrochloride	CID: 9852573	Phase 1	Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference. Astex. 2008.
PT00042	M6APDG00158	MP-0112	CID: 10464700	Phase 1	sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.
PT00009	M6APDG03161	W-198	CID: 9831563	Phase 1	A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors. Oncologist.2012;17(4):512.
PT00112	M6APDG00502	PF-06821497	CID: 118572065	Phase 1	Clinical pipeline report, company report or official report of HaiHe Biopharma.
PT00112	M6APDG01058	DS-3201	CID: 22627096	Phase 1	Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665.
PT00038	M6APDG01864	WP1220	CID: 44554865	Phase 1	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat. 2019 Apr;51(2):510-518.
PT00150	M6APDG03271	Rilapladib	CID: 9918381	Phase 1	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
PT00014	M6APDG00212	L-NIO	CID: 107984	Investigative	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
PT00173	M6APDG01948	CP-271485	CID: 448940	Investigative	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
PT00071	M6APDG01311	3-Methylphenylalanine	CID: 2761494	Investigative	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
PT00176	M6APDG02639	Double Oxidized Cysteine	CID: 6398956	Investigative	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
PT00150	M6APDG02697	2'-deoxythymidine triphosphate	CID: 64968	Investigative	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
PT00014	M6APDG00963	7-Nitroindazole-2-Carboxamidine	CID: 1894	Investigative	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
PT00079	M6APDG01955	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	CID: 449088	Investigative	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
PT00165	M6APDG00744	XL092	CID: 139350422	Phase 1	Clinical pipeline report, company report or official report of Kringle Pharma.
PT00165	M6APDG00922	PF-4217903	CID: 17754438	Phase 1	2012 ASCO Annual Meeting.
PT00165	M6APDG01150	SGX523	CID: 24779724	Phase 1	Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics Volume 16, Issue 2, pages 235-242, February 2002.
PT00165	M6APDG01231	EMD-1204831	CID: 25134692	Phase 1	E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5.
PT00165	M6APDG02915	RXDX-106	CID: 71576419	Phase 1	TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68.
PT00034	M6APDG00823	GSK461364	CID: 15983966	Phase 1	TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther. 2012 Mar;11(3):700-9.
PT00034	M6APDG02383	TAK-960	CID: 53357478	Phase 1	J Clin Oncol 29: 2011 (suppl; abstr 3012).
PT00034	M6APDG02809	MK-1496	CID: 67313626	Phase 1	Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals.
PT00050	M6APDG02202	Pyrotinib	CID: 51039030	Phase 1	Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chem Biol. 2013 February 15; 8(2): 345-352.
PT00140	M6APDG02422	TT-301	CID: 54576073	Phase 1	Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46.
PT00045	M6APDG00388	R763	CID: 11569967	Phase 1	Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012 Dec;30(6):2411-32.
PT00045	M6APDG00706	BI-847325	CID: 135567102	Phase 1	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
PT00045	M6APDG02087	GSK1070916	CID: 46885626	Phase 1	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
PT00045	M6APDG03325	AZD-1152-HQPA	CID: 16007391	Phase 1	Clinical pipeline report, company report or official report of Cyclacel.
PT00045	M6APDG00843	TAK-901	CID: 16124208	Phase 1	Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.
PT00045	M6APDG01174	AMG 900	CID: 24856041	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
PT00045	M6APDG02649	CYC116	CID: 6420138	Phase 1	Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
PT00008	M6APDG02398	Suramin	CID: 5361	Phase 1	Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost. 2006 Mar;4(3):560-5.
PT00022	M6APDG00331	AEW-541	CID: 11476171	Phase 1	A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.
PT00078	M6APDG00652	AG-024322	CID: 135413565	Phase 1	A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
PT00079	M6APDG00652	AG-024322	CID: 135413565	Phase 1	A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
PT00018	M6APDG00265	PX-478	CID: 11234794	Phase 1	ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18.
PT00018	M6APDG00335	ENMD-1198	CID: 11483754	Phase 1	Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1), in patients with refractory solid tumors.Cancer Chemother Pharmacol.2014 Feb;73(2):343-8.
PT00164	M6APDG02915	RXDX-106	CID: 71576419	Phase 1	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
PT00164	M6APDG03026	MRX-2843	CID: 89495685	Phase 1	National Cancer Institute Drug Dictionary (drug name PF-07265807).
PT00239	M6APDG02915	RXDX-106	CID: 71576419	Phase 1	National Cancer Institute Drug Dictionary (drug name PF-07265807).
PT00070	M6APDG00657	PAC1	CID: 135421197	Phase 1	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.
PT00079	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.
PT00073	M6APDG01438	GW-8510	CID: 3536	Investigative	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.
PT00079	M6APDG01438	GW-8510	CID: 3536	Investigative	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.
PT00178	M6APDG00586	NV-5138	CID: 129050791	Phase 1	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33.
PT00212	M6APDG02115	VS-5584	CID: 46912230	Phase 1	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33.
PT00178	M6APDG02115	VS-5584	CID: 46912230	Phase 1	Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J Clin Invest. 2019 Apr 16;129(6):2542-2554.
PT00035	M6APDG00731	Englitazone sodium	CID: 13728795	Phase 1	Effects of DSP-8658, a Novel Selective Peroxisome Proliferator-activated Receptors a/gamma Modulator, on Adipogenesis and Glucose Metabolism in Diabetic Obese Mice. Exp Clin Endocrinol Diabetes. 2015Sep;123(8):492-9.
PT00035	M6APDG01920	GW-409544	CID: 446642	Phase 1	Phrma report (2013 Alzheimers disease)
PT00035	M6APDG02674	Oxeglitazar	CID: 6445229	Phase 1	Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546.
PT00199	M6APDG02674	Oxeglitazar	CID: 6445229	Phase 1	Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546.
PT00035	M6APDG03303	CLX-0921	CID: 9958278	Phase 1	PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61.
PT00050	M6APDG02867	BIBX-1382	CID: 6918508	Phase 1	World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29.
PT00185	M6APDG01394	NBQX	CID: 3272524	Phase 1	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
PT00185	M6APDG01526	Phenethyl-(3-phenyl-propyl)-amine	CID: 408731	Investigative	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
PT00185	M6APDG00171	N,N'-Bis-(4-sec-butyl-phenyl)-guanidine	CID: 10526122	Investigative	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
PT00185	M6APDG00170	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol	CID: 10520673	Investigative	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
PT00015	M6APDG01354	RWJ-67657	CID: 3008319	Phase 1	National Cancer Institute Drug Dictionary (drug name CA102N).
PT00011	M6APDG02436	Metastat	CID: 54678924	Phase 1	Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
PT00132	M6APDG03035	IDH305	CID: 90415637	Phase 1	LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML).  Cancer Res 2020;80(16 Suppl):Abstract nr 6417.
PT00079	M6APDG00295	AT7519	CID: 11338033	Phase 1	Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6.
PT00079	M6APDG00892	AZD-5438	CID: 16747683	Phase 1	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
PT00079	M6APDG01200	CYC065	CID: 24983461	Phase 1	ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health.
PT00079	M6APDG02013	PHA-793887	CID: 46191454	Phase 1	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
PT00079	M6APDG02934	FN-1501	CID: 72195175	Phase 1	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
PT00043	M6APDG00888	GSK690693	CID: 16725726	Phase 1	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
PT00043	M6APDG01574	TCN-P	CID: 43860	Phase 1	Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Cancer Res.2008 Apr 1;68(7):2366-74.
PT00043	M6APDG02889	BAY1125976	CID: 70817911	Phase 1	Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
PT00043	M6APDG03180	SR13668	CID: 9845566	Phase 1	Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Invest New Drugs.2011 Dec;29(6):1381-9.
PT00029	M6APDG02115	VS-5584	CID: 46912230	Phase 1	Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220.
PT00066	M6APDG01232	NKP-1339	CID: 25134754	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1879).
PT00138	M6APDG02190	IMD-0354	CID: 5081913	Phase 1	The NF B pathway: a therapeutic target in glioblastoma. Oncotarget. 2011 August; 2(8): 646-653.
PT00198	M6APDG02116	PWT-33597	CID: 46917355	Phase 1	Adaptive resistance to PI3Kalpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells. Cell Death Dis. 2021 Jan 14;12(1):85.
PT00198	M6APDG02948	HHCYH33	CID: 72550012	Phase 1	National Cancer Institute Drug Dictionary (drug id 714372).
PT00080	M6APDG02013	PHA-793887	CID: 46191454	Phase 1	ClinicalTrials.gov (NCT04557449) Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4). U.S. National Institutes of Health.
PT00080	M6APDG02934	FN-1501	CID: 72195175	Phase 1	Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
PT00081	M6APDG02934	FN-1501	CID: 72195175	Phase 1	Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
PT00209	M6APDG02971	M012	CID: 7411	Phase 1	Targeting the Hepcidin-Ferroportin Axis to Develop New Treatment Strategies for Anemia of Chronic Disease and Anemia of Inflammation. Am J Hematol. 2012 April; 87(4): 392-400.
PT00199	M6APDG01920	GW-409544	CID: 446642	Phase 1	Clinical pipeline report, company report or official report of Tempest Therapeutics.
PT00038	M6APDG00604	C188-9	CID: 1324494	Phase 1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1768).
PT00155	M6APDG03030	M2698	CID: 89808643	Phase 1	Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
PT00092	M6APDG00443	MSX-122	CID: 11687907	Phase 1	Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606.
PT00010	M6APDG00981	AG-270	CID: 202785	Phase 1	Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 22;64(8):4430-4449.
PT00064	M6APDG00501	AZD0156	CID: 118502708	Phase 1	Pharmaceutical products of TORREYA partners. December 2011.
PT00129	M6APDG01002	Norleucine	CID: 21236	Phase 1/2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2734).
PT00072	M6APDG00616	CCS1477	CID: 134457551	Phase 1/2	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
PT00068	M6APDG02528	CPI-0610	CID: 57389999	Phase 3	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
PT00034	M6APDG02875	Rigosertib	CID: 6918736	Phase 3	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
PT00072	M6APDG02977	C 82	CID: 75202656	Phase 1/2	Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137.
PT00033	M6APDG02159	PA-799	CID: 49784945	Phase 1/2	1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401.
PT00186	M6APDG02897	LY3039478	CID: 71236992	Phase 1/2	EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: development of UshStat. PLoS One. 2014 Apr 4;9(4):e94272.
PT00044	M6APDG02990	ONC1-13B	CID: 77461273	Phase 1/2	2011 Pipeline of Adamis Pharmaceuticals.
PT00044	M6APDG03292	APC-100	CID: 99479	Phase 1/2	Clinical pipeline report, company report or official report of Arvinas.
PT00051	M6APDG00797	BDTX-189	CID: 154824631	Phase 1/2	Clinical pipeline report, company report or official report of KLUS Pharma.
PT00142	M6APDG00711	NT219	CID: 135914977	Phase 1/2	APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. 
PT00160	M6APDG00853	CBP-501	CID: 16156006	Phase 1/2	Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem. 1994 Mar;54(3):299-308.
PT00112	M6APDG02993	CPI-1205	CID: 78320408	Phase 1/2	ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
PT00038	M6APDG00590	Atiprimod	CID: 129869	Phase 1/2	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52.
PT00038	M6APDG00711	NT219	CID: 135914977	Phase 1/2	National Cancer Institute Drug Dictionary (drug id 617379).
PT00046	M6APDG00733	APG-2575	CID: 137355972	Phase 1/2	Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112.
PT00165	M6APDG01156	BMS-777607	CID: 24794418	Phase 1/2	Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38.
PT00165	M6APDG01595	MK-2461	CID: 44137946	Phase 1/2	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
PT00044	M6APDG00592	TRC-253	CID: 130229812	Phase 1/2	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
PT00189	M6APDG02897	LY3039478	CID: 71236992	Phase 1/2	Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
PT00125	M6APDG02178	CHR-3996	CID: 49857317	Phase 1/2	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
PT00126	M6APDG02381	TMP269	CID: 53344908	Investigative	HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
PT00197	M6APDG01595	MK-2461	CID: 44137946	Phase 1/2	Company report (Neuronova)
PT00050	M6APDG00797	BDTX-189	CID: 154824631	Phase 1/2	Clinical pipeline report, company report or official report of EpimAb Biotherapeutics.
PT00029	M6APDG02547	CC-223	CID: 58298316	Phase 1/2	Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8.
PT00029	M6APDG02822	ME-344	CID: 68026984	Phase 1/2	CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther. 2015 Jun;14(6):1295-305.
PT00198	M6APDG02159	PA-799	CID: 49784945	Phase 1/2	ETP-46321, a dual p110alpha/ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochem Pharmacol. 2016 Apr 15;106:56-69.
PT00198	M6APDG02888	MLN1117	CID: 70798655	Phase 1/2	Company report (Lilly)
PT00029	M6APDG01852	PF-05212384	CID: 44516953	Phase 2	Company report (Lilly)
PT00239	M6APDG02496	TP-0903	CID: 56839178	Phase 1/2	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.
PT00239	M6APDG03039	ONO-7475	CID: 90645873	Phase 1/2	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
PT00089	M6APDG02977	C 82	CID: 75202656	Phase 1/2	Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463.
PT00016	M6APDG01028	Phenoxodiol	CID: 219100	Phase 1/2	Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416.
PT00092	M6APDG02510	USL311	CID: 56961879	Phase 1/2	CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
PT00032	M6APDG00562	GS-4224	CID: 12439252	Phase 1/2	Clinical pipeline report, company report or official report of Numab Therapeutics.
PT00028	M6APDG03078	APG-115	CID: 91972012	Phase 2	Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015 Apr 30;6(12):10207-21.
PT00033	M6APDG02550	PQR309	CID: 58507717	Phase 2	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
PT00029	M6APDG02550	PQR309	CID: 58507717	Phase 2	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
PT00198	M6APDG02199	GDC-0032	CID: 51001932	Phase 3	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
PT00014	M6APDG00997	MTR105	CID: 210823	Phase 2	Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66.
PT00014	M6APDG01502	L-NAME	CID: 39836	Phase 2	Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7.
PT00014	M6APDG02145	ACCLAIM	CID: 47938	Phase 2	Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61.
PT00025	M6APDG00881	AZD1480	CID: 16659841	Phase 2	Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
PT00025	M6APDG01901	Cerdulatinib	CID: 44595079	Phase 2	The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-97.
PT00025	M6APDG02018	LY2784544	CID: 46213929	Phase 2	Company report (Portola Pharmaceuticals)
PT00025	M6APDG02197	BMS-911543	CID: 50922691	Phase 2	Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3:e109.
PT00025	M6APDG02385	INCB039110	CID: 53380437	Phase 2	Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8.
PT00025	M6APDG02952	CTP-543	CID: 72704611	Phase 2	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
PT00025	M6APDG02544	XL019	CID: 57990869	Phase 3	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
PT00044	M6APDG00254	TOK-001	CID: 11188409	Phase 2	Company report (Astrazeneca)
PT00044	M6APDG00515	MK-0773	CID: 11950726	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8638).
PT00044	M6APDG02690	ASC-J9	CID: 6477182	Phase 2	Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem. 1992 May 15;35(10):1663-70.
PT00051	M6APDG01229	HM-78136B	CID: 25127713	Phase 2	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
PT00051	M6APDG03215	CP-724714	CID: 9874913	Phase 2	N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35.
PT00213	M6APDG01224	GSK2245840	CID: 25108829	Phase 2	Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy.PLoS One.2013 Jun 10;8(6):e64953.
PT00213	M6APDG02205	SEN-196	CID: 5113032	Phase 2	Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52.
PT00062	M6APDG00543	Gallopamil	CID: 1234	Phase 2	Clinical pipeline report, company report or official report of Celladon.
PT00031	M6APDG03078	APG-115	CID: 91972012	Phase 2	Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
PT00114	M6APDG02791	TVB-2640	CID: 66548316	Phase 2	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
PT00114	M6APDG01543	C75	CID: 4248455	Investigative	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
PT00114	M6APDG02255	MORIN	CID: 5281670	Investigative	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
PT00114	M6APDG02228	biochanin A	CID: 5280373	Investigative	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
PT00114	M6APDG02251	3,7,3',4'-TETRAHYDROXYFLAVONE	CID: 5281614	Investigative	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
PT00114	M6APDG02453	4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one	CID: 54737894	Investigative	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
PT00069	M6APDG03269	Exherin	CID: 9916058	Phase 2	Clinical pipeline report, company report or official report of SARomics Biostructures.
PT00241	M6APDG03159	Upamostat	CID: 9830667	Phase 2	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
PT00130	M6APDG00664	VER 50589	CID: 135446210	Phase 2	Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
PT00130	M6APDG00696	NVP-AUY922	CID: 135539077	Phase 2	Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
PT00130	M6APDG00889	BIIB-021	CID: 16736529	Phase 2	Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
PT00130	M6APDG02702	Tanespimycin	CID: 6505803	Phase 2	BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
PT00040	M6APDG00450	AN0128	CID: 11704019	Phase 2	RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res. 2002 Nov;51(11):522-31.
PT00040	M6APDG01026	RDP58	CID: 219021	Phase 2	Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2009 Feb;50(2):771-8.
PT00040	M6APDG02248	BAICALEIN	CID: 5281605	Phase 2	AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na(+) current in primary dog, pig and rat alveolar type II cells. Pulm Pharmacol Ther. 2013 Jun;26(3):356-63.
PT00040	M6APDG02862	Ortataxel	CID: 6918412	Phase 2	DOI: 10.1136/annrheumdis-2015-eular.4042
PT00042	M6APDG02160	PTC299	CID: 49787172	Phase 2	Bispecific antibodies and their applications
PT00146	M6APDG01901	Cerdulatinib	CID: 44595079	Phase 2	ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
PT00146	M6APDG02057	ATI-502	CID: 46851625	Phase 2	Clinical pipeline report, company report or official report of Aclaris Therapeutics.
PT00112	M6APDG00571	DS-3201b	CID: 126481870	Phase 2	An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324-34.
PT00095	M6APDG01133	SB-9200	CID: 24737742	Phase 2	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
PT00101	M6APDG03347	Curcumin	CID: 969516	Phase 3	DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
PT00150	M6APDG01083	HQK-1004	CID: 23622962	Phase 2	Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.
PT00234	M6APDG02872	ABT-510	CID: 6918562	Phase 2	Clinical pipeline report, company report or official report of Immune-Onc Therapeutics.
PT00046	M6APDG01436	Gossypol	CID: 3503	Phase 2	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
PT00174	M6APDG00323	Apratastat	CID: 11452716	Phase 2	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
PT00174	M6APDG00775	N4,N6-dibenzylpyrimidine-4,6-dicarboxamide	CID: 15052873	Investigative	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
PT00174	M6APDG02678	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	CID: 644601	Investigative	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
PT00174	M6APDG02707	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	CID: 651854	Investigative	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
PT00165	M6APDG01183	AMG 208	CID: 24864821	Phase 2	J Clin Oncol 32:5s, 2014 (suppl; abstr 2508).
PT00165	M6APDG01243	SAR-125844	CID: 25182860	Phase 2	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706.
PT00165	M6APDG01607	AMG 337	CID: 44181686	Phase 2	Clinical pipeline report, company report or official report of Eli Lilly.
PT00165	M6APDG02937	APL-101	CID: 72202701	Phase 2	Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011 May 1;17(9):2638-45.
PT00044	M6APDG02869	BAY 86-5044	CID: 6918548	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
PT00044	M6APDG01283	[3H]methyltrienolone	CID: 261000	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
PT00045	M6APDG02017	ABT-348	CID: 46207586	Phase 2	A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
PT00045	M6APDG02468	VX-680	CID: 5494449	Phase 2	Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
PT00022	M6APDG02405	R1507	CID: 5376617	Phase 2	Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
PT00078	M6APDG01093	P-276	CID: 23643976	Phase 2	Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci. 2005 Aug;62(15):1763-71.
PT00078	M6APDG02332	Ro 31-7453	CID: 5327686	Phase 2	P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
PT00137	M6APDG02246	Fucoxanthin	CID: 5281239	Phase 2	Protective effect of Indole-3-carbinol, an NF-B inhibitor in experimental paradigm of Parkinson's disease: In silico and in vivo studies. Brain Behav Immun. 2020 Nov;90:108-137.
PT00018	M6APDG03048	PT2385	CID: 91754484	Phase 2	The biology and chemistry of hyperlipidemia. Bioorg Med Chem. 2007 Jul 15;15(14):4674-99.
PT00172	M6APDG00323	Apratastat	CID: 11452716	Phase 2	Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
PT00196	M6APDG00882	Famitinib	CID: 16662431	Phase 2	The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
PT00018	M6APDG02789	2-Methoxyestradiol	CID: 66414	Phase 2	CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67.
PT00178	M6APDG03332	AZD-2014	CID: 25262792	Phase 2	Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533.
PT00035	M6APDG02802	GED-0507-34-Levo	CID: 67008033	Phase 2	Clinical pipeline report, company report or official report of Avarx.
PT00035	M6APDG03208	FK-614	CID: 9869229	Phase 2	Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006 Jan;38(1):74-84.
PT00167	M6APDG00459	BVD-523	CID: 11719003	Phase 2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1804).
PT00197	M6APDG00882	Famitinib	CID: 16662431	Phase 2	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
PT00196	M6APDG00125	CP-868596	CID: 10366136	Phase 3	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
PT00050	M6APDG02201	Tarloxotinib	CID: 51038316	Phase 2	Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.
PT00050	M6APDG02676	Pelitinib	CID: 6445562	Phase 2	AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61.
PT00050	M6APDG02922	ASP8273	CID: 71667668	Phase 2	Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73.
PT00170	M6APDG01368	VX-745	CID: 3038525	Phase 2	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
PT00015	M6APDG00871	FK-3311	CID: 164009	Phase 2	Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs.Vet J.2014 Apr;200(1):77-81.
PT00015	M6APDG01005	CIMICOXIB	CID: 213053	Phase 2	Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
PT00015	M6APDG03194	SC-75416	CID: 9858913	Phase 2	Effects of the COX-2 inhibitor FK3311 on ischemia - reperfusion injury in the rat lung. J Invest Surg. 2007 May-Jun;20(3):175-80.
PT00057	M6APDG02056	GSK2110183	CID: 46843057	Phase 2	Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
PT00079	M6APDG02332	Ro 31-7453	CID: 5327686	Phase 2	Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
PT00123	M6APDG00011	LY2090314	CID: 10029385	Phase 2	The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
PT00123	M6APDG00287	Tideglusib	CID: 11313622	Phase 2	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
PT00043	M6APDG01198	MK-2206	CID: 24964624	Phase 2	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5.
PT00043	M6APDG02204	GSK2141795	CID: 51042438	Phase 2	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95.
PT00043	M6APDG02329	ARQ 092	CID: 53262401	Phase 2	Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7.
PT00110	M6APDG00459	BVD-523	CID: 11719003	Phase 2	National Cancer Institute Drug Dictionary (drug name SEphB4-HSA).
PT00029	M6APDG00629	OSI-027	CID: 135398516	Phase 2	2011 Pipeline of Intellikine.
PT00029	M6APDG00842	SAR245409	CID: 16123056	Phase 2	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95.
PT00029	M6APDG03339	INK128	CID: 45375953	Phase 2	Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
PT00029	M6APDG02533	LY3023414	CID: 57519748	Phase 2	PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99.
PT00138	M6APDG02946	Parthenolide	CID: 7251185	Phase 2	Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.
PT00165	M6APDG03054	GE-137	CID: 91827375	Investigative	Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.
PT00198	M6APDG02533	LY3023414	CID: 57519748	Phase 2	Company report (BioOncology)
PT00031	M6APDG02498	Cenersen	CID: 56841947	Phase 2	STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002 May 3;277(18):15813-8.
PT00239	M6APDG02020	Bemcentinib	CID: 46215462	Phase 2	Company report (Mirati Therapeutics: formerly MethylGene)
PT00060	M6APDG03033	GSK3326595	CID: 90241742	Phase 2	Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
PT00229	M6APDG01029	PX-12	CID: 219104	Phase 2	Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201.
PT00080	M6APDG03017	G1T38	CID: 86269224	Phase 2	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
PT00081	M6APDG03017	G1T38	CID: 86269224	Phase 2	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
PT00225	M6APDG00781	Disufenton	CID: 151179	Phase 2	KRP-297, MCC-555. Nihon Rinsho. 2001 Nov;59(11):2200-6.
PT00199	M6APDG00668	LY-518674	CID: 135449333	Phase 2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024296)
PT00231	M6APDG02050	AKB-9778	CID: 46700782	Phase 2	The contribution of inositol 1,4,5-trisphosphate and ryanodine receptors to agonist-induced Ca(2+) signaling of airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L347-61.
PT00092	M6APDG01842	TG-0054	CID: 44479007	Phase 2	CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64.
PT00051	M6APDG00301	BMS-690514	CID: 11349170	Phase 2	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
PT00171	M6APDG00503	EFT508	CID: 118598754	Phase 2	Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage. J Neuroinflammation. 2020 May 25;17(1):165.
PT00222	M6APDG00624	ADU-S100	CID: 135390762	Phase 2	National Cancer Institute Drug Dictionary (drug name MK1454).
PT00029	M6APDG03339	INK128	CID: 45375953	Phase 2	Genta obtains orphan drug designation for C-Myb Antisense (LR3001) in chronic myelocytic leukemia. Genta. 2005.
PT00005	M6APDG02589	LIAROZOLE	CID: 60652	Phase 2/3	Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7.
PT00031	M6APDG00097	Thymoquinone	CID: 10281	Phase 2/3	A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
PT00165	M6APDG01263	MGCD516	CID: 25212148	Phase 2/3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
PT00015	M6APDG02673	Darbufelone	CID: 6444826	Phase 2/3	Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49.
PT00065	M6APDG00097	Thymoquinone	CID: 10281	Phase 2/3	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00123	M6APDG00470	BX-912	CID: 11754511	Investigative	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00050	M6APDG01471	WHI-P154	CID: 3795	Investigative	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00078	M6APDG00643	BMS-265246	CID: 135402864	Investigative	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00078	M6APDG01947	aloisine A	CID: 448912	Investigative	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00079	M6APDG01947	aloisine A	CID: 448912	Investigative	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00123	M6APDG00681	RGB-286147	CID: 135473382	Investigative	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00078	M6APDG01575	Quinoxaline1	CID: 438981	Investigative	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00078	M6APDG00898	alsterpaullone 2-cyanoethyl	CID: 16760286	Investigative	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00050	M6APDG01811	6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline	CID: 44442165	Investigative	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
PT00227	M6APDG00042	LY2157299	CID: 10090485	Phase 2/3	Clinical pipeline report, company report or official report of Tissue Gene, Inc.
PT00028	M6APDG02384	RG7388	CID: 53358942	Phase 3	hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 2010 Oct 15;70(20):8077-87.
PT00134	M6APDG01030	NU-100	CID: 21987656	Phase 3	Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62.
PT00035	M6APDG01504	Bardoxolone methyl	CID: 400769	Phase 3	A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6102-6.
PT00014	M6APDG00622	Tilarginine acetate	CID: 135242	Phase 3	Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
PT00193	M6APDG02896	Nicaraven	CID: 71234	Phase 3	Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
PT00193	M6APDG03172	CC-486	CID: 9840076	Phase 3	beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59.
PT00025	M6APDG03330	CYT-387	CID: 25062766	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
PT00025	M6APDG02021	Pacritinib	CID: 46216796	Phase 3	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
PT00025	M6APDG03118	ITF2357	CID: 9804992	Phase 3	National Cancer Institute Drug Dictionary (drug id 609888).
PT00044	M6APDG02916	HC-1119	CID: 71580408	Phase 3	Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492-501.
PT00044	M6APDG03178	ZANOTERONE	CID: 9844827	Phase 3	Clinical pipeline report, company report or official report of Hinova Pharmaceuticals.
PT00084	M6APDG00850	DiaPep-277	CID: 16138701	Phase 3	Clinical pipeline report, company report or official report of Promentis Pharmaceuticals.
PT00074	M6APDG01199	ABT-263	CID: 24978538	Phase 3	New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorg Med Chem Lett. 1999 Feb 8;9(3):333-6.
PT00051	M6APDG03287	Nelipepimut S	CID: 9941306	Phase 3	The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31.
PT00040	M6APDG01376	CPL-7075	CID: 3083542	Phase 3	Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2014 Jun;26(6):581-7.
PT00020	M6APDG00859	Alicaforsen	CID: 16197725	Phase 3	Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 1991 Sep 25;266(27):18162-71.
PT00038	M6APDG00108	Napabucasin	CID: 10331844	Phase 3	Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4.
PT00150	M6APDG02918	FV-100	CID: 71587897	Phase 3	Company report (Takara Bio)
PT00165	M6APDG02830	Savolitinib	CID: 68289010	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
PT00034	M6APDG00156	Volasertib	CID: 10461508	Phase 3	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
PT00050	M6APDG02954	AC0010	CID: 72734520	Phase 3	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
PT00172	M6APDG00508	Marimastat	CID: 119031	Phase 3	AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
PT00011	M6APDG00508	Marimastat	CID: 119031	Phase 3	AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
PT00172	M6APDG03147	CIPEMASTAT	CID: 9824350	Phase 3	Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
PT00196	M6APDG01203	E-3810	CID: 25031915	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
PT00012	M6APDG03347	Curcumin	CID: 969516	Phase 3	DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
PT00012	M6APDG03123	DP-b99	CID: 9810955	Phase 3	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50.
PT00035	M6APDG00993	TESAGLITAZAR	CID: 208901	Phase 3	Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999 Jul;40(7):1177-84.
PT00035	M6APDG03335	Rivoglitazone	CID: 3055168	Phase 3	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
PT00199	M6APDG03203	GFT-505	CID: 9864881	Phase 3	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
PT00035	M6APDG01928	Ragaglitazar	CID: 447458	Phase 3	Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
PT00035	M6APDG02905	CS-038	CID: 71402018	Phase 3	Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
PT00199	M6APDG02905	CS-038	CID: 71402018	Phase 3	Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
PT00035	M6APDG03348	DRF-2593	CID: 9889200	Phase 3	Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
PT00199	M6APDG01928	Ragaglitazar	CID: 447458	Phase 3	Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
PT00035	M6APDG03238	Imiglitazar	CID: 9890879	Phase 3	Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
PT00199	M6APDG03238	Imiglitazar	CID: 9890879	Phase 3	Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
PT00050	M6APDG00533	Almonertinib	CID: 121280087	Phase 3	Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202.
PT00050	M6APDG03267	HKI-272	CID: 9915743	Phase 3	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918.
PT00170	M6APDG00376	Losmapimod	CID: 11552706	Phase 3	The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood. 2001 Aug 1;98(3):667-73.
PT00015	M6APDG03347	Curcumin	CID: 969516	Phase 3	Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015 Jan 1;37(1):197-210.
PT00015	M6APDG03174	CG-100649	CID: 9841854	Phase 3	Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6.
PT00057	M6APDG00915	Enzastaurin	CID: 176167	Phase 3	Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in cli... J Med Chem. 2009 Dec 10;52(23):7360-3.
PT00043	M6APDG01266	AZD5363	CID: 25227436	Phase 3	Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett. 2013 Feb 15;23(4):1051-5.
PT00162	M6APDG02396	AMG 386	CID: 5360545	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
PT00029	M6APDG00357	Ridaforolimus	CID: 11520894	Phase 3	Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
PT00099	M6APDG00600	Rova-T	CID: 131954443	Phase 3	Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase.Mol Cancer Ther.2011 Aug;10(8):1327-36.
PT00198	M6APDG00876	Buparlisib	CID: 16654980	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
PT00080	M6APDG01916	LEE011	CID: 44631912	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2017
PT00081	M6APDG01916	LEE011	CID: 44631912	Phase 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2017
PT00206	M6APDG00216	Tamibarotene	CID: 108143	Phase 3	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
PT00092	M6APDG00271	AMD-070	CID: 11256587	Phase 3	The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).
PT00044	M6APDG03322	Dihydrotestosterone	CID: 10635	Phase 4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
PT00194	M6APDG01282	Dichloroacetate	CID: 25975	Phase 4	PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
PT00241	M6APDG01389	PAI-1	CID: 3246941	Phase 4	Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41.
PT00140	M6APDG01287	Diacerein	CID: 26248	Phase 4	Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther. 2009 Aug;8(8):2286-95.
PT00044	M6APDG03322	Dihydrotestosterone	CID: 10635	Phase 4	An Electrophilic Deguelin Analogue Inhibits STAT3 Signaling in H- Ras-Transformed Human Mammary Epithelial Cells: The Cysteine 259 Residue as a Potential Target. Biomedicines. 2020 Oct 12;8(10):407.
PT00185	M6APDG02892	D-serine	CID: 71077	Phase 4	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
PT00015	M6APDG00442	IMRECOXIB	CID: 11682175	Phase 4	Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
PT00162	M6APDG00848	Amylin	CID: 16132430	Phase 4	Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. Eur J Pharmacol. 2010 Oct 25;645(1-3):185-91.
PT00075	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
PT00079	M6APDG01447	aloisine	CID: 3641059	Investigative	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
PT00073	M6APDG02361	6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine	CID: 5329597	Investigative	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
PT00044	M6APDG02560	GLPG-0492	CID: 59317190	Preclinical	Phase I clinical trail of PF-06260414 for treating cachexia. Pfizer Inc.
PT00236	M6APDG02819	IU1	CID: 675434	Preclinical	The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948.
PT00113	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
PT00079	M6APDG01998	Purvalanol A	CID: 456214	Investigative	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
PT00123	M6APDG01825	Neo-kauluamine	CID: 44448144	Investigative	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
PT00078	M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 11572699	Investigative	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
PT00138	M6APDG01310	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide	CID: 2756390	Investigative	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
PT00163	M6APDG01550	NSC-207895	CID: 42640	Preclinical	DNA-damage-inducible transcript 4 (DDIT4; RTP801). SciBX 3(20); doi:10.1038/scibx.2010.629. May 20 2010
PT00165	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.
PT00165	M6APDG01973	1-benzyl-1H-pyrrolo[3,2-b]pyridine	CID: 45267314	Investigative	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.
PT00165	M6APDG01032	3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine	CID: 22028181	Investigative	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.
PT00165	M6APDG01976	1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine	CID: 45270766	Investigative	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.
PT00165	M6APDG02014	NPS-1034	CID: 46194178	Preclinical	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 2015 May 15;21(10):2297-304.
PT00140	M6APDG00540	Celastrol	CID: 122724	Preclinical	Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis. 2006 September; 1(3): 321-334.
PT00237	M6APDG02121	P22077	CID: 46931953	Preclinical	USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth. Biochem Pharmacol. 2017 May 1;131:29-39.
PT00237	M6APDG02962	HBX19818	CID: 73349008	Preclinical	P22077 inhibits LPS-induced inflammatory response by promoting K48-linked ubiquitination and degradation of TRAF6. Aging (Albany NY). 2020 Jun 9;12(11):10969-10982.
PT00022	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11.
PT00022	M6APDG01571	4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol	CID: 43743432	Investigative	ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11.
PT00078	M6APDG03343	JNJ 7706621	CID: 5330790	Preclinical	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00079	M6APDG03343	JNJ 7706621	CID: 5330790	Preclinical	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00081	M6APDG02249	Chrysin	CID: 5281607	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00231	M6APDG03093	A-420983	CID: 9549183	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00050	M6APDG02515	HTS-05058	CID: 5714572	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00051	M6APDG01316	CL-387785	CID: 2776	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00050	M6APDG00309	Ro-4396686	CID: 11396738	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00079	M6APDG00420	MERIOLIN 1	CID: 11637090	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00075	M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	CID: 2752461	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00074	M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	CID: 2752461	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00078	M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	CID: 2752461	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00081	M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	CID: 2752461	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00050	M6APDG00076	N4-(3-methylphenyl)-4,6-quinazolinediamine	CID: 10220590	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00075	M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	CID: 10946795	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00075	M6APDG00793	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 15422868	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00074	M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	CID: 10946795	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00074	M6APDG00793	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 15422868	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00078	M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	CID: 10946795	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00078	M6APDG00793	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 15422868	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00050	M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	CID: 10946795	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00079	M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	CID: 10946795	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00079	M6APDG00793	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 15422868	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00080	M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	CID: 10946795	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00080	M6APDG00793	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 15422868	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00080	M6APDG02372	1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea	CID: 5330596	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00081	M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	CID: 10946795	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00231	M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	CID: 10946795	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00231	M6APDG00793	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 15422868	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00051	M6APDG00228	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	CID: 10946795	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00051	M6APDG00793	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 15422868	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00051	M6APDG01808	4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole	CID: 44437844	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00231	M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 11572699	Investigative	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
PT00107	M6APDG00732	MS012	CID: 137348638	Preclinical	Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J Med Chem. 2002 Feb 28;45(5):1002-18.
PT00107	M6APDG02983	A-366	CID: 76285486	Preclinical	Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81.
PT00196	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201.
PT00167	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
PT00170	M6APDG01116	RO-316233	CID: 2399	Investigative	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
PT00170	M6APDG01115	Bisindolylmaleimide-I	CID: 2396	Investigative	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
PT00170	M6APDG03091	6-Phenylsulfanyl-9H-purine	CID: 95065	Investigative	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
PT00170	M6APDG00300	9-Benzyl-6-phenylsulfanyl-9H-purine	CID: 11347708	Investigative	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
PT00170	M6APDG00272	6-(4-Fluoro-phenylsulfanyl)-9H-purine	CID: 11265091	Investigative	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
PT00170	M6APDG00332	4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine	CID: 11481564	Investigative	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
PT00170	M6APDG00294	9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine	CID: 11336624	Investigative	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
PT00197	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
PT00118	M6APDG03009	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	CID: 8189	Investigative	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
PT00196	M6APDG03046	5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol	CID: 91643	Investigative	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
PT00197	M6APDG00375	(2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine	CID: 11550535	Investigative	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
PT00050	M6APDG03327	AG1478	CID: 2051	Preclinical	Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a n... J Med Chem. 2003 Dec 4;46(25):5546-51.
PT00071	M6APDG00806	Z-Phe-Ala-diazomethylketone	CID: 155664	Preclinical	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
PT00071	M6APDG03263	L-006235-1	CID: 9912381	Preclinical	CA-074Me inhibits Cathepsin-B and alleviates fibrosis after myocardial infarction. Panminerva Med. 2019 Sep 24.
PT00170	M6APDG03327	AG1478	CID: 2051	Preclinical	The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4666-70.
PT00235	M6APDG02577	ML323	CID: 60167849	Preclinical	Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1169-73.
PT00162	M6APDG02491	Ro-27-3225	CID: 56603736	Preclinical	The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.
PT00199	M6APDG02505	PIRINIXIC ACID	CID: 5694	Preclinical	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021175)
PT00007	M6APDG02055	WZB-117	CID: 46830365	Preclinical	Clinical pipeline report, company report or official report of Roche.
PT00219	M6APDG03077	SPHINX31	CID: 91972002	Preclinical	Piperazine derivatives for treating disorders. US9695160.
PT00051	M6APDG03323	BMS 536924	CID: 135440466	Preclinical	Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
PT00130	M6APDG01569	VER-49009	CID: 4369536	Investigative	Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
PT00015	M6APDG02932	(S)-FLURBIPROFEN	CID: 72099	Preregistration	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
PT00015	M6APDG02177	Fluoro loxoprofen	CID: 49837499	Investigative	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
PT00015	M6APDG00006	5-thia-8,11,14,17-eicosatetraenoic acid	CID: 10019057	Investigative	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
PT00050	M6APDG01907	Icotinib hydrochloride	CID: 44609731	Registered	Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.
PT00035	M6APDG00584	AD-5075	CID: 128440	Terminated	Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7.
PT00005	M6APDG02487	Rogletimide	CID: 56487	Terminated	Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer. 1999 Jun;6(2):197-204.
PT00005	M6APDG02773	MINAMESTANE	CID: 65886	Terminated	Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substitu... J Med Chem. 1987 Sep;30(9):1550-4.
PT00051	M6APDG02779	GW-974	CID: 6603857	Terminated	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
PT00031	M6APDG03278	Pifithrin-alpha	CID: 9929138	Terminated	Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86.
PT00241	M6APDG00912	B-428	CID: 1747	Terminated	Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24.
PT00040	M6APDG00603	MDL-201112	CID: 132408	Terminated	Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. J Rheumatol. 1996 Oct;23(10):1778-83.
PT00146	M6APDG00683	PNU156804	CID: 135484060	Terminated	Immunotherapy for De Novo renal transplantation: what's in the pipeline Drugs. 2006;66(13):1665-84.
PT00146	M6APDG02829	R348	CID: 68254	Terminated	Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15;99(2):680-9.
PT00144	M6APDG00561	SC-47643	CID: 124392	Terminated	Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6.
PT00144	M6APDG00788	L-738167	CID: 153986	Terminated	Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorc, Bioorg. Med. Chem. Lett. 4(15):1835-1840 (1994).
PT00144	M6APDG03228	L-709780	CID: 9885190	Terminated	Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41.
PT00144	M6APDG03282	Ro-43-8857	CID: 9933077	Terminated	Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
PT00144	M6APDG03298	SB-265123	CID: 9952958	Investigative	Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
PT00046	M6APDG00260	ABT-737	CID: 11228183	Terminated	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
PT00153	M6APDG02285	BALANOL	CID: 5287736	Terminated	Identification of p54(nrb) and the 14-3-3 Protein HS1 as TNF-alpha-inducible genes related to cell cycle control and apoptosis in human arterial endothelial cells. J Biochem Mol Biol. 2005 Jul 31;38(4):447-56.
PT00078	M6APDG02663	CGP-60474	CID: 644215	Terminated	Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013; 3(3): 323-338.
PT00172	M6APDG02464	Ro-31-4724	CID: 5487313	Terminated	Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
PT00172	M6APDG03252	RO-319790	CID: 9904965	Terminated	Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase. J Med Chem. 2004 May 20;47(11):2761-7.
PT00172	M6APDG03257	BB-1101	CID: 9908389	Terminated	The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
PT00012	M6APDG03280	CT-1746	CID: 9930721	Terminated	The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
PT00175	M6APDG03257	BB-1101	CID: 9908389	Terminated	The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
PT00196	M6APDG00988	AG1295	CID: 2048	Terminated	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
PT00196	M6APDG02439	RG-13022	CID: 5468216	Terminated	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00197	M6APDG00377	Ki-11502	CID: 11554659	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00196	M6APDG01924	PD-0173955	CID: 447077	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00197	M6APDG01924	PD-0173955	CID: 447077	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00196	M6APDG00399	Bis-(5-hydroxy-1H-indol-2-yl)-methanone	CID: 11601743	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00196	M6APDG00345	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	CID: 11500099	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00196	M6APDG01760	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	CID: 44411967	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00196	M6APDG02367	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone	CID: 5330527	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00196	M6APDG02368	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone	CID: 5330528	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00196	M6APDG02369	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone	CID: 5330535	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00197	M6APDG00345	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	CID: 11500099	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00197	M6APDG01760	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	CID: 44411967	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00197	M6APDG02367	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone	CID: 5330527	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00197	M6APDG02368	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone	CID: 5330528	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00197	M6APDG02369	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone	CID: 5330535	Investigative	Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
PT00012	M6APDG03252	RO-319790	CID: 9904965	Terminated	Clinical pipeline report, company report or official report of DeepDyve.
PT00073	M6APDG02362	PD-0183812	CID: 5330258	Terminated	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
PT00035	M6APDG02605	DARGLITAZONE	CID: 60870	Terminated	A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Redox Rep. 2002;7(5):343-6.
PT00035	M6APDG03151	Sipoglitazar	CID: 9825652	Terminated	Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137.
PT00199	M6APDG03151	Sipoglitazar	CID: 9825652	Terminated	Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137.
PT00035	M6APDG03152	Edaglitazone	CID: 9825701	Terminated	PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J. 2004 Jul;24(1):18-23.
PT00035	M6APDG03181	SB-219994	CID: 9845965	Terminated	Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95.
PT00035	M6APDG01331	GNF-PF-2893	CID: 2815701	Investigative	Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95.
PT00167	M6APDG02212	SB220025	CID: 5164	Terminated	Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
PT00169	M6APDG01985	KT-5720	CID: 454202	Investigative	Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
PT00168	M6APDG01692	6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine	CID: 44387948	Investigative	Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
PT00197	M6APDG02439	RG-13022	CID: 5468216	Terminated	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
PT00197	M6APDG00665	3-Pyridin-4-yl-quinolin-7-ol	CID: 135449022	Investigative	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
PT00197	M6APDG03049	Bis(benzo[b]furan-2-yl)methanone	CID: 9179241	Investigative	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
PT00197	M6APDG00239	Bis(5-aminobenzo[b]furan-2-yl)methanone	CID: 11098310	Investigative	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
PT00197	M6APDG00614	Bis(6-hydroxybenzo[b]furan-2-yl)methanone	CID: 13393486	Investigative	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
PT00197	M6APDG00619	Bis(5-acetoxybenzo[b]furan-2-yl)methanone	CID: 13471348	Investigative	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
PT00197	M6APDG01036	6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline	CID: 22132666	Investigative	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
PT00197	M6APDG01795	(benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone	CID: 44423635	Investigative	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97.
PT00050	M6APDG00902	CGP-52411	CID: 1697	Terminated	WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
PT00185	M6APDG00075	L-698544	CID: 10220180	Terminated	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
PT00185	M6APDG02448	L-698532	CID: 54697468	Terminated	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
PT00185	M6APDG03243	N-(2-methoxybenzyl)cinnamamidine	CID: 9900027	Investigative	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
PT00185	M6APDG00215	4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol	CID: 10806596	Investigative	Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
PT00185	M6APDG00103	L-687414	CID: 10313147	Terminated	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
PT00185	M6APDG00932	DIZOCILPINE	CID: 180081	Terminated	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
PT00185	M6APDG02780	MDL-105519	CID: 6603913	Terminated	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
PT00185	M6APDG00178	4-[2-(3-Phenyl-propylamino)-ethyl]-phenol	CID: 10565541	Investigative	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
PT00185	M6APDG00897	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione	CID: 16760018	Investigative	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
PT00185	M6APDG02449	5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one	CID: 54710618	Investigative	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
PT00185	M6APDG00231	SPERMINE	CID: 1103	Terminated	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
PT00185	M6APDG00574	3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione	CID: 126810	Investigative	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
PT00185	M6APDG00538	L-689560	CID: 121918	Terminated	Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
PT00185	M6APDG00611	AM-92016	CID: 133104	Terminated	CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018.
PT00185	M6APDG00976	RPR-104632	CID: 197644	Terminated	Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem. 2008 Sep 25;51(18):5506-21.
PT00185	M6APDG02440	L-701324	CID: 54682505	Terminated	4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
PT00170	M6APDG02212	SB220025	CID: 5164	Terminated	Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38alpha mitogen-activated protein kinase. J Med Chem. 2011 Apr 14;54(7):2255-65.
PT00015	M6APDG00019	FR-123826	CID: 10042938	Terminated	Characterization of the in vitro oxidative metabolites of the COX-2 selective inhibitor L-766,112. Bioorganic & Medicinal Chemistry Letters Volume 7, Issue 1, 7 January 1997, Pages 53-56.
PT00015	M6APDG00360	SC-58125	CID: 115239	Terminated	Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2.
PT00015	M6APDG00597	ATLIPROFEN METHYL ESTER	CID: 130978	Terminated	Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect ... J Pharmacol Exp Ther. 1995 Sep;274(3):1531-7.
PT00015	M6APDG02898	Flosulide	CID: 71246	Terminated	S 33516 Servier preclinical data. R & D Focus Drug News. July 12, 1999.
PT00015	M6APDG03117	L-745337	CID: 9799453	Terminated	Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101.
PT00015	M6APDG03155	RPR 200765A	CID: 9828952	Terminated	Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat. Kidney Int. 1999 Nov;56(5):1770-8.
PT00015	M6APDG03189	SC-58451	CID: 9851770	Terminated	Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000 May;47(2-3):185-201.
PT00015	M6APDG03204	SC-236	CID: 9865808	Terminated	The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem. 2001 Feb;9(2):537-54.
PT00015	M6APDG03221	RWJ-63556	CID: 9882374	Terminated	Enantioselective HPLC determination of E-6087, a new COX-2 inhibitor, in human plasma: Validation and pharmacokinetic application. Chirality. 2004 May 15;16(5):302-8.
PT00011	M6APDG03141	BB-3644	CID: 9822724	Terminated	Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29.
PT00012	M6APDG01918	MMI270	CID: 446504	Investigative	Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29.
PT00079	M6APDG02362	PD-0183812	CID: 5330258	Terminated	What are next generation innovative therapeutic targets. J Pharmacol Exp Ther. 2009 Jul;330(1):304-15.
PT00081	M6APDG02362	PD-0183812	CID: 5330258	Terminated	What are next generation innovative therapeutic targets. J Pharmacol Exp Ther. 2009 Jul;330(1):304-15.
PT00016	M6APDG03201	F-12509A	CID: 9862964	Terminated	Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.Oncotarget. 2016 Dec 6;7(49):80586-80598. 
PT00175	M6APDG00164	L-696418	CID: 10478364	Terminated	Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics, Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997).
PT00175	M6APDG03252	RO-319790	CID: 9904965	Terminated	Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726-8.
PT00015	M6APDG01463	INDOPROFEN	CID: 3718	Withdrawn from market	Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol. 2002 Feb;127(2):337-43.
PT00193	M6APDG00741	BZ3	CID: 13872	Investigative	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
PT00193	M6APDG01938	TI3	CID: 448087	Investigative	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
PT00193	M6APDG02045	BZ5	CID: 46241905	Investigative	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
PT00193	M6APDG03050	TI4	CID: 91808049	Investigative	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
PT00193	M6APDG03214	EB-47	CID: 9871899	Investigative	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
PT00193	M6APDG02297	[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala	CID: 5289469	Investigative	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
PT00193	M6APDG01535	BZ6	CID: 41673734	Investigative	Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J Med Chem. 2004 Aug 12;47(17):4151-4.
PT00193	M6APDG01719	4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one	CID: 44403404	Investigative	Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J Med Chem. 2004 Aug 12;47(17):4151-4.
PT00112	M6APDG02935	EI1	CID: 72199293	Investigative	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6.
PT00068	M6APDG01077	XD1	CID: 234105	Investigative	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.
PT00068	M6APDG02900	PFI-1	CID: 71271629	Investigative	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.
PT00015	M6APDG03254	DFU	CID: 9906892	Investigative	A selective inhibitor of p38 MAP kinase, SB202190, induced apoptotic cell death of a lipopolysaccharide-treated macrophage-like cell line, J774.1. Biochim Biophys Acta. 2000 Oct 18;1502(2):207-23.
PT00092	M6APDG00857	T22	CID: 16197316	Investigative	A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9.
PT00035	M6APDG00010	COOH	CID: 10025649	Investigative	Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23.
PT00059	M6APDG01103	RM65	CID: 23656549	Investigative	Small molecule regulators of protein arginine methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892-9.
PT00150	M6APDG02980	ITdU	CID: 76	Investigative	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
PT00150	M6APDG01774	1-[6-(triphenylmethoxy)hexyl]thymine	CID: 44418795	Investigative	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
PT00150	M6APDG00838	1-[5-(triphenylmethoxy)pentyl]thymine	CID: 16098859	Investigative	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
PT00150	M6APDG00840	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	CID: 16098875	Investigative	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
PT00150	M6APDG02691	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	CID: 6477686	Investigative	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.
PT00068	M6APDG02221	XD14	CID: 52670832	Investigative	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5.
PT00068	M6APDG02901	CPI-203	CID: 71291068	Investigative	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5.
PT00022	M6APDG01237	JB-1	CID: 25150849	Investigative	SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1744-8.
PT00164	M6APDG02995	G749	CID: 78357765	Investigative	UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77.
PT00148	M6APDG03083	PBIT	CID: 935415	Investigative	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
PT00070	M6APDG03188	M826	CID: 9851134	Investigative	Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis. J Pharmacol Exp Ther. 2003 Jan;304(1):433-40.
PT00185	M6APDG01380	AP-7	CID: 3122	Investigative	3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.
PT00185	M6APDG00946	6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione	CID: 1845	Investigative	3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.
PT00185	M6APDG01486	DNQX	CID: 3899541	Investigative	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
PT00185	M6APDG01746	Ala-Pro-Glu	CID: 44408970	Investigative	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
PT00185	M6APDG01022	3-Hydroxy-1H-benzo[b]azepine-2,5-dione	CID: 21812299	Investigative	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
PT00185	M6APDG00136	8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione	CID: 10400801	Investigative	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
PT00185	M6APDG00194	8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione	CID: 10680274	Investigative	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
PT00185	M6APDG00190	3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione	CID: 10655753	Investigative	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
PT00185	M6APDG00773	8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	CID: 15029643	Investigative	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
PT00185	M6APDG03125	8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	CID: 9815930	Investigative	Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53.
PT00162	M6APDG03285	THIQ	CID: 9938402	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 285).
PT00162	M6APDG03080	MT-II	CID: 92432	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 285).
PT00060	M6APDG02684	cmp5	CID: 6462334	Investigative	Clinical pipeline report, company report or official report of Prelude Therapeutics.
PT00004	M6APDG01296	Heme	CID: 26945	Investigative	Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies. Biochimie. 2020 Jun;173:48-56.
PT00092	M6APDG00846	T140	CID: 16130395	Investigative	A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82.
PT00092	M6APDG00858	T134	CID: 16197445	Investigative	A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82.
PT00092	M6APDG01236	isothiourea-1t	CID: 25147749	Investigative	A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82.
PT00035	M6APDG00965	PAT5A	CID: 18980163	Investigative	Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2954-8.
PT00035	M6APDG01318	T0070907	CID: 2777391	Investigative	Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2954-8.
PT00035	M6APDG01064	BADGE	CID: 2286	Investigative	Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998 Feb;284(2):751-9.
PT00035	M6APDG03154	TZD18	CID: 9827261	Investigative	Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol. 2004 May 3;491(2-3):195-206.
PT00199	M6APDG03154	TZD18	CID: 9827261	Investigative	Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol. 2004 May 3;491(2-3):195-206.
PT00025	M6APDG02467	CMP-6	CID: 5494425	Investigative	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
PT00146	M6APDG02467	CMP-6	CID: 5494425	Investigative	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
PT00050	M6APDG02456	Theliatinib	CID: 54759275	Investigative	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
PT00059	M6APDG03024	AMI-1	CID: 88489	Investigative	National Cancer Institute Drug Dictionary (drug name GSK6097608).
PT00241	M6APDG03136	B-623	CID: 9820186	Investigative	Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv Exp Med Biol. 2000;477:331-41.
PT00130	M6APDG00063	RHEIN	CID: 10168	Investigative	WO patent application no. 2013,1734,36, Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status.
PT00160	M6APDG00306	CMPD1	CID: 11382492	Investigative	Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54.
PT00046	M6APDG00324	TW-37	CID: 11455910	Investigative	Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32.
PT00174	M6APDG00113	SL422	CID: 10344307	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1637).
PT00174	M6APDG03157	WAY170523	CID: 9830392	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1637).
PT00169	M6APDG02318	KN-62	CID: 5312126	Investigative	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
PT00167	M6APDG02318	KN-62	CID: 5312126	Investigative	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
PT00155	M6APDG02318	KN-62	CID: 5312126	Investigative	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
PT00057	M6APDG00248	BX-517	CID: 11161844	Investigative	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
PT00170	M6APDG00877	IN-1166	CID: 16654987	Investigative	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
PT00123	M6APDG02712	3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione	CID: 6539451	Investigative	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
PT00068	M6APDG00705	MS436	CID: 135566899	Investigative	Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. ACS Med Chem Lett. 2013 Jul 16;4(9):835-40.
PT00068	M6APDG00984	BzT-7	CID: 20350618	Investigative	Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9.
PT00068	M6APDG02558	MS417	CID: 59190723	Investigative	Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J Med Chem. 2013 Nov 27;56(22):9251-64.
PT00044	M6APDG03253	AL-43	CID: 9906282	Investigative	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
PT00044	M6APDG00383	LGD-2226	CID: 11560224	Investigative	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
PT00044	M6APDG03143	RU-43044	CID: 9823099	Investigative	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
PT00044	M6APDG03090	5-Methoxyflavone	CID: 94525	Investigative	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
PT00044	M6APDG01307	6-Hydroxyflavanone	CID: 2734580	Investigative	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
PT00044	M6APDG00396	4-(mesityloxy)-2-(trifluoromethyl)benzonitrile	CID: 11587567	Investigative	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
PT00012	M6APDG00113	SL422	CID: 10344307	Investigative	Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxy... Bioorg Med Chem. 2006 Jun 15;14(12):4260-76.
PT00070	M6APDG01056	PETCM	CID: 224859	Investigative	Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.
PT00050	M6APDG01196	PP121	CID: 24905142	Investigative	Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76.
PT00050	M6APDG03177	4557W	CID: 9843206	Investigative	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
PT00051	M6APDG03177	4557W	CID: 9843206	Investigative	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
PT00051	M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 11572699	Investigative	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
PT00022	M6APDG03098	PQ401	CID: 9549305	Investigative	Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway. Bioorg Med Chem Lett. 2009 Jan 15;19(2):373-7.
PT00170	M6APDG02318	KN-62	CID: 5312126	Investigative	Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10.
PT00170	M6APDG02692	Dihydro-quinolinone	CID: 64796	Investigative	Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10.
PT00057	M6APDG02318	KN-62	CID: 5312126	Investigative	Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.
PT00057	M6APDG01115	Bisindolylmaleimide-I	CID: 2396	Investigative	Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.
PT00123	M6APDG01262	IM-12	CID: 25209788	Investigative	Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004 Feb 12;47(4):935-46.
PT00162	M6APDG02085	MK-10	CID: 46877881	Investigative	Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J Med Chem. 1997 Jul 4;40(14):2133-9.
PT00162	M6APDG02665	MK-11	CID: 6442190	Investigative	Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
PT00162	M6APDG01714	Ac-dR[CEHdFRWC]-NH2	CID: 44400402	Investigative	Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
PT00029	M6APDG01196	PP121	CID: 24905142	Investigative	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
PT00033	M6APDG00095	PIK-75	CID: 10275789	Investigative	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
PT00196	M6APDG02370	D-65476	CID: 5330548	Investigative	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
PT00050	M6APDG00386	HDS-029	CID: 11566580	Investigative	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
PT00029	M6APDG02175	torin 1	CID: 49836027	Investigative	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
PT00016	M6APDG01940	SK1-I	CID: 44815217	Investigative	Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444(1):79-88.
PT00103	M6APDG02119	ML315	CID: 46926514	Investigative	Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. ACS Med Chem Lett. 2013 Apr 26;4(6):502-3.
PT00206	M6APDG00041	CD666	CID: 10090192	Investigative	Placental steroidogenesis in rats is independent of signaling pathways induced by retinoic acids. Gen Comp Endocrinol. 2009 Sep 15;163(3):285-91.
PT00092	M6APDG02973	CXCL8	CID: 74974005	Investigative	Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007 Nov 15;50(23):5655-64.
PT00222	M6APDG00232	C-176	CID: 1103958	Investigative	Targeting STING with covalent small-molecule inhibitors. Nature. 2018 Jul;559(7713):269-273.
PT00222	M6APDG01338	C-178	CID: 2866412	Investigative	Clinical pipeline report, company report or official report of F-star Therapeutics.
PT00028	M6APDG01187	MI-219	CID: 24877503	Investigative	Phase I clinical trail of RG7775 for treating Acute myelogenous leukemia. Roche.
PT00035	M6APDG01961	GW0072	CID: 449532	Investigative	A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 1999 Jul;48(7):1415-24.
PT00035	M6APDG02706	GW1929	CID: 6518171	Investigative	T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem. 2002 May 31;277(22):19649-57.
PT00035	M6APDG03301	nTzDpa	CID: 9954280	Investigative	L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. J Biol Chem. 1999 Mar 19;274(12):7913-22.
PT00104	M6APDG00071	NU6140	CID: 10202471	Investigative	Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366.
PT00014	M6APDG01151	AP-Cav	CID: 24779772	Investigative	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
PT00014	M6APDG01393	4-Methyl-piperidin-(2E)-ylideneamine	CID: 3268009	Investigative	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
PT00014	M6APDG01701	(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine	CID: 44399940	Investigative	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
PT00014	M6APDG00909	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid	CID: 173566	Investigative	Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
PT00184	M6APDG03261	MCC950	CID: 9910393	Investigative	National Cancer Institute Drug Dictionary (drug name BMS-986299).
PT00113	M6APDG00405	PF-228	CID: 11612883	Investigative	A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9.
PT00040	M6APDG02842	IK-862	CID: 6914621	Investigative	Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J Med Chem. 2002 May 23;45(11):2289-93.
PT00040	M6APDG03256	PKF-241-466	CID: 9907830	Investigative	Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J Med Chem. 2002 May 23;45(11):2289-93.
PT00146	M6APDG01464	NC1153	CID: 373395	Investigative	Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.
PT00170	M6APDG00901	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	CID: 1694	Investigative	Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.
PT00112	M6APDG00743	MS1943	CID: 139211327	Investigative	National Cancer Institute Drug Dictionary (drug id 756211).
PT00174	M6APDG02842	IK-862	CID: 6914621	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00172	M6APDG01637	RS-39066	CID: 44288042	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00174	M6APDG01642	Ro-37-9790	CID: 44313734	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00172	M6APDG01642	Ro-37-9790	CID: 44313734	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00174	M6APDG00093	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol	CID: 10267279	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00174	M6APDG00804	1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol	CID: 15516781	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00174	M6APDG00973	3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol	CID: 19366856	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00172	M6APDG00973	3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol	CID: 19366856	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00174	M6APDG01640	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	CID: 44294677	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00172	M6APDG01640	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	CID: 44294677	Investigative	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.
PT00174	M6APDG03186	SR-973	CID: 9849669	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00012	M6APDG03186	SR-973	CID: 9849669	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00011	M6APDG03186	SR-973	CID: 9849669	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00173	M6APDG00040	AGELADINE A	CID: 10089677	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00173	M6APDG01845	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CID: 44479701	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00174	M6APDG01845	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CID: 44479701	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00011	M6APDG01845	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CID: 44479701	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00173	M6APDG01841	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CID: 44478925	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00174	M6APDG01841	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CID: 44478925	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00012	M6APDG01841	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CID: 44478925	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00011	M6APDG01841	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CID: 44478925	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00012	M6APDG01176	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide	CID: 24857837	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00173	M6APDG00061	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CID: 10155934	Investigative	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
PT00078	M6APDG00071	NU6140	CID: 10202471	Investigative	Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30.
PT00079	M6APDG00071	NU6140	CID: 10202471	Investigative	Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30.
PT00080	M6APDG00071	NU6140	CID: 10202471	Investigative	Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30.
PT00078	M6APDG00405	PF-228	CID: 11612883	Investigative	Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
PT00078	M6APDG01941	4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine	CID: 44820374	Investigative	Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
PT00078	M6APDG02296	SU9516	CID: 5289419	Investigative	Microxine, a new cdc2 kinase inhibitor from the Australian marine sponge Microxina species. J Nat Prod. 2001 Apr;64(4):525-6.
PT00078	M6APDG02376	K00024	CID: 5330797	Investigative	2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett. 1999 Jan 4;9(1):91-6.
PT00078	M6APDG03097	IN1535	CID: 9549304	Investigative	The kinase inhibitor indirubin-3'-oxime prevents germinal vesicle breakdown and reduces parthenogenetic development of pig oocytes. Theriogenology. 2006 Mar 1;65(4):744-56.
PT00191	M6APDG02908	SR9238	CID: 71478195	Investigative	Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26.
PT00172	M6APDG01918	MMI270	CID: 446504	Investigative	Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39.
PT00011	M6APDG01918	MMI270	CID: 446504	Investigative	Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39.
PT00172	M6APDG03186	SR-973	CID: 9849669	Investigative	The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8.
PT00012	M6APDG00020	ARP100	CID: 10044321	Investigative	Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem. 2004 Apr 8;47(8):1930-8.
PT00012	M6APDG02842	IK-862	CID: 6914621	Investigative	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
PT00011	M6APDG02842	IK-862	CID: 6914621	Investigative	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
PT00175	M6APDG01637	RS-39066	CID: 44288042	Investigative	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
PT00174	M6APDG00972	3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol	CID: 19366844	Investigative	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
PT00172	M6APDG00972	3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol	CID: 19366844	Investigative	11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
PT00164	M6APDG02382	UNC569	CID: 53355503	Investigative	MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102.
PT00035	M6APDG03211	GW7845	CID: 9870584	Investigative	PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independe... Br J Pharmacol. 2003 May;139(1):163-71.
PT00199	M6APDG00887	BMS-687453	CID: 16725047	Investigative	PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independe... Br J Pharmacol. 2003 May;139(1):163-71.
PT00050	M6APDG00851	MG-111	CID: 16143379	Investigative	Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Eur J Cell Biol. 1996 Apr;69(4):327-34.
PT00050	M6APDG01123	BPIQ-I	CID: 2427	Investigative	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
PT00051	M6APDG00386	HDS-029	CID: 11566580	Investigative	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
PT00050	M6APDG02346	AG-538	CID: 5328760	Investigative	Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7.
PT00050	M6APDG02337	N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine	CID: 5328077	Investigative	Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7.
PT00050	M6APDG02350	AG 112	CID: 5328804	Investigative	Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52.
PT00050	M6APDG02798	AG-213	CID: 667601	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00050	M6APDG02637	4-(2-nitrovinyl)phenol	CID: 638437	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00050	M6APDG00189	10-hydroxy-18-methoxybetaenone	CID: 10644450	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00050	M6APDG02638	2-methoxy-4-(2-nitrovinyl)phenol	CID: 638439	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00050	M6APDG01392	4-(2-nitroprop-1-enyl)benzene-1,2-diol	CID: 3260632	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00050	M6APDG02348	2-cyano-3-(3,4-dihydroxyphenyl)acrylamide	CID: 5328768	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00050	M6APDG02465	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	CID: 5491980	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00050	M6APDG02347	2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile	CID: 5328763	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00050	M6APDG00766	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CID: 14862522	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00050	M6APDG02333	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	CID: 5328038	Investigative	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
PT00015	M6APDG00746	SC-558	CID: 1396	Investigative	Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from plat... J Med Chem. 1989 Aug;32(8):1836-42.
PT00079	M6APDG00028	BX-795	CID: 10077147	Investigative	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
PT00123	M6APDG00028	BX-795	CID: 10077147	Investigative	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
PT00079	M6APDG00643	BMS-265246	CID: 135402864	Investigative	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
PT00123	M6APDG00898	alsterpaullone 2-cyanoethyl	CID: 16760286	Investigative	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
PT00079	M6APDG00405	PF-228	CID: 11612883	Investigative	Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur J Med Chem. 2010 Mar;45(3):1158-66.
PT00073	M6APDG01998	Purvalanol A	CID: 456214	Investigative	Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur J Med Chem. 2010 Mar;45(3):1158-66.
PT00079	M6APDG00470	BX-912	CID: 11754511	Investigative	1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11.
PT00078	M6APDG02450	Cdk1 inhibitor	CID: 5472558	Investigative	1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11.
PT00079	M6APDG02296	SU9516	CID: 5289419	Investigative	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
PT00123	M6APDG01397	AMP-PNP	CID: 33113	Investigative	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
PT00080	M6APDG02959	Fascaplysin	CID: 73292	Investigative	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
PT00079	M6APDG02710	PYRAZOLOPYRIDAZINE 1	CID: 6539361	Investigative	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
PT00123	M6APDG02710	PYRAZOLOPYRIDAZINE 1	CID: 6539361	Investigative	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
PT00080	M6APDG02710	PYRAZOLOPYRIDAZINE 1	CID: 6539361	Investigative	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
PT00079	M6APDG02376	K00024	CID: 5330797	Investigative	The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86.
PT00080	M6APDG02376	K00024	CID: 5330797	Investigative	The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86.
PT00123	M6APDG00405	PF-228	CID: 11612883	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG03183	CHIR-98023	CID: 9847557	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG00148	N-(6-bromo-1H-indazol-3-yl)butyramide	CID: 10423871	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG00034	N-(6-phenyl-1H-indazol-3-yl)butyramide	CID: 10085013	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG00091	N-(6-benzyl-1H-indazol-3-yl)butyramide	CID: 10266409	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG00145	N-(6-chloro-1H-indazol-3-yl)butyramide	CID: 10421683	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG03315	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CID: 9993220	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG00036	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CID: 10085818	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG01051	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CID: 22319604	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG00131	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CID: 10380885	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG01048	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CID: 22319511	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG01052	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CID: 22319694	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG00089	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	CID: 10265187	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG00672	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CID: 135458003	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG01049	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CID: 22319573	Investigative	Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
PT00123	M6APDG02647	K00244	CID: 6419766	Investigative	Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg Med Chem Lett. 2002 Jun 3;12(11):1525-8.
PT00029	M6APDG00701	PP-242	CID: 135565635	Investigative	Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
PT00050	M6APDG00123	5,6-Bis-p-tolylamino-isoindole-1,3-dione	CID: 10360970	Investigative	Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
PT00029	M6APDG01499	EM-101	CID: 3971	Investigative	Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct 14;53(19):7146-55.
PT00029	M6APDG02208	Torin2	CID: 51358113	Investigative	Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010 Sep 24;5(9):e12965.
PT00138	M6APDG00405	PF-228	CID: 11612883	Investigative	Company report (Millennium)
PT00151	M6APDG01430	STO609	CID: 3467590	Investigative	7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13.
PT00060	M6APDG03053	DS-437	CID: 91827358	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1256).
PT00016	M6APDG02794	PF-543	CID: 66577038	Investigative	Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium. J Antibiot (Tokyo). 2000 Aug;53(8):759-64.
PT00199	M6APDG01419	GW7647	CID: 3392731	Investigative	Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005 Jun;48(8):1147-53.
PT00175	M6APDG02842	IK-862	CID: 6914621	Investigative	Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole ... Bioorg Med Chem Lett. 2002 Oct 7;12(19):2667-72.
PT00206	M6APDG01848	BMS614	CID: 445091	Investigative	Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol. 1999 Aug;6(8):519-29.
PT00206	M6APDG03226	BMS753	CID: 9884820	Investigative	Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83.
PT00051	M6APDG02798	AG-213	CID: 667601	Investigative	Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents. Bioorg Med Chem. 2010 Jan 15;18(2):880-6.
PT00064	M6APDG02783	CGK733	CID: 6605258	Investigative	Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009 Oct;8(10):2894-902.
PT00192	M6APDG01062	MJN228	CID: 22660592	Investigative	Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs. US8987474.
PT00143	M6APDG00316	MK-0668	CID: 11433918	Investigative	An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85.
PT00035	M6APDG03300	AD-5061	CID: 9953271	Investigative	PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion.Diabetes. 2003 Feb;52(2):291-9.
PT00033	M6APDG01197	PI-3065	CID: 24937012	Investigative	Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44.
PT00033	M6APDG03198	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	CID: 9860529	Investigative	Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44.
PT00033	M6APDG03255	TGX-221	CID: 9907093	Investigative	Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-11.
PT00025	M6APDG03037	BVB-808	CID: 90480481	Investigative	Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43.
PT00028	M6APDG00427	NU-8231	CID: 11648438	Investigative	Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007 Dec 13;450(7172):1001-9.
PT00005	M6APDG00193	flavone	CID: 10680	Investigative	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
PT00005	M6APDG00750	1-(4-Cyanobenzyl)-5-methyl-1H-imidazole	CID: 14231155	Investigative	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
PT00005	M6APDG00179	5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one	CID: 10566470	Investigative	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
PT00005	M6APDG01053	4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one	CID: 2238	Investigative	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
PT00005	M6APDG00180	7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one	CID: 10585323	Investigative	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
PT00005	M6APDG02730	3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539781	Investigative	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
PT00005	M6APDG02744	4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539797	Investigative	A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80.
PT00005	M6APDG02249	Chrysin	CID: 5281607	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02228	biochanin A	CID: 5280373	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02611	4-ANDROSTENE-3-17-DIONE	CID: 6128	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02006	4-(2,2-Diphenyl-vinyl)-pyridine	CID: 4594970	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02753	3-(2,2-Diphenyl-vinyl)-pyridine	CID: 6539811	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG00742	3-Fluoren-9-ylidenemethyl-pyridine	CID: 139138079	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG01278	4-Fluoren-9-ylidenemethyl-pyridine	CID: 256445	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02715	3-Indan-(1Z)-ylidenemethyl-pyridine	CID: 6539760	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02735	4-Indan-(1Z)-ylidenemethyl-pyridine	CID: 6539786	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02738	4-Indan-(1E)-ylidenemethyl-pyridine	CID: 6539790	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG00162	4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one	CID: 10473365	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02720	3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539767	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02721	3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539768	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02716	3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539763	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02717	3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539764	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02718	3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539765	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02719	3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539766	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02724	3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539773	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02725	3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539774	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02726	3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539775	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02729	3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539780	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02731	3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539782	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02732	3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539783	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02733	3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539784	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02734	3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539785	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02736	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539788	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02737	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539789	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02739	3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539791	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02740	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539792	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02741	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539793	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02747	4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539803	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02748	4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539804	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02754	3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539817	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02755	3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539818	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02756	3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539819	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02722	3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539769	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02723	3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539770	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02727	3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539776	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02728	3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539777	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02743	4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539796	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02745	4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	CID: 6539800	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02746	4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	CID: 6539801	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02750	5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole	CID: 6539806	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02751	5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole	CID: 6539807	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02749	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine	CID: 6539805	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00005	M6APDG02752	5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine	CID: 6539808	Investigative	Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
PT00051	M6APDG02483	TA1-RTA	CID: 5595	Investigative	A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002 Jun;8(6):1710-9.
PT00213	M6APDG01267	SRT1720	CID: 25232708	Investigative	Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95.
PT00213	M6APDG00736	(S)-sirtinol	CID: 1376645	Investigative	Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95.
PT00213	M6APDG00737	(R)-sirtinol	CID: 1376646	Investigative	Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95.
PT00213	M6APDG00685	Para-sirtinol	CID: 135491748	Investigative	Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95.
PT00031	M6APDG00427	NU-8231	CID: 11648438	Investigative	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein intera... J Med Chem. 2009 Nov 26;52(22):7044-53.
PT00040	M6APDG00058	Y-39041	CID: 10151575	Investigative	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
PT00174	M6APDG01639	3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol	CID: 44294636	Investigative	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
PT00012	M6APDG01041	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione	CID: 2220392	Investigative	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
PT00011	M6APDG01041	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione	CID: 2220392	Investigative	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
PT00175	M6APDG01041	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione	CID: 2220392	Investigative	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
PT00144	M6APDG00142	AcDRGDS	CID: 10415998	Investigative	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
PT00144	M6APDG02305	SB-207043	CID: 52942958	Investigative	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
PT00144	M6APDG00435	C-[-Arg-Gly-Asp-Acpca33-]	CID: 11670104	Investigative	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
PT00144	M6APDG01165	Cyclo-[-Arg-Gly-Asp-Amp23-]	CID: 24822282	Investigative	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
PT00144	M6APDG01167	Cyclo-[-Arg-Gly-Asp-Amp26-]	CID: 24822444	Investigative	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
PT00144	M6APDG01169	Cyclo-[-Arg-Gly-Asp-Amp21-]	CID: 24822953	Investigative	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
PT00144	M6APDG01170	Cyclo-[-Arg-Gly-Asp-Amp24-]	CID: 24823110	Investigative	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
PT00144	M6APDG01171	Cyclo-[-Arg-Gly-Asp-Amp28-]	CID: 24824620	Investigative	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
PT00144	M6APDG01832	Cyclo-[-Arg-Gly-Asp-Amp27-]	CID: 44456982	Investigative	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
PT00144	M6APDG01809	ST-1646	CID: 44439175	Investigative	Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106.
PT00144	M6APDG01693	E[c(RGDyK)]2	CID: 44388431	Investigative	Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106.
PT00144	M6APDG03071	RGDechi	CID: 91936353	Investigative	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
PT00144	M6APDG01773	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	CID: 44418282	Investigative	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
PT00144	M6APDG01772	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	CID: 44418281	Investigative	Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
PT00009	M6APDG00800	XR-9456	CID: 15511439	Investigative	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
PT00009	M6APDG00818	XR-9577	CID: 15950351	Investigative	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
PT00009	M6APDG01031	XR-9504	CID: 22004473	Investigative	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
PT00009	M6APDG00368	6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol	CID: 11536458	Investigative	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
PT00009	M6APDG00801	XR-9544	CID: 15511440	Investigative	A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5.
PT00112	M6APDG02949	UNC1999	CID: 72551585	Investigative	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5.
PT00174	M6APDG01317	CL82198	CID: 2777	Investigative	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem. 2011 Dec 8;54(23):8174-87.
PT00165	M6APDG03095	SU11274	CID: 9549297	Investigative	Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015 Aug;21(8):955-61.
PT00090	M6APDG03099	octanol	CID: 957	Investigative	Clinical pipeline report, company report or official report of OcuNexus Therapeutics.
PT00044	M6APDG00193	flavone	CID: 10680	Investigative	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.
PT00078	M6APDG02859	CVT-313	CID: 6918386	Investigative	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
PT00079	M6APDG02859	CVT-313	CID: 6918386	Investigative	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
PT00125	M6APDG01596	ST-2986	CID: 44138031	Investigative	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
PT00125	M6APDG00748	8-Phenyl-octanoic acid hydroxyamide	CID: 14098189	Investigative	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
PT00125	M6APDG01279	7-Phenoxy-heptanoic acid hydroxyamide	CID: 25798548	Investigative	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
PT00125	M6APDG01656	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	CID: 44341053	Investigative	Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
PT00125	M6APDG01597	ST-2987	CID: 44138032	Investigative	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
PT00191	M6APDG01935	GW-3965	CID: 447905	Investigative	Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta. Bioorg Med Chem. 2009 May 15;17(10):3519-27.
PT00191	M6APDG02015	GSK2033	CID: 46203250	Investigative	A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem. 2002 Mar 22;277(12):10021-7.
PT00107	M6APDG02038	UNC0638	CID: 46224516	Investigative	Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-42.
PT00107	M6APDG02113	UNC0321	CID: 46901937	Investigative	A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011 Jul 10;7(8):566-74.
PT00107	M6APDG02378	UNC0642	CID: 53315878	Investigative	A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012 Jul 20;7(7):1152-7.
PT00107	M6APDG02970	BRD9539	CID: 73755260	Investigative	Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med Chem Lett. 2014 Jan 2;5(2):205-9.
PT00164	M6APDG02502	LDC1267	CID: 56847486	Investigative	G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19.
PT00108	M6APDG01397	AMP-PNP	CID: 33113	Investigative	Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14.
PT00073	M6APDG01501	NU-6027	CID: 398148	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00079	M6APDG01501	NU-6027	CID: 398148	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00073	M6APDG00420	MERIOLIN 1	CID: 11637090	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00073	M6APDG01111	MERIOLIN 3	CID: 23727981	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00073	M6APDG01112	MERIOLIN 5	CID: 23727982	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00073	M6APDG01157	MERIOLIN 8	CID: 24801181	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00073	M6APDG01158	MERIOLIN 6	CID: 24801185	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00073	M6APDG01160	MERIOLIN 4	CID: 24801697	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00073	M6APDG01161	MERIOLIN 2	CID: 24801699	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00079	M6APDG01111	MERIOLIN 3	CID: 23727981	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00079	M6APDG01112	MERIOLIN 5	CID: 23727982	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00079	M6APDG01157	MERIOLIN 8	CID: 24801181	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00079	M6APDG01158	MERIOLIN 6	CID: 24801185	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00079	M6APDG01160	MERIOLIN 4	CID: 24801697	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00079	M6APDG01161	MERIOLIN 2	CID: 24801699	Investigative	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
PT00167	M6APDG02863	CI-1040	CID: 6918454	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1495).
PT00185	M6APDG00541	[3H]CPP	CID: 1228	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG00009	CGP61594	CID: 10025114	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG00329	[3H]CGP39653	CID: 114756	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG01559	[3H]CGS19755	CID: 4324257	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG01506	[3H]MDL105519	CID: 4023	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG00530	[3H]dizocilpine	CID: 1207	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG02563	L-aspartic acid	CID: 5960	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG03014	D-aspartic acid	CID: 83887	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG01373	homoquinolinic acid	CID: 3080554	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG00537	(R)-2-Amino-5-phosphono-pentanoic acid	CID: 1216	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00185	M6APDG00186	3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione	CID: 10633414	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
PT00205	M6APDG01397	AMP-PNP	CID: 33113	Investigative	National Cancer Institute Drug Dictionary (drug name CYT0851).
PT00022	M6APDG00986	AG 1024	CID: 2044	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1801).
PT00022	M6APDG02489	AZD3463	CID: 56599293	Investigative	Clinical pipeline report, company report or official report of Antisense Therapeutics.
PT00170	M6APDG00439	IN-1130	CID: 11676119	Investigative	Amide-based inhibitors of p38alpha MAP kinase. Part 2: design, synthesis and SAR of potent N-pyrimidyl amides. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2560-3.
PT00170	M6APDG01985	KT-5720	CID: 454202	Investigative	Mitogen-activated protein kinases in innate immunity.Nat Rev Immunol.2013 Sep;13(9):679-92.
PT00170	M6APDG02863	CI-1040	CID: 6918454	Investigative	Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 2003 Sep;48(9):2670-81.
PT00170	M6APDG03110	ML-3375	CID: 9795838	Investigative	From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem. 2002 Jun 20;45(13):2733-40.
PT00170	M6APDG03179	ML-3163	CID: 9845197	Investigative	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
PT00170	M6APDG03131	RWJ-68354	CID: 9819053	Investigative	Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
PT00015	M6APDG01555	LM-4108	CID: 4292	Investigative	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
PT00170	M6APDG02216	SB-218655	CID: 5172	Investigative	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
PT00170	M6APDG02364	PD-0173956	CID: 5330524	Investigative	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
PT00170	M6APDG00834	6-o-tolylquinazolin-2-amine	CID: 16086113	Investigative	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
PT00015	M6APDG02257	Wogonin	CID: 5281703	Investigative	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
PT00015	M6APDG03206	L-761000	CID: 9867333	Investigative	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
PT00015	M6APDG02127	2-(4-(methylsulfonyl)phenyl)pyridine	CID: 46937403	Investigative	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
PT00015	M6APDG00519	1-(4-(methylsulfonyl)phenyl)-1H-indole	CID: 11958319	Investigative	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
PT00015	M6APDG02128	4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline	CID: 46937407	Investigative	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
PT00015	M6APDG02129	Furan-3-yl(4-(methylsulfonyl)phenyl)methanone	CID: 46939837	Investigative	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
PT00015	M6APDG02772	TENOSAL	CID: 65838	Investigative	PAC 10649 Pacific licensing offer, Worldwide excluding South Korea. R & D Focus Drug News. September 22, 2003.
PT00079	M6APDG02001	NU-6102	CID: 4566	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00123	M6APDG02001	NU-6102	CID: 4566	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00080	M6APDG02001	NU-6102	CID: 4566	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00170	M6APDG03296	L-779450	CID: 9950176	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00075	M6APDG01947	aloisine A	CID: 448912	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00073	M6APDG01159	MERIOLIN 7	CID: 24801186	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00074	M6APDG02247	7-hydroxycoumarin	CID: 5281426	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00167	M6APDG00901	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	CID: 1694	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00057	M6APDG00901	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	CID: 1694	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00155	M6APDG00901	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	CID: 1694	Investigative	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
PT00123	M6APDG02863	CI-1040	CID: 6918454	Investigative	9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
PT00123	M6APDG03094	TWS-119	CID: 9549289	Investigative	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029796)
PT00162	M6APDG00045	MCL-129	CID: 10098971	Investigative	Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for... J Med Chem. 2006 Feb 9;49(3):911-22.
PT00162	M6APDG01764	C(his-D-phe-arg-trp-Aoc)	CID: 44413535	Investigative	Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for... J Med Chem. 2006 Feb 9;49(3):911-22.
PT00162	M6APDG01731	C[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]	CID: 44406884	Investigative	Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for... J Med Chem. 2006 Feb 9;49(3):911-22.
PT00162	M6APDG02874	MCL0129	CID: 6918688	Investigative	Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport. 1999 Mar 17;10(4):707-11.
PT00110	M6APDG01397	AMP-PNP	CID: 33113	Investigative	Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007 Dec 14;282(50):36505-13.
PT00045	M6APDG02319	SU 6656	CID: 5312137	Investigative	Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.
PT00199	M6APDG03300	AD-5061	CID: 9953271	Investigative	Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo. Mol Pharmacol. 2009 Feb;75(2):296-306.
PT00103	M6APDG01620	KH-CB19	CID: 44237094	Investigative	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
PT00155	M6APDG01985	KT-5720	CID: 454202	Investigative	Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
PT00155	M6APDG02863	CI-1040	CID: 6918454	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1525).
PT00173	M6APDG01890	RXP470.1	CID: 44580458	Investigative	Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12. ACS Med Chem Lett. 2012 Jul 14;3(8):653-7.
PT00072	M6APDG00703	ischemin	CID: 135566302	Investigative	Clinical pipeline report, company report or official report of FORMA Therapeutics.
PT00072	M6APDG03038	I-CBP112	CID: 90488984	Investigative	Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014 Mar;9(3):438-64.
PT00035	M6APDG02666	LG100754	CID: 6442223	Investigative	A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
PT00199	M6APDG02276	N-oleoylethanolamide	CID: 5283454	Investigative	A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
PT00035	M6APDG03130	L-764406	CID: 9818466	Investigative	Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25.
PT00035	M6APDG03234	L-165461	CID: 9889841	Investigative	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
PT00199	M6APDG01323	Fibrates	CID: 2797	Investigative	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
PT00199	M6APDG03234	L-165461	CID: 9889841	Investigative	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
PT00035	M6APDG00587	Ploglitazone	CID: 12944192	Investigative	Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
PT00035	M6APDG03239	L-796449	CID: 9891946	Investigative	Non thiazolidinedione antihyperglycaemic agents. 2: alpha-Carbon substituted beta-phenylpropanoic acids1, Bioorg. Med. Chem. Lett. 6(17):2127-2130 (1996).
PT00035	M6APDG03176	SB-213068	CID: 9843045	Investigative	Non thiazolidinedione antihyperglycaemic agents. 2: alpha-Carbon substituted beta-phenylpropanoic acids1, Bioorg. Med. Chem. Lett. 6(17):2127-2130 (1996).
PT00035	M6APDG03259	DRF 2519	CID: 9908833	Investigative	Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. J Med Chem. 2001 Jun 21;44(13):2061-4.
PT00035	M6APDG03283	L-783483	CID: 9935197	Investigative	Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Metabolism. 2000 Nov;49(11):1417-23.
PT00193	M6APDG00461	KU-58684	CID: 11725479	Investigative	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
PT00193	M6APDG00462	8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one	CID: 11736764	Investigative	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
PT00193	M6APDG01249	8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one	CID: 25190929	Investigative	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
PT00193	M6APDG01250	8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one	CID: 25190931	Investigative	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
PT00193	M6APDG01251	9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one	CID: 25190932	Investigative	Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3.
PT00193	M6APDG03294	CEP-6800	CID: 9948440	Investigative	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
PT00193	M6APDG01735	Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione	CID: 44407700	Investigative	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
PT00193	M6APDG00347	1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione	CID: 11506860	Investigative	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
PT00193	M6APDG01733	5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	CID: 44407565	Investigative	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
PT00193	M6APDG01734	4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	CID: 44407566	Investigative	Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42.
PT00025	M6APDG01471	WHI-P154	CID: 3795	Investigative	Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58.
PT00146	M6APDG01472	ZM-39923	CID: 3797	Investigative	Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58.
PT00025	M6APDG02421	NSC-1771	CID: 5455	Investigative	Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem. 2005 Apr 7;48(7):2526-33.
PT00028	M6APDG01019	NUTLIN-3	CID: 216345	Investigative	Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2006 Jun 15;49(12):3432-5.
PT00044	M6APDG00977	RU-59063	CID: 197655	Investigative	Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile... J Med Chem. 2000 Aug 24;43(17):3344-7.
PT00044	M6APDG01696	OXENDLONE	CID: 443947	Investigative	Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile... J Med Chem. 2000 Aug 24;43(17):3344-7.
PT00005	M6APDG01624	MR-20496	CID: 44265823	Investigative	Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5215-8.
PT00005	M6APDG00855	3-(4-Amino-phenyl)-pyrrolidine-2,5-dione	CID: 161760	Investigative	Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5215-8.
PT00005	M6APDG00313	1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole	CID: 11413434	Investigative	Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5215-8.
PT00005	M6APDG03132	MR-20492	CID: 9819080	Investigative	Design and synthesis of a new type of non steroidal human aromatase inhibitors. Bioorg Med Chem Lett. 1998 May 5;8(9):1041-4.
PT00005	M6APDG00564	3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione	CID: 124662	Investigative	Design and synthesis of a new type of non steroidal human aromatase inhibitors. Bioorg Med Chem Lett. 1998 May 5;8(9):1041-4.
PT00031	M6APDG01019	NUTLIN-3	CID: 216345	Investigative	An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77.
PT00118	M6APDG03145	CEP-6331	CID: 9823787	Investigative	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
PT00118	M6APDG00309	Ro-4396686	CID: 11396738	Investigative	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
PT00130	M6APDG01562	Macbecin	CID: 433447	Investigative	High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem. 2004 Apr 15;327(2):176-83.
PT00146	M6APDG01471	WHI-P154	CID: 3795	Investigative	Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9.
PT00144	M6APDG00197	C(RGDfF)	CID: 10699123	Investigative	Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20.
PT00144	M6APDG01761	C(Arg-Gly-Asp-D-Phe-Val)	CID: 44411994	Investigative	Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20.
PT00144	M6APDG00919	L-767679	CID: 177364	Investigative	Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists. J Med Chem. 1997 Aug 29;40(18):2843-57.
PT00144	M6APDG03120	L-756568	CID: 9805998	Investigative	1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41.
PT00068	M6APDG02301	I-BET151	CID: 52912189	Investigative	Down-regulation of NF- B transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51.
PT00034	M6APDG01272	GW853606	CID: 25263088	Investigative	Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1694-7.
PT00044	M6APDG00606	RU-56187	CID: 132581	Investigative	Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
PT00044	M6APDG01221	PF-0998425	CID: 25093231	Investigative	Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
PT00044	M6APDG01879	3-chloro-4-(o-tolylthio)benzonitrile	CID: 44565102	Investigative	Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
PT00044	M6APDG01163	LGD-5552	CID: 24816375	Investigative	N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation. J Med Chem. 2009 May 14;52(9):2794-8.
PT00044	M6APDG02230	APIGENIN	CID: 5280443	Investigative	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem. 1998 Oct 22;41(22):4354-9.
PT00044	M6APDG03148	andarine	CID: 9824562	Investigative	Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERalpha-selective antagonist. Bioorg Med Chem Lett. 2013 Jul 15;23(14):4031-6.
PT00191	M6APDG00831	GSK-9772	CID: 16049480	Investigative	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
PT00191	M6APDG01225	WAY-214950	CID: 25113722	Investigative	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
PT00191	M6APDG00026	Riccardin C	CID: 10070992	Investigative	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
PT00191	M6APDG03283	L-783483	CID: 9935197	Investigative	A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther. 2003 Oct;307(1):291-6.
PT00196	M6APDG02356	SU-11652	CID: 5329103	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG02356	SU-11652	CID: 5329103	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG00595	6,7-Dimethoxy-4-phenoxy-quinoline	CID: 13085778	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01654	6,7-Dimethoxy-4-m-tolyloxy-quinoline	CID: 44331325	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01060	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol	CID: 22646527	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01038	6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline	CID: 22132767	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01649	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline	CID: 44331083	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01650	4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline	CID: 44331127	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01034	4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline	CID: 22132626	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01651	4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline	CID: 44331209	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG02342	4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine	CID: 5328512	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01037	6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline	CID: 22132763	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01039	6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline	CID: 22132780	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01652	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline	CID: 44331231	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00050	M6APDG01652	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline	CID: 44331231	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01035	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine	CID: 22132655	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00050	M6APDG02339	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CID: 5328245	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01648	4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	CID: 44330968	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00197	M6APDG01653	4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	CID: 44331261	Investigative	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
PT00020	M6APDG03182	A-286982	CID: 9846729	Investigative	Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.
PT00020	M6APDG02321	Pellitorin	CID: 5318516	Investigative	Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.
PT00020	M6APDG01011	PIPERROLEIN B	CID: 21580213	Investigative	Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.
PT00020	M6APDG02658	Dehydropipernonaline	CID: 6439947	Investigative	Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.
PT00197	M6APDG03209	Ki-20227	CID: 9869779	Investigative	Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J Med Chem. 2003 Nov 6;46(23):4910-25.
PT00050	M6APDG00989	RG-50810	CID: 2052	Investigative	Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
PT00050	M6APDG01330	HTS-02876	CID: 2810910	Investigative	Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
PT00051	M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	CID: 2752461	Investigative	Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
PT00071	M6APDG03264	L-873724	CID: 9913088	Investigative	Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett. 2008 May 1;18(9):2883-5.
PT00015	M6APDG00582	L-748780	CID: 127942	Investigative	From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 6(6):725-730 (1996).
PT00015	M6APDG00527	CLEMATOMANDSHURICA SAPONIN B	CID: 11994182	Investigative	From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 6(6):725-730 (1996).
PT00015	M6APDG02941	HONOKIOL	CID: 72303	Investigative	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
PT00015	M6APDG00802	METHYLHONOKIOL	CID: 155160	Investigative	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
PT00015	M6APDG01896	3 beta-O-acetyloleanolic acid	CID: 44583799	Investigative	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
PT00015	M6APDG03244	5,3'-Dipropyl-biphenyl-2,4'-diol	CID: 9900113	Investigative	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
PT00015	M6APDG01154	4-amino-N-(4-iodophenyl)benzenesulfonamide	CID: 247908	Investigative	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
PT00026	M6APDG01507	DCB-3503	CID: 402628	Investigative	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
PT00011	M6APDG02290	SC-74020	CID: 5288596	Investigative	The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96.
PT00012	M6APDG03162	Ro 28-2653	CID: 9832179	Investigative	The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96.
PT00012	M6APDG01434	2-Amino-N,3,3-Trimethylbutanamide	CID: 3496445	Investigative	The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96.
PT00026	M6APDG00105	PNRI-299	CID: 10318848	Investigative	AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17;20(22):2771-80.
PT00123	M6APDG03296	L-779450	CID: 9950176	Investigative	Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7.
PT00123	M6APDG03302	CT-98024	CID: 9957049	Investigative	Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. Eur J Med Chem. 2010 Feb;45(2):805-10.
PT00029	M6APDG01889	AP-21967	CID: 44576241	Investigative	The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem. 2007 May 4;282(18):13395-401.
PT00029	M6APDG00005	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CID: 10017389	Investigative	The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem. 2007 May 4;282(18):13395-401.
PT00094	M6APDG02457	URMC-099	CID: 54764565	Investigative	Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92.
PT00199	M6APDG03210	GSK-9578	CID: 9870304	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00035	M6APDG01613	(E)-9-Nitrohexadec-9-enoicAcid	CID: 44220886	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00035	M6APDG00425	(E)-9-nitrooctadec-9-enoic acid	CID: 11645581	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00035	M6APDG01615	(E)-5-Nitrooctadec-5-enoic Acid	CID: 44220888	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00035	M6APDG01173	(E)-10-nitrooctadec-9-enoic acid	CID: 24836820	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00035	M6APDG01614	(E)-10-Nitrohexadec-9-enoic Acid	CID: 44220887	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00035	M6APDG01617	(E)-12-Nitrooctadec-12-enoic Acid	CID: 44221100	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00035	M6APDG01618	(E)-13-Nitrooctadec-12-enoic Acid	CID: 44221101	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00199	M6APDG01617	(E)-12-Nitrooctadec-12-enoic Acid	CID: 44221100	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00199	M6APDG01618	(E)-13-Nitrooctadec-12-enoic Acid	CID: 44221101	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00035	M6APDG02662	2-chloro-5-nitro-N-phenylbenzamide	CID: 644213	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00035	M6APDG02269	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid	CID: 5282316	Investigative	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
PT00199	M6APDG03259	DRF 2519	CID: 9908833	Investigative	PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem. 1997 Jul;378(7):651-5.
PT00081	M6APDG02230	APIGENIN	CID: 5280443	Investigative	Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43.
PT00081	M6APDG02959	Fascaplysin	CID: 73292	Investigative	Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43.
PT00006	M6APDG02252	Galangin	CID: 5281616	Investigative	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
PT00006	M6APDG02412	TRISMETHOXYRESVERATROL	CID: 5388063	Investigative	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
PT00006	M6APDG00046	3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan	CID: 10105252	Investigative	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
PT00006	M6APDG00518	4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine	CID: 11957947	Investigative	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
PT00006	M6APDG03166	2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene	CID: 9834747	Investigative	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
PT00092	M6APDG00847	TN-14003	CID: 16130647	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG00245	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CID: 11158428	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01775	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CID: 44418865	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01776	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CID: 44418868	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01777	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CID: 44418869	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01789	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CID: 44418890	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01794	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CID: 44418895	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01778	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CID: 44418872	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01779	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CID: 44418873	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01781	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CID: 44418879	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01782	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CID: 44418880	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01783	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CID: 44418883	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01785	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CID: 44418886	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01786	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CID: 44418887	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01787	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CID: 44418888	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01788	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CID: 44418889	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01790	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CID: 44418891	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01791	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CID: 44418892	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01792	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CID: 44418893	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01793	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CID: 44418894	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01780	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CID: 44418878	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00092	M6APDG01784	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CID: 44418885	Investigative	Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8.
PT00143	M6APDG03298	SB-265123	CID: 9952958	Investigative	Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
PT00144	M6APDG00472	Ac-Asp-Arg-Leu-Asp-Ser-OH	CID: 11764797	Investigative	Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
PT00072	M6APDG02936	SGC-CBP30	CID: 72201027	Investigative	A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol. 2011 Apr 22;18(4):531-41.
PT00035	M6APDG01893	PD-068235	CID: 44581800	Investigative	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
PT00035	M6APDG01142	CHLOROCYCLINONE B	CID: 24762580	Investigative	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
PT00035	M6APDG02882	L-Tryptophan-L-leucine	CID: 6997510	Investigative	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
PT00035	M6APDG01246	L-Tryptophan-L-arginine	CID: 25186251	Investigative	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
PT00035	M6APDG01247	L-Tryptophan-L-glutamine	CID: 25187914	Investigative	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
PT00035	M6APDG02884	L-Tryptophan-L-asparagine	CID: 7020170	Investigative	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
PT00035	M6APDG02883	L-Tryptophan-L-aspartic acid	CID: 7019108	Investigative	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
PT00035	M6APDG01245	L-Tryptophan-L-2-aminoadipic acid	CID: 25185696	Investigative	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
PT00035	M6APDG03140	BRL-48482	CID: 9822139	Investigative	Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8.
PT00035	M6APDG01117	CHLOROCYCLINONE C	CID: 24180661	Investigative	Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8.
PT00035	M6APDG01140	CHLOROCYCLINONE D	CID: 24762578	Investigative	Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8.
PT00035	M6APDG01141	CHLOROCYCLINONE A	CID: 24762579	Investigative	Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8.
PT00035	M6APDG03235	LY-465608	CID: 9890319	Investigative	Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.
PT00199	M6APDG02260	(E)-4-(3,5-dimethoxystyryl)phenol	CID: 5281727	Investigative	Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.
PT00193	M6APDG03113	AG-014376	CID: 9797108	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00193	M6APDG02614	4-benzylphthalazin-1(2H)-one	CID: 616651	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00193	M6APDG01254	3-Phenylquinoline-8-carboxamide	CID: 25208596	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00193	M6APDG03002	N-(4-Phenylthiazol-2-yl)isonicotinamide	CID: 790259	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00193	M6APDG02839	(E)-N-(4-Phenylthiazol-2-yl) cinnamamide	CID: 690181	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00193	M6APDG00866	3-aminobenzo[c][1,5]naphthyridin-6(5H)-one	CID: 16221809	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00193	M6APDG01264	3-(4-cyanophenyl)quinoxaline-5-carboxamide	CID: 25218518	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00193	M6APDG01265	3-(4-aminophenyl)quinoxaline-5-carboxamide	CID: 25218519	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00193	M6APDG03308	3-(4-methoxyphenyl)quinoxaline-5-carboxamide	CID: 9965481	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00193	M6APDG01429	1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one	CID: 345678	Investigative	Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25.
PT00147	M6APDG01116	RO-316233	CID: 2399	Investigative	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
PT00147	M6APDG00151	AdcAhxArg6	CID: 10441484	Investigative	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
PT00147	M6APDG01690	AdcAhxArg4NH(CH2)6NH2	CID: 44387500	Investigative	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
PT00147	M6APDG01691	AdcAhxArg4Lys(biotin)-PEG-OMe	CID: 44387501	Investigative	Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
PT00028	M6APDG01193	NSC-66811	CID: 248986	Investigative	Clinical pipeline report, company report or official report of Hygeia Therapeutics.
PT00044	M6APDG00610	Boldenone	CID: 13308	Investigative	MR appearance of intra-abdominal metastatic melanoma. Magn Reson Imaging. 1992;10(4):705-8.
PT00005	M6APDG00975	Org-33201	CID: 196932	Investigative	High-performance liquid chromatographic determination of FCE 24928, a new aromatase inhibitor, in human plasma. J Chromatogr A. 1994 Feb 4;660(1-2):293-8.
PT00005	M6APDG01285	NSC-94891	CID: 261861	Investigative	An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7.
PT00005	M6APDG01443	NSC-613604	CID: 356713	Investigative	An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7.
PT00005	M6APDG02571	NSC-122427	CID: 5994480	Investigative	An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7.
PT00005	M6APDG02069	2-Imidazol-1-ylmethylxanthen-9-one	CID: 46867544	Investigative	An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7.
PT00005	M6APDG02266	NSC-94258	CID: 5281894	Investigative	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
PT00005	M6APDG03305	ALBANOL A	CID: 9959532	Investigative	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
PT00005	M6APDG03200	MORACHALCONE A	CID: 9862769	Investigative	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
PT00005	M6APDG02322	ISOLICOFLAVONOL	CID: 5318585	Investigative	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
PT00005	M6APDG03205	Broussoflavonol F	CID: 9866908	Investigative	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
PT00005	M6APDG00749	(2S)-abyssinone II	CID: 14218027	Investigative	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
PT00005	M6APDG01899	(2S)-euchrenone a7	CID: 44593508	Investigative	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
PT00005	M6APDG00122	(2S)-5,7,2',4'-tetrahydroxyflavanone	CID: 10356745	Investigative	Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93.
PT00005	M6APDG03251	MDL-18962	CID: 9904788	Investigative	New aromatase inhibitors. Synthesis and inhibitory activity of pyridinyl-substituted flavanone derivatives. Bioorg Med Chem Lett. 2002 Apr 8;12(7):1059-61.
PT00213	M6APDG01116	RO-316233	CID: 2399	Investigative	Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem. 2006 Dec 14;49(25):7307-16.
PT00213	M6APDG01546	2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide	CID: 4262314	Investigative	Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem. 2006 Dec 14;49(25):7307-16.
PT00130	M6APDG02632	Radicicol	CID: 6323491	Investigative	Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5.
PT00144	M6APDG00917	ROXIFIBAN	CID: 177230	Investigative	Molecular model of the alpha(IIb)beta(3) integrin. J Med Chem. 2003 Dec 4;46(25):5316-25.
PT00144	M6APDG03199	SC-54701A	CID: 9862322	Investigative	Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetr... J Med Chem. 2010 Jan 14;53(1):106-18.
PT00112	M6APDG02576	EPZ005687	CID: 60160561	Investigative	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6.
PT00150	M6APDG02788	Edoxudine	CID: 66377	Investigative	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
PT00150	M6APDG00828	5-propyl-2'-deoxyuridine	CID: 160155	Investigative	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
PT00150	M6APDG02206	L-5-iodo-2'-deoxyuridine	CID: 512326	Investigative	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
PT00150	M6APDG00290	3-(2-propyn-1-yl)thymidine	CID: 11323459	Investigative	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
PT00150	M6APDG00660	N2-(3-trifluoromethylphenyl)guanine	CID: 135435057	Investigative	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34.
PT00169	M6APDG00048	AS-601245	CID: 10109823	Investigative	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
PT00169	M6APDG00964	2-(2-butoxypyrimidin-4-ylamino)benzoic acid	CID: 1897784	Investigative	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
PT00169	M6APDG01096	2-(2-propoxypyrimidin-4-ylamino)benzoic acid	CID: 23647240	Investigative	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
PT00169	M6APDG01098	2-(2-phenoxypyrimidin-4-ylamino)benzoic acid	CID: 23647245	Investigative	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
PT00169	M6APDG01797	2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid	CID: 44427133	Investigative	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
PT00169	M6APDG01097	2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid	CID: 23647241	Investigative	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
PT00169	M6APDG01099	2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid	CID: 23647246	Investigative	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
PT00169	M6APDG02506	Phylomers	CID: 56947089	Investigative	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
PT00169	M6APDG03012	N-(6-ethoxypyridin-2-yl)acetamide	CID: 824661	Investigative	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
PT00023	M6APDG00314	5-Bromo-6-methoxy-9H-beta-carboline	CID: 11414735	Investigative	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
PT00169	M6APDG00433	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	CID: 11658882	Investigative	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
PT00169	M6APDG00455	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide	CID: 11715520	Investigative	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
PT00153	M6APDG00155	LY-326449	CID: 10455969	Investigative	Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
PT00068	M6APDG00745	GW841819X	CID: 13953710	Investigative	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33.
PT00176	M6APDG01286	NSC-95397	CID: 262093	Investigative	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
PT00176	M6APDG01753	3-isopropyl-4-phenylnaphthalene-1,2-dione	CID: 44409685	Investigative	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
PT00176	M6APDG01754	3-isopropyl-4-(phenylamino)naphthalene-1,2-dione	CID: 44409841	Investigative	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
PT00176	M6APDG01755	4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione	CID: 44409922	Investigative	Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
PT00044	M6APDG02826	NSC-26745	CID: 68112	Investigative	Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists. Bioorg Med Chem. 2010 May 1;18(9):3159-68.
PT00044	M6APDG03134	CP-409069	CID: 9819614	Investigative	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
PT00044	M6APDG03169	LG-121071	CID: 9839132	Investigative	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
PT00044	M6APDG03297	LG-120838	CID: 9951771	Investigative	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24.
PT00044	M6APDG03137	CP-394531	CID: 9820558	Investigative	Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. J Med Chem. 2007 May 17;50(10):2486-96.
PT00078	M6APDG00023	Microxine	CID: 10061827	Investigative	3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2005 May 2;15(9):2221-4.
PT00078	M6APDG01116	RO-316233	CID: 2399	Investigative	Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
PT00078	M6APDG00014	3,4-bis(indol-3-yl)maleimide derivative	CID: 10033891	Investigative	Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
PT00078	M6APDG02377	(2,6-Diamino-pyridin-3-yl)-phenyl-methanone	CID: 5330842	Investigative	Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
PT00228	M6APDG00431	LY2109761	CID: 11655119	Investigative	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
PT00055	M6APDG00219	SB-201076	CID: 10835222	Investigative	2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3208-11.
PT00191	M6APDG00169	paxilline	CID: 105008	Investigative	Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6.
PT00167	M6APDG01184	SCH772984	CID: 24866313	Investigative	Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6281-7.
PT00197	M6APDG00062	CP-673451	CID: 10158940	Investigative	Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor... J Med Chem. 2009 Jan 22;52(2):278-92.
PT00197	M6APDG00385	TG-100435	CID: 11562302	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00196	M6APDG00309	Ro-4396686	CID: 11396738	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00196	M6APDG01933	PD-0166326	CID: 447700	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00196	M6APDG02343	PD-0173952	CID: 5328733	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00196	M6APDG02364	PD-0173956	CID: 5330524	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00196	M6APDG02365	PD-0173958	CID: 5330525	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00196	M6APDG02366	PD-0179483	CID: 5330526	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00197	M6APDG00309	Ro-4396686	CID: 11396738	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00197	M6APDG01933	PD-0166326	CID: 447700	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00197	M6APDG02343	PD-0173952	CID: 5328733	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00197	M6APDG02364	PD-0173956	CID: 5330524	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00197	M6APDG02365	PD-0173958	CID: 5330525	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00197	M6APDG02366	PD-0179483	CID: 5330526	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00050	M6APDG01933	PD-0166326	CID: 447700	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00050	M6APDG02364	PD-0173956	CID: 5330524	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00196	M6APDG00665	3-Pyridin-4-yl-quinolin-7-ol	CID: 135449022	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00050	M6APDG00824	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CID: 15984068	Investigative	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
PT00197	M6APDG01416	GTP-14564	CID: 3385203	Investigative	Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem. 2003 May 1;11(9):2007-18.
PT00050	M6APDG01316	CL-387785	CID: 2776	Investigative	Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72.
PT00050	M6APDG01729	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CID: 44406548	Investigative	Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72.
PT00050	M6APDG01329	HTS-00213	CID: 2809539	Investigative	Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
PT00050	M6APDG01328	6,7-dimethoxy-N-m-tolylquinazolin-4-amine	CID: 2808977	Investigative	Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
PT00050	M6APDG02351	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	CID: 5328819	Investigative	Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
PT00050	M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 11572699	Investigative	Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
PT00170	M6APDG01721	SB-227931	CID: 44404442	Investigative	Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5095-9.
PT00170	M6APDG02191	Ro31-8220	CID: 5083	Investigative	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
PT00170	M6APDG01933	PD-0166326	CID: 447700	Investigative	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
PT00170	M6APDG02215	SB-216995	CID: 5171	Investigative	Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highl... J Med Chem. 2006 Mar 9;49(5):1562-75.
PT00170	M6APDG02518	ZM-336372	CID: 5730	Investigative	Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (T... J Med Chem. 2005 Sep 22;48(19):5966-79.
PT00015	M6APDG00023	Microxine	CID: 10061827	Investigative	Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90.
PT00015	M6APDG03314	5-Methyl-3,4-diphenyl-isoxazole	CID: 9991673	Investigative	Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90.
PT00015	M6APDG00995	Firocoxib	CID: 208910	Investigative	Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. J Biol Chem. 2007 Jun 1;282(22):16379-90.
PT00015	M6APDG02213	SB 239063	CID: 5166	Investigative	Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts. Biochem Biophys Res Commun. 1994 Jan 28;198(2):536-45.
PT00015	M6APDG02810	NSC-27236	CID: 67316	Investigative	Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhib... Bioorg Med Chem Lett. 2009 Aug 1;19(15):4504-8.
PT00015	M6APDG02890	PHENIDONE	CID: 7090	Investigative	Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole an... Bioorg Med Chem. 2008 Nov 15;16(22):9694-8.
PT00015	M6APDG02930	Prifelone	CID: 71751	Investigative	SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2207-12.
PT00057	M6APDG02191	Ro31-8220	CID: 5083	Investigative	A phthalide with in vitro growth inhibitory activity from an oidiodendron strain. J Nat Prod. 2004 Dec;67(12):2086-9.
PT00011	M6APDG00175	PD-169469	CID: 10549609	Investigative	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
PT00174	M6APDG03230	PKF-242-484	CID: 9886977	Investigative	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
PT00172	M6APDG03230	PKF-242-484	CID: 9886977	Investigative	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
PT00012	M6APDG01757	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CID: 44411812	Investigative	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
PT00123	M6APDG00048	AS-601245	CID: 10109823	Investigative	Novel GSK-3beta inhibitors from sequential virtual screening. Bioorg Med Chem. 2008 Jan 15;16(2):636-43.
PT00123	M6APDG02191	Ro31-8220	CID: 5083	Investigative	Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6.
PT00162	M6APDG03175	ML-253764	CID: 9842665	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01218	Ac-YRMEHdFRWG-NH2	CID: 25078192	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01710	Ac-[CEHdFRWC]-NH2	CID: 44400398	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01709	Ac-YR[CEHFRWC]-NH2	CID: 44400371	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01713	Ac-R[CEHdFRWC]-NH2	CID: 44400401	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG03073	NDP-SYSMEHFRWGKPVG	CID: 91936745	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01708	Ac-YR[CEHdFRWC]-NH2	CID: 44400370	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01712	Ac-YK[CEHdFRWC]-NH2	CID: 44400400	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01711	Ac-YCit[CEHdFRWC]-NH2	CID: 44400399	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG00849	AEKKDEGPYRMEHFRWGSPPKD	CID: 16135998	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG03075	Ac-YRMEHdFRWGSPPKD-NH2	CID: 91936747	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01705	Ac-YR[CEH(pF-dF)RWC]-NH2	CID: 44400321	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01707	Ac-YR[CEHdFRWC]SPPKD-NH2	CID: 44400369	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01219	Ac-YRC(Me)*EHdFRWC(Me)NH2	CID: 25078242	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01704	Ac-YR[CEH(pCl-dF)RWC]-NH2	CID: 44400320	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG01706	Ac-YR[CE(1-Me-H)dFRWC]-NH2	CID: 44400322	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG03072	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	CID: 91936743	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00162	M6APDG00755	1-Methyl-4-(1-phenyl-ethyl)-piperazine	CID: 14364677	Investigative	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
PT00198	M6APDG02120	ETP-46321	CID: 46927938	Investigative	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015 Jan;35(1):175-82.
PT00060	M6APDG03032	EPZ015666	CID: 90241673	Investigative	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood. 2015 Apr 16;125(16):2530-43.
PT00016	M6APDG02978	VPC-94075	CID: 753704	Investigative	A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 2008 Aug 15;112(4):1382-91.
PT00199	M6APDG03235	LY-465608	CID: 9890319	Investigative	Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha. J Lipid Res. 2000 Nov;41(11):1801-7.
PT00175	M6APDG00126	UK-356618	CID: 10370504	Investigative	Inhibition of metalloproteinase by futoenone derivatives, Bioorg. Med. Chem. Lett. 5(15):1637-1642 (1995).
PT00175	M6APDG00175	PD-169469	CID: 10549609	Investigative	Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem. 2007 Nov 16;282(46):33295-304.
PT00208	M6APDG00289	Ryanodine	CID: 11317883	Investigative	Role of ryanodine receptor channels in Ca2+ oscillations of porcine tracheal smooth muscle. Am J Physiol. 1997 Apr;272(4 Pt 1):L659-64.
PT00206	M6APDG00918	AGN193109	CID: 177238	Investigative	Synthesis and biological activity of retinoic acid receptor-alpha specific amides. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8.
PT00206	M6APDG01068	AGN193836	CID: 23001780	Investigative	Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92.
PT00035	M6APDG00185	[3H]GW2331	CID: 10624977	Investigative	A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem. 2000 Jan 21;275(3):1873-7.
PT00035	M6APDG03312	tirotundin	CID: 9975297	Investigative	The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6.
PT00033	M6APDG00522	KU-0060648	CID: 11964036	Investigative	PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005 May;11(5):507-14.
PT00005	M6APDG00615	CGS-18320B	CID: 133966	Investigative	Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem. 1993 May 14;36(10):1393-400.
PT00005	M6APDG01424	NSC-369087	CID: 340000	Investigative	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
PT00005	M6APDG02090	10-EPI-8-DEOXY-CUMAMBRIN B	CID: 46887018	Investigative	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
PT00005	M6APDG02111	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol	CID: 46901610	Investigative	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
PT00005	M6APDG02110	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine	CID: 46901446	Investigative	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
PT00005	M6APDG02112	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol	CID: 46901611	Investigative	Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
PT00005	M6APDG02233	GOSSYPETIN	CID: 5280647	Investigative	CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors. Bioorg Med Chem. 2008 Sep 15;16(18):8349-58.
PT00005	M6APDG02200	1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole	CID: 510040	Investigative	CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors. Bioorg Med Chem. 2008 Sep 15;16(18):8349-58.
PT00114	M6APDG02811	GSK2194069	CID: 67376285	Investigative	C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.
PT00160	M6APDG01915	PF-3644022	CID: 44631903	Investigative	Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6832-5.
PT00144	M6APDG01740	C(RGDfMeF)	CID: 44408450	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG00143	C[RGDf-(S)-alpha-TfmV]	CID: 10416726	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG00346	C[RGDf-(R)-alpha-TfmV]	CID: 11505585	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG00419	C[RGDf-(R)-alpha-TfmF]	CID: 11636164	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG01736	C[RGD-(R)-alpha-TfmfV]	CID: 44408397	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG03160	C[RGDf-(S)-alpha-TfmF]	CID: 9831456	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG03313	C[RGD-(S)-alpha-TfmfV]	CID: 9986643	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG00407	C[RGDf-(S,R)-alpha-Dfm-F]	CID: 11614485	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG00127	C[RGDf-(S)-N-Me-alpha-TfmF]	CID: 10372586	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG00423	C[RGDf-(R)-N-Me-alpha-TfmF]	CID: 11643340	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG01166	Cyclo-[-Arg-Gly-Asp-Amp22-]	CID: 24822283	Investigative	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
PT00144	M6APDG03187	CYCLORGDFV	CID: 9851104	Investigative	N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999 Aug 12;42(16):3033-40.
PT00153	M6APDG01986	PROSTRATIN	CID: 454217	Investigative	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
PT00052	M6APDG00309	Ro-4396686	CID: 11396738	Investigative	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
PT00073	M6APDG02162	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	CID: 49798484	Investigative	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
PT00044	M6APDG00374	WAY-255348	CID: 11543746	Investigative	Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
PT00044	M6APDG01803	Epierenone	CID: 44433505	Investigative	Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49(21):6143-6.
PT00044	M6APDG00837	6-amino-4-trifluoromethylquinolin-2(1H)-one	CID: 16090308	Investigative	Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49(21):6143-6.
PT00044	M6APDG02235	KAEMPFEROL	CID: 5280863	Investigative	(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally po... J Med Chem. 2006 Jan 26;49(2):716-26.
PT00044	M6APDG03224	BMS-564929	CID: 9882972	Investigative	Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5529-32.
PT00191	M6APDG00430	AZ12260493	CID: 11655079	Investigative	An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31.
PT00012	M6APDG01642	Ro-37-9790	CID: 44313734	Investigative	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
PT00011	M6APDG01642	Ro-37-9790	CID: 44313734	Investigative	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
PT00012	M6APDG00719	Folate gamma-hydroxamic acid	CID: 136177317	Investigative	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
PT00011	M6APDG01799	Methotrexate gamma-hydroxamic acid	CID: 44428664	Investigative	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
PT00012	M6APDG01800	Methotrexate gamma-L-proline-hydroxamic acid	CID: 44428667	Investigative	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
PT00011	M6APDG01800	Methotrexate gamma-L-proline-hydroxamic acid	CID: 44428667	Investigative	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
PT00012	M6APDG01822	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CID: 44446277	Investigative	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
PT00011	M6APDG01833	Cis-2-aminocyclohexylcarbamoylphosphonic acid	CID: 44457233	Investigative	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
PT00070	M6APDG00707	AZ10417808	CID: 135665263	Investigative	Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3. J Med Chem. 2004 Dec 16;47(26):6455-8.
PT00073	M6APDG01947	aloisine A	CID: 448912	Investigative	N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J Med Chem. 2004 Jul 15;47(15):3710-22.
PT00185	M6APDG03111	RPR-118723	CID: 9796571	Investigative	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
PT00185	M6APDG01684	4-Bromo-3-hydroxy-1H-quinolin-2-one	CID: 44364603	Investigative	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
PT00185	M6APDG01685	4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one	CID: 44364737	Investigative	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
PT00185	M6APDG01686	4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one	CID: 44364764	Investigative	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
PT00101	M6APDG02805	NSC-622445	CID: 67145	Investigative	SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes. Bioorg Med Chem Lett. 2009 May 15;19(10):2747-51.
PT00170	M6APDG02331	Ro-3201195	CID: 5327067	Investigative	The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
PT00123	M6APDG00901	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	CID: 1694	Investigative	The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
PT00015	M6APDG01411	Oxametacin	CID: 33675	Investigative	Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem. 2004 Dec 30;47(27):6749-59.
PT00015	M6APDG01975	GW-637185X	CID: 45268661	Investigative	Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum. J Nat Prod. 2005 Oct;68(10):1514-8.
PT00015	M6APDG02328	2,6-dihydroxy-1,7-dimethoxyxanthone	CID: 5326145	Investigative	Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum. J Nat Prod. 2005 Oct;68(10):1514-8.
PT00011	M6APDG01567	PNU-107859	CID: 4369084	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00175	M6APDG01567	PNU-107859	CID: 4369084	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00012	M6APDG02493	Roche 28-2653	CID: 56603788	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00011	M6APDG02493	Roche 28-2653	CID: 56603788	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00012	M6APDG02153	5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione	CID: 49292	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00011	M6APDG02153	5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione	CID: 49292	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00012	M6APDG02786	5-Methyl-5-phenyl-pyrimidine-2,4,6-trione	CID: 66160	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00012	M6APDG02404	5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione	CID: 53742316	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00012	M6APDG01688	5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione	CID: 44385624	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00011	M6APDG01688	5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione	CID: 44385624	Investigative	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
PT00079	M6APDG00121	SCH-546909	CID: 10356352	Investigative	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
PT00078	M6APDG00651	10Z-Hymenialdisine	CID: 135413546	Investigative	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
PT00123	M6APDG00008	GSK-3beta inhibitor XI	CID: 10020713	Investigative	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
PT00079	M6APDG01352	NSC-625987	CID: 3004085	Investigative	5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4.
PT00080	M6APDG01352	NSC-625987	CID: 3004085	Investigative	5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4.
PT00080	M6APDG03262	Ro-0505124	CID: 9911652	Investigative	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9.
PT00199	M6APDG00791	reglitazar	CID: 154000	Investigative	Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995 Oct 13;270(41):23975-83.
PT00175	M6APDG01566	PNU-142372	CID: 4369080	Investigative	Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2 P3 Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996).
PT00172	M6APDG01646	N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3	CID: 44324667	Investigative	Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2 P3 Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996).
PT00175	M6APDG01642	Ro-37-9790	CID: 44313734	Investigative	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6.
PT00174	M6APDG00971	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol	CID: 19366816	Investigative	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6.
PT00172	M6APDG00971	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol	CID: 19366816	Investigative	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6.
PT00206	M6APDG01003	Ro 40-6055	CID: 2126	Investigative	A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7129-33.
PT00206	M6APDG02316	Ro 41-5253	CID: 5312120	Investigative	Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58.
PT00155	M6APDG00307	SB-747651A	CID: 11393719	Investigative	3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett. 2001 Mar 12;11(5):635-9.
PT00143	M6APDG00792	C(-GRGDfL-)	CID: 15409414	Investigative	Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalan... Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6.
PT00035	M6APDG00937	tagitinin A	CID: 181254	Investigative	Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol. 2003 Apr;17(4):662-76.
PT00014	M6APDG00913	Acetate Ion	CID: 175	Investigative	Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry. 2001 Nov 13;40(45):13448-55.
PT00147	M6APDG02082	AdoCGlyArg6	CID: 46877398	Investigative	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
PT00147	M6APDG02076	AdoC(Ahx)Arg6	CID: 46877390	Investigative	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
PT00147	M6APDG02078	AdoC(Aoc)Arg6	CID: 46877392	Investigative	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
PT00147	M6APDG02080	AdoC(Aun)Arg6	CID: 46877396	Investigative	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
PT00147	M6APDG02083	AdoC(GABA)Arg6	CID: 46877400	Investigative	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
PT00147	M6APDG02079	AdoC(Dpr)2AlaArg6	CID: 46877395	Investigative	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
PT00147	M6APDG02081	AdoC(beta-Ala)Arg6	CID: 46877397	Investigative	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
PT00147	M6APDG01689	AdcAhxArg4Lys-PEGOMe	CID: 44387499	Investigative	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
PT00147	M6APDG02084	AdoC(betaAsp)2AlaArg6	CID: 46877402	Investigative	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
PT00005	M6APDG02469	GARCINONE D	CID: 5495926	Investigative	Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod. 2008 Jul;71(7):1161-6.
PT00005	M6APDG00529	5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one	CID: 12050204	Investigative	Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod. 2008 Jul;71(7):1161-6.
PT00213	M6APDG02222	splitomicin	CID: 5269	Investigative	Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6.
PT00144	M6APDG00792	C(-GRGDfL-)	CID: 15409414	Investigative	Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2329-33.
PT00038	M6APDG00203	GNF-PF-1399	CID: 107464	Investigative	Clinical pipeline report, company report or official report of Gastroenterology.
PT00046	M6APDG01996	Apogossypol	CID: 454878	Investigative	Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001 Dec 6;44(25):4313-24.
PT00214	M6APDG02009	GNF-PF-2272	CID: 460747	Investigative	Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 2006 Feb;69(2):597-607.
PT00044	M6APDG02787	bisphenol A	CID: 6623	Investigative	Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30.
PT00191	M6APDG01581	desmosterol	CID: 439577	Investigative	A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58.
PT00196	M6APDG02312	HKI-9924129	CID: 5311104	Investigative	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
PT00196	M6APDG02340	4-Benzoimidazol-1-yl-phenylamine	CID: 5328453	Investigative	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
PT00197	M6APDG02340	4-Benzoimidazol-1-yl-phenylamine	CID: 5328453	Investigative	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
PT00196	M6APDG02341	5-Methoxy-1-phenyl-1H-benzoimidazole	CID: 5328466	Investigative	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
PT00197	M6APDG02341	5-Methoxy-1-phenyl-1H-benzoimidazole	CID: 5328466	Investigative	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
PT00197	M6APDG00617	Bis(5-methoxybenzo[b]furan-2-yl)methanone	CID: 13454368	Investigative	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
PT00196	M6APDG02342	4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine	CID: 5328512	Investigative	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
PT00197	M6APDG01381	3-(4-dimethylamino-benzylidenyl)-2-indolinone	CID: 3135	Investigative	Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
PT00070	M6APDG02671	Ac-DEVD-CHO	CID: 644345	Investigative	Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol. 2006 Oct;2(10):543-50.
PT00073	M6APDG02086	RESCOVITINE	CID: 46881287	Investigative	Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
PT00197	M6APDG02312	HKI-9924129	CID: 5311104	Investigative	Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endo... Bioorg Med Chem. 2010 May 15;18(10):3575-87.
PT00050	M6APDG02312	HKI-9924129	CID: 5311104	Investigative	Cochliobolic acid, a novel metabolite produced by Cochliobolus lunatus, inhibits binding of TGF-alpha to the EGF receptor in a SPA assay. J Nat Prod. 1997 Jan;60(1):6-8.
PT00071	M6APDG02286	GNF-PF-5434	CID: 5287864	Investigative	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9.
PT00185	M6APDG00507	Gly-Hyp-Glu	CID: 11902976	Investigative	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
PT00185	M6APDG01205	Gly-Pip-Glu	CID: 25055596	Investigative	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
PT00185	M6APDG01742	Phe-Pro-Glu	CID: 44408683	Investigative	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
PT00185	M6APDG01743	Nle-Pro-Glu	CID: 44408687	Investigative	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
PT00185	M6APDG01745	Gly-b7Pro-Glu	CID: 44408837	Investigative	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
PT00185	M6APDG00304	(D)-Ala-Pro-Glu	CID: 11370470	Investigative	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
PT00185	M6APDG00939	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline	CID: 18326767	Investigative	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
PT00185	M6APDG01638	3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid	CID: 44289108	Investigative	New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.
PT00185	M6APDG01477	TRANSTORINE	CID: 3845	Investigative	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
PT00185	M6APDG00353	H-Gly-dmP-Glu-OH	CID: 11515428	Investigative	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37.
PT00185	M6APDG01744	Gly-Amp-Glu	CID: 44408739	Investigative	2-carboxy indolines and indoles as potential glycine/NMDA antagonists: effect of five-membered ring conformation on affinity. Bioorg. Med. Chem. Lett. 2(12):1627-1630 (1992).
PT00170	M6APDG02214	Oxindole 94	CID: 5169	Investigative	Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
PT00170	M6APDG00449	N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CID: 11703439	Investigative	Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
PT00170	M6APDG01727	N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CID: 44405448	Investigative	Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
PT00170	M6APDG01728	N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide	CID: 44405454	Investigative	Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
PT00015	M6APDG02214	Oxindole 94	CID: 5169	Investigative	SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Pharm Res. 2001 Sep;18(9):1336-44.
PT00079	M6APDG02086	RESCOVITINE	CID: 46881287	Investigative	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
PT00079	M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	CID: 2752461	Investigative	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
PT00075	M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 11572699	Investigative	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
PT00123	M6APDG00133	Manzamine Y	CID: 10393120	Investigative	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40.
PT00123	M6APDG02107	N,8-diphenyl-9H-purin-6-amine	CID: 46894037	Investigative	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40.
PT00123	M6APDG00057	8-O-(4-toluenesulfonyl)manzamine A	CID: 101437199	Investigative	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40.
PT00123	M6APDG01088	8-O-(4-chlorobenzenesulfonyl)manzamine F	CID: 23643731	Investigative	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40.
PT00123	M6APDG02689	Manzamine E	CID: 6474830	Investigative	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
PT00123	M6APDG02704	MANZAMINE A	CID: 6509753	Investigative	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
PT00123	M6APDG01820	6-deoxymanzamine X	CID: 44445400	Investigative	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
PT00123	M6APDG01090	12,13-DEHYDROMANZAMINE A	CID: 23643835	Investigative	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
PT00123	M6APDG01086	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CID: 23643537	Investigative	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
PT00123	M6APDG01087	9-N-METHYL-8-METHOXY-MANZAMINE A	CID: 23643639	Investigative	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
PT00123	M6APDG01091	12,13-DEHYDRO-8-O-ACETYLMANZAMINE A	CID: 23643836	Investigative	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
PT00123	M6APDG01089	8-O-(4-bromobenzenesulfonyl)manzamine F	CID: 23643732	Investigative	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
PT00229	M6APDG00913	Acetate Ion	CID: 175	Investigative	2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther. 2008 Jan;7(1):143-51.
PT00175	M6APDG03230	PKF-242-484	CID: 9886977	Investigative	Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31.
PT00011	M6APDG01730	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CID: 44406790	Investigative	Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31.
PT00104	M6APDG02693	ASN-11124542	CID: 6490494	Investigative	Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett. 2011 Jul 1;21(13):4108-14.
PT00125	M6APDG02640	PSAMMAPLIN A	CID: 6400741	Investigative	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
PT00125	M6APDG02957	santacruzamate A	CID: 72946782	Investigative	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
PT00125	M6APDG01661	1,1,1-Trifluoro-8-phenoxy-octan-2-one	CID: 44342886	Investigative	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
PT00125	M6APDG03307	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	CID: 9965141	Investigative	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
PT00125	M6APDG01066	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CID: 22915465	Investigative	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
PT00125	M6APDG01663	8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one	CID: 44343094	Investigative	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
PT00125	M6APDG01659	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	CID: 44342825	Investigative	Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7.
PT00070	M6APDG01268	Glionitrin A	CID: 25243252	Investigative	Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science. 2003 Jan 10;299(5604):223-6.
PT00001	M6APDG02997	benzylserine	CID: 78457	Investigative	A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646.
PT00185	M6APDG01340	Cycloleucine	CID: 2901	Investigative	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
PT00185	M6APDG03128	2-(4-Phenoxy-benzyl)-1H-benzoimidazole	CID: 9817808	Investigative	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
PT00185	M6APDG03112	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol	CID: 9796984	Investigative	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
PT00185	M6APDG03171	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol	CID: 9839919	Investigative	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
PT00185	M6APDG03225	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine	CID: 9883372	Investigative	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
PT00185	M6APDG03116	6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole	CID: 9797585	Investigative	NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96.
PT00022	M6APDG01242	GSK-1838705A	CID: 25182616	Investigative	Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology. 1997 Apr;138(4):1427-33.
PT00015	M6APDG01995	Nectamazin C	CID: 45487137	Investigative	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
PT00015	M6APDG01836	OCOPHYLLALS A	CID: 44470605	Investigative	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
PT00015	M6APDG02513	2'-hydroxy-3,4,5-trimethoxychalcone	CID: 5709436	Investigative	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
PT00015	M6APDG00267	NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B	CID: 11243755	Investigative	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
PT00243	M6APDG02075	SYMBIOPOLYOL	CID: 46872950	Investigative	US patent application no. 6,312,900, Antisense oligonucleotide compositions and methods for the modulation of activating protein 1.
PT00123	M6APDG02261	ELLAGIC ACID	CID: 5281855	Investigative	Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93.
PT00123	M6APDG02108	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CID: 46894038	Investigative	Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93.
PT00123	M6APDG02179	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CID: 49863103	Investigative	Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93.
PT00213	M6APDG00673	Meta-sirtinol	CID: 135461039	Investigative	Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005 Dec 15;48(25):8045-54.
PT00204	M6APDG02309	Asp-BrPmp-Leu	CID: 52949968	Investigative	CD45 / PTPRC Antibody, Biotin conjugate (OX-30).
PT00191	M6APDG01897	Guttiferone I	CID: 44584005	Investigative	Piperazine derivatives as liver X receptor modulators. US10144715.
PT00020	M6APDG03311	PIPERNONALINE	CID: 9974595	Investigative	ISIS 2302. INXC ICAM1, Oligo-TCS. Drugs R D. 1999 Jan;1(1):85-6.
PT00050	M6APDG01483	LAVENDUSTIN A	CID: 3894	Investigative	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
PT00050	M6APDG01814	6,7-diethoxy-4-styrylquinazoline	CID: 44442181	Investigative	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
PT00050	M6APDG00957	6,7-dimethoxy-4-(2-phenylethynyl)quinazoline	CID: 18770812	Investigative	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
PT00050	M6APDG01815	6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline	CID: 44442182	Investigative	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
PT00050	M6APDG01816	6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline	CID: 44442183	Investigative	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
PT00050	M6APDG01813	4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline	CID: 44442180	Investigative	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
PT00050	M6APDG01812	6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline	CID: 44442168	Investigative	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
PT00185	M6APDG02685	PHENCYCLIDINE	CID: 6468	Investigative	3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
PT00185	M6APDG03007	6-Chloro-1,4-dihydro-quinoxaline-2,3-dione	CID: 81143	Investigative	3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6.
PT00015	M6APDG01837	Ocophyllals b	CID: 44470606	Investigative	1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51.
PT00015	M6APDG03019	THIOCTIC ACID	CID: 864	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG01377	4-(benzylideneamino)benzenesulfonamide	CID: 308405	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG01831	4-phenyliminomethyl-benzenesulfonamide	CID: 44456679	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG00999	4-(3-nitro-benzylideneamino)-benzenesulfonamide	CID: 21177358	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG02486	4-(4-nitro-benzylideneamino)-benzenesulfonamide	CID: 564225	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG02840	4-(4-methyl-benzylideneamino)-benzenesulfonamide	CID: 690836	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG01023	4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide	CID: 21862753	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG01024	4-(4-methyl-phenyliminomethyl)-benzenesulfonamide	CID: 21862824	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG01511	4-(4-hydroxy-benzylideneamino)-benzenesulfonamide	CID: 404202	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG01513	4-(3-methoxy-benzylideneamino)-benzenesulfonamide	CID: 404378	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG01517	4-(3-hydroxy-benzylideneamino)-benzenesulfonamide	CID: 405560	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00015	M6APDG02621	4-(4-methoxy-benzylideneamino)-benzenesulfonamide	CID: 625902	Investigative	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
PT00162	M6APDG00852	NDP-alpha-MSH	CID: 16154396	Investigative	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
PT00199	M6APDG01917	Deoxy-Bigchap	CID: 446320	Investigative	Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81.
PT00208	M6APDG02768	Ruthenium red	CID: 656819	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00208	M6APDG01626	GLYCYLRYANODINE	CID: 44275859	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00208	M6APDG01625	ANHYDRORYANIDINE	CID: 44275813	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00208	M6APDG01629	(O10eq)-beta-alanylryanodine	CID: 44275867	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00208	M6APDG01634	N-methyl ryanodine-succinamidate	CID: 44275929	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00208	M6APDG01627	Benzyloxycarbonyl-glycylryanodine	CID: 44275860	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00208	M6APDG01633	(O10eq)-beta-alanyl-anhydro-ryanodine	CID: 44275928	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00208	M6APDG01632	(O10eq)-beta-guanidinopropionylryanodine	CID: 44275926	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00208	M6APDG01628	(O10eq)-Benzyloxycarbonyl-beta-alanylryanodine	CID: 44275861	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00208	M6APDG01631	Di-Benzyloxycarbonyl-guanidino acetylryanodine	CID: 44275895	Investigative	Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23.
PT00014	M6APDG01406	THIOCITRULLINE	CID: 3353976	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG00580	Pyrrolidin-(2Z)-ylideneamine	CID: 12778904	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG01694	N-(5-Amino-6-oxo-heptyl)-acetamidine	CID: 44393463	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG00581	5-Methyl-pyrrolidin-(2Z)-ylideneamine	CID: 12778906	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG00815	4-Methyl-pyrrolidin-(2Z)-ylideneamine	CID: 15887953	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG03289	3-Methyl-pyrrolidin-(2Z)-ylideneamine	CID: 9942127	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG00087	4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine	CID: 10261068	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG00968	3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine	CID: 19049163	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG00134	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine	CID: 10396852	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG00928	5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine	CID: 17892465	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG00966	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine	CID: 19049121	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00014	M6APDG00967	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine	CID: 19049158	Investigative	Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
PT00044	M6APDG01240	[3H]mibolerone	CID: 251636	Investigative	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009538)
PT00005	M6APDG00620	ANDROSTENEDONE	CID: 13472	Investigative	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
PT00005	M6APDG00725	3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione	CID: 13660218	Investigative	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
PT00005	M6APDG00724	3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione	CID: 13660216	Investigative	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
PT00005	M6APDG00726	3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione	CID: 13660221	Investigative	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
PT00005	M6APDG01445	3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione	CID: 360578	Investigative	Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9.
PT00166	M6APDG00970	Benzylcysteine	CID: 193613	Investigative	Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-... J Med Chem. 1998 Feb 12;41(4):503-8.
PT00166	M6APDG00931	6-Allyloxy-9H-purin-2-ylamine	CID: 179571	Investigative	Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-... J Med Chem. 1998 Feb 12;41(4):503-8.
PT00166	M6APDG03197	6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine	CID: 9860003	Investigative	Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-... J Med Chem. 1998 Feb 12;41(4):503-8.
PT00044	M6APDG01240	[3H]mibolerone	CID: 251636	Investigative	Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009 Jun 25;52(12):3597-617.
PT00123	M6APDG00015	LEUCETTAMINE B	CID: 10037501	Investigative	Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
PT00123	M6APDG02711	PYRAZOLOPYRIDAZINE 2	CID: 6539367	Investigative	Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
PT00123	M6APDG00035	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CID: 10085059	Investigative	Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
PT00103	M6APDG00632	leucettine L41	CID: 135398522	Investigative	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
PT00103	M6APDG02912	WO2013026806C72 	CID: 71529770	Investigative	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
PT00044	M6APDG00001	Palodesangren D	CID: 10005461	Investigative	Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002.
PT00044	M6APDG00085	Palodesangren E	CID: 10255841	Investigative	Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002.
PT00044	M6APDG00196	Palodesangren C	CID: 10696160	Investigative	Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002.
PT00044	M6APDG01758	6,11-dihydrothiochromeno[4,3-b]indol-8-ol	CID: 44411868	Investigative	Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002.
PT00144	M6APDG01467	ISONIPECOTAMIDE	CID: 3772	Investigative	1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2619-22.
PT00150	M6APDG00730	2'-Deoxyuridine	CID: 13712	Investigative	Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010 Nov;6(11):1691-710.
PT00078	M6APDG02184	9-Nitropaullone	CID: 5005498	Investigative	M-phase regulation of the recruitment of mRNAs onto polysomes using the CDK1/cyclin B inhibitor aminopurvalanol. Biochem Biophys Res Commun. 2003 Jul 11;306(4):880-6.
PT00193	M6APDG00873	3-aminobenzamide	CID: 1645	Investigative	Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3. J Med Chem. 2013 Dec 12;56(23):9556-68.
PT00166	M6APDG01127	S-Methylcysteine	CID: 24417	Investigative	Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)gua... J Med Chem. 2000 Nov 2;43(22):4071-83.
PT00170	M6APDG02623	B-Octylglucoside	CID: 62852	Investigative	Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc Res. 2003 Oct 1;59(4):893-900.
PT00015	M6APDG02623	B-Octylglucoside	CID: 62852	Investigative	Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. 2000 Apr 1;60(7):1805-9.
PT00162	M6APDG00086	His-DPhe-Arg-Trp	CID: 10258635	Investigative	Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
PT00162	M6APDG00415	C[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2	CID: 11629290	Investigative	Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
PT00005	M6APDG00056	Isogemichalcone C	CID: 10143276	Investigative	Screening of herbal constituents for aromatase inhibitory activity. Bioorg Med Chem. 2008 Sep 15;16(18):8466-70.
PT00005	M6APDG03242	2-phenyl-2,3-dihydrobenzo[h]chromen-4-one	CID: 9898204	Investigative	Screening of herbal constituents for aromatase inhibitory activity. Bioorg Med Chem. 2008 Sep 15;16(18):8466-70.
PT00078	M6APDG02782	aminopurvalanol A	CID: 6604931	Investigative	A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54.
PT00079	M6APDG02782	aminopurvalanol A	CID: 6604931	Investigative	A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54.
PT00050	M6APDG02679	Cochliobolic acid	CID: 6450172	Investigative	Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45.
PT00080	M6APDG03000	N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide	CID: 787236	Investigative	Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45.
PT00015	M6APDG00511	Nitroflurbiprofen	CID: 119387	Investigative	Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther. 2004 Apr;3(4):417-24.
PT00011	M6APDG01621	Clinopodic acid C	CID: 44254596	Investigative	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6.
PT00012	M6APDG02707	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	CID: 651854	Investigative	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6.
PT00011	M6APDG02661	Lithospermic acid	CID: 6441498	Investigative	Matrix metalloproteinase-2 inhibitors from Clinopodium chinense var. parviflorum. J Nat Prod. 2009 Aug;72(8):1379-84.
PT00183	M6APDG01970	muramyl dipeptide	CID: 451714	Investigative	TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7.
PT00055	M6APDG00950	(-)-hydroxycitrate	CID: 185620	Investigative	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
PT00167	M6APDG00230	Phosphonothreonine	CID: 10976469	Investigative	Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. Bioorg Med Chem Lett. 2006 Jan 1;16(1):55-8.
PT00185	M6APDG01763	H-Gly-D-dmP-Glu-OH	CID: 44413487	Investigative	The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400.
PT00185	M6APDG01644	7-chloro-3-hydroxyquinazoline-2,4-dione	CID: 44315786	Investigative	The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400.
PT00015	M6APDG02636	2'-Hydroxychalcone	CID: 638276	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00015	M6APDG02615	4-benzyloxy-2'-hydroxychalcone	CID: 6172473	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00015	M6APDG02583	2,4-dimethoxy-2'-hydroxychalcone	CID: 6041429	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00015	M6APDG02628	2,3-dimethoxy-2'-hydroxychalcone	CID: 6296545	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00015	M6APDG01269	3,4-dibenzyloxy-2'-hydroxychalcone	CID: 25256831	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00015	M6APDG02989	3-Bromo-2'-hydroxy-4-methoxychalcone	CID: 7729032	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00015	M6APDG01887	6,7'-oxybis(2-phenyl-4H-chromen-4-one)	CID: 44569786	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00015	M6APDG01045	1-(4-(methylsulfonyl)phenyl)-1H-pyrrole	CID: 22316981	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00015	M6APDG00575	3-benzyloxy-4-methoxy-2'-hydroxychalcone	CID: 12681944	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00015	M6APDG02406	1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one	CID: 5376916	Investigative	Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
PT00079	M6APDG02146	Cdk4 inhibitor III	CID: 481747	Investigative	Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem. 2000 Jun 29;43(13):2506-13.
PT00079	M6APDG02639	Double Oxidized Cysteine	CID: 6398956	Investigative	Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem. 2000 Jun 29;43(13):2506-13.
PT00043	M6APDG00626	Akt inhibitor VIII	CID: 135398501	Investigative	DOI: 10.1016/S1359-6349(10)71767-5
PT00193	M6APDG01425	3-Hydroxy-benzamide	CID: 342403	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00098	2H-Isoquinolin-1-one	CID: 10284	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00674	2,8-Dimethyl-3H-quinazolin-4-one	CID: 135463574	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG01859	2-Benzyl-2H-indazole-7-carboxamide	CID: 44549372	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00695	8-Methyl-2-phenyl-3H-quinazolin-4-one	CID: 135531482	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00648	8-Methoxy-2-methyl-3H-quinazolin-4-one	CID: 135411146	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00661	8-Methoxy-2-phenyl-3H-quinazolin-4-one	CID: 135439437	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00694	8-Hydroxy-2-phenyl-3H-quinazolin-4-one	CID: 135528341	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00671	8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one	CID: 135457978	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00675	2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one	CID: 135463623	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00655	8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	CID: 135417274	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00680	2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one	CID: 135471356	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00686	8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	CID: 135492389	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00644	2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one	CID: 135407310	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00193	M6APDG00679	2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one	CID: 135471354	Investigative	Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56.
PT00114	M6APDG02648	(-)-CATECHINGALLATE	CID: 6419835	Investigative	3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4620-3.
PT00114	M6APDG02225	GALLOCATECHIN GALLATE	CID: 5276890	Investigative	3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4620-3.
PT00144	M6APDG00550	Gly-Arg-Gly-Asp-Ser	CID: 123811	Investigative	Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65.
PT00071	M6APDG03013	Diphenylacetic Acid	CID: 8333	Investigative	Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I). Bioorg Med Chem Lett. 2004 Oct 18;14(20):5113-6.
PT00123	M6APDG00631	indirubin deriv. 8a	CID: 135398521	Investigative	The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92.
PT00044	M6APDG01283	[3H]methyltrienolone	CID: 261000	Investigative	Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol. 2004 Feb 12;214(1-2):175-87.
PT00005	M6APDG00478	ALPHA-NAPHTHOFLAVONE	CID: 11790	Investigative	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
PT00005	M6APDG01095	1-Naphthalen-2-yl-1H-imidazole	CID: 23644748	Investigative	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
PT00005	M6APDG00348	3-(6-methoxynaphthalen-2-yl)pyridine	CID: 11506923	Investigative	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
PT00005	M6APDG00382	3-(6-Ethoxy-naphthalen-2-yl)-pyridine	CID: 11557864	Investigative	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
PT00005	M6APDG00408	3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine	CID: 11616637	Investigative	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42.
PT00005	M6APDG01270	MONODICTYOCHROMONE B	CID: 25256842	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG00220	6-Imidazol-1-yl-isoquinoline	CID: 10845522	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG02104	1-(2-phenoxybenzyl)-1H-imidazole	CID: 46889432	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG02067	4-Imidazol-1-ylmethylxanthen-9-one	CID: 46867542	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG02070	1-Imidazol-1-ylmethylxanthen-9-one	CID: 46867545	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG02068	4-Imidazol-1-ylmethylthioxanthen-9-one	CID: 46867543	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG02071	1-(4-nitro-2-phenoxybenzyl)-1H-imidazole	CID: 46867546	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG02064	4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one	CID: 46867416	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG02065	4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one	CID: 46867417	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG02066	4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one	CID: 46867540	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00005	M6APDG02072	1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole	CID: 46867547	Investigative	Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. 
PT00144	M6APDG01750	Cypate-[(RGD)2-NH2]1	CID: 44409497	Investigative	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
PT00144	M6APDG03066	Cypate-[(RGD)2-NH2]2	CID: 91936295	Investigative	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
PT00144	M6APDG03067	Cypate-[(RGD)3-NH2]2	CID: 91936296	Investigative	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
PT00144	M6APDG03068	Cypate-[(RGD)4-NH2]2	CID: 91936297	Investigative	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
PT00144	M6APDG03069	Cypate-[(RGD)3-NH2]1	CID: 91936298	Investigative	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
PT00144	M6APDG03070	Cypate-[(RGD)4-NH2]1	CID: 91936299	Investigative	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
PT00144	M6APDG01749	Cyclo(RGDfV) (control)	CID: 44409460	Investigative	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
PT00144	M6APDG01771	3-(3-(carbamoyl)benzamido)propanoic acid	CID: 44418280	Investigative	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
PT00144	M6APDG01751	Cyclo[RGDfK(cypate)]	CID: 44409643	Investigative	Emerging targets in osteoporosis disease modification. J Med Chem. 2010 Jun 10;53(11):4332-53.
PT00176	M6APDG00809	2-Sulfhydryl-Ethanol	CID: 1567	Investigative	Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9.
PT00176	M6APDG01277	6,7-dibromoquinoline-5,8-dione	CID: 255964	Investigative	Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9.
PT00176	M6APDG01752	3-isopropyl-4-(phenylthio)naphthalene-1,2-dione	CID: 44409669	Investigative	Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9.
PT00185	M6APDG02960	1,3-ditolylguanidine	CID: 7333	Investigative	Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52.
PT00128	M6APDG00809	2-Sulfhydryl-Ethanol	CID: 1567	Investigative	Avontec Announces Results of a Multiple Dose Clinical Phase I Study with Its Drug Candidate AVT-02 UE Ointment After Topical Treatment in Male Healthy Volunteers. Avontec. 2008.
PT00015	M6APDG02239	Alpha-linolenic acid	CID: 5280934	Investigative	The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3271-4.
PT00162	M6APDG03074	GPYRMEHFRWGSPPKD-NH2	CID: 91936746	Investigative	Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4973-8.
PT00162	M6APDG02984	1-Benzyl-4-methyl-piperazine	CID: 763557	Investigative	Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4973-8.
PT00045	M6APDG02784	quinazoline deriv. 1	CID: 6610278	Investigative	Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
PT00080	M6APDG02711	PYRAZOLOPYRIDAZINE 2	CID: 6539367	Investigative	Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27.
PT00080	M6APDG02374	1-Pyridin-2-yl-3-quinolin-5-yl-urea	CID: 5330598	Investigative	Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27.
PT00080	M6APDG02373	1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea	CID: 5330597	Investigative	Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27.
PT00080	M6APDG02371	1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea	CID: 5330595	Investigative	Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27.
PT00199	M6APDG00926	eicosatetranoic acid	CID: 1780	Investigative	Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. J Med Chem. 2004 May 6;47(10):2422-5.
PT00028	M6APDG01762	PLSQETFSDLWKLLPEN-NH2	CID: 44412124	Investigative	Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening str... J Med Chem. 2006 Jun 29;49(13):3759-62.
PT00005	M6APDG02471	Docosapentaenoic acid	CID: 5497182	Investigative	Org 33201: a new highly selective orally active aromatase inhibitor. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):681-2.
PT00078	M6APDG01460	Indirubin-5-sulfonate	CID: 3708	Investigative	SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Biochem Biophys Res Commun. 2003 Oct 24;310(3):1026-31.
PT00191	M6APDG00556	27-hydroxycholesterol	CID: 123976	Investigative	Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
PT00191	M6APDG03167	2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione	CID: 983732	Investigative	Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
PT00167	M6APDG01115	Bisindolylmaleimide-I	CID: 2396	Investigative	Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21.
PT00015	M6APDG02532	3,4-dihydroxyxanthone	CID: 5748382	Investigative	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
PT00147	M6APDG02077	AdoC(beta-Ala)2AlaArg6	CID: 46877391	Investigative	Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and... J Biol Chem. 1996 Oct 18;271(42):26157-64.
PT00150	M6APDG00952	6-Hydroxypropylthymine	CID: 1865	Investigative	Crystal structure of varicella zoster virus thymidine kinase. J Biol Chem. 2003 Jul 4;278(27):24680-7.
PT00169	M6APDG00411	Aminopyridine deriv. 2	CID: 11624601	Investigative	Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
PT00153	M6APDG00391	8-Octyl-benzolactam-V9	CID: 11574614	Investigative	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
PT00191	M6APDG00899	22R-hydroxycholesterol	CID: 167685	Investigative	Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat Chem Biol. 2013 Feb;9(2):126-33.
PT00191	M6APDG01179	4-dehydroxyriccardin C	CID: 24860513	Investigative	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
PT00191	M6APDG01177	17-dehydroxyriccardin C	CID: 24860511	Investigative	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
PT00191	M6APDG01178	12-dehydroxyriccardin C	CID: 24860512	Investigative	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
PT00191	M6APDG01181	4,17-dehydroxyriccardin C	CID: 24860515	Investigative	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
PT00191	M6APDG01180	12,17-dehydroxyriccardin C	CID: 24860514	Investigative	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
PT00191	M6APDG01182	4,12,17-dehydroxyriccardin C	CID: 24860516	Investigative	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
PT00191	M6APDG00184	2-(2-phenethylphenyl)isoindoline-1,3-dione	CID: 10616182	Investigative	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
PT00191	M6APDG01810	5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione	CID: 44440475	Investigative	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
PT00070	M6APDG01560	Ac-Asp-Glu-Val-Asp-CHO	CID: 4330	Investigative	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
PT00070	M6APDG00188	Isoquinoline-1,3,4(2H)-trione	CID: 10640	Investigative	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
PT00070	M6APDG00417	2-allylisoquinoline-1,3,4-trione	CID: 11629882	Investigative	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
PT00070	M6APDG00302	2-benzylisoquinoline-1,3,4-trione	CID: 11357566	Investigative	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
PT00070	M6APDG00429	2-phenethylisoquinoline-1,3,4-trione	CID: 11652039	Investigative	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
PT00070	M6APDG00441	2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione	CID: 11680763	Investigative	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
PT00070	M6APDG00358	2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione	CID: 11522185	Investigative	Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23.
PT00123	M6APDG02713	GSK-3beta inhibitor II	CID: 6539732	Investigative	Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Bioorg Med Chem. 2004 Jun 15;12(12):3167-85.
PT00054	M6APDG03042	6-Phosphogluconic Acid	CID: 91493	Investigative	Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. Bioorg Med Chem. 2010 Jul 15;18(14):5056-62. 
PT00193	M6APDG00776	Quinoline-8-carboxamide	CID: 150664	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG00991	5-aminoisoquinolin-1(2H)-one	CID: 2072	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG01258	2-ethylquinoline-8-carboxamide	CID: 25208752	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG01259	3-Ethylquinoline-8-carboxamide	CID: 25208904	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG01001	2-Methylquinoline-8-carboxamide	CID: 21195867	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG01255	3-Methylquinoline-8-carboxamide	CID: 25208598	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG01600	2-phenylquinoline-8-carboxamide	CID: 44156952	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG01256	3-Ethynylquinoline-8-carboxamide	CID: 25208746	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG01257	3-Ethenylquinoline-8-carboxamide	CID: 25208747	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG01260	3-Prop-1-ynylquinoline-8-carboxamide	CID: 25208905	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG00052	2,3-dihydro-1H-benzo[de]isoquinolin-1-one	CID: 10130246	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00193	M6APDG01261	2-(4-methoxyphenyl)quinoline-8-carboxamide	CID: 25209058	Investigative	Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77.
PT00040	M6APDG01468	2-Propanol, Isopropanol	CID: 3776	Investigative	A novel anti-rheumatic drug suppresses tumor necrosis factor-alpha and augments interleukin-10 in adjuvant arthritic rats. Eur J Pharmacol. 2000 Dec 15;409(3):331-5.
PT00191	M6APDG03158	acetyl-podocarpic dimer	CID: 9830426	Investigative	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 602).
PT00071	M6APDG00366	Cbz-Ile-Leu-Ala-LeuVSMe	CID: 11534625	Investigative	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
PT00071	M6APDG00444	Ac-hPhe-Leu-Phe-LeuVSMe	CID: 11693148	Investigative	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
PT00071	M6APDG00410	PTosyl-Glu(OtBu)-Ala-LeuVSMe	CID: 11621347	Investigative	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
PT00071	M6APDG00352	Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe	CID: 11513217	Investigative	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
PT00071	M6APDG00024	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate	CID: 10062714	Investigative	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68.
PT00071	M6APDG00378	Ac-hPhe-Leu-Ala-LeuVSMe	CID: 11556056	Investigative	The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33.
PT00162	M6APDG00238	Ac-His-DPhe-Arg-Trp-NH2	CID: 11093672	Investigative	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
PT00162	M6APDG01818	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2	CID: 44445084	Investigative	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
PT00162	M6APDG01149	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	CID: 24774519	Investigative	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
PT00162	M6APDG01817	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	CID: 44445083	Investigative	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
PT00162	M6APDG01819	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	CID: 44445085	Investigative	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
PT00014	M6APDG00645	N-omega-allyl-L-arginine	CID: 135409360	Investigative	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
PT00014	M6APDG02299	N5-(1-iminobutyl)-L-ornithine	CID: 5289555	Investigative	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
PT00014	M6APDG01900	N5-(1-iminopropyl)-L-ornithine	CID: 44593548	Investigative	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
PT00014	M6APDG03064	N5-(1-iminobut-3-enyl)-L-ornithine	CID: 91935539	Investigative	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
PT00014	M6APDG01548	6-(3-Fluoropropyl)-4-methylpyridin-2-amine	CID: 42625617	Investigative	Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
PT00014	M6APDG00786	2-amino-4-methylpyridine	CID: 1533	Investigative	Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8.
PT00014	M6APDG02999	2-Methyl-2,4-Pentanediol	CID: 7870	Investigative	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
PT00014	M6APDG03108	Azepan-(2Z)-ylideneamine	CID: 9793728	Investigative	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
PT00014	M6APDG01069	[1,3]Oxazinan-(2E)-ylideneamine	CID: 23042899	Investigative	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
PT00014	M6APDG00068	2-Amino-5-(N-nitro-guanidino)-pentanoic acid	CID: 10198326	Investigative	2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
PT00041	M6APDG02953	2-aminophenoxazine-3-one	CID: 72725	Investigative	APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64.
PT00125	M6APDG00283	6-Phenoxy-hexane-1-thiol	CID: 11298778	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00320	N-(6-Mercapto-hexyl)-benzamide	CID: 11447748	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00241	8-Mercapto-octanoic acid phenylamide	CID: 11149404	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00317	6-Mercapto-hexanoic acid phenylamide	CID: 11436024	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00305	7-Mercapto-heptanoic acid phenylamide	CID: 11379392	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00401	5-Mercapto-pentanoic acid phenylamide	CID: 11608171	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG01716	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CID: 44401339	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00297	7-Mercapto-heptanoic acid pyridin-3-ylamide	CID: 11345433	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00130	7-Mercapto-heptanoic acid quinolin-3-ylamide	CID: 10379373	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00259	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CID: 11220728	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00298	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CID: 11346934	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG01660	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	CID: 44342872	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00263	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	CID: 11231829	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00125	M6APDG00270	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CID: 11254470	Investigative	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
PT00191	M6APDG00539	24(S)-hydroxycholesterol	CID: 121948	Investigative	27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87.
PT00012	M6APDG01756	Carboxylated glucosamine	CID: 44411803	Investigative	Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100.
PT00011	M6APDG00403	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CID: 11609208	Investigative	Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100.
PT00197	M6APDG00082	3-((E)-Styryl)-quinoline	CID: 10243001	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00196	M6APDG00081	3-Thiophen-3-yl-quinoline	CID: 10242258	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00196	M6APDG00117	7-Chloro-3-pyridin-4-yl-quinoline	CID: 10354294	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00196	M6APDG00682	3-Pyridin-4-yl-quinoline-5,7-diol	CID: 135474209	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00197	M6APDG00117	7-Chloro-3-pyridin-4-yl-quinoline	CID: 10354294	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00197	M6APDG00682	3-Pyridin-4-yl-quinoline-5,7-diol	CID: 135474209	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00196	M6APDG00116	6-Methoxy-3-pyridin-4-yl-quinoline	CID: 10354094	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00197	M6APDG00116	6-Methoxy-3-pyridin-4-yl-quinoline	CID: 10354094	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00196	M6APDG00022	6,7-Dimethoxy-3-pyridin-4-yl-quinoline	CID: 10061448	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00196	M6APDG01383	5,7-Dimethoxy-3-pyridin-4-yl-quinoline	CID: 3139	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00197	M6APDG00022	6,7-Dimethoxy-3-pyridin-4-yl-quinoline	CID: 10061448	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00197	M6APDG03317	5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline	CID: 9994707	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00196	M6APDG00460	6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline	CID: 11722903	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00197	M6APDG00033	3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline	CID: 10083699	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00197	M6APDG00460	6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline	CID: 11722903	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00196	M6APDG03309	3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline	CID: 9971060	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00196	M6APDG00018	3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline	CID: 10040402	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00197	M6APDG00018	3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline	CID: 10040402	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00050	M6APDG02344	2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile	CID: 5328753	Investigative	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
PT00162	M6APDG01765	C(his-D-phe-arg-trp-Ahp)	CID: 44413536	Investigative	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
PT00162	M6APDG01766	C(his-D-phe-arg-trp-Ahx)	CID: 44413537	Investigative	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
PT00162	M6APDG01767	C(his-D-phe-arg-trp-Abu)	CID: 44413577	Investigative	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
PT00162	M6APDG01748	Tic-D-Phe-Arg-2-Nal-NHCH3	CID: 44409257	Investigative	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
PT00162	M6APDG01732	C[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]	CID: 44406905	Investigative	Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6.
PT00162	M6APDG01768	C(his-L-phe-arg-trp-Aoc)	CID: 44413592	Investigative	Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic ap... J Med Chem. 2006 Jul 27;49(15):4745-61.
PT00045	M6APDG03065	7-bromoindirubin-3-oxime	CID: 91936028	Investigative	Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem. 2006 Feb 9;49(3):955-70.
PT00054	M6APDG00234	(2R)-2-Methyl-4,5-dideoxy	CID: 11064567	Investigative	Sugar derivatives as new 6-phosphogluconate dehydrogenase inhibitors selective for the parasite Trypanosoma brucei. Bioorg Med Chem. 2003 Apr 3;11(7):1207-14.
PT00144	M6APDG03063	E[c(RGDyK)]2-PTX conjugate	CID: 91933274	Investigative	Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32.
PT00125	M6APDG02979	N-(2-aminophenyl)benzamide	CID: 759408	Investigative	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.
PT00125	M6APDG01549	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CID: 42632368	Investigative	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.
PT00125	M6APDG01067	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CID: 22915475	Investigative	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.
PT00125	M6APDG00826	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CID: 15986510	Investigative	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.
PT00191	M6APDG01390	24(S), 25-epoxycholesterol	CID: 3247059	Investigative	Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997 Feb 7;272(6):3137-40.
PT00196	M6APDG02591	1-Phenyl-1H-benzoimidazole	CID: 606669	Investigative	Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov;22(4):449-58.
PT00197	M6APDG00077	Di(1H-indol-2-yl)methanone	CID: 10220822	Investigative	Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
PT00014	M6APDG03016	Piperidin-(2E)-ylideneamine	CID: 85237	Investigative	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
PT00014	M6APDG00794	[1,4]Thiazepan-(5E)-ylideneamine	CID: 15463447	Investigative	Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
PT00025	M6APDG00338	5-phenyl-1H-indazol-3-amine	CID: 11492186	Investigative	Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41.
PT00146	M6APDG00834	6-o-tolylquinazolin-2-amine	CID: 16086113	Investigative	Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41.
PT00005	M6APDG00488	3-(naphthalen-2-yl)pyridine	CID: 11845485	Investigative	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
PT00005	M6APDG00944	5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one	CID: 18407230	Investigative	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
PT00005	M6APDG01082	1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole	CID: 23585406	Investigative	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
PT00005	M6APDG01094	2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one	CID: 23644623	Investigative	In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
PT00005	M6APDG00496	3-(imidazolylmethyl)flavone	CID: 11847316	Investigative	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
PT00005	M6APDG00497	3-(imidazolylmethyl)-4'-nitroflavone	CID: 11847317	Investigative	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
PT00005	M6APDG00498	4'-bromo-3-(imidazolylmethyl)flavone	CID: 11847318	Investigative	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
PT00005	M6APDG00499	4'-cyano-3-(imidazolylmethyl)flavone	CID: 11847319	Investigative	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
PT00005	M6APDG00500	3-(imidazolylmethyl)-4'-methoxyflavone	CID: 11847320	Investigative	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
PT00005	M6APDG02761	3-(3,4-dihydronaphthalen-2-yl)pyridine	CID: 6540047	Investigative	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
PT00005	M6APDG00494	4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone	CID: 11847170	Investigative	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
PT00005	M6APDG00495	4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone	CID: 11847171	Investigative	Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80.
PT00144	M6APDG01168	Cyclo-[-Arg-Gly-Asp-Amp25-]	CID: 24822784	Investigative	Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90.
PT00014	M6APDG00692	N-omega-propargyl-L-arginine	CID: 135512453	Investigative	Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem. 2008 Jun 1;16(11):5962-73.
PT00014	M6APDG01431	S-Ethyl-N-Phenyl-Isothiourea	CID: 347590	Investigative	Endothelial nitric oxide synthase: the Cinderella of inflammation Trends Pharmacol Sci. 2003 Feb;24(2):91-5.
PT00150	M6APDG01274	L-5-(bromovinyl)deoxyuridine	CID: 25323027	Investigative	3'-[4-Aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine analogues as potent and selective inhibitors of human mitochondrial thymidine kinase. J Med Chem. 2010 Apr 8;53(7):2902-12.
PT00046	M6APDG01470	4,5-dibenzylbenzene-1,2-diol	CID: 379493	Investigative	The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther. 2004 Dec;3(12):1513-24.
PT00068	M6APDG02523	isoxazole azepine compound 3	CID: 57345400	Investigative	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012 Nov 26;55(22):9831-7.
PT00125	M6APDG01345	8-Oxo-8-phenyl-octanoic acid	CID: 298878	Investigative	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
PT00125	M6APDG00229	Octanedioic acid hydroxyamide pyridin-4-ylamide	CID: 10967421	Investigative	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
PT00125	M6APDG00363	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CID: 11528707	Investigative	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
PT00125	M6APDG03223	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	CID: 9882812	Investigative	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
PT00125	M6APDG00237	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CID: 11086699	Investigative	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
PT00073	M6APDG01999	6-O-Cyclohexylmethyl Guanine	CID: 4564	Investigative	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
PT00073	M6APDG02359	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	CID: 5329516	Investigative	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
PT00079	M6APDG02359	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	CID: 5329516	Investigative	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
PT00073	M6APDG02358	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	CID: 5329512	Investigative	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
PT00079	M6APDG02358	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	CID: 5329512	Investigative	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
PT00079	M6APDG02361	6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine	CID: 5329597	Investigative	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93.
PT00050	M6APDG02778	Benzyl-quinazolin-4-yl-amine	CID: 6603129	Investigative	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38.
PT00050	M6APDG00446	4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline	CID: 11696664	Investigative	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38.
PT00015	M6APDG00907	N-(1H-indazol-5-yl)acetamide	CID: 17164245	Investigative	Cyclooxygenase (COX)-1 and -2 inhibitory labdane diterpenes from Crassocephalum mannii. J Nat Prod. 2008 Jun;71(6):1070-3.
PT00015	M6APDG01866	CLEMATOMANDSHURICA SAPONIN A	CID: 44559170	Investigative	Triterpene saponins from clematis mandshurica. J Nat Prod. 2006 Nov;69(11):1591-5.
PT00015	M6APDG00262	3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone	CID: 11231439	Investigative	Triterpene saponins from clematis mandshurica. J Nat Prod. 2006 Nov;69(11):1591-5.
PT00162	M6APDG01747	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3	CID: 44409240	Investigative	Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5.
PT00162	M6APDG01769	Ac-His-D-Phe-Arg-2-Nal-NHCH3	CID: 44413876	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG02961	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2	CID: 73347136	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG00367	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2	CID: 11535237	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG00397	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2	CID: 11593084	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG00451	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2	CID: 11707715	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG01738	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2	CID: 44408408	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG00343	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	CID: 11498895	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG00356	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2	CID: 11520823	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG00416	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2	CID: 11629326	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG00436	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2	CID: 11672424	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG00447	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	CID: 11700730	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG00448	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2	CID: 11700739	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG01737	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2	CID: 44408400	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00162	M6APDG01741	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	CID: 44408515	Investigative	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
PT00174	M6APDG01495	1-Methyloxy-4-Sulfone-Benzene	CID: 3952261	Investigative	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
PT00173	M6APDG02886	N-[(4-methoxyphenyl)sulfonyl]-D-alanine	CID: 705712	Investigative	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
PT00173	M6APDG03168	3-Benzenesulfonyl-heptanoic acid hydroxyamide	CID: 9838786	Investigative	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
PT00174	M6APDG03168	3-Benzenesulfonyl-heptanoic acid hydroxyamide	CID: 9838786	Investigative	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
PT00172	M6APDG03126	3-Benzenesulfinyl-heptanoic acid hydroxyamide	CID: 9816867	Investigative	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
PT00172	M6APDG03168	3-Benzenesulfonyl-heptanoic acid hydroxyamide	CID: 9838786	Investigative	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
PT00172	M6APDG00974	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID	CID: 194777	Investigative	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
PT00125	M6APDG00292	N-(2-aminophenyl)nicotinamide	CID: 1133083	Investigative	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
PT00125	M6APDG01830	N-(4-hydroxybiphenyl-3-yl)benzamide	CID: 44454650	Investigative	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
PT00125	M6APDG01828	N-(4-aminobiphenyl-3-yl)nicotinamide	CID: 44454415	Investigative	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
PT00125	M6APDG00825	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CID: 15986508	Investigative	Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
PT00125	M6APDG01073	Cyclostellettamine derivative	CID: 23327627	Investigative	Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5.
PT00125	M6APDG01657	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	CID: 44341224	Investigative	Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5.
PT00125	M6APDG01324	4-Phenylbutyrohydroxamic acid	CID: 279980	Investigative	Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309.
PT00175	M6APDG01495	1-Methyloxy-4-Sulfone-Benzene	CID: 3952261	Investigative	A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics s... J Med Chem. 2004 Jun 3;47(12):3065-74.
PT00011	M6APDG02404	5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione	CID: 53742316	Investigative	A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics s... J Med Chem. 2004 Jun 3;47(12):3065-74.
PT00147	M6APDG00633	Cyclic Guanosine Monophosphate	CID: 135398570	Investigative	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
PT00078	M6APDG02708	Thieno analogue of kenpaullone	CID: 6538761	Investigative	4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70.
PT00078	M6APDG00947	4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile	CID: 18516979	Investigative	4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70.
PT00196	M6APDG02800	1-Phenyl-1H-benzoimidazol-5-ol	CID: 667662	Investigative	Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1999 Jul 1;42(13):2373-82.
PT00197	M6APDG02800	1-Phenyl-1H-benzoimidazol-5-ol	CID: 667662	Investigative	Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1999 Jul 1;42(13):2373-82.
PT00001	M6APDG02891	p-nitrophenyl glutamyl anilide	CID: 7090494	Investigative	New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak. J Physiol. 2004 Jun 15;557(Pt 3):747-59.
PT00071	M6APDG01674	Z-Arg-Leu-Val-Agly-Val-Ala-NH2	CID: 44355111	Investigative	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
PT00015	M6APDG00129	5-Ethyl-3,4-diphenyl-isoxazole	CID: 10377376	Investigative	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
PT00015	M6APDG02058	Resveratrol Potassium3-Sulfate	CID: 46855054	Investigative	Nitrogen-containing phorbol esters from Croton ciliatoglandulifer and their effects on cyclooxygenases-1 and -2. J Nat Prod. 2006 Jun;69(6):887-90.
PT00123	M6APDG02708	Thieno analogue of kenpaullone	CID: 6538761	Investigative	2-N-Methyl modifications and SAR studies of manzamine A. Bioorg Med Chem. 2008 Jul 15;16(14):6702-6.
PT00092	M6APDG02224	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	CID: 5275843	Investigative	Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
PT00014	M6APDG01699	[1,4]Oxazepan-(3E)-ylideneamine	CID: 44396203	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00014	M6APDG01700	[1,4]Thiazepan-(3E)-ylideneamine	CID: 44396204	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00014	M6APDG00201	4-Ethyl-pyrrolidin-(2Z)-ylideneamine	CID: 10725313	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00014	M6APDG01698	(5-Imino-[1,4]thiazepan-3-yl)-methanol	CID: 44396191	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00014	M6APDG00954	3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine	CID: 18721724	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00014	M6APDG00805	7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	CID: 15552206	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00014	M6APDG00953	2-Methyl-[1,4]thiazepan-(5E)-ylideneamine	CID: 18721719	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00014	M6APDG00955	3-Methyl-[1,4]thiazepan-(5E)-ylideneamine	CID: 18721726	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00014	M6APDG00070	(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine	CID: 10198539	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00014	M6APDG00319	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid	CID: 11446787	Investigative	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
PT00005	M6APDG00960	7-hydroxy-2-phenylchroman-4-one	CID: 1890	Investigative	Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3.
PT00005	M6APDG00218	7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one	CID: 10823163	Investigative	Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3.
PT00005	M6APDG00092	1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole	CID: 10267149	Investigative	Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3.
PT00005	M6APDG00714	3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione	CID: 13596072	Investigative	Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3.
PT00005	M6APDG02408	3-Nitro-4'-nitro-trans-stilbene	CID: 5377857	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02549	3-Amino-4'-amino-trans-stilbene	CID: 5844100	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG00751	4-(3,4-Dimethoxyphenethyl)aniline	CID: 14256024	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02660	3-Methoxyl-4'-amino-trans-stilbene	CID: 6440384	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG00708	3,4'-(Ethane-1,2-diyl)dibenzenamine	CID: 13580711	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02164	3,5-Diamino-4'-amino-trans-stilbene	CID: 49798900	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG01449	4-(3,4,5-Trimethoxyphenethyl)aniline	CID: 364705	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG00752	4-(3,5-Dimethoxyphenethyl)benzenamine	CID: 14256034	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG00959	3,5-Dimethoxy-4'-amino-trans-stilbene	CID: 18785180	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02163	3,5-Diacetoxy-4'-amino-trans-stilbene	CID: 49798801	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02165	2,4-Dimethoxy-3'-amino-trans-stilbene	CID: 49799639	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02166	2,3-Dimethoxy-4'-amino-trans-stilbene	CID: 49799640	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02167	3,4-Dimethoxy-4'-amino-trans-stilbene	CID: 49799648	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02170	2,4-Dimethoxy-4'-amino-trans-stilbene	CID: 49799655	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02407	2,5-Dimethoxy-4'-amino-trans-stilbene	CID: 5377410	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02012	3,5-Dihydroxyl-4'-amino-trans-stilbene	CID: 46191176	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG00811	3,4,5-Trimethoxy-4'-amino-trans-stilbene	CID: 15696376	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02168	3,4,5-Trimethoxy-3'-amino-trans-stilbene	CID: 49799650	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02169	2,3,4-Trimethoxy-4'-amino-trans-stilbene	CID: 49799652	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02171	2,3,5-Trimethoxy-4'-amino-trans-stilbene	CID: 49799657	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02192	Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine	CID: 508445	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00005	M6APDG02394	2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone	CID: 53600	Investigative	Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. 
PT00015	M6APDG02059	Resveratrol Potassium4,-Sulfate	CID: 46855201	Investigative	Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43.
PT00015	M6APDG00591	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one	CID: 13015959	Investigative	Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43.
PT00014	M6APDG03193	4-methyl-6-propylpyridin-2-amine	CID: 9855524	Investigative	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
PT00014	M6APDG01898	3-Bromo-1H-indazole-7-carbonitrile	CID: 44585510	Investigative	Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
PT00025	M6APDG02972	1,2,3,4,5,6-hexabromocyclohexane	CID: 74603	Investigative	Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem. 2004 Aug 13;279(33):34547-52.
PT00050	M6APDG02655	4-(2-nitrovinyl)benzene-1,2-diol	CID: 6439158	Investigative	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
PT00015	M6APDG00577	2-(p-Methylsulfonylbenzoyl)furan	CID: 12701751	Investigative	Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low... J Med Chem. 2010 Nov 11;53(21):7879-82.
PT00162	M6APDG03076	Ser-Tyr-Ser-Nle-Glu-His-Dphe-Arg	CID: 91971100	Investigative	Squalene-derived flexible linkers for bioactive peptides. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3310-3.
PT00162	M6APDG01687	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2	CID: 44366173	Investigative	Squalene-derived flexible linkers for bioactive peptides. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3310-3.
PT00029	M6APDG01888	C-16-(S)-3-methylindolerapamycin	CID: 44576240	Investigative	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
PT00029	M6APDG00712	2-(6-morpholino-9H-purin-2-yl)phenol	CID: 135955185	Investigative	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
PT00029	M6APDG00713	4-(6-morpholino-9H-purin-2-yl)phenol	CID: 135955186	Investigative	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
PT00029	M6APDG00830	3-(6-morpholino-9H-purin-2-yl)phenol	CID: 16049458	Investigative	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
PT00029	M6APDG01217	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CID: 25074312	Investigative	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
PT00029	M6APDG02039	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CID: 46225260	Investigative	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
PT00029	M6APDG01214	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CID: 25069592	Investigative	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
PT00125	M6APDG01827	N-(4-aminobiphenyl-3-yl)benzamide	CID: 44454143	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02217	Octanedioic acid bis-hydroxyamide	CID: 5173	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02052	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	CID: 46830327	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02053	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CID: 46830328	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02092	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CID: 46887334	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02101	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CID: 46887439	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02054	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CID: 46830345	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02091	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CID: 46887333	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02093	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CID: 46887378	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02095	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CID: 46887380	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02096	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CID: 46887381	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02099	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CID: 46887437	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02094	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CID: 46887379	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02100	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CID: 46887438	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00125	M6APDG02102	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CID: 46887475	Investigative	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
PT00070	M6APDG00905	2-methylisoquinoline-1,3,4-trione	CID: 1714901	Investigative	Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7.
PT00070	M6APDG03170	5-(azepan-1-ylsulfonyl)indoline-2,3-dione	CID: 9839586	Investigative	Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7.
PT00070	M6APDG03247	5-(azetidin-1-ylsulfonyl)indoline-2,3-dione	CID: 9903426	Investigative	Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7.
PT00070	M6APDG01532	5-(piperidin-1-ylsulfonyl)indoline-2,3-dione	CID: 4117383	Investigative	Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7.
PT00050	M6APDG00678	3-Pyridin-4-yl-quinoline-6,7-diol	CID: 135469328	Investigative	Novel antiproliferative agents derived from lavendustin A. J Med Chem. 1994 Nov 25;37(24):4079-84.
PT00050	M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	CID: 2752461	Investigative	5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9.
PT00185	M6APDG01065	2-Methylamino-succinic acid(NMDA)	CID: 22880	Investigative	Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6.
PT00080	M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	CID: 2752461	Investigative	Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem. 2008 Aug 15;16(16):7728-39.
PT00175	M6APDG00923	8-chloro-quinoline-3-carbonitrile	CID: 17759555	Investigative	Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1970-6.
PT00231	M6APDG01308	3,4-diphenyl-1H-pyrrole-2,5-dione	CID: 2752461	Investigative	Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55.
PT00014	M6APDG00067	6-isobutyl-4-methylpyridin-2-amine	CID: 10197851	Investigative	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
PT00014	M6APDG01547	6-(2-Fluoropropyl)-4-methylpyridin-2-amine	CID: 42625451	Investigative	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
PT00014	M6APDG01801	1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea	CID: 44430622	Investigative	Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
PT00193	M6APDG01858	2-phenyl-2H-indazole-7-carboxamide	CID: 44549251	Investigative	Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett. 2010 Jan 15;20(2):448-52.
PT00193	M6APDG00940	5-amino-3,4-dihydroisoquinolin-1(2H)-one	CID: 18369509	Investigative	Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett. 2010 Jan 15;20(2):448-52.
PT00125	M6APDG00485	4-Benzoylamino-N-hydroxy-benzamide	CID: 11817702	Investigative	Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetyla... Eur J Med Chem. 2009 Nov;44(11):4470-6.
PT00012	M6APDG01799	Methotrexate gamma-hydroxamic acid	CID: 44428664	Investigative	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
PT00011	M6APDG01798	Folate gamma-L-proline-hydroxamic acid	CID: 44428663	Investigative	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
PT00012	M6APDG01821	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	CID: 44446270	Investigative	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
PT00011	M6APDG01821	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	CID: 44446270	Investigative	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
PT00035	M6APDG02662	2-chloro-5-nitro-N-phenylbenzamide	CID: 644213	Investigative	A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999 Nov 15;59(22):5671-3.
PT00015	M6APDG01529	2-Phenyl-1,2-dihydro-indazol-3-one	CID: 411519	Investigative	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
PT00015	M6APDG01974	2,4'-Dimethoxy-5,3'-dipropyl-biphenyl	CID: 45267390	Investigative	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
PT00015	M6APDG02306	(E)-2-(4-(methylsulfonyl)styryl)furan	CID: 52946891	Investigative	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
PT00015	M6APDG02195	(E)-2-(4-(methylsulfonyl)styryl)thiophene	CID: 50908698	Investigative	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
PT00015	M6APDG02308	(E)-3-(4-(methylsulfonyl)styryl)thiophene	CID: 52949357	Investigative	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
PT00015	M6APDG02307	(E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide	CID: 52946892	Investigative	Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
PT00015	M6APDG01530	2-Benzyl-1,2-dihydro-indazol-3-one	CID: 411523	Investigative	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
PT00015	M6APDG01619	(Z)-2'-des-methyl sulindac sulfide	CID: 44224199	Investigative	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
PT00015	M6APDG02555	2-Methyl-1,2-dihydro-indazol-3-one	CID: 590513	Investigative	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
PT00015	M6APDG00768	2-Phenethyl-1,2-dihydro-indazol-3-one	CID: 14898714	Investigative	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
PT00015	M6APDG00813	5-Phenyl-pentanoic acid benzyl-hydroxy-amide	CID: 157806	Investigative	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
PT00015	M6APDG00770	2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one	CID: 14898717	Investigative	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
PT00015	M6APDG02194	(E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide	CID: 50908697	Investigative	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
PT00015	M6APDG00771	2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one	CID: 14898720	Investigative	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
PT00015	M6APDG01871	4,5-Bis(4-chlorophenyl)isothiazole	CID: 44564456	Investigative	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
PT00015	M6APDG01870	4,5-Bis(4-methoxyphenyl)isothiazole	CID: 44564415	Investigative	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
PT00015	M6APDG01612	1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate	CID: 44219619	Investigative	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
PT00057	M6APDG00207	Inositol 1,3,4,5-Tetrakisphosphate	CID: 107758	Investigative	The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9.
PT00162	M6APDG01435	Melanocortin-4 Receptor antagonist	CID: 3496888	Investigative	Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor. Bioorg Med Chem. 2007 Mar 1;15(5):1989-2005.
PT00193	M6APDG00172	Benzo[c][1,5]naphthyridin-6(5H)-one	CID: 10535869	Investigative	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
PT00193	M6APDG00943	Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	CID: 18382004	Investigative	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
PT00193	M6APDG01860	2-(2-Chlorophenyl)-2H-indazole-7-carboxamide	CID: 44549373	Investigative	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
PT00193	M6APDG01861	2-(3-Chlorophenyl)-2H-indazole-7-carboxamide	CID: 44549374	Investigative	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
PT00193	M6APDG01862	2-(4-Chlorophenyl)-2H-indazole-7-carboxamide	CID: 44549375	Investigative	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
PT00193	M6APDG02172	2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide	CID: 49799912	Investigative	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
PT00193	M6APDG01863	2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide	CID: 44549505	Investigative	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85.
PT00005	M6APDG02714	3-Indan-(1E)-ylidenemethyl-pyridine	CID: 6539759	Investigative	Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg Med Chem. 2005 Jun 2;13(12):4063-70.
PT00044	M6APDG00349	2-chloro-4-(o-tolyloxy)benzonitrile	CID: 11507014	Investigative	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
PT00044	M6APDG01883	3-methoxy-4-(p-tolyloxy)benzonitrile	CID: 44565152	Investigative	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
PT00044	M6APDG00956	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane	CID: 18728	Investigative	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
PT00044	M6APDG01557	4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile	CID: 43138559	Investigative	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
PT00044	M6APDG01885	4-(mesitylthio)-2-(trifluoromethyl)benzonitrile	CID: 44565205	Investigative	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
PT00044	M6APDG01878	4-(isopentylthio)-2-(trifluoromethyl)benzonitrile	CID: 44564659	Investigative	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8.
PT00044	M6APDG00437	3-chloro-4-(o-tolyloxy)benzonitrile	CID: 11673174	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01874	4-(butylthio)-2-methoxybenzonitrile	CID: 44564582	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG00381	3-methoxy-4-(o-tolyloxy)benzonitrile	CID: 11557752	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG00456	2-methoxy-4-(o-tolyloxy)benzonitrile	CID: 11715659	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01873	2-methoxy-4-(propylthio)benzonitrile	CID: 44564581	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01880	2-methoxy-4-(m-tolyloxy)benzonitrile	CID: 44565104	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01881	2-methoxy-4-(p-tolyloxy)benzonitrile	CID: 44565150	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01882	3-methoxy-4-(m-tolyloxy)benzonitrile	CID: 44565151	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01872	4-(mesitylthio)-2-methoxybenzonitrile	CID: 44564580	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01602	4-(isopropylthio)-2-methoxybenzonitrile	CID: 44157042	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01877	4-(isopentylthio)-2-methoxybenzonitrile	CID: 44564585	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01220	2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile	CID: 25093227	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01563	4-(butylthio)-2-(trifluoromethyl)benzonitrile	CID: 43615786	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01886	2-methoxy-4-(2-methoxyphenylthio)benzonitrile	CID: 44565206	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG00402	4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile	CID: 11608821	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01558	4-(propylthio)-2-(trifluoromethyl)benzonitrile	CID: 43138589	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01561	4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile	CID: 43320723	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01876	4-(cyclobutylmethylthio)-2-methoxybenzonitrile	CID: 44564584	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01875	4-(cyclopropylmethylthio)-2-methoxybenzonitrile	CID: 44564583	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01884	4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile	CID: 44565202	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01601	4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile	CID: 44157041	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00044	M6APDG01603	4-(isopropylthio)-2-(trifluoromethyl)benzonitrile	CID: 44157043	Investigative	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3.
PT00185	M6APDG00167	N,N'-Bis-(4-butyl-phenyl)-guanidine	CID: 10496171	Investigative	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
PT00185	M6APDG00760	N,N'-Bis-(4-ethyl-phenyl)-guanidine	CID: 14771671	Investigative	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
PT00185	M6APDG03138	N,N'-Bis-(4-hexyl-phenyl)-guanidine	CID: 9821194	Investigative	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
PT00185	M6APDG00183	N,N'-Bis-(4-butoxy-phenyl)-guanidine	CID: 10594376	Investigative	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
PT00185	M6APDG00739	N,N'-Bis-(4-isopropyl-phenyl)-guanidine	CID: 13781937	Investigative	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
PT00185	M6APDG03295	6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole	CID: 9950054	Investigative	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
PT00185	M6APDG01643	6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	CID: 44315523	Investigative	Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302.
PT00138	M6APDG00314	5-Bromo-6-methoxy-9H-beta-carboline	CID: 11414735	Investigative	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
PT00138	M6APDG02885	2-amino-5-phenylthiophene-3-carboxamide	CID: 703965	Investigative	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
PT00138	M6APDG00398	4-amino-biphenyl-3-carboxylic acid amide	CID: 11600944	Investigative	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
PT00138	M6APDG00344	6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine	CID: 11499583	Investigative	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
PT00138	M6APDG02218	2-amino-quinoline-3-carboxylic acid amide	CID: 5200228	Investigative	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
PT00138	M6APDG00452	5-amino-2-phenyl-oxazole-4-carboxylic acid amide	CID: 11708263	Investigative	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
PT00138	M6APDG00373	5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide	CID: 11543063	Investigative	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
PT00138	M6APDG03010	3-amino-benzo[b]thiophene-2-carboxylic acid amide	CID: 821974	Investigative	Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
PT00014	M6APDG00938	N-(Chlorophenyl)-N'-Hydroxyguanidine	CID: 181426	Investigative	Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med. 2007;45(12):1683-7.
PT00125	M6APDG02998	N-(2-aminophenyl)-4-methoxybenzamide	CID: 785232	Investigative	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
PT00125	M6APDG01207	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CID: 25065710	Investigative	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
PT00185	M6APDG02433	3-phenyl-4-hydroxyquinolin-2(1H)-one	CID: 54677756	Investigative	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
PT00185	M6APDG03219	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline	CID: 9877750	Investigative	4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
PT00015	M6APDG01085	2-(2,3,4-trimethoxyphenyl)-1H-indene	CID: 23627032	Investigative	Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90.
PT00015	M6APDG01806	2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid	CID: 44434501	Investigative	Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90.
PT00092	M6APDG00293	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CID: 11331592	Investigative	Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4124-9.
PT00173	M6APDG01991	5-(biphenyl-4-yl)-3-oxopentanoic acid	CID: 45483008	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00173	M6APDG00983	2-(2-(biphenyl-4-yl)ethylthio)acetic acid	CID: 20348772	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00173	M6APDG01990	5-(biphenyl-4-yl)-3-methoxypentanoic acid	CID: 45482998	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00173	M6APDG01007	2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid	CID: 21496278	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00173	M6APDG01992	2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid	CID: 45483015	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00174	M6APDG01992	2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid	CID: 45483015	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00173	M6APDG01843	N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide	CID: 44479457	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00174	M6APDG00061	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CID: 10155934	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00012	M6APDG00061	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CID: 10155934	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00011	M6APDG00061	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CID: 10155934	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00173	M6APDG01912	5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	CID: 44626352	Investigative	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
PT00193	M6APDG00709	5-Chloro-2-methyl-3H-quinazolin-4-one	CID: 135875707	Investigative	Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J Med Chem. 2004 Oct 21;47(22):5467-81.
PT00005	M6APDG00476	4-Imidazol-1-yl-2-phenyl-chroman-7-ol	CID: 11779089	Investigative	6 beta-Propynyl-substituted steroids: mechanism-based enzyme-activated irreversible inhibitors of aromatase. J Med Chem. 1997 Sep 26;40(20):3263-70.
PT00150	M6APDG00839	1-[7-(triphenylmethoxy)heptyl]thymine	CID: 16098874	Investigative	Synthesis, in vitro, and in silico evaluation of organometallic technetium and rhenium thymidine complexes with retained substrate activity toward ... J Med Chem. 2008 Nov 13;51(21):6689-98.
PT00125	M6APDG01210	N8,2-dihydroxy-N1-phenyloctanediamide	CID: 25065929	Investigative	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
PT00125	M6APDG00256	N-Hydroxy-4-phenylacetylamino-benzamide	CID: 11196500	Investigative	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
PT00125	M6APDG01211	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CID: 25065930	Investigative	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
PT00125	M6APDG01208	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CID: 25065713	Investigative	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
PT00125	M6APDG01212	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CID: 25065931	Investigative	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
PT00125	M6APDG01209	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CID: 25065925	Investigative	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5.
PT00005	M6APDG00486	4-(1-Imidazol-1-yl-vinyl)-benzonitrile	CID: 11819989	Investigative	Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem. 1991 Feb;34(2):725-36.
PT00005	M6APDG00181	3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one	CID: 10588478	Investigative	Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem. 1991 Feb;34(2):725-36.
PT00241	M6APDG00878	1-guanidino-7-isoquinolinesulphonamide	CID: 16658352	Investigative	Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
PT00241	M6APDG02925	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	CID: 716930	Investigative	Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
PT00241	M6APDG00879	4-chloro-1-guanidino-7-isoquinolinesulphonamide	CID: 16658353	Investigative	Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
PT00015	M6APDG01192	4,5-Bis(4-chlorophenyl)-1,2-selenazole	CID: 24884694	Investigative	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
PT00015	M6APDG01188	4,5-Bis(4-methoxyphenyl)-1,2-selenazole	CID: 24884690	Investigative	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
PT00015	M6APDG01190	5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole	CID: 24884692	Investigative	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
PT00015	M6APDG01191	4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole	CID: 24884693	Investigative	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
PT00015	M6APDG01805	2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid	CID: 44434500	Investigative	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
PT00015	M6APDG01839	N-(3-phenylamino-4-pyridinyl)methanesulfonamide	CID: 44475843	Investigative	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
PT00162	M6APDG01604	AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2	CID: 44158031	Investigative	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
PT00005	M6APDG02109	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine	CID: 46901444	Investigative	Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J Nat Prod. 2006 Apr;69(4):700-3.
PT00005	M6APDG02757	5-Indan-(1E)-ylidenemethyl-1H-imidazole	CID: 6540032	Investigative	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
PT00005	M6APDG02758	5-Indan-(1Z)-ylidenemethyl-1H-imidazole	CID: 6540033	Investigative	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
PT00005	M6APDG00727	3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione	CID: 13660225	Investigative	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
PT00005	M6APDG02759	5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole	CID: 6540042	Investigative	Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805.
PT00241	M6APDG00911	4-iodobenzo[b]thiophene 2-carboxamidine	CID: 1746	Investigative	Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):491-5.
PT00197	M6APDG00399	Bis-(5-hydroxy-1H-indol-2-yl)-methanone	CID: 11601743	Investigative	Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8.
PT00185	M6APDG00607	4-Benzyl-1-(2-phenoxy-ethyl)-piperidine	CID: 1328600	Investigative	Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1619-24.
PT00170	M6APDG03003	N-(4-methyl-benzyl)-4-phenoxy-benzamide	CID: 7916852	Investigative	A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5383-7.
PT00015	M6APDG03258	Primary alcohol metabolite of celecoxib	CID: 9908776	Investigative	Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
PT00015	M6APDG00721	(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid	CID: 13640140	Investigative	Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
PT00015	M6APDG00723	(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid	CID: 13640144	Investigative	Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
PT00174	M6APDG00049	N1,N3-bis(3-methoxybenzyl)isophthalamide	CID: 10111838	Investigative	Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13. Bioorg Med Chem Lett. 2009 Jan 1;19(1):47-50.
PT00125	M6APDG01715	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CID: 44401305	Investigative	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
PT00125	M6APDG03276	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	CID: 9927379	Investigative	Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
PT00073	M6APDG02360	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	CID: 5329517	Investigative	Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.
PT00079	M6APDG02360	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	CID: 5329517	Investigative	Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.
PT00185	M6APDG00583	4,6-Dichloro-1H-indole-2-carboxylic acid	CID: 127988	Investigative	Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41.
PT00231	M6APDG02895	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	CID: 712152	Investigative	A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6.
PT00092	M6APDG02150	viral macrophage inflammatory protein-II	CID: 486830	Investigative	Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.
PT00133	M6APDG00691	7n-Methyl-8-Hydroguanosine-5'-Diphosphate	CID: 135509116	Investigative	J Clin Oncol 33, 2015 (suppl; abstr 2533).
PT00125	M6APDG00236	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CID: 11075845	Investigative	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
PT00125	M6APDG01829	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CID: 44454416	Investigative	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
PT00125	M6APDG00421	6-phenylsulfanylhexanoic acid hydroxamide	CID: 11637291	Investigative	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
PT00125	M6APDG00389	6-benzenesulfonylhexanoic acid hydroxamide	CID: 11572583	Investigative	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
PT00125	M6APDG01375	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	CID: 3082127	Investigative	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
PT00197	M6APDG00618	Bis(5-hydroxybenzo[b]furan-2-yl)methanone	CID: 13454380	Investigative	Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
PT00185	M6APDG00223	4-[3-(4-Phenyl-butylamino)-propyl]-phenol	CID: 10853103	Investigative	Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52.
PT00015	M6APDG01823	1-(4-(methylsulfonyl)phenyl)-3-phenylurea	CID: 44447099	Investigative	Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9.
PT00015	M6APDG00722	(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid	CID: 13640143	Investigative	Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9.
PT00123	M6APDG01047	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CID: 22319484	Investigative	Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9.
PT00123	M6APDG01050	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CID: 22319580	Investigative	Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9.
PT00123	M6APDG01046	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CID: 22319483	Investigative	Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9.
PT00014	M6APDG00128	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine	CID: 10375155	Investigative	Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropy... Bioorg Med Chem Lett. 2002 Sep 2;12(17):2291-4.
PT00014	M6APDG01641	4-Methyl-3,6-dihydro-1H-pyridin-(2Z)-ylideneamine	CID: 44313256	Investigative	Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropy... Bioorg Med Chem Lett. 2002 Sep 2;12(17):2291-4.
PT00014	M6APDG03109	4-Methyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine	CID: 9793827	Investigative	Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropy... Bioorg Med Chem Lett. 2002 Sep 2;12(17):2291-4.
PT00241	M6APDG00934	(2R)-1-(2,6-dimethylphenoxy)propan-2-amine	CID: 180621	Investigative	Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
PT00241	M6APDG02816	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	CID: 674651	Investigative	Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
PT00125	M6APDG00445	6-benzenesulfinylhexanoic acid hydroxamide	CID: 11694528	Investigative	Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
PT00125	M6APDG01101	N-(2-aminophenyl)quinoxaline-6-carboxamide	CID: 23648267	Investigative	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
PT00125	M6APDG01138	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CID: 24759251	Investigative	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
PT00012	M6APDG01845	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CID: 44479701	Investigative	Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7.
PT00050	M6APDG00483	N4-(3-chlorophenyl)quinazoline-4,6-diamine	CID: 11807783	Investigative	Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35.
PT00050	M6APDG01121	N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine	CID: 2426	Investigative	Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35.
PT00015	M6APDG00243	N-(3-phenoxy-4-pyridinyl)ethanesulfonamide	CID: 11150126	Investigative	Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4440-3.
PT00015	M6APDG01515	4-((4-methoxyphenyl)diazenyl)benzenesulfonamide	CID: 405489	Investigative	Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4440-3.
PT00173	M6APDG01730	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CID: 44406790	Investigative	Synthesis of novel ageladine A analogs showing more potent matrix metalloproteinase (MMP)-12 inhibitory activity than the natural product. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5461-3.
PT00044	M6APDG00956	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane	CID: 18728	Investigative	Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3233-7.
PT00044	M6APDG01759	11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol	CID: 44411876	Investigative	Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3233-7.
PT00005	M6APDG00224	1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one	CID: 10853186	Investigative	Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. J Med Chem. 2007 Jun 14;50(12):2799-806.
PT00005	M6APDG02180	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine	CID: 49864181	Investigative	Monodictyochromes A and B, dimeric xanthone derivatives from the marine algicolous fungus Monodictys putredinis. J Nat Prod. 2008 Nov;71(11):1793-9.
PT00241	M6APDG02815	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	CID: 674641	Investigative	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
PT00241	M6APDG02817	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	CID: 674656	Investigative	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
PT00241	M6APDG02878	4-methoxy-N'-(2-phenylacetyl)benzohydrazide	CID: 695069	Investigative	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
PT00241	M6APDG02881	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	CID: 699665	Investigative	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
PT00241	M6APDG02814	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	CID: 674628	Investigative	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
PT00241	M6APDG00880	1-guanidino-N-phenyl-7-isoquinolinesulphonamide	CID: 16658631	Investigative	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
PT00241	M6APDG01807	(4-guanidino-benzyl)-carbamic acid benzyl ester	CID: 44436702	Investigative	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
PT00174	M6APDG02695	4-(methyl(4-phenylthiazol-2-yl)amino)phenol	CID: 649391	Investigative	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
PT00012	M6APDG02678	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	CID: 644601	Investigative	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
PT00174	M6APDG02594	Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate	CID: 607092	Investigative	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
PT00125	M6APDG01666	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CID: 44349481	Investigative	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
PT00125	M6APDG00299	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	CID: 11347053	Investigative	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
PT00125	M6APDG00291	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CID: 11323577	Investigative	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
PT00172	M6APDG01724	4-Butoxy-N-hydroxycarbamoylmethyl-benzamide	CID: 44404479	Investigative	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
PT00172	M6APDG02143	N-Hydroxycarbamoylmethyl-4-methoxy-benzamide	CID: 47697	Investigative	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
PT00172	M6APDG01725	4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide	CID: 44404521	Investigative	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
PT00172	M6APDG01722	N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide	CID: 44404461	Investigative	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
PT00172	M6APDG01723	N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide	CID: 44404478	Investigative	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
PT00172	M6APDG00177	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	CID: 10565532	Investigative	Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96.
PT00197	M6APDG00225	PDGF receptor tyrosine kinase inhibitor III	CID: 10907042	Investigative	Identification of potent and selective inhibitors of PDGF receptor autophosphorylation. J Med Chem. 2006 Apr 6;49(7):2186-92.
PT00185	M6APDG01484	Benzyl 4-aminobutyl(3-aminopropyl)carbamate	CID: 389610	Investigative	Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
PT00170	M6APDG00275	4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine	CID: 11277481	Investigative	Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5389-94.
PT00015	M6APDG01194	8alpha,19-dihydroxylabd-13 E-en-15-oic acid	CID: 24899923	Investigative	Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71.
PT00015	M6APDG00326	N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide	CID: 11460185	Investigative	Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71.
PT00029	M6APDG01234	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	CID: 25141337	Investigative	Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. Anticancer Res. 2016 Jan;36(1):95-102.
PT00199	M6APDG02269	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid	CID: 5282316	Investigative	Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol... J Med Chem. 2010 Apr 8;53(7):2854-64.
PT00051	M6APDG02641	4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole	CID: 6411478	Investigative	Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8.
PT00051	M6APDG00253	4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole	CID: 11183327	Investigative	Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8.
PT00051	M6APDG00863	4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole	CID: 16216595	Investigative	Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8.
PT00051	M6APDG01635	(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine	CID: 44279279	Investigative	Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8.
PT00114	M6APDG02454	4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one	CID: 54737904	Investigative	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
PT00166	M6APDG00935	6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine	CID: 181029	Investigative	Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7.
PT00174	M6APDG00803	4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol	CID: 15516780	Investigative	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
PT00172	M6APDG00803	4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol	CID: 15516780	Investigative	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
PT00172	M6APDG01726	N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide	CID: 44404537	Investigative	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
PT00174	M6APDG00945	3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol	CID: 18411961	Investigative	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
PT00174	M6APDG00177	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	CID: 10565532	Investigative	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
PT00174	M6APDG03004	4-(2,2'-bithiophen-5-ylmethyleneamino)phenol	CID: 796420	Investigative	Heterocycle-based MMP inhibitors with P2' substituents. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.
PT00078	M6APDG01942	4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine	CID: 44820377	Investigative	Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. J Med Chem. 2005 Mar 24;48(6):1886-900.
PT00012	M6APDG00403	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CID: 11609208	Investigative	Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3105-10.
PT00015	M6APDG00769	2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one	CID: 14898715	Investigative	Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21.
PT00015	M6APDG03001	4-amino-N-(4-chlorophenyl)benzenesulfonamide	CID: 788021	Investigative	Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21.
PT00015	M6APDG01189	5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole	CID: 24884691	Investigative	Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evalu... Bioorg Med Chem Lett. 2009 Jun 1;19(11):3014-8.
PT00015	M6APDG01391	2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl	CID: 325144	Investigative	Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2009 Jul 15;17(14):5312-7.
PT00193	M6APDG00281	9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one	CID: 11288114	Investigative	4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5.
PT00193	M6APDG01717	3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one	CID: 44403357	Investigative	4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5.
PT00193	M6APDG01718	4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one	CID: 44403402	Investigative	4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5.
PT00005	M6APDG00310	7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one	CID: 11401873	Investigative	Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J Med Chem. 2004 Dec 30;47(27):6792-803.
PT00169	M6APDG00901	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	CID: 1694	Investigative	Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. J Med Chem. 2006 Jul 27;49(15):4455-8.
PT00125	M6APDG03318	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	CID: 9994848	Investigative	Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
PT00172	M6APDG00093	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol	CID: 10267279	Investigative	Phosphoramidate peptide inhibitors of human skin fibroblast collagenase. J Med Chem. 1990 Jan;33(1):263-73.
PT00070	M6APDG01531	5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione	CID: 4117381	Investigative	Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study. Eur J Med Chem. 2010 Sep;45(9):3858-63.
PT00050	M6APDG02334	N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine	CID: 5328042	Investigative	Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discover... J Med Chem. 2007 May 31;50(11):2605-8.
PT00050	M6APDG03319	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CID: 9995195	Investigative	Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907.
PT00050	M6APDG02345	2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile	CID: 5328755	Investigative	Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907.
PT00071	M6APDG00812	1-(phenyl(p-tolyl)methylene)thiosemicarbazide	CID: 15722900	Investigative	Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70.
PT00185	M6APDG00039	4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol	CID: 10086803	Investigative	5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86.
PT00185	M6APDG00182	5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione	CID: 10591750	Investigative	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).
PT00185	M6APDG02700	5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione	CID: 650260	Investigative	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).
PT00185	M6APDG01074	5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	CID: 23354226	Investigative	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).
PT00185	M6APDG00221	5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione	CID: 10849325	Investigative	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).
PT00011	M6APDG01822	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CID: 44446277	Investigative	Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic mat... J Med Chem. 2008 Mar 13;51(5):1406-14.
PT00029	M6APDG01216	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CID: 25074311	Investigative	Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2949-52.
PT00045	M6APDG02088	4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine	CID: 46885627	Investigative	Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
PT00014	M6APDG01702	(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine	CID: 44399941	Investigative	Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2881-5.
PT00005	M6APDG00264	1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole	CID: 11232117	Investigative	Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9.
PT00005	M6APDG00339	N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide	CID: 11493409	Investigative	Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9.
PT00005	M6APDG00426	N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide	CID: 11646165	Investigative	Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9.
PT00241	M6APDG00777	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	CID: 1507	Investigative	Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. J Med Chem. 2007 Dec 27;50(26):6638-46.
PT00241	M6APDG02832	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	CID: 6852210	Investigative	Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995 Apr 7;270(14):8361-6.
PT00165	M6APDG01977	1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine	CID: 45272467	Investigative	Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
PT00071	M6APDG00715	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone	CID: 136002679	Investigative	Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.
PT00170	M6APDG00250	9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine	CID: 11175093	Investigative	Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.
PT00015	M6APDG02041	2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline	CID: 46232132	Investigative	Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also ... Bioorg Med Chem. 2010 Jan 15;18(2):597-604.
PT00123	M6APDG00002	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CID: 10016510	Investigative	Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. J Nat Prod. 2009 Dec;72(12):2199-202.
PT00193	M6APDG00688	2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one	CID: 135508369	Investigative	Novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2007 Jan 15;17(2):542-5.
PT00005	M6APDG00440	N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide	CID: 11680642	Investigative	Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem. 2007 Apr 5;50(7):1635-44.
PT00005	M6APDG00844	N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide	CID: 16125122	Investigative	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
PT00005	M6APDG02764	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine	CID: 6540051	Investigative	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
PT00005	M6APDG02765	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine	CID: 6540052	Investigative	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
PT00005	M6APDG02766	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine	CID: 6540053	Investigative	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
PT00005	M6APDG02762	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine	CID: 6540049	Investigative	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
PT00005	M6APDG02763	3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine	CID: 6540050	Investigative	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31.
PT00046	M6APDG00835	2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide	CID: 16090303	Investigative	Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906.
PT00044	M6APDG03248	6-N-propyl -4-trifluoromethylquinolin-2(1H)-one	CID: 9903530	Investigative	Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1527-31.
PT00125	M6APDG00465	Octanedioic acid hydroxyamide pyridin-2-ylamide	CID: 11747496	Investigative	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20.
PT00125	M6APDG03290	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CID: 9943996	Investigative	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20.
PT00125	M6APDG01508	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CID: 403373	Investigative	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20.
PT00125	M6APDG01667	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CID: 44350626	Investigative	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
PT00125	M6APDG01670	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	CID: 44350718	Investigative	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
PT00125	M6APDG01668	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CID: 44350655	Investigative	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
PT00125	M6APDG01662	1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one	CID: 44342905	Investigative	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
PT00125	M6APDG01669	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CID: 44350703	Investigative	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
PT00050	M6APDG00222	3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one	CID: 10850934	Investigative	Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.
PT00051	M6APDG01636	(1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine	CID: 44279444	Investigative	Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.
PT00015	M6APDG00176	5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline	CID: 10561174	Investigative	The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines. Ann N Y Acad Sci. 2004 Dec;1030:37-42.
PT00015	M6APDG02985	(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide	CID: 769367	Investigative	Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. Bioorg Med Chem. 2008 Feb 15;16(4):1948-56.
PT00014	M6APDG00051	4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine	CID: 10130105	Investigative	Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4.
PT00014	M6APDG00159	1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea	CID: 10467406	Investigative	Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4.
PT00044	M6APDG01804	3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile	CID: 44434099	Investigative	(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mine... J Med Chem. 2007 Dec 27;50(26):6443-5.
PT00022	M6APDG01565	4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol	CID: 43680262	Investigative	Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900.
PT00015	M6APDG00759	2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid	CID: 14762941	Investigative	'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18.
PT00015	M6APDG01796	1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene	CID: 44424402	Investigative	'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18.
PT00015	M6APDG01512	4-(4-fluoro-benzylideneamino)-benzenesulfonamide	CID: 404324	Investigative	Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J Med Chem. 2007 Dec 13;50(25):6367-82.
PT00015	M6APDG01826	1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene	CID: 44452471	Investigative	Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4842-5.
PT00015	M6APDG01994	5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole	CID: 45484514	Investigative	Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1029-33.
PT00015	M6APDG02196	(E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide	CID: 50908699	Investigative	Synthesis of biflavones having a 6-O-7'' linkage and effects on cyclooxygenase-2 and inducible nitric oxide synthase. Bioorg Med Chem Lett. 2009 Jan 1;19(1):74-6.
PT00173	M6APDG01993	5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	CID: 45483018	Investigative	Clinical pipeline report, company report or official report of Vernalis.
PT00074	M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 11572699	Investigative	Clinical pipeline report, company report or official report of Onconova.
PT00144	M6APDG02481	N-(3,5-dichlorophenyl)imidodicarbonimidic diamide	CID: 558969	Investigative	alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J Med Chem. 2009 Nov 26;52(22):7029-43.
PT00174	M6APDG01912	5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	CID: 44626352	Investigative	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment ... Bioorg Med Chem Lett. 2010 Jan 15;20(2):576-80.
PT00078	M6APDG01802	2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile	CID: 44430881	Investigative	Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41.
PT00079	M6APDG00433	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	CID: 11658882	Investigative	Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41.
PT00191	M6APDG01233	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole	CID: 25137977	Investigative	Guttiferone I, a new prenylated benzophenone from Garcinia humilis as a liver X receptor ligand. J Nat Prod. 2005 Apr;68(4):617-9.
PT00191	M6APDG01989	N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide	CID: 45481863	Investigative	Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
PT00196	M6APDG03277	4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	CID: 9927943	Investigative	The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):421-424 (1997).
PT00197	M6APDG03277	4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	CID: 9927943	Investigative	The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):421-424 (1997).
PT00050	M6APDG00457	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CID: 11717472	Investigative	The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem. 2006 Jun 15;49(12):3544-52.
PT00071	M6APDG02042	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone	CID: 46232967	Investigative	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
PT00170	M6APDG00784	(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone	CID: 15311937	Investigative	Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3745-8.
PT00079	M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 11572699	Investigative	Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006 Sep 7;49(18):5470-7.
PT00080	M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 11572699	Investigative	Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006 Sep 7;49(18):5470-7.
PT00081	M6APDG00390	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	CID: 11572699	Investigative	WO patent application no. 2007,0898,78, Sutures and anti-scarring agents.
PT00033	M6APDG03245	3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol	CID: 9901372	Investigative	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer. 2009 Jul;45(10):1846-54.
PT00024	M6APDG03380	Siltuximab	.	Approved	Leadership in BioBusiness. Dr Gurinder S Shahi. Page(36).
PT00009	M6APDG00044	Linagliptin	CID: 10096344	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG00268	Saxagliptin	CID: 11243969	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG00384	Apremilast	CID: 11561674	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG00599	Fosamprenavir	CID: 131536	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG00994	Lapatinib	CID: 208908	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG00998	Propranolol	CID: 21138	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG01281	Carvedilol	CID: 2585	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG01319	Clobazam	CID: 2789	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG01351	Maraviroc	CID: 3002977	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG01489	Nadolol	CID: 39147	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG01568	Sitagliptin	CID: 4369359	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG02442	Pravastatin	CID: 54687	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG02451	Dolutegravir	CID: 54726191	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG02509	Naloxegol	CID: 56959087	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG02545	Pibrentasvir	CID: 58031952	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG02818	Ledipasvir	CID: 67505836	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG02820	Velpatasvir	CID: 67683363	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG03031	Voxilaprevir	CID: 89921642	Approved	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG01967	Paritaprevir	CID: 45110509	Phase 2	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG02801	Glecaprevir	CID: 66828839	Phase 2	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG03344	Dasabuvir	CID: 56640146	Phase 3	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00009	M6APDG02458	Ombitasvir	CID: 54767916	Phase 4	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
PT00176	M6APDG01894	5,6,7,8-tetrahydroanthracene-1,4-dione	CID: 44582382	Investigative	Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11).